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This Thesis comprises an investigation of [Mn(ppy)(CO)4] (ppy = 2-phenylpyridyl), 88, and 
related Mn(I) tetracarbonyl complexes, for application as carbon monoxide-releasing molecules 
(CORMs). The photochemical behaviour of [Mn(ppy)(CO)4] was studied using ultrafast time-
resolved infrared spectroscopy (TRIR) to probe light-triggered CO-release (Chapter 2). 
Compared to the isoelectronic complex [Cr(bpy)(CO)4], a striking difference in the balance 
between CO-release and unreactive excited state formation is observed, providing insight into 
why photo-CO release is inefficient in some compounds. Novel intermediates in light-triggered 
CO dissociation were detected on the picosecond timescale including C-H σ-complexes. Over 
longer (minute) timescales, complementary in situ infrared experiments suggested possible 
production of multinuclear Mn-hydroxy clusters in wet organic solvents. Thus, new evidence for 
the light-triggered CO-release mechanism is provided.  
 
Three novel ferrocene-containing [Mn(ppy)(CO)4]-derived CORMs, a family of compounds 
incorporating two organometallic therapeutic moieties within the same molecule, are described 
(Chapter 3). Although these CORMs are all redox-active and were all capable of photo-induced 
CO-release it was not possible to achieve redox-triggered CO-release. To further probe the 
possibility of redox-triggered CO-release, tetracarbonyl Mn compounds incorporating a 
cyclometalated azo ligand, a metal-free redox-active moiety, also shown to increase the CO-
release wavelength of tricarbonyl Mn(I) complexes, were synthesised (Chapter 4). Although CO-
release at a higher wavelength of light can be attributed to the azo, redox-release is not possible 
and TRIR shows that unreactive excited states dominate over CO photodissociation. Thus, this 
work demonstrates the need to consider both efficiency and wavelength in designing triggered-
CO release and emphasises the value of the mechanistic work described.  
Finally, fluorescent labelling of a [Mn(ppy)(CO)4] derivative is reported (Chapter 5). Confocal 
microscopy of mammalian and bacterial samples proves that viable cells of both types will uptake 
such CORMs and the methodology for assaying the antibiotic activity of photoCORMs is 
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The toxicity of carbon monoxide (CO) is well-known. But CO is also produced endogenously in 
low concentrations by healthy mammals. It is now widely understood that CO is an important 
signalling molecule.  
Administration of exogenous CO has been shown to have a wide range of beneficial effects but 
controlling the dose of CO gas in a meaningful way can be challenging. As a result, prodrugs 
termed CO-releasing molecules (CORMs), designed to display a well-defined and controlled CO 
release profile, have been developed. A range of delivery methods and CO-release triggers has 
been used. Mechanistic studies have also been employed to understand how to design CORMs 
with desirable properties. 
This introduction begins by discussing the role of CO in biology and then provides examples of 
its therapeutic applications. Methods to administer CO, including the use of CORMs, will then 
be discussed. A summary of the techniques used for mechanistic insight into CO release is 
provided, and finally the aims and objectives of the work in this Thesis will be outlined.   
 Carbon Monoxide in Biology 
1.1.1 Toxicity 
The toxicity of carbon monoxide (CO) is well-known, having been studied since the 19th century. 
Headaches, confusion, hyperventilation, disturbed vision, and palpitations were among the 
symptoms of CO poisoning listed by John Scott Haldane in 1895, when he reported the effects of 
breathing different mixtures of air and “carbonic oxide” upon himself and mice.1 Haldane showed 
that CO binds to the Fe-based O2 carrier haemoglobin (Hb). Colourimetric assays on blood 
samples established that CO binds to Hb more strongly than O2 by more than two orders of 
magnitude.2 This work led to the introduction of CO safety measures: use of small animals as an 
early warning system in coal mines, where many workers died of CO poisoning.3 Safe levels of 
CO are currently considered to be exposure below 50 ppm over 8 hours.4 
The early explanation of the toxicity of CO came from Haldane’s observations that CO binds to 
Hb. It was proposed that the resulting disturbance to the Hb O2 transport mechanism was 
responsible for tissue hypoxia (O2 starvation).1 However, more recent research suggests that the 
level of carboxyhaemoglobin (CO-Hb) does not share a simple proportional relationship with the 
symptoms and outcomes experienced by patients,5 as would be predicted from Haldane’s 
proposal. For example, experiments to restrict O2 availability in other ways have showed that 
simple lack of O2 transport in the blood (hypoxaemic hypoxia) is insufficient to explain the effects 
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of CO poisoning. Okeda and co-workers performed experiments in the 1980s on anesthetised cats, 
where blood oxygen content was controlled by breathing N2/O2 mixtures.6 The results showed 
that hypoxia alone was not enough to cause damage to brain tissue, as the circulatory system was 
able to adjust to the O2 deficiency.6 Induction of an accompanying drop in blood pressure, an 
additional effect of CO poisoning, along with hypoxia, was required to cause damage to brain 
tissue.6 Earlier experiments suggested that inhalation of CO gas is considerably more toxic to 
dogs than receiving CO as CO-Hb in blood transfusions to reach the same CO-Hb levels.7 The 
extra toxicity of inhaled CO cannot be accounted for within Haldane’s initial explanation.  
The treatment for CO poisoning, however, has remained unchanged since the times of Haldane, 
who recommended the administration of oxygen.1 Experiments in dogs showed that CO-Hb levels 
dropped faster in animals breathing O2 or CO2/O2 mixtures compared to air, though this was 
before it was realised that CO-Hb levels are not always a reliable indicator of symptoms or 
outcome.8 Normal and hyperbaric pressures of oxygen are used to treat CO poisoning.9–11 The 
success levels of treatment do not appear to have a simple relationship with the partial pressure 
of O2.12 
Another hypothesis for the toxicity of CO that has been examined is the inhibition of cytochrome 
c oxidase, another Fe-based protein, by CO. Just as with Hb, CO can bind to the iron of the haem 
group  within cytochrome c oxidase, the terminal acceptor in the electron transport chain of 
aerobic respiration.13 This is in turn associated with an increase reactive oxygen species (ROS),14 
which can cause further damage to DNA, proteins and cell membranes.14 Although the formation 
of, and damage caused by, reactive oxygen species has been implicated in the toxicity of CO in 
numerous studies,14–19 it is unclear how much the inhibition of cytochrome c oxidase contributes 
to the overall observed toxicity of CO.15 Experiments in which CO coordination to cytochrome c 
oxidase has been observed have typically been under high concentrations of CO and low 
concentrations of O2 that are unlikely to be replicated in vivo.15  
A full understanding of the mechanisms of CO toxicity remains elusive despite over a century of 
research.15 This is due in no small part to the discovery that CO is produced endogenously in 
healthy mammals and plays important roles as a signalling molecule, many of which are yet to be 
fully characterised.20  
1.1.2 Endogenous CO Production 
In 1949, Sjӧstrand discovered that CO is endogenously produced in humans.21 Subjects with 
diseases such as cancer, high blood pressure, and anaemia exhibited higher levels of CO in their 
breath than healthy people.21 The elevated CO levels returned to match those of healthy subjects 
upon recovery from disease.21 These observations were the first suggestion that this highly toxic 
gas plays an important physiological role in both healthy and diseased states.  
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Sjӧstrand later provided the first evidence that endogenous CO production was linked to the 
metabolism of haem groups.22 Indeed the vast majority of endogenous CO production is 
accounted for by the oxidative metabolism of haem, catalysed by haem oxygenase (HO) enzymes 
(Scheme 1).23  
 
Scheme 1: Metabolism of haem with the formation of CO. 
The first three steps in Scheme 1 are catalysed by haem oxygenases. The metabolism of haem 
begins with hydroxylation to generate α-meso-hydroxyhaem, which occurs via a peroxy 
intermediate.24 Loss of CO from the α-carbon then occurs and the ring is cleaved open. Reduction 
by NADPH catalysed by cytochrome p450 results in formation of Fe(II), which is lost from the 
porphyrin and sequestered by ferritin, leaving the bile pigment biliverdin.24 Biliverdin is 
subsequently reduced by NADPH in a reaction catalysed by a second enzyme, biliverdin 
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reductase, to yield bilirubin, which is solubilised by conjugation with glucuronic acid and 
excreted.25  
Three HOs have been identified, two of which are well-characterised.26 Haem oxygenase 1 (HO-
1) can be expressed by all mammalian cells.27 Its expression may be induced by a very broad 
range of stresses including hypoxia,28–30, shear stress,31 heat shock32 H2O2 exposure,33,34 and UV 
irradiation.33–35 The observation that HO-1 is expressed under hypoxic conditions is particularly 
intriguing as CO produced from HO-1 activity would be expected to make the hypoxic stress 
worse. This point illustrates the importance of the various cellular targets in the biology of CO as 
opposed to simple effects on O2 transport. 
 Haem oxygenase 2 (HO-2) is mainly found in the circulatory system.36 It is the product of a 
different gene to HO-1, and  constitutively expressed rather than being induced by stressful 
stimuli.36 Less is known about the role of haem oxygenase 3 (HO-3). It shares > 90 % structural 
similarity with HO-2, but appears to be a poor catalyst for haem degradation, leading to the 
suggestion that it plays a regulatory role by binding haem.37 
 
Figure 1: X-ray crystal structure of HO-1 with its haem substrate bound. Image produced from 
Protein Data Bank entry 1N4538 using PyMOL.39  
Experiments studying the upregulation or knockout of the hmox1 gene that codes for HO-1 have 
shown that the haem oxygenases are vital in responding to stress and preventing inflammation.40 
A study of hmox1 gene-deleted mice exposed to a range of oxidants (including H2O2, paraquat 
and hemin), showed a much greater susceptibility to oxidative damage, suggesting that HO-1 
activity can play a role as an antioxidant during oxidative stress.41 An in vivo study comparing 
wound healing rates in wild-type mice with HO-2 knockouts showed that the anti-inflammatory 
and injury reparative responses were severely depleted without HO-2.42 The products of haem 
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breakdown can induce expression of HO-1. It has therefore been suggested that the constitutively 
expressed HO-2 plays a regulatory role which can promote HO-1 production to increase haem 
degradation.42 
Many of the effects of HO activity can be replicated by the exogenous administration of one or 
more HO products.43 For example, in vitro experiments with bile pigments biliverdin and bilirubin 
have shown their antioxidant properties and protective effects in models of cardiovascular and 
lung disease.44 However, the therapeutic viability of bile pigments is relatively unexplored and 
represents another means of understanding and conveying the beneficial effects of HO activity. 
The therapeutic effects of administering exogenous CO have been studied far more widely and 
are discussed below. 
1.1.3 Physiological and Therapeutic Effects of CO 
Initially dismissed as a waste product of haem degradation, CO is now established as a signalling 
molecule of importance in numerous biochemical pathways. The following sections detail some 
examples of the interplay of CO signalling pathways and its relationship with physiological 
outcomes. The examples chosen are intended to display the wide range of physiological effects 
associated with CO.  
1.1.3.1 Relationship of CO with Soluble Guanylyl Cyclase 
One of the most significant mechanisms in CO signalling is through the activity of soluble 
guanylyl cyclase (sGC). This enzyme catalyses the conversion of guanosine triphosphate (GTP) 
into cyclic guanosine monophosphate (cGMP), as shown in Scheme 2.45 Cyclic GMP is a ‘second 
messenger’, meaning that it is released by cells upon exposure to a ‘first messenger’ such as CO. 
Carbon monoxide can activate sGC to produce cGMP, as does NO – another highly toxic gas that 
acts as a gasotransmitter in lower concentrations.46 
 
Scheme 2: Formation of cGMP from GTP. 
The role of cGMP is to trigger the activation of protein kinases which phosphorylate other 
proteins. Phosphorylation is often a trigger for the activation, transport or interaction of proteins, 
including enzymes, which can have significant physiological implications.47 In particular, cGMP 
is associated with effects such as inhibition of platelet aggregation (preventing blood clots) and 
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smooth muscle relaxation (regulating blood pressure by causing vasodilation).47 Importantly, 
these same therapeutic effects from the production of cGMP can be replicated in vivo from the 
administration of exogenous CO, for example in vivo studies have shown that exogenous CO 
inhibits platelet aggregation,48 and causes vasodilation49 and bronchodilation.50 
The link between sGC and CO has been demonstrated by the observation that CO exposure results 
in vasodilation and in an increase in cGMP concentration in vascular smooth muscle cells, even 
when NO did not have any effect.51 Aortic ring relaxation was also induced by CO, in the absence 
of other gasotransmitters, and effect was diminished when an inhibitor of sGC was added - in 
these conditions both CO and sGC are necessary for aortic ring relaxation to occur.52 Evidence of 
CO binding to sGC has been observed spectroscopically, confirming that CO interacts directly 
with sGC.53 
Nitric oxide is a stronger activator of sGC than CO.54 It is possible to increase the level of 
activation of sGC by CO using a second activator. Compounds YC-1 and BAY 41-2272 (Figure 
2), can bind to sGC at the same time as CO, to increase the activity of the enzyme to the levels 
achieved by NO activation.53,55 Although CO can mediate physiological effects without these 
second activators, the extent of the response can be dramatically improved by their presence – for 
example CO-induced aortic ring relaxation was increased tenfold by the presence of compound 
YC-1.52 
 
Figure 2: Structure of compounds YC-1 and BAY 41-2272. 
However, these compounds were made synthetically and so far there is no evidence that any 
related naturally-occurring compounds bind to sGC synergistically with CO to increase enzymatic 
activity. It is unclear whether synergistic activation of sGC is a requirement to have a 
physiological effect, or whether the smaller activating effect of CO on its own is sufficient. 
1.1.3.2 Relationship of CO with Reactive Oxygen Species  
As discussed in Section 1.1.1, there is evidence that CO can bind to cytochrome c oxidase, the 
terminal enzyme in the electron transport chain of respiration, generating reactive oxygen species 
(ROS). Although there is no conclusive evidence that the effects of CO upon the mitochondria 
play a significant role in its toxicity, important physiological effects are apparent in healthy cells 
at lower concentrations of CO.56 
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Aerobic respiration uses electrons from the oxidation of sugars to reduce O2 to H2O. Energy 
released from this reaction is used to phosphorylate adenosine diphosphate (ADP) to form the 
adenosine triphosphate (ATP), the key energy carrier of the cell. Cytochrome c oxidase is a haem-
containing protein that performs the reduction of O2 to H2O. Figure 3 shows a hypothesis for how 
CO interferes with this process to generate ROS. Inhibition of cytochrome c oxidase with CO 
slows down O2 reduction and ATP production in the mitochondria, leading to a build-up of 
reduced electron carriers (Complex III in Figure 3).57 This can in turn lead to an increased rate of 
side-reactions such as the partial reduction of O2, leading to the production of reactive oxygen 
species (ROS). The initial species produced is the superoxide radical, [O2˙]−, which can 
disproportionate to form O2 and H2O2 catalysed by the enzyme superoxide dismutase (SOD).57 
The H2O2 is able to leave the mitochondria.58 It has been shown that CO-induced production is 
not dependent on hypoxia but rather a build-up of reducing equivalents in the electron carriers in 
the mitochondria due to a reduced rate of O2 reduction to H2O. There is also evidence that CO 
induces expression of SOD.57 
 
Figure 3: Mechanistic hypothesis for the CO-induced generation of ROS in the mitochondria by 
inhibition of cytochrome c oxidase. Adapted from C. S. F. Queiroga, A. S. Almeida and H. L. A. 
Vieira, Biochem. Res. Int., 2012, Article ID 749845, 9 pages under a Creative Commons Attribution 
Licence.17 
Reactive oxygen species are common and important components of signalling; for example some 
transcription factors and protein kinases are activated by the cellular redox environment.57 Bursts 
of ROS from CO inhibition of cytochrome c oxidase could therefore lead to localised biochemical 
changes, for example CO-derived H2O2 is implicated in mitochondrial biogenesis: increasing the 




1.1.3.3 Effect of CO on Inducible NO Synthase 
The role of NO as a gasotransmitter has been extensively studied; it is known to be a 
neurotransmitter, vasorelaxant, and is generated as part of the inflammatory response.59–61 The 
roles of CO and NO appear to be closely linked; having related signalling roles and mediating 
their effects in similar ways. For example, the two gases both act as neurotransmitters and may 
sometimes act as cotransmitters, meaning that release of both CO and NO is required for 
transmission of some nerve impulses in the brain.62 It has also been shown that CO is involved in 
regulating NO production, and vice versa.63   
Endogenous NO is produced from L-arginine in a reaction catalysed by a haem-containing 
enzyme called Nitric Oxide Synthase (NOS).64 As with HO, NOS has both constitutively 
expressed and inducible (known as iNOS) isoforms.60 It has been shown that CO can inhibit the 
activity of iNOS by binding to the haem group of the active site, thereby lowering the rate of NO 
production.64 The involvement of NO in the inflammatory response suggests that iNOS inhibition 
by CO could be one mode of action for the anti-inflammatory effects induced by CO,43 but more 
work is required to establish the relationship between CO and NO and to understand their 
respective biological roles. It is clear that CO and NO signalling are intricately related. 
1.1.3.4 Effect of CO on Ion Channels 
The effects of CO also extend to ion channels in the cell membrane. It has been shown that L-
type Ca2+ ion channels, which are important in regulating vascular tone in the circulatory system, 
are a target for CO, which inhibits the channels.65 This may play a role in the cardioprotective 
properties of CO. The effect may be mediated by mitochondira-generated ROS since antioxidants 
reversed the effect of CO.65 This helps to explain HO-1 is upregulated and when the 
cardiovascular system is under stress, for example myocardial infarction. Exogenous CO has been 
shown to reduce injury from myocardial infarction in mice.43  
Carbon monoxide is also involved in activation of some ion channels, such as ‘big-conductance’ 
calcium-activated potassium (BKCa) channels. These channels excrete K+ ions when Ca2+ ions are 
detected, regulating the potential across the plasma membrane, and are linked to smooth muscle 
relaxation and vasodilation.66 This shows how CO can play a role in blood pressure regulation. 
There is evidence to suggest that activation of BKCa channels mediated through several of the 
pathways discussed above, including release of ROS, direct binding to haem proteins associated 
with the channels, and sGC activity.66 
1.1.3.5 Role of CO in Mitrogen-Activated Protein Kinase Pathways 
At least some of the anti-inflammatory properties of HO activity are known to derive from CO, 
based on experiments involving exogenous administration of CO. The way in which the CO 
mediates this effect appears to involve one of three important protein kinase signalling cascades 
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known as mitrogen-activated protein kinase (MAPK) pathways. These pathways play significant 
roles in the inflammatory and immune response by increasing production of pro-inflammatory 
cytokines; compounds released as part of the immune response to potential pathogens. It is 
ultimately the overproduction of these molecules that results in the potentially fatal tissue damage 
caused by septic shock. The relationship of CO with MAPK pathways makes CO a promising 
anti-inflammatory agent. 
The effect of CO was studied using in vitro and in vivo models of sepsis. The results showed that 
CO administration resulted in lower levels of three pro-inflammatory cytokines: tumour necrosis 
factor-α, interleukin-1β, and macrophage inflammatory protein-1β. Meanwhile, the CO led to an 
increased concentration of anti-inflammatory cytokine interleukin-10.67 
The in vitro experiment was performed with RAW 264.7 macrophages. Interestingly, the 
concentration of cGMP in the macrophages did not increase upon CO exposure, which suggested 
that the anti-inflammatory effect in this case was independent of the activation of sGC.67 By 
comparison, an over 1000-fold increase in cGMP concentration was observed in the positive 
control experiment with smooth muscle cells (which relax in the presence of CO to cause 
vasodilation).  
Instead of sGC activation, the study found an increase in the activity of MAPKs (particularly one 
of the three classes of kinase called p38) upon exposure to 250 ppm CO.67 Mice without the ability 
to activate the p38 MAPK pathway did not receive the same beneficial effect in the presence of 
CO, confirming that p38 MAPK is a target for CO.67 
The examples discussed above rely on the ability of CO to bind to haem groups, yet in p38 
MAPKs there are no haem groups for CO to interact with and no binding site for CO has been 
identified thus far.20 It is therefore unclear how CO exerts its effect on this pathway. It is likely 
that CO has an indirect effect through other haem-based proteins, that can interact with both CO 
and a species involved in the p38 MAPK pathway. For example, it has been observed that 
antioxidants prevent CO activation of the p38 MAPK pathway.14 This suggests that ROS may 
play a role in this signalling pathway, perhaps derived from CO inhibition with cytochrome c 
oxidase.  
The anti-inflammatory effects of CO are also mediated by other pathways. As discussed in Section 
1.1.3.3, CO can influence NO production, which is involved in the inflammatory response. It has 
also been shown that CO can inhibit the function of toll-like receptors; proteins in the immune 
system that detect conserved molecular structures from pathogens to initiate the immune response 
and activate inflammatory pathways.68 
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1.1.3.6 Applications of CO in Cancer 
The extent of the therapeutic potential for CO treatment against cancer is still unclear as 
contrasting results have been obtained in different studies.69 It appears that both HO-1 activity 
and CO can aid tumour growth under low CO concentrations, as CO can also be associated with 
a cytroprotective effect, cell proliferation and the development of new blood vessels 
(angiogenesis).69 Yet these roles of CO may still be exploitable as a cancer therapeutic. Higher 
concentrations of CO can be used to cause metabolic exhaustion of the cancer cells by 
overstimulation of these pathways resulting in ‘metabolic exhaustion’.70 It has been shown that 
CO weakens prostate cancer cells towards chemotherapeutic agents without affecting normal 
cells.71 The addition of CO caused more consumption of O2 by the mitochondria but also 
generated more reactive oxygen species.71 Human prostate cancer tumours grafted onto mice 
showed inhibited growth when mice were exposed to 250 ppm CO for 1 hour per day and was 
correlated with increased apoptosis of the tumour cells.71 A number of CO-releasing pro-drug 
systems have also been shown to cause apoptosis of cancer cells derived from the released CO.72,73 
The conflicting results obtained in different studies suggest that whether HO-1 or CO have anti-
cancer effect may be highly dependent on the type of tumour and the dosage of CO.70 More work 
is needed to understand the full impact of CO upon cancer cell metabolism. One thing that is clear 
is that exquisite control of dosage and localisation of CO is beneficial to the investigation of CO 
as a therapeutic agent and any subsequent development of pharmaceuticals will necessitate a 
delivery method with these properties.  
1.1.3.7 Antimicrobial Properties of CO 
Carbon monoxide is toxic to a range of pathogenic bacteria, typically at tens of micromolar 
concentrations.74,75 Studies in this area have been reviewed comprehensively; bactericidal effects 
on Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa have been 
observed.4,69,75 Bactericidal activity has been attributed mainly to the binding of CO to 
haemoproteins in the bacterial respiratory chain, preventing ATP synthesis.75 These effects are 
promising given the escalating problem of antimicrobial resistance and the resulting need for new 
antimicrobials with novel modes of action. Carbon monoxide also induces dormancy of 
Mycobacterium tuberculosis, which could be used to slow infections down to enable the immune 
system to clear the infection. Carbon monoxide can bind to the haem-containing sensory proteins 
DosS and DosT which causes regulatory proteins to induce the dormancy response.76  
However, mechanisms by which CO acts are not always clear. This is because most antimicrobial 
experiments with CO have used prodrugs, called carbon monoxide-releasing molecules 
(CORMs), to deliver CO.43 The use of CORMs could potentially cause the biological effects of 
CO to be accompanied by further effects of the by-products from CO release. The importance of 
this point is highlighted by the observation that some CORMs are considerably more toxic to 
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bacteria than CO gas.75 This observation may be due to more effective localisation of CO into 
bacterial cells than can be achieved with CO gas, or it may be related to the effects of the CORM 
and its degradation products. The therapeutic properties of CO must therefore be clearly 
distinguished from the biological activity of the remaining fragments of the prodrug.  
The application of CORMs, as opposed to just CO, as antimicrobials will be further discussed in 
Section 1.3.1. 
1.1.4 Summary 
The study of the biochemical mechanisms that constitute CO signalling in healthy humans, as 
discussed above, reveals the basis for a wide range of possible targets and therapeutic 
applications. The exploration of CO in breath as a tool for monitoring inflammation and oxidative 
stress also remains an active area of research.68 Additional evidence of therapeutic effects has 
been found for a range of other disease states. This considerable body of research shows that CO 
is a promising therapeutic molecule with a range of possible targets.  
 Delivery Methods for CO 
In many of the studies discussed above, CO was administered as a gas. However, for the last 20 
years it has been apparent that greater localisation and control of CO delivery is required if this 
molecule is to realise its potential as a therapeutic agent. The goal is to provide well-defined, 
reproducible, and localised doses. Improvements in CO delivery aid studies of CO physiology 
and provide a starting point towards developing prodrugs that release CO in therapeutic doses.43 
This Section outlines the variety of possible methods available to deliver CO to biological targets.  
1.2.1 Inhalation of CO Gas 
Commercialisation of a CO gas delivery system for spontaneous and ventilator breathing is 
currently being explored by CO therapeutics company Proterris.77Previously, some details have 
been published of the development of a medical device for the administration of CO gas called 
the Covox DS (delivery system). The Covos DS system has been used to delivery CO to human 
volunteers.43 It gives precise control over the amount of CO inhaled and absorbed by allowing 
adjustments for the body weight and breathing rate of the subject. In trials on healthy volunteers 
the elevation of CO-Hb levels was reproducibly around 12 % when a dosage of 3 mg kg-1 h-1 was 
used for one hour.43 However, as discussed in Section 1.1.1, it is unclear whether CO-Hb is a 
reliable measurement of CO dosage due to the other variability or symptoms and outcomes with 
CO-Hb levels, since CO interacts with many other targets in the body. This raises the question of 
how much CO is actually absorbed into the body when breathing CO gas and it is unclear whether 
a reliable method can be developed to quantify CO doses given to a population of patients. 
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Furthermore, CO gas delivery is unselective, as CO can be transported through the blood and 
hence spread throughout the body. As a result, treatment with CO gas is likely to require larger 
doses compared to delivery methods with greater selectivity to ensure the dose at the site of action 
is sufficient. This in turn requires careful monitoring and control of the CO administered in a 
clinical setting to monitor exposure over time following a given dose. Use of CO gas is therefore 
far less flexible and convenient compared to other CO release methods such as the use of 
prodrugs.78   
1.2.2 Metal-Based CORMs 
The use of CORMs as prodrugs that release CO has been proposed as a more selective method of 
delivering a controllable, well-defined dose of CO compared to CO gas inhalation.23 This has 
prompted study of triggered CO release from a diverse range of organic and organometallic 
compounds for therapeutic application.43,66,78,79 A CORM is designed to react when exposed to a 
physical or chemical trigger to release CO (Scheme 3).80 Crucially, CORMs are able to replicate 
many of the physiological effects of CO and HO activity.43 Due to the extensive coordination 
chemistry of CO with transition metals, most CORMs are metal carbonyl complexes,69 although 
some non-metallic CORMs are known.79  
 
Scheme 3: How prodrugs can be used to release CO upon exposure to a trigger. M represents a 
transition metal with co-ligands L, whereas A and B are nonmetallic compounds. 
The most common triggers for CO release from metal-based CORMs are ‘thermal’, 
photochemical, and enzymatic reactions.78 Each method has its advantages over the others and 
will be discussed in turn. 
1.2.2.1 Carbon Monoxide as a Ligand 
The salient feature of the chemistry of CO in the coordination sphere of a metal is its ability to 
behave as a π-acid ligand.81 This property enables it to form strong M-CO bonds with electron-
rich transition metals, including to the reduced form of haem groups in biological systems. Metal 
carbonyl complexes can therefore be exploited for the storage and controlled release of CO.  
Carbon monoxide behaves as a Lewis base, typically acting as a two-electron donor to transition 
metals through the C atom. Terminal or bridging (μ2 or μ3) coordination modes through just the 
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C atom are the most common. Bridging can sometimes occur either through a second (and 
sometimes third) electron pair shared from the π-bond (Figure 4). 
 
Figure 4: Common binding modes of CO to transition metals 
Despite the electronegativity difference in the C and O atoms the dipole moment of CO is only 
0.12 D,82 as the HOMO is based primarily on the C atom. As a result of this, CO is considered a 
soft ligand. The molecular orbital (MO) diagram for CO is shown in Figure 5. 
 
 
Figure 5: The MO diagram for CO. 
The MO diagram shows that the Highest Occupied Molecular Orbital (HOMO) is the 5σ orbital. 
Historically, the 5σ orbital has been described as an antibonding orbital, as an explanation for 
why the infrared stretching frequency of non-classical metal carbonyls increases from that of CO. 
However, recent computational work has suggested that the 5σ orbital is slightly bonding in 
character,83 and that the infrared stretching frequencies of non-classical metal carbonyls can be 
explained by the behaviour of the π-system.84 The description of the 5σ orbital as weakly bonding 
is consistent with the absence of a node between the C and O nuclei (Figure 6). The 5σ orbital 
MO of CO can form a σ-bond to metal-based orbitals as shown below on the left of Figure 6. As 
a result, coordination to a metal centre to form an M-C bond would be expected to result in a 
strengthening of the C≡O bond due to the removal of antibonding electron density. However, the 
π-backdonation from occupied metal-based orbitals into the antibonding 2π orbitals of the CO 
ligand ensures that there is an overall weakening in the C≡O bond upon coordination to an 
52 
 
electron-rich metal centre, as shown in the centre of Figure 6. On the right of Figure 6 is shown a 
third interaction: π-donation from the occupied 1π orbitals into vacant metal-based orbitals. This 
effect is often overlooked as a more minor interaction but can strengthen or weaken the M-C bond 
depending on whether the π-electrons can interact with empty or filled metal-based orbitals. 
 
Figure 6: Interactions of CO MOs with transition metal orbitals. 
1.2.2.2  ‘Thermal’ CORMs 
Thermal CORMs have a simple, unselective release trigger, in which the metal complex releases 
CO upon dissolution in solution at 37 °C, the average normal body temperature. The term 
‘thermal’ CORM is commonly interchanged with other terms such as ‘solvent-induced’ or 
‘spontaneous’ CORM.85 This is because the mechanism of degradation of thermal CORMs 
typically involves a ligand substitution reaction whereby a solvent molecule replaces CO. This 
Section describes the development of thermal CORMs.  
A timeline of some of the developments and publications to be discussed in this Section is 
provided in Figure 7. The timeline shows how the initial testing of CORMs was based on verifying 
that the CO released by a metal carbonyl could mimic the effects attributed to CO gas, verifying 
the biological effect of CO and the strategy of using CORMs to deliver it. As the field has 
developed, the more recent work has focused on modulation of the CO release rate and the 
biological properties, such as water solubility, tissue localisation or specific therapeutic activity. 
There is now a wide range of thermal CORMs available and design strategies are based on 
derivatising existing complexes to confer desirable properties or release characteristics and there 
has been a shift in focus latterly towards the greater control over CO release rate and localisation 







Figure 7: A timeline of some of the published developments in the field of thermal CORMs discussed 
in this Section, from the first CORMs paper in 2002 to the more recent shift to more sophisticated 
design strategies and CO release triggers.86–96  
The first published example of a thermal CORM used for therapeutic CO release was complex 1, 
[Ru(CO)3Cl2]2, also known as CORM-2 (Scheme 4), in 2002.86 As this complex displayed low 
water solubility it was solubilised in dimethyl sulfoxide (DMSO). Dissolution of CORM-2 in 
DMSO followed by mixing with an aqueous solution of deoxymyoglobin (deoxy-Mb) induced 
CO release, as detected by carboxymyoglobin (Mb-CO) formation in the UV-visible spectrum of 
the solution. The conversion of deoxy-Mb to Mb-CO is a very common technique to assess CO 
release and will be discussed in more detail in Section 1.3.2.1. 
The mechanism for CO release from CORM-2 was also investigated by infrared and NMR 
spectroscopies. The DMSO complexes 2-4 were observed to form from a freshly-prepared sample 
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of 1, confirming that CO release from CORM-2 is initiated by ligand substitution of the solvent 
to produce dicarbonyl and tricarbonyl complexes.86 Although CORM-2 is often termed a 
‘thermal’ CORM in the literature, it is more accurately a solvent-triggered CORM.  The DMSO 
plays a much more significant role than a simple solubilising agent. It is possible that a similar 
mechanism could occur in water but CORM-2 was not soluble enough in water to test this 
hypothesis.   
 
Scheme 4: Decomposition of CORM-2, 1, in DMSO. 
It was then shown in the initial 2002 paper that the CO released from CORM-2 resulted in the 
vasodilation of precontracted rat aortas.86 Control experiments showed that this was not caused 
by the decomposition products of CORM-2 or the DMSO used as a delivery vehicle, showing 
that the released CO was responsible for the effect. The mechanism of vasodilation was shown to 
occur via a cGMP-dependent pathway.86  These experiments showed that CO released from a 
CORM can elicit a therapeutically relevant effect in the same way as CO gas. Low levels of 
cytotoxicity from CORM-2 and its degradation products were also observed.86 
The promising therapeutic results obtained for CORM-2 led to a search for a water-soluble 
alternative, and such an example was published in 2004.87 Reaction of CORM-2 with glycine and 
sodium ethoxide yielded water-soluble complex 5, also known as CORM-3, as shown in Figure 
8.97 An additional advantage of using an amino acid to confer water solubility as a CORM co-
ligand is that glycine is already well-known in biological systems. Although the precise 
mechanism for CO loss from CORM-3 is not known, one of the degradation products of CO loss 





Figure 8: Structure of CORM-3, complex 5. 
It was demonstrated that CO released from CORM-3 is able to mimic the cardioprotective 
properties associated with CO by increasing the resistance of cardiac muscle cells to oxidative 
stress and ischaemia-reperfusion (lack of O2 followed by re-supply of O2, which causes oxidative 
damage).97 Another finding was that CORM-3 improved survival rates of transplanted hearts in a 
mouse model.97 The development of CORM-3, the first water-soluble source of CO, represented 
an enormous opportunity for in vitro studies of the role of CO in biology and the development of 
therapeutics. There is now a large range of published applications for this compound in animal 
models.69 These include improved outcomes in organ transplantation,98,99 reduced injury from 
myocardial infarction,100 treatment of sepsis101, treatment of Pseudomonas aeruginosa 
infections,102 and reduction of inflammation in arthritis.103 Indeed CORM-3 is now commercially 
available from Sigma-Aldrich (catalogue number SML0496).104 
However, purification of CORM-3 has been problematic and raises questions about the reliability 
of its synthesis for therapeutic application. In addition to the bands of CORM-3 (complex 5), the 
infrared spectrum contains metal carbonyl bands at 2137, 2072 and 2058 cm-1 that suggest a facial 
tricarbonyl impurity.105 Further bands at 1985 and 2058 cm-1 (the latter overlapping the 
tricarbonyl impurity) were also observed and suggest that a dicarbonyl impurity is also present.105 
The presence of impurities resulted in a study of the aqueous chemistry of CORM-3.106 A key 
finding of this work was the formation of tricarbonyl complex 6 upon addition of HCl to CORM-
3 (Scheme 5). Complex 6 matches the tricarbonyl impurity typically found in samples of CORM-
3.105 Subsequent loss of the glycine ligand can then take place to form 7. It was also noted that 
CORM-3 underwent nucleophilic attack by water at low pH to produce isomer mixture 9 
consistent with the dicarbonyl impurities observed in CORM-3 samples. Upon increasing the pH, 
two more equilibria were established. These were assigned to deprotonation and ligand exchange, 
although the order of these events was not conclusively assigned due to uncertainly of the 
approximate pKa values in complex 9.106 It is unclear how, and to what extent, the impurities in 
CORM-3 affect the therapeutic effects observed. The equilibria in acidic and basic aqueous 
solutions shown in Scheme 5 makes the preparation of a pure sample of CORM-3 difficult. 
Instead, CORM-3 may be regarded as a mixture of compounds, where complex 5 is accompanied 




Scheme 5: Some aqueous chemistry of CORM-3, complex 5. 
A further point of interest is that CORM-3 only releases around one equivalent of CO to 
myoglobin despite being a tricarbonyl complex. It has been observed that CORM-3 can also 
participate in the water-gas shift reaction, in which CO from the CORM reacts with water to 
produce CO2 and H2 (Equation 1).91 
          H2O + CO ⇌ CO2 + H2                  (Equation 1) 
This reactivity usually requires high temperatures and pressures, but direct detection of CO2 and 
H2 above the headspace of CORM-3 solutions provides evidence of that CORMs can participate 
in similar reactivity.91 Such side-reactions illustrate the importance of directly detecting CO 
release from metal carbonyl complexes, as it cannot be assumed that all CO ligands are lost, nor 
can it be assumed that loss of CO ligands from the metal actually results in release of CO gas. 
Common methods for direct CO detection are discussed in Section 1.3.2.   
Although the aqueous chemistry of CORM-3 must be studied to understand its CO release 
properties, other CO release mechanisms are at work in biological systems. Results published by 
the Bernardes group in 2011 showed that, as well as being a thermal CORM, CORM-3 can react 
with common plasma proteins to product protein-CORM complexes which subsequently 
degrade.91 Figure 9 shows a crystal structure of a protein-CORM complex between lysozyme and 
CORM-3.91 The metal centre remains in the +2 oxidation state but the glycinate, chloride and one 
CO molecule have dissociated. The octahedral complex with the protein comprises two carbonyl 
ligands, three water molecules and a nitrogen lone pair from a histidine residue. One of the 
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carbonyl ligands in Figure 9 is bent – in the crystal structures of CORM binding sites the Ru-C-
O angle ranged from 178° to 139°, the latter of which is unusually low, but not unheard of for a 
terminal metal carbonyl.91 No hypothesis, such as a specific interaction of the carbonyl ligand 
with the surrounding protein, was offered for such a small Ru-C-O angle. This kind of reactivity 
is also thought to have very poor selectivity, as reactions take place with other common plasma 
proteins such as myoglobin and albumin.107 Therefore, in biological systems, the mechanism of 
CO release from CORM-3 may instead involve CO loss from the CORM-protein complex. It was 
later shown in 2015 that the CORM-3 protein complexes can spontaneously release CO. This 
work. shows the importance of understanding CORM behaviour within the complex biological 
systems into which they are to be introduced, since different CO release mechanisms may become 
available. 
  
Figure 9: Crystal structure of the complex formed by CORM-3 and a histidine residue in hen egg 
white lysozyme. Reproduced with permission from T. Santos-Silva, A. Mukhopadhyay, J. D. Seixas, 
G. J. L. Bernardes, C. C. Romão and M. J. Romão, J. Am. Chem. Soc., 2011, 133, 1192–5. 
A disadvantage of ‘thermal’ or ‘solvent-triggered’ CORMs is that CO release begins immediately 
upon mixing with a solvent, as soon as the CORM solution is prepared. This can reduce the 
selectivity of CO release from the CORM. The choice of co-ligands can still provide some 
flexibility for tuning CO release rate, solubility, and the nature of decomposition products. An 
example of how CO release rate can be tuned by co-ligands is the work of Doctorovich and co-
workers, who synthesised a series of Ir(III) tetrachlorocarbonyl CORMs in which they placed 




Figure 10: Thermal CORMs synthesized and tested by Doctorovich and co-workers.92 
The thermal CO release rates to Mb were shown to be independent of Mb concentration, so that 
the kinetics of thermal CO release could be measured. The CO is lost by ligand substitution with 
H2O. Figure 11 shows the broad correlation between the DFT-calculated Ir-CO bond strength and 
the thermal CO release rate in this series of complexes.92 In turn, the Ir-CO bond strength is 
modulated by the trans effect of the ligand L. For example, the protonated DMApy ligand is a 
good π-acceptor ligand, which withdraws electron density from the metal and weakens the Ir-CO 
bond, whereas chloride and hydroxide can only behave as π-donors. However, an associative 
substitution mechanism (i.e. for CO loss is likely due to the negative entropy of activation of the 
reaction92 and the assignment of associative ligand substitution mechanisms to other Ir(III) 
complexes.108 This means that although the M-CO bond is weakened by the strong donor ligand 
trans to CO, the substitution takes place by association of a water molecule to form a 7-coordinate 
intermediate, from which the CO is then lost. Despite the associative mechanism it is clear that 
the properties of the co-ligand L still affect the thermal CO substitution kinetics and can therefore 




Figure 11: Relationship of DFT-calculated Ir-CO bond strength (in kcal/mol) and the observed rate 
constant for CO loss (plotted on a logarithmic scale in units of s-1). The red line was added to show 
the qualitative trend. Reprinted with permission from D. E. Bikiel, E. G. Solveyra, F. Di Salvo, H. M. 
S. Milagre, M. N. Eberlin, R. S. Corrêa, J. Ellena, D. A. Estrin and F. Doctorovich, Inorg. Chem., 
2011, 50, 2334–2345. Copyright 2011 American Chemical Society. 
Numerous other systems have been shown to release CO thermally; a selection of the diverse 




Figure 12: A selection of thermal metal-based CORMs. B12 refers to the cyanocobalamin cofactor. 
Like CORM-3, complex 14 is another CORM-2 derivative, this time incorporating a galactose-
derived co-ligand to help confer water solubility and leave a biocompatible degradation product.94 
The galactose derivative was also part of a design to target asialoglycoprotein receptors in the 
liver to cause accumulation of CO, which was confirmed in mice.94 Only one equivalent of CO 
was released per equivalent of CORM, despite complex 14 being a tricarbonyl, as was the case 
for CORM-3. Complex 14 delivered a therapeutic effect in two models of cerebral malaria.94  
Another thermal CORM incorporating a biocompatible ligand is complex 15, a CORM conjugate 
of the cofactor cyanocobalamin (vitamin B12). The cofactor is bound to a thermal CORM that is 
unstable in water, derived from [NEt4]2[ReBr4(CO)2]. Conjugation takes place via the cyanide 
ligand of the cyanocobalamin. The CO release displayed by complex 15 is induced by substitution 
of CO with water ligands and was observed to be much slower than the parent complex 
[NEt4]2[ReBr4(CO)2]. Again, despite the presence of two carbonyl ligands on complex 15, only 
one equivalent of CO was released to Mb per mole of complex 15 within 2 hours. This molecule 
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has been used in vitro to demonstrate some cardioprotective properties of CO, such as protection 
against ischaemia-reperfusion injury.93  
Release of CO from histidine complex 16 has also been shown to play a therapeutic role in 
ischaemia-reperfusion injury, in neuronal cells, by preventing apoptosis via the p38 MAPK 
pathway.109 This complex also displays thermal CO release and uses a biocompatible co-ligand.43 
The number of equivalents of CO and the in vitro and in vivo toxicity were not published.   
Fairlamb and co-workers synthesised a range of η1 and η4 pyrone complexes that purportedly 
release CO thermally.88,89 Pyrones are known to have their own biological activity, particularly as 
anti-cancer compounds.110,111 The incorporation of ancillary ligands with biological activity of 
their own raises the possibility of multiple modes of action within the same drug, where co-ligands 
liberated after CO release go on to have a further therapeutic effect. Halogen-substituted 
complexes 19c-e showed thermal CO release whereas unsubstituted complexes did not.88 A 
possible explanation for this is that the electron-withdrawing effect causes weaker coordination 
of the CO to the pyrone, though it is not known whether pyrone loss is the initial step in CO 
release. It is important to state that, although the term ‘thermal’ release was used for the pyrone 
complexes no control experiment in the absence of Mb or buffer solution was performed and CO 
release triggered by these species cannot be ruled out. The rate of CO release was slow if any at 
all, with less than one equivalent, and frequently less than 0.1 equivalents, of CO per CORM 
released within 60 minutes in all cases.88,89 
Numerous Co2(CO)6 alkynyl complexes have been shown to have anti-cancer properties, 
including conjugates with nucleosides112 and aspirin.113 The mechanism of the anti-cancer activity 
is unclear but the Co2(CO)6 moiety is required as the alkynyl ligands are inactive on their own. It 
is unclear in these studies whether CO is released. A series of binuclear cobalt alkynyl complexes 
was also synthesised by Fairlamb and co-workers to investigate the CO-release properties of this 
family of compounds.90 The substituents on the alkyne had a dramatic effect on the CO release 
rate. Complex 20b released CO to myoglobin with a few minutes whereas 20c took hours and 
20d-f did not release a detectable amount of CO in two hours.90 Unusually, complex 20a released 
only one equivalent of CO despite the presence of many more CO ligands, whereas 20b was 
shown to release up to three equivalents of CO.90 Unlike with the pyrone complexes, direct 
evidence of thermal CO release was obtained, through experiments in DMSO. Coordination of 
DMSO and CO loss leads to the cleavage of the Co-Co bond and formation of [Co(CO)4]-.90 A 
similar mechanism could be envisaged for water as DMSO is behaving as a 2-electron donor 
ligand. However, many of these complexes displayed poor cytotoxicity results on healthy human 
cell lines, suggesting that their therapeutic use may be limited.90 
Iron CORMs such as 21 and 22 are a popular choice due to the abundance of iron chemistry in 
biology. This can be helpful when considering clearance of CORM-derived by-products after CO 
62 
 
release, although the toxicity of each CORM must be assessed on a case-by-case basis. Complex 
22 has been shown to be a vasorelaxant and releases CO thermally.114 Although 22 can release 
CO in anaerobic media, one of its related derivatives, in which the imine is replace by an amide, 
only releases CO in aerobic media, and an oxo-bridged diiron species was detected as an 
intermediate in the decomposition, showing that O2 can also trigger CO release.114 Complex 21 
comprises an unusual dithiocarbamate ligand to convey water solubility.115 A major advantage is 
that it releases all three equivalents of CO, as each ligand is successively displaced by a water 
molecule.115 However, cytotoxicity studies on RAW 264.7 macrophages showed significant toxic 
effects at tens of micromolar concentrations and no therapeutic applications have been 
demonstrated thus far. 
Finally, a recent innovation with the area of thermal CORMs has been the use of magnetic heating 
to cause CO loss. Janiak and co-workers attached a Ru(II) tricarbonyl thermal CORM complex 
to magnetic maghemite (Fe2O3) nanoparticles using a dihydroxyphenylalanine-derived ligand 23 
(Figure 13).95 In the presence of an alternating magnetic field, localised heating occurs at the 
nanoparticles which is sufficient to increase the rate of solvent-triggered CO release from the 
CORM. In this way, a slow-releasing thermal CORM can be converted into one with a completely 
different CO release profile using a different, controllable, CO release trigger. 
 
Figure 13: Thermal CORM 23 triggered by magnetic heating of maghemite nanoparticles. 
Despite the possibility for selective accumulation in tissues and control of CO release rates, the 
lack of stability in water of thermal CORMs can lower the selective delivery of CO compared to 
a CORM triggered by another mechanism. If a CORM is not stable in water, it is inevitable that 
some CO will be released before the CORM reaches its target. More selectivity can be obtained 
through other CO-release triggers, but numerous thermal CORMs have been shown to have 
therapeutic effects derived from CO release, including in vivo studies.  
1.2.2.3 Enzyme-Triggered CORMs 
A method for gaining more selective CO release is to use CORMs that target enzymes. Such 
CORMs are stable in the presence of air, water and common plasma proteins but can be 
decomposed by enzymes localised in the target tissue or disease site. Such CORMs are described 
as ‘enzyme-triggered’ CORMs, or ET-CORMS.  
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One example of this is the use of acyloxybutadienyl iron carbonyl complexes as a method for 
targeting esterase enzymes, a strategy published in 2011.116 These compounds (Scheme 6) are 
stable in solution as dienylesters, but the corresponding dienol complexes are not stable in water. 
The ester complex 24 can be readily converted into the unstable dienol by the action of esterases 
that cleave specific ester bonds. Following ester hydrolysis, the resulting enol 25 tautomerises to 
the keto form and degrades rapidly to release CO.  
 
Scheme 6: Mechanism of CO release from esterase-targeting ET-CORMs. 
By altering the substitution patterns of a series of acyloxybutadienyl iron carbonyl complexes, 
different esterase enzymes can be targeted (Figure 14). Since different concentrations of esterase 
enzyme can be found in different tissues and disease states, CORMs can be designed with a much 
more specific target in mind. In this work, the ET-CORMs could be designed to be activated by 
pig liver esterase or by a lipase enzyme found in the fungal pathogen Candida rugosa, as shown 
in Figure 14 and Table 1. The release of CO to myoglobin was only observed when the appropriate 
esterase was present, showing that the CORMs are thermally stable and do not degrade upon 
reactivity with the myoglobin itself. As a control, complex 30, which cannot tautomerise to the 
unstable enone form, was not activated by either esterase.  
 
Figure 14: Esterase-triggered ET-CORMs. 
Table 1: Reactivity of ET-CORMs towards two esterase enzymes. 
Enzyme 27a 27b 28 29 30 
Pig liver esterase No No Yes Yes No 




One drawback of this work is that the CORMs are synthesised as a racemate.116 Compelling 
evidence for the esterase-triggered CO release mechanism was obtained in the observation that 
the esterase carries out a kinetic resolution of the racemate. However, administering racemic 
mixtures as therapeutics can be impractical due to the high dosage required and possible 
detrimental effects of the undesired enantiomer, with separation of enantiomers often a 
challenging and expensive process. Furthermore, there could be significant issues with regulatory 
approval of a racemic mixture for therapeutic use. In the case of these compounds, the cytotoxicity 
was also high, with IC50 values for the two CORMS shown above determined to be within the 
tens of micromolar range.116 Nevertheless, when stimulated by an appropriate esterase, this class 
of compounds displayed a striking inhibition of NO production at CORM concentrations as low 
at 5 µM.116 This series of compounds illustrates how modularity within the ancillary ligands of a 
CORM can be exploited to provide targeted CO release.  
The same framework was later (2015) adapted to produce CORMs that are activated by 
proteases;117 increased production of proteases occurs in cardiovascular disease and cancer,118,119 
for which CO may confer therapeutic benefits.43  
 
Scheme 7: Generalised scheme for ET-CORM activation using amide bond cleavage catalyzed by 
proteases.117 
Recently, a similar strategy targeting esterases has been employed for the delivery of 
persulfides.120 Hydrogen sulfide and persulfides are known to play a physiological role and the 
development of persulfide delivery agents will aid research into possible therapeutic applications. 
1.2.2.4 Metal Carbonyl PhotoCORMs 
A very common method of CORM activation is photolysis. Compounds used to release CO upon 
photolysis are termed photoCORMs. Such complexes must be stable in the dark in aqueous 
solution and in biological systems, only releasing CO when irradiation is supplied. This provides 
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selective CO release to a particular area and is especially applicable to surfaces. The vast array of 
compounds developed has been discussed in several recent reviews.66,121–123 Irradiation of metal 
carbonyls initially prepares metal-to-ligand charge transfer (MLCT) excited states in which 
electron density is transferred to carbonyl ligands from the metal 1MLCT(CO). These excited 
states acquire CO-dissociative character by mixing with higher-energy d-d transitions, though the 
ligand field excited states themselves typically lie much higher in energy than the MLCT bands.124 
Further discussion of the photophysical and photochemical processes linked to CO 
photodissociation is provided in Section 2.1, where CO loss from low-energy excited states of 
1MLCT(bpy) character [Cr(bpy)(CO)4] (bpy = bipyridyl) is discussed alongside the 1MLCT(CO) 
states. It is important to study the primary photochemical processes involved in CO dissociation 
in order to understand how photoCORMs can be improved. 
The early examples of photoCORMs were simple homoleptic carbonyls such as Fe(CO)5 and 
Mn2(CO)10. In the same 2002 paper in which they coined the term ‘CORM’ and published the 
thermal releaser CORM-2, Motterlini and co-workers showed that light-induced CO release from 
Mn2(CO)10 resulted in vasodilation in rat hearts, in the first demonstration of a therapeutically 
relevant effect from a photoCORM.86  
Light-triggered loss of CO from many metal carbonyls may be achieved from using UV light.123 
However, CO release wavelengths in the visible region, preferably near-infrared (NIR) light 
represent the most therapeutically useful. This is because UV irradiation has inferior tissue 
penetration125 and can cause tissue damage.126 As a result, it is desirable to increase the CO release 
wavelength of photoCORMs. The choice of metal, oxidation state and ancillary ligands of a 
photoCORM can be used to tune the CO release wavelength. A successful approach taken by 
Mascharak and co-workers was to use π-acceptor co-ligands, which led low-energy CO-
dissociative excited states in a series of Mn(I) tricarbonyls, leading to visible light CO release.127 
This strategy will be discussed in detail in Chapter 4, where a similar method is applied to a 
different family of compounds to tune the CO release wavelength of the compounds in this Thesis. 
Comparable methodologies have been used by other groups (Figure 15). For example, 
Darensbourg and co-workers designed diazabutadiene complex 36, which releases CO at 560 
nm.128 TD-DFT calculations suggested that CO release takes place by population of an MLCT 
excited state in which electron density is transferred from Mn-CO bonding orbitals into the low-
lying imine π* manifold, which confirms that the presence of low-lying vacant orbitals can result 
in a lower-energy CO-dissociative transition.128 However, CO release was not quantified from 




Figure 15: Recent photoCORMs.128–133 
Incorporation of amino acids as biocompatible co-ligands has also been employed, in conjunction 
with Mn(I) tricarbonyl complexes. Histidine (38) and tryptophan (37) have both been used as 
tridentate and bidentate photoCORM co-ligands respectively. Complex 38, prepared by 
Schatzschneider and co-workers released only one equivalent of CO to Mb photochemically with 
365 nm irradiation.129 Complex 37, synthesised by Fairlamb and co-workers, known in the 
literature as TryptoCORM, displayed visible light CO release to Mb at both 400 and 465 nm, 
although only 2.0 and 1.4 equivalents of CO were released from this tricarbonyl complex.130 Low 
cytotoxicity to RAW 264.7 macrophages of both TryptoCORM and its degradation products was 
demonstrated, and light-triggered CO release prevented the growth of E. coli cultures.130 Recently, 
it has been demonstrated that TryptoCORM can also elicit antimicrobial effects in the dark against 
N. gonorrhoeae.131 
Two interesting examples are complexes 39 and 40. Both complexes are thermally stable display 
photochemical CO release to Mb (irradiation above 400 nm), yet neither contains an extended π-
system in the first coordination sphere of the metal carbonyl moiety. These systems show that it 
is possible to tune the CO photodissociation wavelength even in the absence of an unsaturated 
chromophore or π-acid ligand with a low-lying π* orbital. Complex 39, known as CORM-S1, 
released ca. 1.1 equivalents of CO after 15 minutes of continuous irradiation at (470 ± 10) nm 
with a 20 W LED.132 The therapeutic potential of CORM-S1 was demonstrated by showing that 
upon irradiation the released CO activates big-conductance potassium channels, showing that the 
CO-release profile from the CORM is compatible with biological activity.132  
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Westerhausen and co-workers used cysteamine as a sulfur-bridging ligand to produce binuclear 
Mn(I) tricarbonyl complex 40 (CORM-EDE1).133 Cysteamine is produced physiologically from 
the amino acid cysteine which makes it appealing as a biocompatible co-ligand.133 The authors 
proposed the use of frozen aqueous stock solutions for storage and transport, however the complex 
is unstable in the presence of phosphate buffer solution, precipitating MnHPO4.133 One asset of 
this system is that CO release elicited from 365 nm or 470 nm irradiation yielded six equivalents 
of CO per dinuclear complex, which represents an excellent ratio of CO delivery for a relatively 
low molecular weight compound, such that lower concentrations of photoCORM can be used to 
deliver therapeutic doses of CO. The CO released from CORM-EDE1 was also shown to activate 
big-conductance potassium channels.133  
Another approach to achieve visible light CO release is to use a photosensitiser that absorbs a 
longer wavelength of light but induces CO dissociation from a photoCORM. Palladium complex 
41, Figure 16, was used as a photosensitiser to absorb 635 nm red light.134 Such a methodology 
has recently been applied to improve the therapeutic viability of Mn2(CO)10 (42) by increasing 
the CO-release wavelength from UV to red light.134 
 
Figure 16: Photosensitiser complex 41. 
Complex 41 absorbs at a longer wavelength than Mn2(CO)10 and after singlet excitation undergoes 
intersystem crossing to a triplet excited state that lives for hundreds of microseconds. The lifetime 
of this triplet excited state is sufficient for collisional energy transfer between this complex and 





Scheme 8: Principle of photosensitisation to induce CO release. 
The practicality of using a photosensitiser in conjunction with a photoCORM does limit its use as 
both the CORM and photosensitiser need to be localised in the same place and the toxicity of two 
compounds and their by-products must now be considered. Schiller and co-workers addressed 
this problem in their work by incorporating complex 41 and Mn2(CO)10 together in an electrospun 
polymer fabric.134 This CO-releasing system could therefore be incorporated into fabrics such as 
bandages, where the anti-inflammatory and antibacterial properties of CO release could provide 
a beneficial effect. Irradiation with an LED gave good control of CO release depending on the 
power used.134 However, therapeutic effects from such a system are yet to be demonstrated and it 
is unclear whether the formation of degradation products from CO release, such as MnO2, brings 
about any toxicity issues, depending on the toxicity of the compound and how well it is retained 
within the polymer. This would have to be investigated further by monitoring the release of 
complex 41 and any CORM degradation products.  
1.2.2.5 Development of CORM Co-Ligands  
The examples so far have shown how the choice of CORM co-ligands can be used to modulate 
CO release rate, wavelength, water solubility, biocompatibility and drug-like properties. This has 
led to a wide range of CORMs with different properties that are available for further adaptation 
and application. For example, it may be desirable to develop CORMs with slow CO release rates 
(half-lives of tens of minutes to hours) for some applications where the CORM is intended to 
mimic CO production by haem oxygenase enzymes, giving a low-level continuous supply of CO 
rather than a very large and short dose. On the other hand, applications such as antimicrobial 
activity appear to require CORMs with faster CO release rates. 
As the CORMs field has developed over the last fifteen years, the design of the co-ligands around 
CORMs has become an increasingly important consideration.78 This has led to development of 
targeted CORM systems through co-ligand design, moving away from simple broad-spectrum 
complexes like CORM-2 and CORM-3 towards complexes with specific targets and applications. 
Examples of this discussed above have been the localisation of sugar conjugate 14 in the liver and 
the active transport of vitamin B12 conjugate 15 into fibroblast cells. Given the large range of 
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possible therapeutic applications for CO, there is a very broad scope for designing many such 
targeted CORM systems where the co-ligands are optimised for a specific application of CO 
delivery. The modification of the ancillary ligands is part of designing the ‘drug sphere’ of 
CORMs: the outer coordination sphere of the metal, as coined by Romão et al..78 The inner 
coordination sphere of the metal may be used to control the release rate, number equivalents of 
CO released and wavelength of CO release in the case of photoCORMs. However, several of 
these features, as well as the drug-like properties of metal-based CORMs can be designed by 
considering the outer drug sphere, to which medicinal chemistry principles can be applied more 
readily (Figure 17).78 
 
Figure 17: Coordination and drug spheres of a metal-based CORM as coined by Romão et al.. 
The idea of incorporating modularity into drug sphere CORM design has been explored by several 
different research groups. Schatzschneider and co-workers developed a tripodal Mn(I) 
photoCORM 43 so that the co-ligand contained a terminal alkyne, which could be functionalised 
with a Sonogashira coupling or a Cu-catalysed azide-alkyne cycloaddition (CuAAC).135 The 
CuAAC reaction is one of the reactions described by Sharpless as ‘click’ chemistry, a robust 
group of reactions with high functional group tolerance, mild conditions, high yields, and simple 
purification.136 These properties make the CuAAC reaction a highly appealing one for 
synthesising libraries of modular CORMs and to conjugate functional co-ligands into the drug 
sphere. To illustrate this idea, a peptide sequence was incorporated into a CORM to show the 
functional group tolerance of the reactions (Scheme 9). The peptide sequence chosen is part of 
the binding site of a transcription factor with anti-cancer properties. In future it may be possible 
to incorporate biologically active peptide sequences or make biomolecule conjugates so that CO 




Scheme 9: Modular synthesis of CORM-peptide conjugates using Sonogashira and ‘click’ chemistry. 
Fairlamb and co-workers have used a click chemistry approach to incorporate biotin into a Mn(I) 
photoCORM (Scheme 10).137 Biotin is an enzyme cofactor that binds exceptionally strongly to 
the proteins avidin (found in eggs) and streptavidin (produced by some strains of Streptomyces 
bacteria). The dissociation constant for the binding of biotin and avidin is of the order 10-15, 
making this one of the strongest known noncovalent interactions.138 As with Schatzschneider’s 
compounds, the Mn(I) centre in clickable alkyne 46 survives the CuAAC reaction conditions. 
Calorimetry experiments showed that compound 48 was able to bind to streptavidin, albeit less 
strongly than biotin itself.137 With a robust CuAAC reaction and a modular system, other bioactive 




Scheme 10: Conjugation of a Mn photoCORM with biotin using CuAAC.  
Complex 49 (Figure 18) is another CORM conjugate with cobalamin, like thermal CORM 15, but 
this compound is thermally stable and is conjugated through the ribose group of the B12 cofactor 
rather than through the cyanide ligand bound to the cobalt centre.139 In this example, the B12 
conjugate serves not only as a biocompatible co-ligand, but as part of a strategy to increase 
photoCORM uptake in cells. Zobi and co-workers were able to show accumulation of complex 
49 in a single fibroblast cell using infrared microspectroscopy. This technique enables the 
production of images based on the absorption of infrared bands by the metal carbonyls. The results 
showed that thermal cobalamin CORM 15 did not accumulate in cells but photoCORM 49 was 
present in millimolar amounts.139 This suggests that photoCORM 49 was actively transported into 
the cell (it entered the cell against a concentration gradient). Such a strategy opens up the 
possibility of a ‘Trojan horse’ type mechanism for CO delivery analogous to the methodology 
used in siderophore-conjugated antibiotics.140 One idea for the future could be to produce a Trojan 
horse CORM-siderophore conjugate using the modular click chemistry discussed above.  
 
Figure 18: Conjugate of a Mn photoCORM with vitamin B12, where the Co represents the 
cyanocobalamin. 
Another strategy to improve cellular uptake of a CORM is extension of the drug sphere to include 
‘carrier’ systems for CORMs. The iron storage protein ferritin has been used as a CORM ‘carrier’ 
system by Ueno and co-workers to improve uptake into human cell lines.141 Conjugation of 
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CORM-2 with ferritin produced cis-Ru(CO)2 fragments coordinated to multiple binding sites of 
the ferritin. The amino acid residues primarily involved were histidine (N-donor), cysteine (S-
donor) and glutamic acid (O-donor). This behaviour is much like the reactivity observed for 
CORM-3.91 Crystal structures of the bound Ru dicarbonyl fragments identified CORM binding 
sites and mutations to alter the electronic properties of the ligands were used to modulate the CO 
release rate.141 The ferritin conjugates showed slower CO release than CORM-2 itself (different 
mutants ranging from 8 to 18 times slower). This was attributed to the ferritin protecting the Ru 
centre from intracellular donors such as cysteine and glutathione, preventing the ligand 
substitution reactions that lead to thermal CO release.141 A four-fold increase in cellular uptake 
by two human cell lines was also observed when the ferritin conjugate was used. The slower CO 
release and greater cellular uptake led to greater CO-induced activation of the signalling molecule 
nuclear factor κB than CORM-2.141 The ferritin carrier methodology was later extended to 
thermally stable Mn carbonyl complexes that produced a ferritin-caged photoCORM.142 However, 
it is not clear how reproducible the synthesis of these conjugates would be, given the many 
binding sites available for the metal centre; this could affect the reproducibility of the amount and 
rate of CO delivery. Although the use of a large protein as part of a drug presents challenges with 
handling, and toxicity of the degradation products from the Ru fragments have not been well-
characterised, the authors suggest that the main application of this system is to provide CO release 
to biological systems for research into CO biology.142  
Similar strategies have also been applied using other nanoscale structures to deliver CORMs.143 
The glycinate amino acid side-chain in CORM-3 has been derivatised to incorporate 
poly(ethylene glycol) (PEG) units and a hydrophobic side-chain, which leads to formation of 
CORM-3-containing micelles of 30-40 nm in diameter.144 The micelles displayed an enhanced 
anti-inflammatory effect compared to CORM-3 alone.144  
Attachment of CORMs to nanoparticles has also been investigated. Ford and co-workers showed 
how this can be particularly advantageous in the photoCORMs field; nanoparticles can take part 
in ‘upconversion’ of NIR light, absorbing a low-energy photon and emitting a visible light photon 
that can be absorbed by a photoCORM.145 In this case, the photoCORM was encapsulated into a 
polymer matrix surrounding the nanoparticle. However, the use of a NIR laser was required in 
this system and it is unclear whether it would be practical to use such a high intensity of NIR light 
in a biological application. Although the polymer matrix is designed to reduce leaching of 
degradation products and aid solubility and excretion of the nanoparticles, the toxicity of the 
particles in a biological system was not assessed. These issues must be addressed before the 
system can be used as a therapeutic. 
Despite the increasing development of the ‘drug sphere’ in the examples given above, the metal 
centre and its first coordination sphere remain relatively unchanged in most of these examples. It 
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is therefore important to also gain insight into the fundamental chemical processes involved in 
CO release in order to improve the efficiency of these CORMs. 
1.2.3 Metal-Free CORMs 
Although most CORMs are metal carbonyls, a smaller range of metal-free CORMs has also been 
exploited for therapeutic CO release. The first of these was Na2[H3BCO2], known as CORM-A1, 
shown in Scheme 11. 
 
Scheme 11: Carbon monoxide release from CORM-A1, compound 50. 
The rate of CO release from CORM-A1 is pH-dependent, CORM-A1 exhibiting rapid CO release 
to myoglobin under acidic conditions but releasing more slowly at physiological pH; the half-life, 
t1/2 for CO release was 27 minutes at pH 7.4 but only 2 minutes at pH 5.5, both at 37 °C.146 The 
relatively slow CO release from CORM-A1 compared to, for example, CORM-3, which has t1.2 
= 3.6 minutes87 in blood plasma was also reflected in the speed of the physiological response 
achieved: CORM-3 results in rapid vasorelaxation of rat aortas within the first few minutes after 
administration, whereas CORM-A1 had the strongest effect after 33 minutes.146 This observation 
confirms that the development of CORMs with different CO release rates is important for 
controlling the therapeutic effect.  
Many metal-free CORMs rely on the thermodynamic driving force of extrusion of CO from 
organic molecules. The loss of CO from bridged bicyclic systems such as 56 can form 
enthalpically-favourable aromatic products along with the entropically-favourable loss of CO. 
The first application of this in the CORMs field was by Wang and co-workers, who used a “click 
and release” strategy. A Diels-Alder reaction between compound 54 and strained alkyne 55 





Scheme 12: Diels-Alder cycloaddition reaction followed by extrusion of CO as a strategy for CO 
release.147 
However, this is a poor strategy for therapeutic CO release as it relies upon the co-localisation of 
two compounds and the resulting intermediate 56. Furthermore, the use of extended conjugated 
aromatic systems presents a challenge for water solubility; compounds such as 57 would need to 
be solubilised through further derivatisation to add more polar or H-bond donor/acceptor groups. 
It is also desirable to gain more control over the CO release rate. The “click and release” system 
was subsequently modified to involve an intramolecular cycloaddition based on structure 58 
(Scheme 13), which eliminates the issue of co-localisation and provides greater control of CO 
release rate through the linker length and the alkyne substituent, which control the strain and steric 
properties upon forming the intermediate 59.148 In this case the drugs were solubilised by 
conjugation with glucose (R4 in Scheme 13, other R groups are still aromatics). The solubility 
was sufficient to allow the therapeutic effect of this CORM family to be demonstrated using an 
animal model of colitis (inflammation of the intestine). A further advantage of this strategy is the 
formation of extensively conjugated fluorescent products which could be used in the future to 
track and monitor CO release using microscopy and flow cytometry techniques.148 Examples of 
how this has been achieved in other systems is discussed in Section 1.3.3.6.   
 
Scheme 13: General mechanism of the intramolecular ‘click and release’ methodology created by 
Wang and co-workers.148 
An alternative strategy for gaining for control over CO extrusion was published by Larsen and 
co-workers (Scheme 14).149 In this methodology, pro-drugs derived from 61 contain an acidic 
proton and a good leaving group (bromide) such that E1cB elimination takes place to reveal the 
norbornadienone 63 which undergoes extrusion of CO. By controlling the nature of the R groups, 
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and the nature of the leaving group, the kinetics of the rate-determining E1cB elimination can be 
tuned to produce a series of thermal CORMs with different release rates. 
 
Scheme 14: General mechanism for control of CO extrusion from complex 63 through E1cB 
elimination.149 
Another method to control CO extrusion is to perform the reaction photochemically; examples of 
metal-free photoCORMs are structures derived from 65 and 67 (Scheme 15). Complex 65 is 
unusual for a metal-free CORM in that it releases more than one equivalent of CO per molecule 
of pro-drug.150 It was encapsulated by micelles to avoid precipitation of the poorly-soluble 
anthracene product 66, and serves to prevent conversion of the ketones into the corresponding 
hydrates, which do not extrude CO.150 Again, the fluorescence of the photoproducts in Scheme 
15 is of interest for monitoring CORM localisation. 
 
Scheme 15: Two organic photoCORMs with visible light activation. 
Limited mechanistic work has been performed to understand how CO is extruded from these 
compounds. An isotopic labelling study in which the carboxylic acid of compound 67 was labelled 
with 18O, found that the ketone O atom in compound 69 is derived from the carboxylic acid, 
leading to the proposal of unstable intermediate 68.151 The authors assumed that the CO released 
also comprised 18O from the labelled carboxylic acid, but this was not proven. Infrared 
spectroscopy of the headspace above a solution of complex  could have been used to confirm this.  
Mechanistic work on organic photoCORMs represents an underexplored area. The CO release 
wavelengths are in the visible light region of the spectrum, which an improvement on many UV-
triggered metal photoCORMs but is still not as high as the optimal NIR wavelengths desired for 
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therapeutic use. More understanding of the CO release mechanism could lead to further 
improvements in the CO release wavelength through more informed design.  
Metal-free photoCORMs can produce a therapeutic effect from CO release without the production 
of possibly toxic metal-based degradation products. However, the extended π-conjugated 
products formed from CO extrusion must also be tested for solubility and toxicity on their 
individual merits. Furthermore, the metal fragments from metal-based CORMs may have a role 
to play in enhancing the therapeutic effect of CORMs (Section 1.3.1.).   
 Understanding and Designing CORMs 
A number of physiological experiments have been used to show that CO from CORMs has a 
therapeutic effect, including aortic ring relaxation;86 disease models for sepsis,152 bacterial 
infections,102 ischaemia-reperfusion;153 and ion channel activation.132,133 Although these 
experiments can be used to show how CORMs behave in a similar manner to CO, it is clear that 
mechanistic understanding of CO release is also necessary. Mechanistic insight requires direct 
methods to detect CO to establish CO-release profiles from CORMs. It also requires 
characterisation of CORM degradation products and an understanding of their effects on the 
physiological outcomes. In this Section, a case study of CORMs as antimicrobials is discussed to 
introduce the importance CORM degradation products and show how they can be understood. 
This is followed by discussion of and mechanistic tools to study the properties of CORMs and 
their degradation products, including methods to directly detect CO. 
1.3.1 Effects of Metal Fragments – CORMs as Antimicrobials 
The metal fragments derived from CORMs can have a substantial influence on both the toxicity 
profile and the therapeutic effect produced. It is widely recognised that the apparent antimicrobial 
effect of CO delivery from CORMs can be enhanced, or even overshadowed, by effects from the 
metal-based decomposition products.154 An early indication of the striking effect that CORMs can 
have compared to CO gas administration was published by Saraiva and co-workers a decade 
ago.74 The antimicrobial effect of a flux of CO gas (Figure 19) on cultures of E. coli and S. aureus  
was compared to CO release from CORM-2 (Figure 20). The percentage survival of bacteria was 
assessed by the ratio of the number of colonies grown from CO or CORM-treated cultures to 
untreated cultures, and plated serial dilutions were also used to illustrate the difference in survival 




Figure 19 A: Effect of CO gas (15 min/hour) on survival of E. coli and S. aureus under microaerobic 
conditions. B: Plated serial dilutions of cultures after 4h of exposure to CO (+) or N2 (-). Reproduced 
with permission from L. S. Nobre, J. D. Seixas, C. C. Romao and L. M. Saraiva, Antimicrob. Agents 
Chemother., 2007, 51, 4303–4307. Copyright American Society for Microbiology 2007.  
 
Figure 20 A: Effect of CORM-2 on survival rates of E. coli and S. aureus. B: Plated serial dilutions 
of cultures after four hours of exposure to CO (+) or N2 (-) in the presence or absence of Hb. 
Reproduced with permission from L. S. Nobre, J. D. Seixas, C. C. Romao and L. M. Saraiva, 




The results showed that CO delivery from CORM-2 and CORM-3 had a far greater bactericidal 
effect than CO gas. When haemoglobin was added to the cultures to scavenge CO, the bactericidal 
effect of CORM-2 and CORM-3 against S. aureus was lost, confirming that CO release is the 
main cause of the observed antimicrobial effect, perhaps through inhibition of the respiratory 
chain and the production of reactive oxygen species.74 It is difficult to compare how much CO 
gas was actually delivered to the cells from the above experiments, but it is clear that CORMs 
provide a practical, effective method of delivering CO in a way that can elicit a bactericidal effect. 
It is also known that E. coli cultures can survive CO levels close to the saturated concentration in 
water of ~1 mM; delivery from a CORM appears to increase the cytotoxicity.75  
A recent study by Poole and co-workers with CORM-3 has provided some thought-provoking 
results on CORM antimicrobial assays.155 The CO-release profile of a CORM is generally 
determined by a CO scavenger such as Mb in the presence of a reductant (Section 1.3.2.1). But 
antimicrobial assays take place in growth media, which can expediate CORM-3 decomposition 
relative to the Mb assay conditions. As a result, most of the CO release occurs within the first few 
minutes of CORM addition to cultures in Poole’s experimental conditions, but a bactericidal 
effect towards E. coli was still found.155 Since the bactericidal effect of CORM-3 appears to persist 
over a period of hours, the question arises as to how much of a role the CO plays in the cytotoxicity 
in these experiments. It was also observed that the antimicrobial effect of CORM-3 was strongly 
dependent on the growth media employed. Surprisingly, media in which greater antimicrobial 
effects were observed also had some of the lowest levels of CO release.155 This shows that for 
thermal CORMs such as CORM-3, caution must be taken in relating the CO release profile from 
a Mb assay to experiments in a growth medium where the CO release profile could be completely 
different. It was not investigated how the richness of the growth media also affected the 
susceptibility of the bacteria to CORM-3. 
Experiments using NMR spectroscopy showed that the Ru(II) derived from CORM-3 can bind to 
thiols such as cysteine and reduced glutathione.in a 1:1 ratio.155 Addition of amino acids capable 
of complexing the Ru(II) to the growth medium was then shown to alleviate the antimicrobial 
effect of CORM-3 (Figure 21), and mass spectrometric measurement of Ru(II) content showed 
that the antimicrobial activity of CORM-3 correlated with Ru(II) content. Therefore, the 
cytotoxicity of CORM-3 in Poole’s experiments was attributed to the Ru(II) fragment complexing 
thiols and disturbing the redox balance of the cell, an effect that could persist long after the 
released CO had dissipated.155 It was already known that CORM-3 depletes free cellular thiol 
levels,156 presumably due to formation of reactive oxygen species derived from CO inhibition of 
the respiratory chain.157 However, using pre-degraded CORM-3, also known as the iCORM 
(inactive CORM), still caused a smaller but significant depletion in thiol levels, suggesting that 
Ru-derived products also play a role in this effect. It has already been shown that CORM-2 
generates reactive oxygen species (ROS), including as the hydroxyl radical, in cell-free solutions. 
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Metal-derived ROS could therefore play a role in CORM toxicity. Under the same conditions, 
however, the iCORM does not produce ROS, and neither does CORM-2 when haemoglobin is 
used to scavenge CO; formation of ROS may still somehow depend on CO release.157 More work 
is needed to study the formation of ROS from the metal fragments of CORMs to quantify these 
effects and understand how widespread they are within the different families of CORMs.115 
 
Figure 21: Addition of amino acids (arrows indicate the time of addition) protects E. coli from the 
cytotoxic effects of CORM-3. Black circles show no addition, white circles 60 μM CORM only and 
red triangles 60 μM CORM-3 and 120 μM of the amino acid. Adapted with permission from H. M. 
Southam, T. W. Smith, R. L. Lyon, C. Liao, C. R. Trevitt, L. A. Middlemiss, F. L. Cox, J. A. 
Chapman, S. F. El-Khamisy, M. Hippler, M. P. Williamson, P. J. F. Henderson and R. K. Poole, 
Redox Biol., 2018, 18, 114–123.  
The conflicting evidence uncovered in these experiments shows that the effects attributed to 
CORMs must be clearly distinguished from those of CO, because the metal ion and other 
degradation products can often play a role in the cytotoxic effects observed. Such an explanation 
could account for why CORM-2 and CORM-3 are so effective against E. coli cultures, whereas 
near saturation with CO gas can be tolerated.75 However, the toxicity of the Ru(II) fragment from 
CORM-3 towards bacterial cells also affects mammalian cells,155 so that Ru(II) binding to thiols 
is unlikely to provide a therapeutically viable effect in itself. It is still possible that a contribution 
to the antimicrobial effect of CORMs comes from the localised CO delivery from CORMs, which 
exposes the bacteria to higher intracellular concentrations than would be possible with CO gas, 
akin to a ‘Trojan horse’ type mechanism.158 
Strong evidence of antimicrobial activity has recently been obtained for TryptoCORM, complex 
37. Growth curves of the bacteria were monitored by the optical density at 600 nm (OD600) which 
increases with the number of bacteria through scattering and absorbance of the light by the cells. 
Control experiments with E. coli showed that the bacterial cultures grew in the dark in the 
presence of solubilising agent DMSO and that irradiation in the presence of CO has only a small 
effect. When TryptoCORM was added, the bacteria still grew when cultured in the dark, but the 




Figure 22: Antimicrobial effect of TryptoCORM, complex 37, on E. coli. Reproduced with permission 
from J. S. Ward, J. M. Lynam, J. Moir and I. J. S. Fairlamb, Chem. Eur. J., 2014, 20, 15061–15068.130 
TryptoCORM is active against E. coli when CO release is triggered by light, but also displayed 
activity against N. gonorrhoeae in the dark.131 To determine whether the antimicrobial activity of 
TryptoCORM against N. gonorrhoeae was caused by CO, leghaemoglobin (LegHb) was used as 
a CO scavenger in cultures, and it was shown that LegHb protects the bacteria from the effects of 
TryptoCORM.131 Therefore, some CO release from TryptoCORM can take place in the dark in 
bacterial cultures, and this is sufficient to exert an antimicrobial effect. The mechanism of the 
dark CO release is likely to be thermal substitution, but the identiy of the incoming ligand (e.g. 
water, buffer salts, or amino acid side chains) is unknown. It was already known that N. 
gonorrhoeae is one of the most sensitive pathogenic bacteria to CO, and given the development 
of antibiotic-resistant strains of N. gonorrhoeae it is a realistic antimicrobial target for CO. This 
work, along with the previously reported low cytotoxicity to mammalian cells,130 is an example 
of a study that shows that there could be a place for CORMs as antimicrobials. The next stage for 
TryptoCORM would be to study its efficacy in animal models of infection.  
The earlier experiments of Saraiva and co-workers showed that CO can be the primary cause of 
an antimicrobial effect,74 because a CO scavenger alleviates the cytotoxicity, but the work of 
Poole and co-workers shows that extent of this effect can vary under different experimental 
conditions. Metal-based degradation products can sometimes dominate the apparent antimicrobial 
effects. This may be through the coordination thiols and amino acids as discussed above, or other 
mechanisms such as generation of reactive oxygen species by the reaction of O2 or other oxygen 
species with the metal centre. Caution should therefore be exercised when CORMs show an 
antimicrobial effect if the cytotoxicity towards mammalian cells has not been assessed. Thermal 
CORMs that are unstable and degrade in buffer solutions or growth media, such cytotoxicity tests 
must occur under as similar conditions as possible with verification of the CO release profile of 
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the CORM. Control experiments involving the administration of the iCORMs are sometimes 
performed,66 but even these experiments fail to capture all the intermediate species encountered 
during CO release since iCORMs are only the end products of CORM degradation. A clear 
distinction must therefore be made between the biological activity of CO and the biological 
activity of CORMs, and experiments with CORM-2 and CORM-3 must be evaluated carefully in 
light of the toxicity of the metal fragment. 
1.3.2 Methods of CO Detection 
Direct CO detection, to quantify the rate and amount of CO-release, is important to compare 
CORMs and to investigate the mechanisms of their decomposition. It is therefore imperative to 
have accurate, precise, and adaptable methods for the detection of CO. Indirect methods, such as 
measuring the decay of spectral features belonging to CORMs or formation of iCORMs is 
insufficient to demonstrate CO release because CORM degradation can result in side-reactions, 
including CO2 production or CO migratory insertion.91,159 Degradation of a CORM is therefore 
not always indicative of CO release. 
1.3.2.1 Myoglobin Assay 
By far the most commonly-used method to directly detect CO release from CORMs is the 
myoglobin CO-release assay. This assay relies on the coordination of CO released from the 
CORM to deoxy-Mb, which causes a shift of the porphyrin electronic absorptions in the UV-
visible spectrum (Figure 23). Quantification of the CO released can be achieved because the 




Figure 23: Spectral changes upon the binding of CO to deoxy-Mb, forming Mb-CO. The ligand L 
represents a histidine residue to which the haem cofactor is bound. 
The assay relies on the myoglobin to capture all of the CO released. A layer of paraffin oil is 
placed on top of the myoglobin solution to prevent CO escape.160 The concentrations of CORM 
are typically tens of μM, which means that the CO concentration in solution never approaches 
saturated levels (around 1 mM).161 Myoglobin degradation and CO escape mean that the assay is 
not normally continued beyond several hours.160 
Quantification of CO release with myoglobin enables rates of CO release to be measured. 
However, caution should be taken with the fitting of oversimplified rate equations to the data as 
most CORMs contain multiple CO ligands, which will be released at different rates, and 
competing processes that do not release CO may also be taking place. As a result, it is difficult to 
directly relate observed rate constants to those of the fundamental CO release processes of 
interest. To provide a relative comparison for the rate of CO loss of different CORMs, the half-
life, t1/2, for CO release is often quoted.78 The half-life is defined as the time taken for 𝑥 moles of 
a CORM to release 0.5𝑥 moles of CO.78 The value of 𝑥 used can sometimes vary between different 
studies, and it is occasionally found for some compounds that the measured half-life varies with 
the value of 𝑥.162 Despite its limitations the half-life can be a useful comparative tool for 
comparing CO release rates in a series of CORMs. 
One issue with the Mb assay that needs to be addressed is that the CORM being studied may also 
absorb at 540 nm, particularly as there is a drive towards producing visible light-absorbing 
photoCORMs. This can be corrected for using the isosbestic points of deoxy-Mb and Mb-CO to 
fit and subtract the absorbance of the CORM and its degradation products from the measured 
data.160 Therefore, the sensitivity of the method is often limited by the size of the errors in the 




















































isosbestic point correction. Errors in the correction compared to spectra generated from reference 
data are typically below, 1%, so that the method is able to to distinguish concentrations to the 
nearest μM with acceptable precision in a typical assay when concentrations of tens of μM are 
reached. A step-by-step example of the isosbestic point correction is provided in Section 3.4.3.  
Such a correction is not suitable for all CO-releasing molecules, however - poorly soluble 
CORMs, those containing strong absorbing groups, or nanoscale particles that could scatter light 
are all problematic. In such cases, two separate solutions can be used within a sealed vessel: one 
containing the CORM releasing CO and another containing aqueous Mb, such that CO release 
can be detected.86 Henry’s Law constants could be used to measure the total amounts of CO 
released in the sealed system, although this is not used: other tests for CO release are generally 
employed when the UV-visible spectrum of the Mb and CORM in the same solution cannot be 
recorded.85 
Another limitation of the myoglobin assay is that it must be performed under reducing conditions 
because the active site of the as-isolated form of myoglobin contains O2-bound to the iron centre 
to give an Fe3+ superoxide. The oxygen ligand must be removed by reduction of the iron centre 
with sodium dithionite.160 Sodium dithionite produces an anaerobic environment in the assay by 
reducing the oxygen in solution163 (Equations 2 and 3), and the solution is layered with paraffin 
oil to provide a barrier to CO and O2 exchange with the atmosphere, minimising CO escape and 
reaction of deoxy-Mb with O2.  
       S2O42- + 0.5O2 + H2O → 2HSO3-            (Equation 2) 
       S2O42- + 1.5O2 + H2O → 2HSO4-            (Equation 3) 
The use of sodium dithionite as a reductant means that CORMs that react with the reductant could 
appear to release CO when they would be stable in its absence. It is also not possible to separate 
out reactivity of the CORM with the Mb, water or buffer salts. Therefore, the Mb assay cannot be 
used to distinguish between thermal and protein-triggered CO release. An additional consequence 
of sodium dithionite use is that this assay is unable to identify CORMs that are triggered 
selectively by oxidising conditions. It is advantageous to design CORMs that release CO under 
oxidising conditions due to the role of reactive oxygen species in diseases states and oxidative 
stress, yet such activity cannot be tested for using the Mb assay. The assay can, however, be used 
to show stability of a CORM to all of these factors followed by photolytic CO release, and this 
makes the Mb assay a good choice for photoCORM activity.123 However, the CO release kinetics 
are rarely comparable between studies due to different irradiation powers and path lengths being 
used. 
Despite the limitations discussed above, the myoglobin assay remains the most popular method 
of CO detection employed to study CORMs.66 The assay readily provides data on CO release rate 
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and stoichiometry in a way that lends itself to comparison with other CORMs, as long as the 
experimental setup is kept the same. The assay can be adapted to study photoCORMs by 
incorporating irradiation and provides a convenient means of confirming photoCORM stability 
in aqueous buffer solution and in the presence of a protein. The materials required for the assay 
are commercially available, and the equipment needed is commonly found in synthetic chemistry 
laboratories. 
A synthetic Rh complex that binds CO has been developed for assaying CO release in organic 
solvents, in an analogous way to the myoglobin assay.164 For studies of therapeutic or biological 
effects, the CO release profile in water is more relevant. 
1.3.2.2 Electrochemical CO Detection 
Some studies have used electrochemical oxidation of CO to CO2 at an electrode to produce a 
measurable current.146,161 In 2005, a prototype electrochemical CO sensor, similar to a nitric oxide 
(NO) sensor, was used to detect CO release from CORM-A1.146 The sensor contained a gas-
permeable membrane through which the CO released by the CORM diffuses before oxidation 
occurs at the electrode. The membrane prevents solution interferents that may be produced during 
the decomposition of CORM-A1 from also being oxidised and contributing to the measured 
current. However, the selectivity of the electrode for CO over other gases was not discussed, and 
therefore this electrode would therefore be of limited use in a more complex system, such as a 
biological sample. In a biological sample, other gases (including NO) could also diffuse through 
the membrane and reach the electrode surface, where the interferent gas could lead to 
measurement of an increased or decreased current, leading to inaccurate measurement of the CO 
concentration. 
A system with two working electrodes to separately detect CO and NO release both selectively 
and simultaneously.161 Two platinum disk electrodes were used, one of which was modified by 
the electrochemical deposition of tin on the surface, which was shown to provide greater 
selectivity for the oxidation of CO over NO.161 The different sensitivities to CO and NO at each 
electrode enabled accurate determination of CO and NO concentrations.161 This system was tested 
against numerous interferents likely to be present in biological samples: nitrite, ascorbic acid, uric 
acid, acetaminophenone and dopamine did not affect the sensor at concentrations below 500 
μM.161 The selectivity and sensitivity of this system enabled it to be used to detect both CO and 
NO, two key signalling molecules, in biological systems: the sensor was used to detect CO and 
NO levels in live mouse kidney tissue.161 
1.3.2.3 Turn-on Fluorescent Probes 
Palladium dimer 72, a fluorescent probe for CO known as COP-1, has been developed for use in 
microscopy experiments to study localisation of CO in cells.165 Complex 72 constitutes a useful 
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tool for studying the mechanism of CO release in cells, undergoing carbonylation when exposed 
to CO, to fluorescent carboxylic acid 73, which can be used in imaging (Scheme 16). 
 
Scheme 16: Turn-on fluorescent probe for CO detection. 
This probe has been used to image CO released from CORM-3 into live cells from the human cell 
line HEK293T. It can be used to detect the micromolar levels used in typical therapeutic doses of 
CO release and is highly selective for CO over common reactive oxygen, nitrogen and sulfur 
species commonly encountered in biology.165 Another fluorescent probe is known as COSer; this 
is a biosensor which contains CO-binding haem protein CooA and yellow fluorescent protein. 
Upon CO coordination, a conformational change occurs which increases the fluorescence of the 
protein and this system can also sense micromolar concentrations of CO.166 Detection of CO by 
fluorescent probes is an alternative imaging tool to the CORM-based fluorophores discussed in 
Section 1.3.3.6 and Chapter 5 of this Thesis, although this fluorescent CO detection method could 
in itself be incorporated into a CORM drug sphere. 
1.3.2.4 Headspace Analysis 
The release of CO gas can also be detected by analysis of the headspace above the CORM solution 
using a gas-tight cell. Common techniques for this include infrared spectroscopy and gas 
chromatography.167 The very high sensitivity of CO detection by gas chromatography (down to 
0.03 ppm) makes this a suitable technique for very low levels of CO, although therapeutically 
active levels of CO gas are typically of the order of hundreds of ppm so such a low detection limit 
is unlikely to be required.69  
The distinctive fundamental band in the infrared spectrum of gas-phase CO features P and R 
branches from its rotational fine structure and is centred at 2142 cm-1. However, the intensity of 
the bands in gas phase infrared spectra are dependent on pressure due to intermolecular collisions 
which affect the line width. This means that aliquots need to be removed from the headspace 
above the solution, injected into a gas cell under vacuum and re-pressurised with an inert gas to 
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the same pressure each time to ensure consistent readings.167 A calibration curve with known 
quantities of CO can be used to obtain quantitative data. 
These methods have the additional benefit that if the concentration in the headspace can be 
quantified Henry’s Law constants could be used to calculate the solution concentrations of CO. 
However, if the concentration of CO were to get too high this could affect the dissociation of CO 
from the CORM if CO loss is reversible; this is dependent on the CO release mechanism of the 
CORM. 
1.3.3 Mechanistic Tools to Study CORMs 
Monitoring the formation of degradation products spectroscopically does not provide evidence 
that a compound is releasing CO. The techniques described here are to characterise CORM 
degradation products and should be used in conjunction with other experiments that provide direct 
evidence of CO release. This is further complicated by the fact that the Mb CO release assay takes 
place under anaerobic conditions due to the presence of sodium dithionite, whereas many of the 
other techniques described (and biological CO release) take place under aerobic conditions. 
Different kinetics and speciation may therefore appear compared to the myoglobin assay. 
1.3.3.1 Infrared Spectroscopy 
As well as for direct detection of the CO released, infrared spectroscopy may be used as a means 
of understanding the mechanisms of CORM degradation, particularly for metal carbonyl 
photoCORMs. The studies on B12-conjugated CORM 49 also showed that infrared spectroscopy 
can be used as an imaging tool in biological systems.139 
Carbonyl ligands exhibit strong infrared stretching vibrations, the wavenumbers and intensities 
of which are highly sensitive to the electronic environment and symmetry of the metal centre. 
Infrared spectroscopy is therefore very useful for detecting intermediates from CORMs that still 
contain carbonyl ligands. Metal carbonyl photoCORMs typically contain more than one CO 
ligand, yet only release a single CO in their solution photochemistry, leaving the other carbonyls 
as infrared reporter groups. The initial degradation products can therefore be studied with time-
resolved spectroscopy using flash photolysis and pump-probe techniques. In this way, it is 
possible to use infrared spectroscopy to monitor CO release on timescales from picoseconds to 
days, providing insight from the fundamental photochemical steps involved in CO release through 
to the species formed over timescales relevant to biological systems. Ultrafast time-resolved 
infrared (TRIR) studies on photoCORMs will be discussed in detail in Section 2.1.1. 
The assignments of such intermediates can be assisted by theoretical methods such as Density 
Functional Theory (DFT). Although DFT does not account for anharmonicity in vibrations and 
usually requires scaling factors to produce absolute values in line with the experimental 
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wavenumbers,168 the main advantage of DFT is that it enables quantitative prediction of the 
differences in vibrational wavenumber between different compounds.  
One of the disadvantages of infrared spectroscopy is that it is often unable to reveal the final fate 
of the metal fragment if all the CO ligands are released, since the carbonyl ligands are the main 
spectroscopic handle. Furthermore, bubbles of gas and precipitates can form during CO release, 
which can cause problems for in situ measurements, although use of an attenuated total reflectance 
(ATR) geometry can at least partially mitigate this.105 Characterisation of metal carbonyl-
containing solids is often more difficult to interpret compared to the solution phase due to packing 
effects which can alter the number and intensity of the bands. Furthermore, organic solvents or 
D2O must typically be used, as an infrared band for liquid water overlaps with the metal carbonyl 
region from 1800-2200 cm-1.  
1.3.3.2 Magnetic Resonance 
The use of NMR spectroscopy in studying CORM degradation is often limited by the formation 
of degradation products containing paramagnetic metal species, or by precipitation (also a 
problem for most other methods), both of which can affect the homogeneity of the magnetic field 
and lead to poor-quality spectra. Studies on several Mn(I) tricarbonyl photoCORMs by 
Mascharak and co-workers showed the formation of paramagnetic Mn(II) species, confirmed by 
electron paramagnetic resonance (EPR) spectroscopy – the same spectra could be acquired by 
mixing solutions of Mn(II) salts with their CORM co-ligands in buffer solution.73 In one case X-
ray crystal structures of two Mn(II) complexes, 75 and 76, derived from photoCORM 74 were 
solved.169 As the stoichiometry of these reactions is not balanced, it is unclear what happens to 
the remaining Mn ions, but it is clear that the presence of paramagnetic species can be a problem 




Scheme 17: Formation of paramagnetic species 75 and 76 in CORM degradation. 
However, as discussed above, NMR spectroscopy has been used to study CORM-2 and CORM-
3 because the Ru(II) degradation products are diamagnetic, enabling the assignment of the 
mixture of dicarbonyl and tricarbonyl degradation products by NMR spectroscopy.97 Binding 
constants for CORM-3 to reduced glutathione and several amino acids were obtained; the strength 
of this binding was used to account for the cytotoxicity of CORM-3-derived Ru(II) fragments.155 
1.3.3.3 UV-Visible Spectroscopy 
The main use of UV-visible spectroscopy is in the study of photoCORMs, where the absorption 
spectrum of the CORM can be used to determine optimal wavelengths for CO release. The 
interpretation of these spectra is often accompanied by TD-DFT calculations to model the orbital 
components involved in each transition – this helps to determine which transitions are likely to 
be CO dissociative. The absorption bands can then be tuned by co-ligand design.127  
On the ultrafast timescale, transient absorption (TA) spectroscopy is a pump-probe technique that 
can be used to study excited state formation of metal carbonyl complexes by detecting electronic 
absorptions. This has been used to study the photochemistry of many organic and metal carbonyl 
systems,170–175 and provides a complementary spectroscopic technique to the structural 
information from TRIR spectroscopy (or other vibrational spectroscopy such as Raman).176 
However, specifically in the CORM field, the TRIR spectroscopy has been more commonly used 
to study ultrafast photochemistry due to the diagnostic metal carbonyl bands. Ultrafast 
spectroscopic measurements typically require greater amounts of sample due to the requirement 
for a flow system that avoids buildup of degradants in the sample, and the sensitivity may be 
limited, as with other spectroscopic methods, by the difference in absorption between the starting 
materials and products studied. 
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Changes in the electronic absorption spectrum may provide clues as to the nature of the CORM 
decomposition products formed, though little structural information can usually be obtained from 
just the electronic spectrum. Although it can be more difficult to assign the UV-visible bands of 
intermediate species compared to the diagnostic infrared spectroscopic analysis, UV-visible 
spectroscopy can be used in conjunction with other techniques to characterise CORM degradation 
products such as magnetic resonance and infrared spectroscopy; several groups have applied UV-
visible spectroscopy as part of wider mechanistic studies.127,130,177 The loss of UV-visible 
absorption bands of a CORM and formation of intermediates can be monitored spectroscopically 
to provide kinetic profiles of CORM degradation, although care must be taken with comparing 
experiments under different conditions (e.g. different irradiation path lengths in photochemical 
experiments). 
1.3.3.4 Mass Spectrometry 
Mass spectrometry is sometimes used to study CO release mechanisms, usually with ‘soft’ 
ionization techniques to detect charged molecular ions or adducts with cations such as H+. These 
methods can be used to provide proposed structures for intermediates. Removing aliquots from a 
solution of the degrading CORM enables the intermediate species in CO release to be tracked 
over time, usually on the timescale of seconds to minutes. Fairlamb and co-workers previously 
used mass spectrometry to show that CO insertion can occur into a Mn-C bond during degradation 
of the photoCORM family derived from [Mn(ppy)(CO)4] (ppy = 2-phenylpyridyl).159 Side-
reactions such as this account for why non-integer equivalents of CO are sometimes released from 
CORMs. More details are given in the background to the [Mn(ppy)(CO)4] CORM family in 
Section 1.4. 
However, in the absence of standards to calibrate the data these results do not provide quantitative 
information. As a result, it may sometimes be unclear whether the intermediates being observed 
are present in large enough amounts to significantly impact upon the overall CO release 
mechanism. 
1.3.3.5 Quantum Yield 
For photoCORMs, a comparatively useful measurement of the efficiency of CO release is the 
quantum yield for CO photodissociation, Φ, given by equation 4:  
Φ =  
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑝ℎ𝑜𝑡𝑜𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑓𝑜𝑟𝑚𝑒𝑑
𝑀𝑜𝑙𝑒𝑠 𝑜𝑓 𝑝ℎ𝑜𝑡𝑜𝑛𝑠 𝑎𝑏𝑠𝑜𝑟𝑏𝑒𝑑
   Equation 4 
The quantum yield is an important parameter because it facilitates comparison between the 
efficiency of CO release from different photoCORMs. The myoglobin CO release assay does not 
lend itself well to comparison of CO release efficiency because of the different light sources and 
irradiaition powers used in different experiments. Furthermore, the CO release profiles measured 
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in the myoglobin assay may include the thermal release of a second or third CO ligand which 
cannot be distinguished from the photochemical behavior. 
The value of Φ is usually strongly dependent on wavelength because of the changing nature of 
the transitions involved in different absorption bands and overlapping transitions within the same 
spectral features. As a result, a filter or other means of generating monochromatic light must be 
used to ensure that only a narrow region of the absorption spectrum is pumped. The intensity of 
the light is then calibrated using actinometry, where a process with a known quantum yield (such 
as ferrioxalate photoreduction) is studied so that the intensity of the light source can be 
measured.178 
Furthermore, the extinction coefficient of the photoCORM, and whether visible light can be used 
to induce CO loss, are also important considerations when thinking about the efficiency of 
photoCORMs. Measurements of quantum yield are complemented by time-resolved pump-probe 
experiments – such experiments can provide the mechanistic insight into the other ultrafast 
photochemical and photophysical processes occurring when a photoCORM absorbs a photon, 
such as formation of unreactive excited states or dissociation of the non-CO co-ligands. The setup 
required to measure quantum yields is not widely available in all synthetic laboratories, but 
understanding the balance of these processes informs the assessment and design photoCORMs. 
1.3.3.6 Luminescence 
A useful tool for studying CORMs biological systems is the ability to visualize the location of 
CO release at the same time as monitoring release rate. To this end, CORMs with fluorescent tags 
have begun to be developed, along with those displaying ‘turn-on’ luminescence, or changes in 
the wavelength of emission, when CO is released. A particularly fruitful area has been the study 
of  Re(I) tricarbonyl carbonyl polypyridine photoCORMs, which display shifts in luminescence 
wavelength upon CO release, allowing distinction between the intact CORM and the 
photoproducts after irradiation.179,180 One of the first examples of this was the luminescent Re(I) 




Scheme 18: Photochemical CO release from luminescent Re(I) photoCORM 77. 
The photoCORM 77 displayed luminescence with a maximum at 515 nm upon 405 nm 
excitation.181 Upon loss of a CO and coordination of a water molecule, photoproduct 78 formed, 
which was also luminescent but displayed a red-shifted emission. The different luminescence 
profiles of these two molecules enabled monitoring of CO-release inside prostate carcinoma cells 
using confocal fluorescence microscopy (Figure 24). 
 
Figure 24: Confocal fluorescence microscopy images during CO release from photoCORM 77 inside 
cells. Left 465-496 nm emission from photoCORM 77. Right: The same sample after 405 nm 
photolysis showing emission above 660 nm. Adapted with permission from A. E. Pierri, A. Pallaoro, 
G. Wu and P. C. Ford, J. Am. Chem. Soc., 2012, 134, 18197–18200. Copyright, American Chemical 
Society, 2012. 
These results show that complex 77 enters cells intact before releasing CO photochemically inside 
the cells, confirming that this complex is stable to the cell culture conditions and the contents of 
the cytosol.  
The use of luminescence has been extended further: experiments on a similar Re(I) tricarbonyl, 
this time with a benzathiazole-derived co-ligand, showed the same behavior as complex 77 in the 
microscopy experiments, entering the cells before photochemical uncaging of CO.182 Because of 
the change in luminescence wavelength upon CO release, flow cytometry was then used to sort 
cancer cells containing the luminescent CORM based on the extent of CO release. This was used 
to show that the cells that had been exposed to more photochemically released CO displayed 
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increased apoptosis.182 A chitosan-based Re(I) photoCORM has also been imaged in live cells 
and caused apoptosis of colorectal cancer cells.72 
 PhotoCORMs Based on [Mn(ppy)(CO)4]  
The CORMs studied in this Thesis are derived from [Mn(ppy)(CO)4] (ppy = 2-phenylpyridyl), 
complex 79. This Section summarises previous work on this family of compounds. 
The synthesis of [Mn(ppy)(CO)4], via the cyclomanganation of 2-phenylpyridine with 
[BnMn(CO)5], was first reported in 1975 by Bruce and co-workers.183 Based on this reaction, a 
library of complexes based on substituted ppy ligands was envisaged, with the substituents 
providing an opportunity to modulate the CO release and to confer drug-like properties. Recently, 
[Mn(ppy)(CO)4]  and derivatives bearing substituents on the 4' position of the ppy ligand have 
been investigated as photoCORMs (Scheme 19).159,184 
 
Scheme 19: Synthesis of the family of photoCORMs based on [Mn(ppy)(CO)4] and known 
derivatives. 
Derivatives of these complexes have included groups to accommodate further functionalisation 
or improve water solubility. For example, bromide 91 was further functionalised via a Suzuki 
coupling to produce complex 95 (Scheme 20).184 This was made possible using a Buchwald pre-
catalyst that works with only mild heating, avoiding thermal decomposition of solutions of 91 at 




Scheme 20: Reaction scheme for a Suzuki-Miyaura cross-coupling using mild conditions to 
functionalise a photoCORM. 
Compounds in this family are stable in the dark to myoglobin-containing buffer solution, but 
release CO upon irradiation with 365 nm or 400 nm LEDs.159 Exhaustive photolysis in the 
presence of myoglobin led to the release of an average of ca. three equivalents of CO per molecule 
of CORM.184 The extent and rate of release of the complexes appeared to change slightly when 
the substituent on the ppy ligand was changed, although any differences in water solubility of the 
complexes, which are not reflected in the myoglobin CO release assay, could also account for the 
different CO release rates. 
Complexes 92-94 were subsequently tested in cell viability studies.159 The alamarBlue assay was 
used to measure the reduction of a coloured redox indicator by living cells (in this case RAW 
264.7 macrophages from mice), whilst lactate dehydrogenase (LDH) levels were also monitored 
to measure lysis of the cells. The results showed that the cells remained viable at 10 μM for each 
derivative, though compound 92 was highly toxic moving up to 50 μM. Cells exposed to 
complexes 93 and 94 on the other hand, retained good to excellent viability up to 100 μM. These 
two derivatives therefore showed promising results, but the results confirm that the toxicity of 
every photoCORM should be assessed on an individual basis. Following the success of the 
mammalian toxicity studies for complex 94, its antimicrobial properties were also explored, and 
these will be discussed further in Chapter 5. 
Finally, photochemical decomposition products from 400 nm irradiation of 94 were detected in 
an ESI mass spectrometry study (Scheme 21).159 These results must be treated with a degree of 
caution as the experiment was not quantitative and so some of the species may only be minor 
decomposition products, whilst some species may be produced or fragment within the mass 
spectrometer. When a 50:50 H2O:MeCN solution of complex 94 was irradiated, ESI mass spectra 
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suggested that loss of a CO ligand is followed by replacement with MeCN to form tricarbonyl 
species 99. The detection of the protonated form of the substituted ppy ligand, along with 
tricarbonyl complex [Mn(MeCN)3(CO)3]+  indicates that loss of the ppy ligand may take place 
prior to further CO loss. Finally, the observation of carboxylic acid 101 has been attributed to CO 
insertion into the Mn-C bond to the ppy ligand. This is expected to occur through formation of a 
solvent complex such as 99 (S = MeCN or H2O) which blocks the vacant coordination site left by 
CO insertion. Such a side-reaction may help to explain why the tetracarbonyl prodrug releases 
only ca. three equivalents of CO. Other pathways such as the water-gas shift reaction or formation 
of a thermally stable monocarbonyl unreactive at the irradiation wavelength chosen could also 
explain why four equivalents of CO are not released, although no evidence was obtained for these 
alternatives in this preliminary study. Another hypothesis is that the final equivalent of CO is 
either not released or is released in a way that is not captured by the myoglobin assay. For 
example, the timescale of the myoglobin assay is restricted to several hours because of CO escape 
and myoglobin degradation and slower release would not be detected in a typical assay.160 
 
Scheme 21: Species observed by mass spectrometry in a photochemical study by Fairlamb and co-
workers.159 
Although this preliminary study provides some understanding of the decomposition pathways of 
the [Mn(ppy)(CO)4] family of photoCORMs, the photoproducts on the ultrafast timescale have 
not been elucidated. Understanding and controlling the primary photochemical and photophysical 
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properties of these compounds will enable the evaluation of these complexes as photoCORMs 
and can then be used to inform the design of more efficient targets.  
 Aims and Objectives 
Despite its well-known toxicity, the role of CO in biology is still not understood. One thing is 
clear: CO plays a role in cell signalling in mammalian cells, both healthy and diseased. The 
therapeutic potential of CO is clear but its administration is challenging. The development of 
CORMs as a delivery method for CO over the last 15 years has resulted in some key 
considerations for CORM design. Ideally, CORMs should be stable to ambient conditions for 
storage and transport but release a well-defined dose of CO upon exposure to a selective trigger. 
In the case of photoCORMs, visible or NIR light is preferable and CO release should be the main 
photoproduct (i.e. the quantum yield is high). Both the CORM itself and its degradation products 
need to be well-characterised and their toxicity, absorption, distribution, metabolism and 
excretion should be studied. Finally, tailored co-ligands should be incorporated to provide more 
than a scaffold for CO release. Depending on the purpose of the CORM, this could include 
modulation of CO release rate/wavelength, inclusion of a fluorophore for imaging, or a 
bioconjugate or drug molecule for a second therapeutic mode of action. 
A range of mechanistic tools is available to capture CO release from CORMs, but just as important 
is understanding the nature of the degraded CORM fragments, as these can have substantial 
effects in biological systems. For photoCORMs, it is important to understand the fundamental 
photochemical steps involved in CO release so that more efficient, visible light-releasing 
compounds can be designed. 
The aims and objectives of the work in this Thesis are: 
• Study the photochemical CO release properties and degradation mechanisms of 
[Mn(ppy)(CO)4] and derivatives (Chapter 2). 
o Use time-resolved infrared (TRIR) spectroscopy to study the ultrafast 
photoproducts of MLCT excitation interpretation and understand the subsequent 
reactivity of the photoproducts (picoseconds to microseconds).  
o Interpret DFT calculations to help assign the species involved in the TRIR 
experiments. 
o Use in situ infrared spectroscopy to study the decomposition of [Mn(ppy)(CO)4] 




• Synthesise, characterise, and assess redox-tagged CORMs based on [Mn(ppy)(CO)4]. 
(Chapter 3). 
o Synthesise and characterise CORMs containing ferrocenyl co-ligands with 
different linker lengths between the Mn and Fe centres. 
o Study the electrochemical behaviour of the ferrocenyl CORM complexes with 
cyclic voltammetry and infrared spectroelectrochemistry. 
o Investigate the CO release properties of the complexes using in situ infrared and 
UV-visible spectroscopies and the Mb CO-release assay. 
 
• Investigate and evaluate a method of increasing the wavelength of CO release of Mn(I) 
tetracarbonyl CORMs further into the visible region. The redox properties of these 
complexes will also be studied (Chapter 4). 
o Synthesise a series of Mn(I) tetracarbonyl complexes with azo co-ligands, 
o Assess the photochemical CO release wavelengths using the Mb assay. 
o Perform a spectroelectrochemical study to test for redox-triggered CO release. 
 
• Synthesise a fluorescent [Mn(ppy)(CO)4] derivative for imaging in live cells, with a view 
to assessing its antimicrobial properties (Chapter 5). 
o Synthesise and characterise a fluorophore-tagged derivative of [Mn(ppy)(CO)4] 
using a click chemistry methodology. 
o Study the CO release properties of the fluorophore-tagged complex. 
o Image the complex in a human cell line. 




2 Ultrafast Time-Resolved Infrared Spectroscopy of 
[Mn(ppy)(CO)4] 
One of the main methods for initiating CO loss from CORMs is through photolysis (Section 
1.2.2.4). Absorption of a photon by a metal carbonyl photoCORM initiates ultrafast photophysical 
and photochemical behaviour, such as formation of electronically excited states and CO 
dissociation.124 Studying these ultrafast processes and the subsequent evolution of the 
photoproducts allows the photochemical properties, reactivity and CO release mechanisms of 
these compounds to be mapped, which is a requirement to inform the design of more efficient 
photoCORMs.  
In this Chapter, the use of ultrafast Time-Resolved Infrared (TRIR) spectroscopy to study the 
photochemistry of the photoCORM [Mn(ppy)(CO)4] (ppy = 2-phenylpyridyl) (complex 88) is 
described. Changes in the infrared stretching frequencies of the carbonyl ligands of the 
photoproducts provide structural information about the photoproducts formed, supported by DFT 
calculations. The results reveal that the qualitative balance between photodissociation and non-
dissociative triplet excited state formation is markedly different to the well-studied isoelectronic 
[Cr(bpy)(CO)4] (bpy = bipyridyl) system. Complex 88 is subsequently demonstrated as a useful 
model system for studying metal-solvent interactions following CO photolysis. 
All TRIR data were obtained at the Central Laser Facility (CLF) of the Rutherford Appleton 
Laboratory. Experiments were enabled by the assistance of Dr Ian Clark, Dr Igor Sazanovich and 
Professor Michael Towrie. All DFT calculations reported in this Chapter were performed by Dr 
Jason Lynam. 
2.1 Background 
2.1.1 Ultrafast TRIR Studies of PhotoCORMs  
The key primary photochemical reactions of metal carbonyls often take place within 
femtoseconds to nanoseconds after the absorption of a photon.124 Therefore, ultrafast 
spectroscopic techniques are powerful tools for investigating metal carbonyl photochemistry 
because they provide direct structural characterisation of the primary photoproducts whilst also 
enabling the evolution of the photoproducts to be monitored.  
Ultrafast spectroscopic experiments typically involve a ‘pump-probe’ approach, in which an 
initial ‘pump’ pulse prompts a photochemical behaviour of interest and a subsequent ‘probe’ pulse 
is used to characterise the resulting products. Transient absorption (TA) spectroscopy, where 
photoproducts are characterised by a UV-visible probe pulse, and time-resolved infrared (TRIR) 
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spectroscopy, where an infrared probe is used, are often chosen to study metal carbonyl 
complexes.124 The latter of these is particularly useful for structural characterisation because of 
the high sensitivity of carbonyl stretching frequencies to their electronic environment. These 
techniques, in conjunction with insight from theoretical calculations, have been used to 
characterise metal carbonyls comprising a range of metal and co-ligand combinations in the gas 
phase and in solution.124,176,186,187  
The photochemistry of simple early photoCORMs, such as Mn2(CO)10, was already well-
characterised before their therapeutic relevance was demonstrated. The primary ultrafast 
photochemical reactivity of Mn2(CO)10 was studied both in the gas phase and a range of solvents 
(including alkanes and alcohols) using traditional flash photolysis experiments,188 ultrafast TA 
spectroscopy,171,189 and ultrafast mass spectrometry.170 This work revealed competing ultrafast 
pathways: Mn-Mn bond homolysis to form two Mn(CO)5 radicals, and CO loss to form 
Mn2(CO)9.170 Ultrafast TRIR spectroscopy was subsequently applied to study the 310 nm 
photolysis of Mn2(CO)10 in cyclohexane,190 providing the structural information to confirm that 
CO loss and Mn-Mn bond homolysis compete on the ultrafast timescale. 
In one of the first ultrafast photochemical studies of a purpose-designed photoCORM, the groups 
of Nuernberger and Schatzschneider studied CO dissociation from the Mn(I) tricarbonyl species 
[Mn(tpm)(CO)3][PF6] (tpm = Tris(2-pyrazolyl)methane) (103) in D2O on the picosecond 
timescale with TRIR spectroscopy.191 Photochemical loss (at 264 or 347 nm) of one carbonyl 
ligand followed by D2O solvent coordination to form [Mn(tpm)(CO)2(OD2)]+ was the major 
photochemical process observed; this took place within the first few picoseconds after photolysis 
(Scheme 22).  
 
Scheme 22: The CO-release process from tpm complex 103 studied by TRIR spectroscopy. 
The infrared spectrum of the remaining carbonyl ligands of the photoproduct initially appeared 
broad. This broadness is due to vibrational excitation of the photoproduct which accompanies 
electronic excitation. Nuernberger and co-workers concluded that the vibrational energy does not 
cause excitation of the CO stretches themselves – if this were the case the photoproduct bands 
would move by much more than a few wavenumbers, as observed in the hot bands after photolysis 
of [M(CO)6] (M = Cr, Mo, W).192 Therefore in [Mn(tpm)(CO)3]+, the vibrational excitation 
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involves low-frequency vibrations that couple to the CO stretches to give the broadening of the 
carbonyl bands. The bands sharpened over the first few tens of picoseconds, representing the 
vibrational relaxation or ‘cooling’ of the photoproduct as energy is transferred away by collisions 
with the solvent. Vibrational relaxation is also accompanied by a small shift of the bands to higher 
wavenumber due to a slight strengthening and shortening of bonds in the ground vibrational state. 
Geminate recombination of CO with the [Mn(tpm)(CO)2]+ fragment was also observed.191 
Although this process took place faster than the ps time resolution of these experiments, its effect 
could still be observed in the ground state bleach bands. The slight recovery of the bleach bands 
on the ps timescale reflects the vibrational relaxation of [Mn(tpm)(CO)3]+ following geminate 
recombination within 1 ps. Rapid geminate recombination of this kind has been further studied in 
other systems such as the group 6 homoleptic carbonyls.193 
Another notable feature of this work was that two successive UV laser pulses (the first pump 
pulse followed by a ‘re-pump’ pulse at the same wavelength 200 ps later) did not initiate further 
photochemical degradation of the photoproduct.191 This observation led the authors to invoke 
previous work suggesting that subsequent photoCORM decomposition is non-photochemical and 
involves oxidation of the Mn.191 Although the absorption spectra of the photoproducts were not 
known, and so specific CO-dissociative transitions were not targeted in the ‘re-pump’ experiment, 
this work shows how TRIR spectroscopy can be adapted for use in mechanistic studies of 
photoCORMs. 
In another study, Pryce and co-workers used ultrafast TRIR spectroscopy to characterise the 
photochemistry of the chromium amino carbene complex [Cr(CO)5C(NC4H4)(Me)] 105.194 In this 
system, photoproduct bands assigned to an excited state appear within the first 3 ps after 400 nm 
laser photolysis in n-heptane. The bands for the excited state are replaced by those of a second set 
species over ca. 50 ps. This species was identified as the solvated complex 106, in which a heptane 
solvent molecule is weakly bound to the coordination site vacated by one of the CO ligands 
(Scheme 23). The replacement of CO with a solvent molecule on the picosecond timescale is 
consistent with theoretical calculations predicting a small energy barrier to CO loss in the CO-
dissociative excited state.  
The related complex [Cr(CO)5C(OMe)(Me)] (107) displays similar behaviour upon photolysis at 
320 nm. However, this complex does not always lose a CO ligand to form a solvent complex. 
Instead, a metallaketene species is formed upon 400 nm excitation.195 For chromium, this was 
proposed to occur through excitation to a singlet state, though in the analogous tungsten complex 





Scheme 23: Photochemical behavior of two chromium carbene CO-releasing molecules as 
determined by TRIR spectroscopy.194,195 
Harris and co-workers used ultrafast TRIR spectroscopy when investigating the behaviour of 
CORM-2 derivatives (Scheme 24).196 Since CORM-2 degrades when solubilised in dimethyl 
sulfoxide (DMSO), a solution of pre-degraded CORM-2 featuring the two DMSO complexes 3 
and 4 in approximately 3:2 ratio was analysed. The dominant photoproduct in the infrared 
spectrum after 1.7 ns was assigned as the monocarbonyl species 111 on the basis DFT predictions. 
This suggests that the first step in the photochemical degradation of these complexes, as many of 
the other systems discussed above, is CO-loss. 
 
Scheme 24: CORM-2 degrades in DMSO solution but further CO release can be prompted 
photochemically. Harris and co-workers used TRIR spectroscopy to show that degradation products 
3 and 4 lose a CO ligand on the ultrafast timescale.196 
The use of TRIR spectroscopy in the photoCORM field has revealed the primary photochemical 
behaviour of several classes of photoCORMs. The first step in the degradation of the complexes 
discussed above was CO-loss followed by solvation, which takes place in competition with 
formation of other excited states and vibrational relaxation. As the results of the studies above 
show, loss of CO is commonly the dominant photochemical pathway in metal carbonyl 
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photochemistry. However, this behaviour is not universal: the reaction or loss of co-ligands and 
formation of non-dissociative excited states can dominate in other complexes.124 
2.1.2 Photochemistry of [Cr(bpy)(CO)4] 
Although relatively little is known about the photochemistry of [Mn(ppy)(CO)4], the isoelectronic 
complex [Cr(bpy)(CO)4] (bpy = 2,2'-bipyridyl), 112 has been extensively studied and may 
provide an informative comparison. Ultrafast TRIR and TA spectroscopies and theoretical 
calculations have been used to understand the photochemistry of 112 and this system represents 
an interesting balance between the formation of non-dissociative excited states and CO loss.197  
According to quantum mechanical calculations by Daniel and co-workers, the three highest 
occupied molecular orbitals in [Cr(bpy)(CO)4] are metal-based, arising from three of the Cr 3d 
atomic orbitals, while the three lowest-energy unoccupied molecular orbitals are ligand-based and 
have bpy π*bpy character.198 As a result, the lowest-energy spin and symmetry-allowed transitions 
in [Cr(bpy)(CO)4] produce singlet metal-to-ligand charge transfer (MLCT) states.198 This leads to 
a broad, solvatochromic band of MLCT(bpy) absorptions in the visible part of the electronic 
absorption spectrum with a maximum at around 500 nm.199 Transitions of a 1MLCT(CO) nature, 
from the Cr 3d orbitals into the π*CO orbitals, were calculated to be weaker and slightly higher in 
energy (bordering the UV region) than the 1MLCT(bpy) states.198 
Ultrafast TA and TRIR spectroscopy studies by Vlček and co-workers have characterised the 
photoproducts that arise from the different types of MLCT transitions. The major photochemical 
pathway in [Cr(bpy)(CO)4] produces two non-dissociative excited states.200 Irradiation of the low-
energy bands produces two 3MLCT states within 1 ps, which dominate the TRIR spectra for the 
first tens to hundreds of picoseconds before decaying to the ground state, as indicated by recovery 
of the bleached ground state bands.200 The 3MLCT states were found to have lifetimes of 
τ1 = 8 ± 3 ps and τ2 = 76 ± 7ps in CH2Cl2 solution with 400 nm excitation.200 Since direct 
transitions to triplet excited states break the spin selection rule and are therefore extremely weak, 
the 3MLCT states observed are formed through intersystem crossing following initial excitation 
to the low-energy 1MLCT(bpy) states. A recent TA spectroscopy study by Yartsev and co-
workers showed that intersystem crossing took place within around 100 fs, with sequential 
population of the short-lived 3MLCT state followed by the second longer-lived, lower-energy 
3MLCT state.175 
Excitation to the low-energy 1MLCT(bpy) states also results in some CO dissociation as a minor 
photochemical pathway.200–202 Loss of CO leads to sub-picosecond formation of solvent 
complexes of the form fac-[Cr(bpy)(S)(CO)3] (S = CH2Cl2 or pyridine).200 Daniel and co-workers 
calculated that the low-energy 1MLCT(bpy) excited states are very weakly bound along the axial 
Cr-CO coordinate with only a small barrier to CO loss.203 At longer Cr-CO bond lengths there is 
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an avoided crossing between the 1MLCT(bpy) excited states and d-d excited states of the same 
symmetry, resulting in the mixing of some d-d transition character with the 1MLCT(bpy) states.203 
Wavepacket dynamics simulations for [Cr(bpy)(CO)4] along the axial Cr-CO coordinate 
predicted excitation of the wavepacket onto the repulsive part of the 1MLCT(bpy) potential due 
to the longer equilibrium bond length in the excited state. This led to the prediction of complete 
photodissociation within 600 fs, in good agreement with the experimentally-observed timescale 
of CO loss.203 
Although the potential energy surfaces for the slightly higher-energy 1MLCT(CO) excited states 
were not calculated, calculations on the isoelectronic complex [W(en)(CO)4] (en = 1,2-
diaminoethane) show that the lowest-energy 1MLCT(CO) comprises charge transfer from the 
metal and equatorial carbonyls [the Cr(COeq)2 moiety] to the axial carbonyls [COax].204 The lack 
of π-acceptor ability makes this the lowest-energy excited state in[W(en)(CO)4].   
The behaviour of the 1MLCT(CO) and 1MLCT(bpy) can be compared by examining the 
wavelength-dependence of [Cr(bpy)(CO)4] photochemistry. In CH2Cl2 at an excitation 
wavelength of 500 nm, only the 1MLCT(bpy) states are populated, whereas at 400 nm both 
1MLCT(bpy) and 1MLCT(CO) transitions take place.200 Upon moving from 518 nm to 419 nm, 
the quantum yield for photodissociation increases approximately threefold from 3.83 × 10-2 to 
1.07 × 10-1.202 The 3MLCT states are still the major photoproducts. This suggests that the 
1MLCT(CO) states of [Cr(bpy(CO)4] behave in a similar manner to 1MLCT(bpy) but that the 
1MLCT(CO) states result in more CO loss and less 3MLCT formation compared to 1MLCT(bpy) 




Figure 25: Schematic of key excited states in the photochemistry of [Cr(bpy)(CO)4], updated 
from the summary by Vlček and co-workers200 to reflect sequential population of the 
3MLCT states.175  
The same rationale for the dissociative nature of 1MLCT(CO) states is used as was described 
above for the 1MLCT(bpy) states.205 Calculations on [Cr(CO)6] predict low-energy 1MLCT(CO) 
excited states that are CO dissociative: axial elongation of M-CO bonds in leads to mixing with 
higher-energy dissociative d-d states, resulting in photodissociation from initial population of the 
MLCT(CO) state.172,206–208  
In contrast to [Cr(bpy)(CO)4], most other metal carbonyl complexes do not possess low-lying 
vacant orbitals from α-diimine co-ligands such as bpy, and as such the lowest-energy excited 
states are the 1MLCT(CO) states.199 The unoccupied d-orbitals are again much higher in energy 
than the CO ligand-based orbitals. As a result, in most metal carbonyl complexes CO loss from 
1MLCT(CO) excited states on the sub-ps timescale is the major photochemical pathway,209 as was 
the case for the photoCORM examples in Section 2.1.1. It is the presence of the low-lying bpy-
based unoccupied orbitals that dictates the different photochemical behaviour of [Cr(bpy)(CO)4]. 
The 1MLCT(bpy) absorbances, with a lower quantum yield for CO dissociation,200 compete with 
the 1MLCT(CO) states, and both types of excitations can lead to ‘trapping’ in unreactive 3MLCT 
1MLCT(bpy)
3MLCT τ = 76 ± 7 ps 







states. Thus, the example of [Cr(bpy)(CO)4] shows that the nature of the co-ligand can be hugely 
influential on the photochemical pathways observed when designing photoCORMs.  
2.1.3 Time-Resolved Multiple Probe Spectroscopy (TRMPS)  
The TRIR spectroscopy method used in this Chapter is Time-Resolved Multiple Probe 
Spectroscopy (TRMPS). Using TRMPS, it is possible to study processes from sub-picosecond to 
millisecond timescales on the same spectrometer in a single experiment.210 
In the study of [Mn(ppy)(CO)4], a UV pump pulse must be used to excite the CO dissociative 
transition(s), because CO loss is known to take place at 365 and 400 nm. An infrared probe pulse 
then records the infrared spectrum of the photoproducts after the chosen delays. The time 
resolution is limited by the length of the pulses; in this work pump pulses of 100 fs duration and 
probe pulses of 50 fs were used. 
Unlike a typical ‘pump-probe’ experiment, TRMPS uses a ‘pump-probe-probe-probe…’ sequence 
(Scheme 25).210 The pump and probe lasers have different repetition rates such that multiple probe 
pulses (every 100 s) occur in between each pump pulse (every 1 ms), providing a succession of 
ten infrared pulses after each pump pulse. This is useful for obtaining a series of relatively long 
delays. Further delays between the pump and probe lasers are achieved with either an optical 
delay line (ps to ns delays) or a combination of optical and electronic delays (ns to s delays).210  
 
Scheme 25: Illustration of the sequence of laser pulses in a TRMPS experiment.210 
A schematic of the TRMPS setup is shown in (Scheme 26). The wavelength of the laser pulse is 
tuned using an optical parametric amplifier (OPA). The timing of the UV pump pulse is controlled 
using the optical and electronic delays before passing through the sample. The sample must be 
flowed and rastered to prevent a build-up of photoproducts in the cell. The infrared probe beam 
is split into two beams: one beam passes through the sample and the other is diverted to a reference 
detector. Subtraction of the reference detector readings from the data provides a way of correcting 
1 kHz UV pump






data for shot-to-shot variation in the laser pulse intensities. The resulting spectra are typically 
presented as difference spectra with respect to the last spectrum in the ten-probe pulse sequence. 
 
Scheme 26: Schematic representation of the setup used in TRMPS.210 
In summary, a wide range of timescales can be investigated using TRMPS, allowing the both the 
structural information about the primary photoproducts, and information about their subsequent 
reactivity to be studied. The method used to collect the data in this Chapter and details of the 
subsequent data processing are discussed in more depth in the experimental section (Section 7.1). 
2.2 Spectroscopic Characterisation of [Mn(ppy)(CO)4] 
Before reporting the results of the TRMPS experiments, it is necessary to introduce and discuss 
the vibrational and electronic spectroscopic characterisation of [Mn(ppy)(CO)4]. 
The number and symmetry of carbonyl ligands at a metal centre can be determined using 
vibrational spectroscopy and group theory: this combination will also be used later to aid the 
assignment of photoproducts.  
Experimental UV-visible spectra, combined with DFT calculations, will be used to understand 
the electronic transitions in [Mn(ppy)(CO)4]. This provides insight into the nature of the low-
energy electronic transitions to be probed in the TRIR experiments and facilitates comparison 
with other metal carbonyl systems. 
2.2.1 Ground State Infrared Spectrum of [Mn(ppy)(CO)4] (88) 
Four metal carbonyl stretching bands183 are observed in the ground-state infrared spectrum of 
[Mn(ppy)(CO)4] 88: in MeCN these are at 1933, 1976 (shoulder), 1989 and 2076 cm-1. The 





















Figure 26: Infrared spectrum of [Mn(ppy)(CO)4] in MeCN, recorded at 2 cm-1 resolution. 
Assignments based on vibrational analyses of analogous cis-[ML2(CO)4] complexes.211 
The appearance of the spectrum can be compared with a group theoretical vibrational analysis 
that predicts the number of infrared-active C≡O stretching bands. The point group of 
[Mn(ppy)(CO)4] is Cs, though the molecule may also be considered to possess pseudo-C2v 
symmetry if the differences in masses, bond lengths and angles for the C and N atoms of the ppy 
ligand are taken to be small. The C2v point group contains the two elements in Cs [the identity E 
and mirror plane σ(yz)], plus two more: a C2 axis and σ(yz) in which the C and N atoms of the 




Figure 27: Symmetry elements (excluding the idenity) of the C2v point group superimposed on 
complex [Mn(ppy)(CO)4]. The Cs point group features only the identity and σ(yz) symmetry elements. 
This molecule may be considered to have Cs or pseudo-C2v symmetry.  
 
Using vectors pointing in the directions of the four carbonyl ligands as a basis set in the Cs point 
group, the reducible representation Гvib(CO) in the bottom row of Table 2 is obtained.  
Table 2: Character table of the Cs point group showing the reducible representation of the carbonyl 
ligands of [Mn(ppy)(CO)4] underneath. 
Cs E σh Linear Functions 
A' 1 1 x, y 
A'' 1 -1 z 
Гvib(CO) 4 2  
Inspection of the character table shows that the reducible representation comprises 3A' + A''. Only 
vibrational modes that transform in the same way as the linear (x,y or z) functions can be infrared-
active, as they transform in the same way as the electric dipole moment operator. Since in this 
case the linear functions can transform as either of the two non-degenerate irreducible 
representations in the group, all four vibrational modes are predicted to be infrared-active.  
An analysis using the pseudo-C2v point group also predicts four bands. The reducible 
representation is shown with the character table in Table 3. Inspection of the character table for 
the C2v point group reveals that the M-CO bond basis set spans the irreducible representations 
2A1 + B1 + B2. As the linear functions transform as either A1, B1, or B2, all four of the stretching 
modes are again predicted to be infrared-active.  
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Table 3: Character table of the C2v point group showing the reducible representation of the carbonyl 
ligands of [Mn(ppy)(CO)4] underneath. 
C2v E C2 σ(xz) σ(yz) Linear Functions 
A1 1 1 1 1 z 
A2 1 1 -1 -1  
B1 1 -1 1 -1 x 
B2 1 -1 -1 1 y 
Гvib(CO) 4 0 2 2  
Assignment of the observed bands to each symmetry mode, as shown above in Figure 26, may be 
made based on analyses of other cis-[ML2(CO)4] complexes.211 For example, the infrared 
spectrum of [Cr(bpy)(CO)4], which is isoelectronic to [Mn(ppy)(CO)4]  and is C2v symmetric, 
displays the same intensity pattern as [Mn(ppy)(CO)4].212 The B1 mode involves the asymmetric 
stretch of the mutually trans carbonyl ligands, whilst the B2 mode comprises the asymmetric 
stretch of the two mutually cis carbonyls in the plane of the ppy ligand. This ordering is consistent 
with the expectation of higher force constants for a carbonyl trans to a strong π-acceptor.211 The 
two A1 modes involve totally symmetric vibrations comprising the symmetric stretches of the two 
carbonyls in the plane of the ppy ligand (of lower wavenumber and higher intensity) and the 
mutually trans carbonyl ligands (the weak, high-wavenumber band). As these two modes are of 
the same symmetry, there could also be some mixing between them. A visualisation of the 
vibrational modes is shown in  
 
Figure 28: Visualisation of the vibrational modes for [Mn(ppy)(CO)4]. Normal modes of the same 




2.2.2 Electronic transitions of [Mn(ppy)(CO)4] 
A series of UV-visible absorption spectra of [Mn(ppy)(CO)4] at a range of concentrations in 
acetonitrile are shown in Figure 29. The most intense absorption [λmax = 230 nm,  = 
(2.56 ± 0.08) × 104 dm3 mol-1 cm-1] is assigned to ligand-based π-π* transitions on the ppy ligand.  
 
Figure 29: UV-visible spectra of [Mn(ppy)(CO)4] in acetonitrile at low concentrations to show the 
intense π-π* ppy transitions. Left: Spectra at the concentrations shown. Right: Beer-Lambert plot 
with linear fit giving (230 nm) = (2.56 ± 0.08) × 104 dm3 mol-1 cm-1. 
However, since photochemical CO release takes place at 400 and 365 nm,159,184 it is excitation of 
the lower-energy shoulder, assigned to CO-dissociative MLCT transitions, between ca. 425-325 
nm that is of greatest interest in this work. A photolysis wavelength of 355 nm [ = 
(3.05 ± 0.11) × 103 dm3 mol-1 cm-1] was therefore selected for the subsequent TRIR studies 
outlined in Section 2.3. 
 
Figure 30: UV-visible spectra of [Mn(ppy)(CO)4] in acetonitrile at higher concentrations to show 
the low-energy band. Left: Spectra at the concentrations shown. Right: Beer-Lambert plot with 
linear fit giving (355 nm) = (3.05 ± 0.11) × 103 dm3 mol-1 cm-1. 
The molecular orbitals of [Mn(ppy)(CO)4] were calculated using DFT at the pbe0/def2-TZVPP 
level of theory, using Cs symmetry (Figure 31). Looking first at the highest occupied molecular 
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orbitals, the calculations show that both the HOMO and (HOMO − 1) are predominately based 
on the phenyl moiety of the ppy ligand, with a smaller contribution from Mn d-orbitals. This is 
consistent with the concept of the ppy ligand as an electron-rich formally anionic donor ligand. It 
is only when moving down to the (HOMO – 2) that an orbital with more d-character is found: this 
molecular orbital shows the Mn-CO π-backbonding interaction with the C≡O π* orbitals of the 
two CO ligands in the plane of the ppy ligand. These results are in contrast to calculations on 
related complexes with neutral co-ligands, such as bpy in [Cr(bpy)(CO)4] and tpm in 
[Mn(CO)3(tpm)]+, in which all three of the highest occupied molecular orbitals are dominated by 
metal d-orbital contributions.191,198 
Turning to the lowest unoccupied molecular orbitals of [Mn(ppy)(CO)4], the LUMO and (LUMO 
+ 1) are located on the ppy ligand, mostly on the pyridyl ring. The character of the (LUMO + 2) 
orbital is very different as it does not involve the ppy ligand. Instead, it is spread across the metal 
and the mutually trans CO ligands, containing a large contribution of C≡O π* character and a 
contribution from the Mn dz2 orbital. Complexes such as [Cr(bpy)(CO)4] and other group six 
‘diimine’ complexes have similar low-lying delocalised orbitals over the mutually trans CO 
ligands.204 Delocalisation over the Mn-CO moiety was also observed in calculated the low-lying 




Figure 31: DFT-optimised structure and calculated molecular orbitals for [Mn(ppy)(CO)4] (carbon 
grey, hydrogen white, manganese pink, nitrogen blue, oxygen red). Isosurfaces shown at 0.5 e Å -3. 
The electronic absorptions of [Mn(ppy)(CO)4] were also modelled by DFT calculations. The 
results suggest that the lowest-energy feature (425-325 nm) in the spectrum is dominated by two 
distinct absorptions with maxima at 345 and 342 nm. Both transitions feature substantial 
contributions from the same two components (Table 4).  
Table 4: DFT-Calculated excitation wavelengths, intensities and orbital components for the low-











Coefficient / % 
345 0.345 × 10-1  A' 19a'' 20a'' 75.9 
   
62a' 63a' 14.1 
   
62a' 68a' 2.3 
342 0.180 × 10-1 A’ 62a' 63a' 56. 3 
   
19a'' 20a'' 18.2 
   62a' 68a' 11.3 
19a'' (HOMO) 20a'' (LUMO)
62a' (HOMO – 2) 63a' (LUMO + 2) 







The first component of importance is the HOMO-LUMO transition (19a'' → 20a''). There is 
largely a ppy ligand-based π-π* transition, redistributing electron density from the phenyl to 
pyridyl moiety. There is also a small component of charge transfer from the Mn to the ppy ligand, 
similar to the predominant character of the 1MLCT(bpy) states of [Cr(bpy)(CO)4].198 No such 
ligand-based transition is seen at low energy for [Cr(bpy)(CO)4] as the highest occupied molecular 
orbitals are all metal-based.198 This reflects the more uneven distribution of electron density in 
the complexed ppy ligand compared to in bpy. As most of the transfer of electron density takes 
place within the ppy ligand in this component, it is unlikely that component (19a'' → 20a'') confers 
strongly CO-dissociative character to the transitions at 342 and 345 nm. 
The second contribution of note is from the component (62a' → 63a'). In this case, electron density 
moves out of a metal d-orbital that is M-(COeq)2 bonding into an orbital delocalised across the 
two COax ligands. This is analogous to the CO-dissociative 1MLCT(CO) transitions studied 
previously in [W(en)(CO)4],204 and to the excitation from Mn d-orbitals to the delocalised Mn-
CO orbitals in [Mn(CO)3(tpm)]+.191 Based on these comparisons, the (62a' → 63a') component is 
proposed to be the main mechanism for CO dissociation. As the excitations at 342 and 345 nm 
are both comprised of this component to different extents, they are both proposed to have CO-
dissociative character. Finally, there is a small component in both orbital contributions that 
populates orbital 68a’, which appears to be more of a dissociative COeq component, unlike the 
typical behaviour of metal carbonyls. However, the small contributions of these transitions 
suggests that they are unlikely to dominate the photochemical behaviour. These observations are 
a useful starting point to understand the fundamental photochemistry of [Mn(ppy)(CO)4], and 
through comparing to the different ligand spheres of known complexes an understanding of how 
the ligands, metal and oxidation state tune the photochemical behaviour is sought. 
2.3 Ultrafast TRIR Spectroscopy of [Mn(ppy)(CO)4] 
Although the water solubility of [Mn(ppy)(CO)4] is adequate for CO release and toxicity studies, 
it is not sufficiently for the millimolar concentrations required by TRIR spectroscopy. The 
photochemical properties must therefore be probed in other solvents. The effects of the different 
physical properties and coordinating abilities of different solvents can provide insight into the 
reactivity and solvation of the photoproducts produced. 
2.3.1 Acetonitrile 
Photolysis of a solution of [Mn(ppy)(CO)4] at 355 nm in the polar coordinating solvent 
acetonitrile was studied by TRMPS. The results are presented as difference spectra with reference 
to background spectra recorded at pump-probe delays of 900 to 1000 μs. For example, the 
background spectrum for a pump-probe delay of 10 μs was recorded at a pump-probe delay of 
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910 μs. The positive bands therefore represent photoproduct species, and the negative bands 
reflect bleaching of the ground state. The resulting spectra are presented in Figure 32, along with 
a spectrum of the ground state of [Mn(ppy)(CO)4] in MeCN (from Figure 26) for reference. 
 
 
Figure 32: TRIR spectra of [Mn(ppy)(CO)4] in MeCN at selected pump-probe delays with a pump 
wavelength of 355 nm. The asterisks and insets show the triplet excited state. A spectrum of the 
ground state of [Mn(ppy)(CO)4] in MeCN is provided for reference, scaled by a factor of 100. 
The difference spectra show a set of negative bands that match well to the position and intensity 
profile of the ground state of [Mn(ppy)(CO)4]. This shows that the ground state of 
[Mn(ppy)(CO)4] is depleted during the experiment - due to absorption of the pump pulse and 
formation of the photoproducts (positive bands).  
Two sets of photoproduct bands formed within the first few picoseconds. The major photoproduct 
exhibited a broad feature centred just below 1900 cm-1 and a band at around 2000 cm-1 on the 
edge of a bleach. Over the course of the first 20-30 ps, these bands sharpened and shifted to higher 
wavenumber, resulting in bands at 1898 cm-1 and 2006 cm-1. These changes to the bands on this 
timescale are consistent with solvation of the photoproduct and subsequent vibrational cooling, 
as commonly seen in the first few ps after CO loss (previously discussed in Section 2.1.1). The 
small shift in the bands upon cooling suggests that the CO stretches themselves were not 
vibrationally excited. For comparison, photolysis of [W(CO)6] in n-heptane to form 
[W(CO)5(C7H16)] gives a ‘hot’ photoproduct band, but there was a large shift of 27 cm-1 between 
the v= 0 → 1 and v = 1 → 2 bands.210 The vibrational cooling behaviour observed in 
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[Mn(ppy)(CO)4] more likely reflects coupling of the CO stretches to other excited vibrational 
modes as observed in [Mn(tpm)(CO)3]+.191 After cooling, the bands for this photoproduct 
remained unchanged through the nanosecond and microsecond timescales.  
The intensity pattern of the major photoproduct bands is characteristic of a facial tricarbonyl 
species, similar to the fac-[Cr(bpy)(S)(CO)3] complexes observed by Vlček and co-workers,200 in 
which the two low-energy bands appear together as a broad feature, with a third sharper and more 
intense band at higher wavenumber. For meridional tricarbonyl species, three bands are also 
expected, but the band at higher wavenumber should appear much weaker relative to the other 
bands as it corresponds to the stretching of the mutually trans carbonyl ligands.201 Furthermore, 
the separation of the two low-wavenumber bands is typically larger for meridional than for facial 
isomers.201 In the experimental data, these two bands are so close together that they form a single 
broad band, supporting a facial tricarbonyl. 
The infrared spectra and relative energies of the facial and two possible meridional isomers were 
also predicted using DFT (Scheme 27). The calculations were run at the D3-PBE0/def2-
TZVPP//BP86/SVP(P) level with a COSMO solvent correction in acetonitrile. 
 
Scheme 27: Photolysis of [Mn(ppy)(CO)4] in MeCN results in the formation of solvent complex 
[113MeCN]. The structures of three possible isomers of 113MeCN are shown along with their Free 
Energies at 298 K relative to the fac-isomer. For each isomer, the predicted infrared stretching 
frequency and scaled intensity of their vibrational modes in the metal carbonyl region are given at 
the D3-PBE0/def2-TZVPP//BP86/SVP(P) level with COSMO solvent correction in MeCN. 
The calculations confirm that the facial isomer is the most thermodynamically stable. This is to 
be expected for metal carbonyl complexes as the strong trans effect of CO has a destabilising 
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effect on mutually trans CO ligands. The predicted intensity patterns of the meridional isomers 
are in line with the above discussion and do not match the species observed, whereas the predicted 
intensities for the facial isomer match the experimental data much better. Based on this evidence, 
the major photoproduct species was assigned as fac-[Mn(ppy)(MeCN)(CO)3]. This is consistent 
with the earlier mass spectrometry study with complex 95 in which a tricarbonyl acetonitrile 
complex 102 was observed. 
Returning to Figure 32, much weaker bands (marked with an asterisk and shown in the insets) 
corresponding to the second photoproduct also appear within 1 ps, comprising a feature between 
the bleaches at 1950 cm-1 and a broad band between 2010-2050 cm-1. Unlike the major 
photoproduct, this species is not long-lived; instead it decays over the first 20 ps. The bands for 
this species closely resemble the appearance of the 3MLCT excited states of [Cr(bpy)(CO)4] in 
TRIR studies in its broad features, the timescale of its decay, and its position relative to the 
bleaches.200 The upward shift of the carbonyl stretching bands in the excited state relative to the 
ground state is typical of charge transfer excited states.213 The shift is consistent with a loss of 
electron density from the metal, as predicted by the DFT calculations in Section 1092.2.2. The 
broadness of the bands is also typical for charge transfer in an excited state.213 This is because 
redistribution of the electrons in the excited state leads to relatively large bond length changes, 
affording access to a greater number of vibrationally excited states. Based these points, this 
photoproduct was assigned as one or more triplet excited states of [Mn(ppy)(CO)4]. 
The lifetime(s) of the excited state(s) could be determined by monitoring the exponential decay 
of the feature at 2010-2050 cm-1. A plot of change in absorbance over the first 50 ps for the 




Figure 33: The change in absorbance of the excited state at 2019 cm-1 from 1 to 50 ps. The dashed 
line represents a single exponential fit with a lifetime of 4.1 ± 0.2 ps. 
The decay of the excited state was modelled well by a single exponential fit with a lifetime of (4.1 
± 0.2) ps (the errors reported are 95% confidence intervals). Fitting to a bi-exponential function 
returned two identical lifetimes of (4.1 ± 0.2) ps. The same process was then performed at 2033 
cm-1 to determine if another excited state was present elsewhere within the same broad band. The 
single exponential fit at 2033 cm-1 yielded a lifetime of (4.1 ± 0.3) ps, and the bi-exponential fit 
yielded lifetimes of (4.1 ± 0.3) ps and (13.1 ± 110) ps. The failure of the bi-exponential fits at 
both 2019 cm-1 and 2033 cm-1 suggests that a single excited state is formed in this experiment. 
Fitting of the feature at 1950 cm-1 was not undertaken due to its position between the bleaches, 
although decay over the first ca. 20 ps is qualitatively observed. 
On the same timescale that the excited state decayed, a small recovery in the bleach bands was 
observed qualitatively (Figure 32, page 113). This suggests that the excited state molecules 
ultimately return to the ground state rather than undergoing CO dissociation. Single exponential 
fits to the bleach recovery displayed very large standard errors and could not be precisely 
quantified and compared to the decay of the excited state.  
There are several reasons why the bleach recovery lifetime is not comparable to that of the excited 
state decay. Firstly, the molecules returning to the electronic ground state from the excited state 
may still be vibrationally excited, leading to broad bands in the ground state that sharpen as the 
ground state cools. Secondly, geminate recombination of the CO ligand would have a similar 
effect. Although geminate recombination for metal carbonyl complexes can occur faster than the 
picosecond timescale,191,193 which is not directly observable in this experiment, the subsequent 
vibrational relaxation of the ground state typically occurs on the picosecond timescale and would 
lead to a small recovery of the bleach bands, as was observed in the study of [Mn(tpm)(CO)3]+.191 
Thirdly, the bleaches only undergo small changes and some are close in wavenumber to 
117 
 
photoproduct bands also undergoing vibrational relaxation, which further affects the bleach 
recovery kinetics. Together, these three effects convolute the bleach recovery kinetics. However, 
the small extent of overall bleach recovery does support the conclusion that the excited state is a 
minor photoproduct. Most of the intensity of the bleaches persists because CO loss is the major 
pathway.  Similar triplet excited states were observed in a range of solvents: further discussion 
and a table of the lifetimes is included in Section 2.5.1. 
A third photoproduct in Figure 32 (page 113) featuring a small band at 1815 cm-1 can be observed 
from ca. 30 ps (Figure 32, page 113). This band persists into the microsecond timescale. Several 
possibilities were considered for this species. Based on the earlier mass spectrometry work 
(Section 1.4) suggesting that CO insertion into the Mn-C bond of the ppy ligand can take place, 
a metal acyl species was considered. However, the infrared stretching frequencies for metal acyl 
species are typically much lower (appearing at ca. 1600 cm-1) than the observed value of 1815 
cm-1.214–216 Similarly, thermal substitution of a second CO ligand by MeCN solvent may be ruled 
out based on the DFT-calculated infrared bands of the dicarbonyl;  cis-[Mn(ppy)(MeCN)2(CO)2] 
was predicted to have υ(CO) bands at 1942 and 1993 cm-1, whilst the υ(CO) band for 
[Mn(ppy)(MeCN)3(CO)] was predicted to absorb at 1961 cm-1. Therefore, the small band at 
1815 cm-1 could not be assigned. This band was not observed in any of the other solvents used in 
this Chapter. 
The dependence on pump pulse wavelength was investigated (Figure 34). Given the wavelength-
dependent behaviour of [Cr(bpy)(CO)4], it might be expected that less CO loss and more excited 
state formation takes place at longer pump wavelengths. Changing the pump pulse wavelength 
from 355 nm to 400 nm resulted in much smaller intensities for all bands due to the low extinction 
coefficient of [Mn(ppy)(CO)4] at this wavelength. The key finding of this experiment was that 
qualitatively, the photochemical behaviour was still dominated by CO loss and formation of fac-
[Mn(ppy)(MeCN)(CO)3], with the excited state bands very weakly visible at early delays. It is 
also notable that the intensity of the bleach bands seems smaller relative to the photoproduct bands 
when compared to the 355 nm pump experiment in Figure 32 (page 113). One reason for this 
might be the different vibrational cooling dynamics of the photoproduct bands when 400 nm 




Figure 34: TRIR spectra showing the photolysis of [Mn(ppy)(CO)4] at a pump wavelength of 400 nm. 
The asterisks show the positions of the triplet excited state bands. 
The dominant fac-[Mn(ppy)(MeCN)(CO)3] could also be prepared in a synthetic chemistry 
laboratory by irradiation with a 400 nm LED. Continuous irradiation of a solution of 
[Mn(ppy)(CO)4] in acetonitrile produced the same photoproduct, observed by in situ infrared 
spectroscopy over a period of 30 minutes (Figure 35). The results are displayed as difference 




Figure 35: Continuous irradiation of an acetonitrile solution of [Mn(ppy)(CO)4], monitored by in situ 
infrared spectroscopy at a resolution of 4 cm-1, with spectra collected after the irradiation times 
indicated. The solution was irradiated by a 400 nm LED drawing 6.0 W power. The difference spectra 
shown are relative to a reference spectrum recorded immediately before irradiation began. 
The spectra show the progressive appearance of negative bands corresponding to the loss of 
[Mn(ppy)(CO)4] with the gain of the bands for fac-[Mn(ppy)(MeCN)(CO)3]. The C-N stretch of 
the bound acetonitrile ligand was either too weak to be observed or obscured by the MeCN solvent 
subtraction. From 10-30 minutes, the bleaches continued to grow whilst the tricarbonyl 
photoproduct bands remained constant. This shows that there was some loss of the photoproduct 
over this timescale. However, no new metal carbonyl bands appeared during this time suggesting 
that the subsequent decomposition was either too rapid to observe in this way or resulted in 
insoluble products. Due to the continuous irradiation employed in this experiment rather than the 
pump-probe approach used in TRIR spectroscopy, the decomposition of 113MeCN observed here 
may be due to absorption of a second photon, such as photolytic loss of a second CO ligand. The 
same process would not be possible in the TRIR experiment as only a single ‘pump’ laser pulse 
was used. 
2.3.2 Alkane Solvents  
To further probe the reactivity of [Mn(ppy)(CO)4] and its photoproducts, loss of CO followed by 
solvent coordination was studied in n-heptane, a much less polar, weaker-coordinating solvent 
than MeCN. Selected spectra obtained at short pump-probe delays (up to 100 ps) are presented in 




Figure 36: TRIR spectra of [Mn(ppy)(CO)4] in n-heptane at selected pump-probe delays up to 100 ps, 
using a pump wavelength of 355 nm. The asterisks show the triplet excited state. An infrared 
spectrum of the ground state of [Mn(ppy)(CO)4], recorded on an FTIR spectrometer, is included at 
1 % scale for reference. 
The major photoproduct bands in the first few ps are broad absorbances at 1912, 1924 and 
2013 cm-1. The spectral pattern is similar to that observed in MeCN and suggests formation of the 
solvated facial tricarbonyl complex, fac-[Mn(ppy)(C7H16)(CO)3]. Formation of alkane complexes 
after photolysis of CO from metal carbonyls is very well established from TRIR and NMR 
spectroscopic studies.124,173,217–219 Due to relatively weaker intermolecular interaction between 
complexes and the solvent in n-heptane compared with MeCN, the bands in n-heptane are 
sufficiently sharp that the two low-wavenumber stretches can be individually resolved in the 
bleach bands. The ground state spectra provided as a reference with the MeCN and n-heptane 
spectra confirms that the different appearance of the bleaches is caused by the ground state 
spectrum, not due to photoproduct absorptions in this region. Indeed, four bands are observed in 
the bleaches for all other solvents discussed for the remainder of this Chapter, similar to n-heptane 
although a little less sharp: it is MeCN that is unusual in having such overlap of the two central 
bleaches. Ground state peak positions for all of the solvents are tabulated in Section 7.1.1. 
Over the first few tens of ps, the photoproduct bands sharpen and shift to higher wavenumber, 
resulting in a set of bands at 1923, 1933 and 2019 cm-1. This is similar behaviour to that observed 
in MeCN. This is most likely to be caused vibrational relaxation of the solvated tricarbonyl 
photoproduct. However, an alternative explanation for this shift was also considered: heptane 
could bind to the Mn centre as a σ-complex through either a terminal or an internal C-H bond and 
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it is therefore conceivable that interconversion of the two coordination isomers could be 
responsible for this change. Calculations to predict the relative energies and infrared spectra of 
both the terminal and internal heptane C-H complexes are discussed in Section 2.3.6. 
The small, broad bands at short delays, marked with asterisks in Figure 36, were assigned to a 
triplet excited state [a single exponential fit gave τ = (3.7 ± 0.8) ps at 2032 cm-1] similar to the 
one observed in MeCN, the decay of which was accompanied by partial bleach recovery.  
After the first 100 ps, the bands assigned to fac-[Mn(ppy)(C7H16)(CO)3] (113hep) began to decay, 
and were completely replaced by a new set of bands of the same symmetry within 10 ns (Figure 
37). 
 
Figure 37: TRIR spectra of [Mn(ppy)(CO)4] in n-heptane at selected pump-probe delays of 100 ps 
and longer, using a pump wavelength of 355 nm. The asterisks show the triplet excited state. 
This new set of bands had lower C≡O stretching wavenumbers (1904, 1919 and 2006 cm-1) than 
the bands for fac-[Mn(ppy)(C7H16)(CO)3]. The downward shift of 10-20 cm-1 for each band 
suggests that the coordinated solvent molecule has been substituted by a stronger donor ligand. 
As the spectra were run under ambient conditions, the solvent contained water and so the resulting 
complex was assigned as fac-[Mn(ppy)(OH2)(CO)3] (113hep) (Scheme 28). This is analogous to 
the study by Nuernberger and co-workers where [Mn(tpm)(CO)3]+ was photolysed in D2O to form 
[Mn(tpm)(CO)2(D2O)]+ (Section 2.1.1).191 Substitution of alkane donor ligands by water 
impurities is known from previous TRIR studies on [Cr(CO)6] (M = Cr, Mo, W).210,220,221 The 
displacement of alkane ligands by other stronger two-electron donors such as heterocycles has 




Scheme 28: Summary of the photochemical behavior of 88 in n-heptane. 
A repeat of this experiment was then performed with a different batch of freshly-opened 
anhydrous’ n-heptane (Figure 38). The flow system was placed under an N2 atmosphere and 
sealed. 
 
Figure 38: TRIR spectra of [Mn(ppy)(CO)4] in n-heptane under an N2 atmosphere at the pump-probe 
delays shown, using a pump wavelength of 355 nm. Conversion of 113hep into 113OH2 is observed going 
from bottom to top. Experiment performed by Anders Hammarbӓck. 
The initial photoproduct formed (spanning ps to ns delays) was again complex 113hep, but as with 
the experiment under air, the weakly-coordinating n-heptane ligand was displaced. Two sets of 
bands replaced complex 113hep. One of these species corresponds to the thermodynamically-
favoured complex 113OH2, which once again persists into the μs timescale. The use of an N2 
atmosphere and anhydrous n-heptane slowed the formation of 113hep down. Under these 
conditions the water complex formed over hundreds of nanoseconds to microseconds, compared 
to a few nanoseconds in the experiment performed under air. The rate of the substitution of the n-
heptane ligand with water is likely to be a reflection of the timescale of diffusion of water through 
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the solvent with different concentrations of water in the samples. Some variation in the rate might 
also be accounted for by a lack of temperature control of the flow system. 
In addition to formation of 113OH2, bands for a second species that also replaced 113hep were also 
present in (Figure 38).  Two bands were observed, at 1959 and 2025 cm-1. This species decayed 
on the microsecond timescale, appearing to convert to complex 113OH2, which was the dominant 
product at 10 s. Since this species appears to be formed from 113hep and decay into 113OH2, 
another facial tricarbonyl complex was considered a possibility: the relatively small amount of 
this complex formed means that a further third band could be hidden by the bleach around 1940 
cm-1. The bands shift upwards in wavenumber relative to the decaying 113hep bands. If the new 
complex is a result of another ligand displacing the n-heptane, the resulting ligand must be either 
a weaker σ-donor or stronger π-acceptor than n-heptane. It is suggested that this complex could 
be formed through displacement of the n-heptane solvent by olefin impurities in the solvent. This 
hypothesis would also account for why the result is dependent on the batch of n-heptane used – 
in the ‘wet’ experiment there is more water and this outcompetes the impurities by diffusing on a 
faster timescale. Coordination of an alkene would also explain the increase in wavenumber of the 
carbonyl stretching bands, since the alkene can behave as a π-acceptor ligand when n-heptane and 
water cannot.  
To examine how long-lived water complex 113OH2 is in an alkane solvent, a continuous irradiation 
experiment, this time in n-hexane, was performed in a synthetic chemistry laboratory. Irradiation 




Figure 39: Continuous irradiation of an n-hexane solution of [Mn(ppy)(CO)4], monitored by in situ 
infrared spectroscopy at a resolution of 4 cm-1, with spectra collected after the irradiation times 
shown on the graph. The solution was irradiated by a 400 nm LED drawing 6.0 W power. The 
difference spectra shown are relative to a reference spectrum recorded immediately before 
irradiation began. 
The product bands in the spectrum after 30 minutes were dominated by a broad band from circa 
1890-1920 cm-1 and a band at 2006 cm-1, similar to complex 113OH2 from the TRIR experiments 
in n-heptane (1904, 1919 and 2006 cm-1). At later times, the broad low-wavenumber feature 
remained, but the band at 2006 cm-1 became less intense and another band at 2024 cm-1 grew in. 
Further peaks near to the bleaches at 1940 and 1981 cm-1 also appeared – it is unclear whether 
these are artifacts due to changes in the nearby bleaches or if they are additional products. The 
broad, low-wavenumber feature (1890-1920 cm-1) with a single higher-wavenumber stretch 
(2024 cm-1) suggests that another facial tricarbonyl complex formed. Returning to the mass 
spectrometry study of complex 85 (see Section 1.4) a mass corresponding to some isomer of the 
tricarbonyl complex [Mn(CO)3(MeCN)3]+ was detected suggesting that loss of the ppy ligand, 
presumably through protonation of the Mn-C bond, can take place during the photochemical 
degradation. A complex of the form fac-[Mn(CO)3(OH2)3]+ (Scheme 29) was therefore considered 
for the new species observed in Figure 39. The species fac-[Mn(CO)3(OH2)3]+ itself is known but 
has bands at 1944 and 2051 cm-1, too high to be the species seen in (Figure 39).224  High-nuclearity 
MnI carbonyl complexes with bridging hydroxide ligands are known. For example, {fac-
[Mn(CO)3(μ3-OH)3]}4 is readily accessible from oxidation of Mn2(CO)10 with Me3N-O·2H2O at 
ambient temperature.225 This tetranuclear complex has infrared stretches at 1891, 1932 and 2027 
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cm-1 which provides a good match for the bands observed in Figure 39, and has been shown to 
form slowly from fac-[Mn(CO)3(OH2)3]+.224 A larger cluster, [Mn7(μ3-OH)8(CO)18], has also been 
identified.225 
 
Scheme 29: Possible mechanism for decomposition of 113OH2 into Mn hydroxy clusters. 
Mechanistic studies using infrared, UV-visible and EPR spectroscopies on Mn(I) tricarbonyl 
photoCORMs containing tripodal ligands have suggested that subsequent oxidation of the Mn 
centre occurs with loss of all CO ligands, leading to dimerization.177 No evidence of this was 
found in our in situ infrared studies. It is possible that the next steps in decomposition after cluster 
formation is oxidation of the of the manganese centre, but if concomitant loss of the CO ligands 
were to take place this would prevent these species from being observed in this study where the 
infrared stretches of the metal carbonyls were monitored.  
2.3.3 Dichloromethane 
When photolysis of [Mn(ppy)(CO)4] was carried out in CH2Cl2 solvent (Figure 40), similar 
behaviour to the n-heptane behaviour was observed. The early photoproduct spectra were 
dominated by formation of fac-[Mn(ppy)(CH2Cl2)(CO)3] (113CH2Cl2) within the first few ps 
followed by sharpening of the bands due to vibrational relaxation to give bands at 1908 and 2012 





Figure 40: TRIR spectra of [Mn(ppy)(CO)4] in CH2Cl2 at selected pump-probe delays up to 1 ns. A 
pump wavelength of 355 nm was used. The asterisks show the triplet excited state. 
The solvated tricarbonyl complex persists into the microsecond timescale. However, over tens of 
microseconds, the bands assigned to fac-[Mn(ppy)(CH2Cl2)(CO)3] were replaced by lower-
wavenumber bands of the same symmetry at 1900 and 2004 cm-1 (Figure 41). It should be noted 
that the apparent slight bleach recovery on the tens of microseconds timescale as seen in Figure 
41 is an artifact caused by flow of the pumped sample out of the probe area. A small loss of 
photoproduct intensity is also expected as a result of this effect, but this is more difficult to see in 




Figure 41: TRIR spectra of [Mn(ppy)(CO)4] in CH2Cl2 at selected pump-probe delays of 1 ns and 
longer. A pump wavelength of 355 nm was used. The asterisks show the triplet excited state. 
The bands for the species that formed over tens of microseconds are close in wavenumber to those 
seen for the aquo complex 113OH2 in n-heptane (Section 2.3.2). It was therefore concluded that 
113OH2 also forms in dichloromethane depending on the water content of the solvent. The low-
energy stretches for 113OH2 in CH2Cl2 and n-heptane appear at slightly different wavenumbers: 
1904 and 1919 cm-1 for n-heptane and a broader band with a maximum at 1898 cm-1 for CH2Cl2. 
However, in the ground state infrared spectrum of [Mn(ppy)(CO)4], the bands in n-heptane also 
appear at higher wavenumber. For example, the lowest-energy mode is at 1933 cm-1 in CH2Cl2 
and 1940 cm-1 for n-heptane, showing the sensitivity of the infrared stretches to solvent 
environment. A full table of the ground state infrared bands in all solvents used is provided in 
Section 7.1.1. 
2.3.4 Toluene 
Spectra obtained in toluene solution showed comparable behaviour to CH2Cl2 and n-heptane. The 
initially-dominant fac-[Mn(ppy)(toluene)(CO)3] complex (113tol) exhibited bands at 1906 and 




Figure 42: TRIR spectra of [Mn(ppy)(CO)4] in toluene at selected pump-probe delays up to 1 ns. A 
pump wavelength of 355 nm was used. The asterisks show the triplet excited state. 
Subsequent replacement of the bands for 113tol with bands at 1884, 1898 and 2001 cm-1 took place 
between 100 ns and 2 μs (Figure 43). This species was again attributed to formation of complex 
113OH2 due to replacement of the toluene ligand with water in the solvent. The structure of 113tol 
is could comprise a C-H σ-complex or a C=C π-complex; either of these coordination modes 
would provide two electrons to form 18-electron solvent complexes analogous to those observed 
above in other solvents. These possibilities are discussed in conjunction with their DFT-calculated 




Figure 43: TRIR spectra of [Mn(ppy)(CO)4] in toluene at selected pump-probe delays of 1 ns and 
longer. A pump wavelength of 355 nm was used. The asterisks show the triplet excited state. 
2.3.5 Ethers 
2.3.5.1 Tetrahydrofuran 
The photochemical behaviour of [Mn(ppy)(CO)4] in ether solvents was also studied. This class of 
compounds represents an interesting comparison to the n-heptane case in that ethers contain both 
C-H bonds and available O lone pairs, both of which are donors that coordinated to the metal 
centre in the n-heptane experiments in Section 2.3.2. 




Figure 44: TRIR spectra of [Mn(ppy)(CO)4] in THF under air at selected pump-probe delays. A 
pump wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows 
indicate the direction of change in absorbance of the bands over time. 
Spectra recorded at short pump-probe delays showed broad bands at 1912 and 2011 cm-1, which 
were assigned to a fac-[Mn(ppy)(THF)(CO)3] complex. These bands were then completely 
replaced within ca. 50 ps by another facial tricabonyl complex. The wavenumbers of the bands 
for this second, later species are lower than the initial solvent complex (1889, 1899 and 1999 cm-
1), close those of to the water complex 113OH2 observed in n-heptane, CH2Cl2 and toluene. This 
set of bands then persists for the remainder of the experiment (beyond the μs timescale). 
The interconversion between the two tricarbonyl complexes observed in this experiment shows a 
different kind of reactivity to other solvents used so far. The timescale of the reaction, which is 
complete within 50 ps, is much too fast for even a diffusion-controlled reaction between a solvent 
complex and trace water in the solvent.226 The process in Figure 44 is also not solvation of the 16-
electron unsaturated complex [Mn(ppy)(CO)3]. Solvation is expected to take place within just the 
first few picoseconds, as seen in the other solvents tested in this Chapter. The timescale of 
solvation is in accordance with the previous studies photoCORMs191,194,196 (Section 2.1.2) and 
[Cr(bpy)(CO)4].200  
Reaction on the picosecond timescale as observed in Figure 44 is suggestive of a unimolecular 
reaction or a further reaction with the solvent. The shift in the infrared bands to lower wavenumber 
suggests that the second species formed contains a stronger donor ligand that increases the 
electron density on the Mn centre, allowing greater π-backbonding to the CO ligands. This is 
consistent with a change in the coordination mode of the THF solvent complex from initial weak 
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binding via a C-H σ-complex 113THF(σ)  to coordination through an oxygen lone pair, 113THF(O), 
as shown in Scheme 30. 
A comparable isomerisation reaction in alcohol solvents has been reported. Harris and co-workers 
studied the photolysis of [Cr(CO6] in alcohols and found that initial coordination via a C-H σ-
complex precedes formation of the more stable O-bound species.227 The single exponential 
lifetimes of these reactions were highly dependent on the alcohol solvent used but were hundreds 
of picoseconds or longer.227  
 
Scheme 30: Summary of the reactions after CO loss from 88 in THF. Solvent coordination 
predominately occurs via a C-H bond to form 113THF(σ) before isomerisation to the more stable O-
bound complex 113THF(O) . Note that the unsaturated complex in brackets is not observed.  
The mean lifetime for the interconversion between 113THF(σ) and 113THF(O) was obtained by fitting 
the absorbances at 1912 cm-1 and 1999 cm-1 to single exponential fits (Figure 45). The fits were 
started from 5 ps because the first few ps are dominated by the rise of the solvated complex 
113THF(σ) and its cooling. A function with both single exponential growth and decay components 
was considered to help model the growth at very early times, however there are very few points 
in the initial rise of 113THF(O) and this was considered likely to affect the overall quality of the 
fitted data.  
When choosing the time to begin fitting the data the dominance of vibrational cooling at early 
times must be balanced against the need to fit as much of the data from the interconversion of 
113THF(σ) and 113THF(O) as possible. Although the shifting and sharpening of the bands caused by 
vibrational relaxation takes place over a longer timescale than 5 ps and was not modelled in the 
analysis, the decay of 113THF(σ) and the rise of 113THF(O)  gave lifetimes of (15.1 ± 2.2) ps and 
(18.9 ± 1.6) ps respectively such that the 95 % confidence intervals just overlap, confirming that 




Figure 45: Kinetics of the isomerisation of 113THF(σ) to 113THF(O) in THF under air. The bands at 1912 
cm-1 for complex 113THF(σ) (black squares) and 1999 cm-1 for complex 113THF(O) (red circles) were 
monitored over time. The dashed lines represent single exponential fits to the data giving mean 
lifetimes of (15.1 ± 2.2) ps for 113THF(σ) and (18.9 ± 1.6) ps for 113THF(O) The open symbols represent 
the delays from 1-4 ps which were excluded from the single exponential fits due to the effect of initial 
vibrational cooling and solvation. 
From the spectra above in Figure 44, is difficult to determine the extent of competition between 
initial formation of σ-complex 113THF(σ) and direct formation of O-bound species 113THF(O) 
[formation of the O-bound species 113THF(O) without the intermediate formation of 113THF(σ)] at 
very early delays. A qualitative comment on direct formation of 113THF(O) can be made. Direct 
formation of 113THF(O) would be expected to result in broad, vibrationally excited bands at lower 
wavenumber than the bands of the vibrationally relaxed molecules. For example, two of the 
‘cooled’ bands of 113THF(σ) are at 1889 and 1899 cm-1, and if 113THF(O) were present at very short 
times a significant absorbance below 1889 cm-1 would be expected from the vibrationally excited 
bands. In the spectra in Figure 44 there is only a very low absorbance in this region and some of 
this will be caused by the broad vibrationally excited 113THF(σ) bands. As such the dominant 
pathway is formation of 113THF(σ) followed by isomerisation to 113THF(O) with little or no direct 
formation of 113THF(O). 
To verify whether this result is reproducible, the experiment was repeated using a fresh bottle of 
commercially-available >99.9 % anhydrous, inhibitor-free THF under an atmosphere of N2. 




Figure 46: TRIR spectra of [Mn(ppy)(CO)4] in dry THF under N2 at selected pump-probe delays. A 
pump wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows 
indicate the direction of change in absorbance of the bands over time. 
The spectra show that essentially identical behaviour is observed in THF under an atmosphere of 
N2 as under the ambient atmosphere. When the interconversion of 113THF(σ) to 113THF(O) in the N2 
experiment was quantified, the bleach of 113THF(σ) at 1912 cm -1 and growth of 113THF(O) at 1999 
cm -1 gave single exponential mean lifetimes of (17.6 ± 1.3) ps and (18.7 ± 0.8) ps respectively 
(fitting delays from 5 to 92 ps, Figure 47). These values confirm that there is no significant 




Figure 47: Kinetics of the isomerisation of 113THF(σ) to 113THF(σ) in dry THF under N2 from 5 to 99 ps. 
The bands at 1912 cm-1 for complex 113THF(σ) (black squares) and 1999 cm-1 for complex 113THF(O) 
(red circles) were monitored over time. The dashed lines represent single exponential fits to the data 
giving mean lifetimes of (17.6 ± 1.3) ps for 113THF(σ) and (18.7 ± 0.8) ps for 113THF(O).  
Another experiment was then performed in deuterated solvent, THF-d8, to test for a kinetic 
isotope effect. If a C-H or C-D bond is broken or made (primary kinetic isotope effect) in the rate-
determining state of the interconversion of 113THF(σ)  and 113THF(O), the rate will change when 
THF-d8 is used.228 Spectra are shown in Figure 48 and the kinetic plots in Figure 49. Note that 
the high-wavenumber band of the ground state was not observable in THF-d8 as this region of 




Figure 48: TRIR spectra of [Mn(ppy)(CO)4] in THF-d8 at selected pump-probe delays. A pump 
wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows indicate the 
direction of change in absorbance of the bands over time. The high-wavenumber bleach at 2073 cm-1 
was not observable due to absorbance by the solvent. 
  
Figure 49: Kinetics of the isomerisation of 113THF(σ)to 113THF(O) in THF-d8 from 5 to 99 ps. The bands 
at 1911 cm-1 for complex 113THF(σ) (black squares) and 1999 cm-1 for complex 113THF(O) (red circles) 
were monitored over time. The dashed lines represent single exponential fits to the data giving mean 
lifetimes of (17.7 ± 3.7) ps for 113THF(σ) and (17.0 ± 1.8) ps for 113THF(O). 
The lifetimes for the isomerisation reaction in THF-d8 were (17.7 ± 3.7) ps from the bleach of 
113THF(σ) and (17.0 ± 1.8) ps for the growth of 113THF(O). There is therefore no significant 
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difference to the kinetics in THF-d8 compared to the experiments in the protio solvent. The lack 
of a kinetic isotope effect for the interconversion of 113THF(σ) and 113THF(O) suggests that there is 
no C-H or C-D bond breaking in the rate-determining state. This is consistent with a mechanistic 
pathway in which the C-H / O-bound isomerisation does not involve an oxidative addition and/or 
C-H bond cleavage.  
Reaction of the photoproducts with CO to re-form [Mn(ppy)(CO)4] was also studied. As 
mentioned in Section 2.1.1, the study on [Mn(tpm)(CO)3]+ by Nuernberger and co-workers 
concluded that geminate recombination with CO occurs for this molecule on the sub-ps 
timescale.191 This was based on the partial recovery of the bleached bands on the ps timescale 
rather than direct recombination. It may be that [Mn(ppy)(CO)3] undergoes similar recombination 
with CO on the sub-ps timescale.  
However, since diffusion-controlled processes are typically limited to the nanosecond 
timescale,226  CO would not be able to diffuse through the solvent quickly enough to affect the 
isomerisation reaction of 113THF(σ) to 113THF(O) on the ps timescale and any CO recombination 
taking place on the sub-ps timescale must come from the CO ligand that has photodissociated. 
Displacement of the O-bound ligand by CO over a longer timescale could re-form 
[Mn(ppy)(CO)4]. To test for re-formation of [Mn(ppy)(CO)4] in THF, a TRIR experiment was 
performed under an atmosphere of CO (see Appendix 4 for results).  
The single exponential fits for the loss of the 113THF(σ) band at 1911 cm-1 and the gain of the 
113THF(σ) band at 1999 cm-1 gave mean lifetimes of (17.3 ± 1.3) ps and (19.8 ± 0.8) ps respectively. 
Although in this case the 95 % confidence intervals did not overlap, these values are very close 
to the mean lifetimes for other experiments THF isomerisation experiments (Table 6) and suggests 
that there is no effect on the ps timescale upon the isomerisation caused by performing the 
experiment under CO.  
The CO atmosphere does enable examination of the kinetics at longer delays, in order to observe 
whether CO gas can displace the O-bound complex. Spectra were recorded at longer pump-probe 
delays, under 1 atm CO. The exact concentrations of both CO and the photoproduct complex are 
not known in the experiment as they were not accurately measured. No measured solubility data 
for CO in THF could be found, but data for a range of organic solvents, including ethers, suggests 
millimolar concentrations would likely be achieved; for example, the solubility of 1,4-dioxane at 
290 K and 1 bar was measured to be 5.5 mM.229 Given that [Mn(ppy)(CO)4] is only present at 
around 15 mM in these experiments, and that only a fraction of the complex is photolysed (the 
photoproduct bands lead to mO.D.-scale absorbances but the [Mn(ppy)(CO)4] ground state bands 
are around 2 orders of magnitude stronger), these estimates suggest that the CO is present in 
substantial excess, such that a pseudo-first order rate constant could be measured if a reaction 




Figure 50: TRIR spectra of [Mn(ppy)(CO)4] in THF under a CO atmosphere at long pump-probe 
delays. A pump wavelength of 355 nm was used. The asterisks show the triplet excited state. The 
arrows indicate the direction of change in absorbance of the bands over time. 
Over hundreds of microseconds, the pumped photoproducts are flowed out of the probe volume 
leading to loss of both the ground state bleaches and photoproduct bands. It would therefore be 
difficult to distinguish variation in flow rates with re-formation of [Mn(ppy)(CO)4] from 113THF(O) 
on this timescale so 10 μs is the longest delay shown.  
This experiment shows that any reaction of CO with 113THF(O) to re-form Mn(ppy)(CO)4 takes 
place slower than the microsecond timescale. Due to the ps-timescale isomerisation of 113THF(σ) 
to 113THF(O), displacement of the σ-complex by CO cannot be studied - a similar experiment in n-
heptane, where the σ-complex is much longer-lived, would be required to study such a process, 
although the presence of trace water in the flow system would again interfere (as in Section 2.3.2). 
Studies of the re-formation of solvent complexes after CO loss have shown that CO can displace 
weaker donors. For example, George and co-workers photolysed [CpRe(CO)3] (Cp = 
cyclopentadienyl) in n-heptane to produce [CpRe(CO)2(n-heptane)], which reacts to re-form 
[CpRe(CO)3] under a CO atmosphere.230 However, these reactions took place on the millisecond 
timescale at two atmospheres of CO, showing that even alkane complexes can be somewhat stable 
to CO substitution.230  
Further experiments using derivatised ppy complexes 94 and 95 (structures on page 92) were also 
performed (see Appendix 4 for spectra and kinetic plots) to verify that the isomerisation observed 
with 88 occurs with other ppy-derived ligands and compare the kinetics of the isomerisation. The 
results of the kinetics experiments in THF are summarised in Table 5.  
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Table 5: Summary of kinetics of the isomerisation of complexes 88, 94 and 95 in THF.   
Complex Solvent Atmosphere  THF() / ps  THF(O) / ps 
88 THF Air 15.1 ± 2.2  18.9 ± 1.6 
88 THF N2 17.6 ± 1.3 18.7 ± 0.8 
88  THF-d8 Air 17.7 ± 3.7 17.0 ± 1.8 
88 THF CO 17.3 ± 1.3 19.8 ± 0.8 
94  THF Air 19.0 ± 1.6 19.8 ± 1.0 
95  THF Air 17.9 ± 0.9 22.2 ± 4.3 
 
2.3.5.2 1,4-Dioxane 
The isomerisation behaviour in THF was compared to another cyclic ether solvent: 1,4-dioxane 
(Figure 51).  
 
Figure 51: TRIR spectra of [Mn(ppy)(CO)4] in 1,4-dioxane at selected pump-probe delays. A pump 
wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows indicate the 
direction of change in absorbance of the bands over time. 
The results show a similar behaviour to the experiments performed in THF: initial broad bands at 
1919 and 2011 cm-1 are replaced over tens of picoseconds by bands at 1899, 1911 and 1999 cm-
1. This suggests that a similar isomerisation from a σ-complex 113diox(σ) to the O-bound species 
113diox(O) also takes place in 1,4-dioxane. As with THF, at early times there is little evidence for 
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the vibrationally excited O-bound complex 113diox(O) suggesting that most of the tricarbonyl 
fragments produced by photolysis are initially solvated by binding to C-H bonds in the solvent 
before isomerisation, rather than by direct binding to the O atoms of the solvent. Formation of a 
σ-complex remains the major reaction pathway in spite of the lower ratio of C-H bonds to O atoms 
within 1,4-dioxane (4 C-H bonds per O atom) compared to THF (8 C-H bonds per O atom). The 
kinetics of the isomerisation are shown in Figure 52. 
 
Figure 52: Kinetics of the isomerisation of 113diox(σ)  to 113diox(O) in 1,4-dioxane from 5 to 74 ps. The 
bands at 1919 cm-1 for complex 113diox(σ) (black squares) and 1999 cm-1 for complex 113diox(O) (red 
circles) were monitored over time. The dashed lines represent single exponential fits to the data giving 
mean lifetimes of (10.8 ± 1.2) ps for 113diox(σ) and (12.8 ± 0.8) ps for 113diox(O). 
The bleach of the 113diox(σ) feature at 1919 cm-1 and the growth of the 113diox(O) band at 1999 cm-
1 both fit single exponential functions with lifetimes respective lifetimes of (10.8 ± 1.2) ps and 
(12.8 ± 0.8) ps. 
2.3.5.3 n-Bu2O 
A similar experiment performed in the linear ether n-Bu2O was also performed. The spectra 
(Figure 53) indicate a similar isomerisation to the two cyclic ethers examined so far. The early 
bands for 113nbu2o(σ) at 1916 and 2016 cm-1 are replaced by the O-bound species 113nbu2o(O) with 
bands at 1891, 1909 and 2004 cm-1. However, the timescale of the interconversion is considerably 





Figure 53: TRIR spectra of [Mn(ppy)(CO)4] in n-Bu2O at selected pump-probe delays. A pump 
wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows indicate the 
direction of change in absorbance of the bands over time. 
 
Figure 54: Kinetics of the isomerisation of 113nbu2o(σ) to 113nbu2o(O) in n-Bu2O from 5 to 1000 ps. The 
bands at 1918 cm-1 for complex 113nbu2o(σ) (black squares) and 2004 cm-1 for complex 113nbu2o(O) (red 
circles) were monitored over time. The dashed lines represent single exponential fits to the data giving 
mean lifetimes of (103 ± 26) ps for 113nbu2o(σ) and (88 ± 29) ps for 113nbu2o(σ). 
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The mean lifetimes for the isomerisation reactions of the three ether solvent complexes are 
summarised in Table 6. 






per O Atom 
(CO) 113S()  
/ cm-1 
(CO) 113S(O) / 
cm-1 
 113S() / 
ps 




4 1919, 2011 1899, 1911, 
1999 
10.8 ± 1.2 12.8 ± 0.8 
THF 8 1912, 2011 1889, 1899, 
1999 
15.1 ± 2.2 18.9 ± 1.6 
n-Bu2O 18 1916, 2016 1891, 1909, 
2004 
103 ± 26 88 ± 29 
 
The data show a similar trend for all three ether solvents; the carbonyl stretches for the initial σ-
complexes appear at similar wavenumbers in the three solvents, although the two low-
wavenumber bands are not resolved due to vibrational excitation at early delays. The subsequent 
O-complex bands also appear at similar wavenumbers in the three solvents. The shift in 
wavenumber of the bands upon isomerisation is very similar in all three cases. The highest-
wavenumber mode decreases by 12 cm-1 upon isomerisation. Comparing the mid-point of the two 
low-wavenumber modes in 113S(σ) with the low-wavenumber feature of 113S(O) gives a downward 
shift of between 14-18 cm-1 across the three solvents. 
The timescale of the isomerisation is different in each case. The isomerisation in THF has a mean 
lifetime in the region of ca. 15-20 ps. The precision of this measurement was indicated by 
reproducibility of the kinetics in experiments under N2, in THF-d8 and with derivatives 94 and 
95. Therefore, the mean lifetime of the σ-complex with 1,4-dioxane is significantly shorter than 
that with THF. In n-Bu2O the mean lifetime of the σ-complex is much longer than both the cyclic 
ethers and is approximately an order of magnitude longer than the 1,4-dioxane complex. 
The trend in the mean lifetimes of the σ-complexes correlates with the ratio of C-H bonds to O 
atoms in the molecule. The more C-H bonds per O atom, the longer the mean lifetime of the σ-
complex. The implications of this trend on the possible mechanisms for interconversion of the σ-
complexes to the O-bound isomers are discussed in Section 2.5.2.  
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2.3.6 Dimethyl sulfoxide 
The final solvent investigated in this study was dimethyl sulfoxide (DMSO). This solvent has the 
potential for further complexity compared to the ether solvents as, in addition to six C-H bonds 
and an oxygen atom, there is also a sulfur atom in the molecule that may capable of coordinating 
to the tricarbonyl metal fragment. The TRIR spectra in DMSO are shown in Figure 55.  
 
Figure 55: TRIR spectra of [Mn(ppy)(CO)4] in DMSO at selected pump-probe delays. A pump 
wavelength of 355 nm was used. The asterisks show the triplet excited state. The arrows indicate the 
direction of change in absorbance of the bands over time. Experiment conducted by Anders 
Hammarbӓck. 
The intensities of the positive bands are relatively low compared to the bleaches and the bands 
are much broader than the bleaches – this was assumed to be due to vibrational cooling and the 
mixture of different broad, overlapping bands of the different products formed. There also 
qualitatively appears to be a relatively strong excited state band, though the relative ratio of 
photoproduct to excited state or quantum yields have not been quantified for any of the 
complexes. 
Considering the low-wavenumber region of the spectrum first, short delays show a very broad 
band with a maximum at around 1907 cm-1. This feature is replaced on the picosecond timescale 
by a broad band centred at approximately 1880 cm-1. These spectral changes resemble the σ-
complex isomerisation observed in the ether solvents.  
The region around 2000 cm-1 displayed different behaviour to the ether solvents. At short delays, 
a photoproduct band at 2007 cm-1 is observed. This band began to decay slightly in the first 10 













































ps, presumably at the same time as competing sharpening and shifting of the bands through 
vibrational relaxation. However, a feature at the same position grew in again from around 20 ps. 
The feature at 2007 cm-1 then persisted for the remainder of the experiment. 
Additionally, a small photoproduct band grew in at 1994 cm-1. This band only became prominent 
in the spectrum at around 50 ps but its proximity to the ground state bleach at 1987 cm-1 made 
subtler early changes difficult to see. The band at 1994 cm-1 also persisted for the remainder of 
the experiment.  
The formation of the two bands at 1994 cm-1 and 2007 cm-1 on the ps timescale and their 
persistence into the μs timescale suggests that both S and O coordination to the facial tricarbonyl 
fragment occurred (Scheme 31). These two bands formed too rapidly to be complexation by 
water, oxygen or other impurities, and are too long-lived to be the σ-complex (based on the 
timescales of the ether isomerisations) or the unsaturated 16-electron complex. The initial 
photoproduct species with bands at 1907 cm-1 and 2007 cm-1 was assigned as the σ-complex 
113DMSO(σ) due to the similar wavenumbers of the bands for this species compare to the ether 
solvent σ-complexes and because of the shift of the bands to lower wavenumber upon subsequent 
S or O coordination.  
 
Scheme 31: Summary of the reactions after CO loss from 88 in DMSO. Solvent coordination 
predominately occurs via a C-H bond before isomerisation to the give the S- and O-bounds species.  
The two low-energy bands for each of the S-bound species 113DMSO(S) and O-bound species 
113DMSO(O) overlap, leading to a broad feature between 1870-1890 cm-1 containing these four 
bands. Distinction between 113DMSO(S) and 113DMSO(O) is therefore only possible using the highest 
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wavenumber stretch (i.e. 1994 or 2007 cm-1). The assignment shown in Figure 55 was based on 
DFT predictions of their infrared spectra: this is discussed in Section 2.3.6.  
The kinetics of the isomerisation from 113DMSO(σ) to 113DMSO(S) and 113DMSO(O) were investigated. 
The decay of the 113DMSO(σ) band at 1907 cm-1 was analysed from 5 to 100 ps (Figure 56). A single 
exponential fit yielded a mean lifetime of (11.9 ± 1.5) ps. As there is the possibility of conversion 
from 113DMSO(σ) to both 113DMSO(S) and 113DMSO(O), fitting to a bi-exponential decay was also 
attempted but this returned mean lifetimes of (19.3 ± 12.3) ps and (4.8 ± 4.8) ps. The better fit to 
the first-order exponential suggests that there are not two clearly distinguishable first order decay 
processes. If there are two separate first order processes taking place from formation of 113DMSO(S) 
and 113DMSO(O) it may be more likely that their individual lifetimes are similar and not 
distinguishable. This may be the case if the conversion to 113DMSO(S) and 113DMSO(O) takes place 
at similar rates.  
When the formation of the bands for 113DMSO(O) at 1994 cm-1 and 113DMSO(S) at 2007 cm-1 (Figure 
56) were analysed, the mean lifetimes were (19.6 ± 1.5) ps and (23.0 ± 7.9) ps respectively. Due 
to the decreasing absorbance of 113DMSO(σ) dominating at 2007 cm-1 at early times, the fit for this 
band was begun from 15 ps rather than 5 ps. This suggests that the O- and S-bound complexes do 
form at similar rates, contributing to the decay of 113DMSO(σ) which is approximately twice as fast 




Figure 56: Kinetic plots to study the isomerisation of 113DMSO(σ) to 113DMSO(S) and 113DMSO(O) in DMSO 
from 5 to 100 ps. The bands at 1907 cm-1 for complex 113DMSO(σ) (blue triangles), 1994 cm-1 for complex 
113DMSO(O) (red circles), and 2007 cm-1 (black squares) for 113DMSO(S) were monitored over time. The 
fit for 113DMSO(S) was started at 20 ps due to overlap with a decaying band of vibrationally hot 
113DMSO(σ) at early times. The dashed lines represent single exponential fits to the data giving mean 
lifetimes of (11.5 ± 1.5) ps for 113DMSO(σ), (19.6 ± 1.5) ps for 113DMSO(O) and (23.0 ± 7.9) ps for 113DMSO(σ). 
As the bands at early times were extremely broad, a small amount of direct coordination through 
the S or O atoms rather than via the intermediate complex 113DMSO(σ) (Scheme 31) cannot be ruled 
out. The broad absorbance of the low-energy bands at short times stretches below 1850 cm-1 and 
could contain a contribution from direct formation of vibrationally excited 113DMSO(O) and/or 
113DMSO(S). However, much of this very broad feature at early times is at similar or higher 
wavenumber than the bands from vibrationally cooled 113DMSO(O) and 113DMSO(S). This shows that 
a significant contribution to this band must come from a different species to 113DMSO(O) and 
113DMSO(S), i.e. complex 113DMSO(σ), because vibrational cooling results in an increase in 
wavenumber. Hence a large proportion of the initial solvation of the facial tricarbonyl fragment 
is once again concluded be via a C-H σ-complex (Scheme 31), but direct coordination of S- and 
O-bound complexes cannot be ruled out. 
Finally, an in situ infrared spectroscopy study, with continuous 365 nm LED irradiation, was 
performed to determine whether interconversion between the O-bound and S-bound complexes 




Figure 57: Continuous irradiation of a DMSO solution of [Mn(ppy)(CO)4], monitored by in situ 
infrared spectroscopy at a resolution of 4 cm-1, with spectra collected after the irradiation times 
shown on the graph. The solution was irradiated by a 365 nm LED drawing 6.0 W power. The 
difference spectra shown are relative to a reference spectrum recorded immediately before 
irradiation began. 
A similar experiment has previously been performed by Dr. Benjamin Moulton with similar 
results to those reported here.231 Looking at the difference spectrum after 15 minutes, bands at 
1902 and 2013 cm-1 have grown in, whilst the bleach at 1928 cm-1 appears much smaller than 
usual, suggesting the presence of a third product band in this region. This is consistent with a 
single facial tricarbonyl photoproduct at this timepoint, though the infrared bands do not match 
either 113DMSO(O) or 113DMSO(S): both these DMSO complexes observed in the TRIR experiments 
are presumed to degrade on the timescale of milliseconds to seconds. The product observed was 
again tentatively assigned to be a multinuclear Mn hydroxy cluster as discussed for alkane 
solvents in Section 2.3.2.225 However, there are many more possibilities for DMSO than in an 
alkane solvent. Not only could both DMSO or water-derived hydroxide act as bridging ligands, 





Scheme 32: Possible dimerization and cluster products formed in the continuous irradiation study. 
Additionally, a band at 1870 cm-1 begins to grow in after 30 minutes (Figure 57), accompanied 
by a small decline in the other photoproduct bands, suggesting that further decomposition is taking 
place. However, attempts in this work and in the previous work by Moulton to further isolate or 
characterise these species were not successful.231 A small amount of a brown precipitate also 
formed on the ATR prism, which was found to be insoluble in all solvents tested and did not 
contain discernible metal carbonyl bands. No further characterisation of this solid was performed, 
but it would be useful in future work to identify it, as this may be the final Mn-based degradation 
product. It would be desirable to avoid the formation of precipitate in biological systems and so 
understanding what this product is and how it forms could be an important part in the evaluation 
of this CORM system. 
In biological systems, the role of other two-electron donors such as N, O or S residues of amino 
acids should be considered – these could play a role in coordinating to the metal centre as opposed 
to the water molecules. No mechanistic studies have so far been performed on this family of 
complexes to study how the CORM degradation products react with amino acids/proteins, but it 
is known that thermal CORM degradation products do form complexes with proteins, as was 
discussed in Section 1.2.2.2. 
2.4 DFT Calculations 
To aid the assignments made for the tricarbonyl photoproducts following CO loss, the infrared 
spectra of the solvent complexes discussed in Section 2.3 were calculated using DFT. The relative 
energies of the photoproducts were also calculated relative to heptane complex 113hep using the 








Table 7: Assignment of the experimentally observed infrared bands and their unscaled DFT calculated wavenumbers. Relative changes to electronic energies (corrected 
for zero-point energy), E and Gibbs energies at 298 K, G298, for the reaction in Scheme 33 are given at the D3-PBE0/def2-TZVPP//BP86/SVP(P) level with COSMO 
solvent correction in heptane. All calculations were performed by Dr Jason Lynam. 
Complex Predicted Bands / cm-1 Observed Bands / cm-1   
 
IR (1) IR (2) IR (3) IR (4) IR (1) IR (2) IR (3) IR (4) E / kJ mol-1 G298 / kJ mol-
1 113DMSO() 1960 1978 2039 - 1907 2007 - 3 3 
113hep (terminal) 1951 1977 2039 - 1923 1933 2019 - 0 0 
113THF() (3 position) 1957 1976 2038 - 1912 2011 - -1 -3 
113tol() 1958 1977 2039 - - 
 
- - - -5 -4 
113hep (central) 1954 1975 2037 - 1923 1933 2019 - -11 -5 
113Dioxane() 1956 1976 2036 - 1919 2011 - -12 -12 
113H2O() 1957 1981 2051 - - - - -5 -14 
113THF() (2 position) 1954 1972 2034 - 1912 2011 - -13 -14 
113nBu2O() (terminal) 1960 1977 2039 - 1916 2016 - 
 
-9 -15 
113tol() 1949 1969 2030 - 1906 2007 - -23 -15 








113nBu2O() (2-position) 1952 1973 2035 - 1916 
 
2016 - -24 -18 
113H2O(O) 1958 1973 2036 - 1904 1919 2006 - -26 -32 
113Dioxane(O) 1945 1967 2032 - 1899 1911 1999 - -43 -37 
113THF(O) 1943 1966 2030 - 1889 1899 1999 - -44 -37 
113DMSO(O) 1929 1965 2026 - ? 
 
? 
? 1994 - -46 -43 
113nBu2O(O) 1939 1968 2031 - 1891 1909 2004 - -59 -49 
113MeCN 1962 1984 2038 - 1898 
 
2006 - -60 -61 
113DMSO(S) 1946 1978 2039 - ? 
 
? 2007 - -89 -81 




The first point to note is that the DFT calculations systematically overestimate the CO stretching 
wavenumbers of all the photoproducts. This is typical of DFT-calculated vibrational spectra; the 
main cause is that the calculations do not model the anharmonicity of the vibrational modes.168 
As a result, scaling factors derived from experimental data are sometimes applied to correct the 
DFT-calculated band positions, though the scaling factors used vary according to the exact  
DFT method used.168,232,233 As such, it is more informative to study the relative shifts in the bands 
and the trends with different ligands, rather the absolute values of the predicted infrared bands.  
For example, the calculated spectra for THF capture the small downward shifts of each of the 
three carbonyl bands upon conversion of 113THF(σ) to 113THF(O). This is replicated in the 
experimental data, consistent with coordination of the more strongly-donating O-centred ligand. 
Similar shifts are observed in both the experimental and computational spectra for both the 1,4-
dioxane and nBu2O complexes.  
In the cases of THF and nBu2O, C-H bonds from more than one chemical environment are 
available to coordinate to the metal. In THF, σ-complexes involving coordination of a C-H bond 
from the C2 or C3 positions of the ring were calculated, but the predicted infrared bands of two 
σ-complexes are only 3-4 cm-1 apart, rendering the two coordination modes indistinguishable in 
the broad, vibrationally hot early spectra (the full width half maximum of the THF band at 2011 
cm-1 was 9 cm-1 after 10 ps). Similarly, coordination through C-H bonds from different positions 
on the alkyl chains of nBu2O were not distinguishable. 
Looking at the calculated free energy changes, reactions to form the ether solvent σ-complexes 
are much less thermodynamically favourable than formation of their O-bound isomers. This is 
consistent with the σ-complexes being the kinetic products of solvation of the facial tricarbonyl 
fragment, followed by ultrafast isomerisation to the thermodynamically favoured coordination 
mode. Different C-H bonds in the same solvent did not always have similar energies when 
coordinated as σ-complexes. For example, THF bound through a C2 C-H bond is calculated to be 
around 10 kJ mol-1 lower in energy than the corresponding C3 complex, although as discussed 
above isomerisation of the σ-complexes was not observable experimentally. 
In DMSO, the lower bands for both 113DMSO(O) and 113DMSO(S) are significantly lower in 
wavenumber than in 113DMSO(σ), in line with experimental data. The assignment of the O-bound 
and S-bound species can be made by looking at the band at highest wavenumber for each species. 
Experimentally, for the initial photoproduct 113DMSO(σ), this band appears at 2007 cm-1 and in the 
two subsequent complexes it appears at 2007 cm-1 and 1994 cm-1. In the calculations, this band is 
predicted to be in the same position for 113DMSO(σ) and 113DMSO(S), consistent with the overlap 
observed experimentally, with the band for 113DMSO(O) at lower wavenumber, and the assignments 
of 113DMSO(S) and 113DMSO(O) were made on this basis. The difference in the Gibbs free energy 
changes for the formation of complexes 113DMSO(O) and 113DMSO(S) is quite large, with 113DMSO(S) 
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the more stable complex by around 40 kJ mol-1. However, as reported in Section 2.3.6, the bands 
for both 113DMSO(S) and 113DMSO(O) persisted into the μs timescale, suggesting that there is a 
sufficient kinetic barrier to prevent isomerisation on this timescale. Further discussion is provided 
in Section 2.5.2.  
Moving on to the photoproducts in weaker-coordinating solvents such as n-heptane, CH2Cl2 and 
toluene, the experimental data summarised in (Table 7) show a shift to lower wavenumber upon 
displacement of the solvent and formation of complex 113OH2. The magnitude of this shift appears 
quite small in CH2Cl2 and toluene with the bands shifting downwards by only a few wavenumbers, 
though in n-heptane the experimental shift is 10-20 cm-1. The DFT calculations predict that the 
bands for complex 113OH2 will in fact be quite close in wavenumber to the initial solvent 
complexes, with only a small decrease or indeed a small increase in wavenumber of the bands 
upon forming 113OH2. The σ-complex 113OH2(σ) was also calculated and the predicted infrared 
bands are very similar to the 113hep species, at much higher wavenumbers than for 113OH2. 
As with the ether solvents, multiple binding modes are possible for toluene, CH2Cl2, and n-
heptane. The infrared spectra and energies of the different coordination modes available were 
calculated using DFT. In n-heptane, a similar situation occurs as for the ether solvents: even 
though the bands are relatively sharp in this solvent, the stretching wavenumbers of the different 
C-H σ-complexes are unlikely to be distinguishable because they are predicted to lie within 2-3 
cm-1 of one another. As a result, it was concluded that the sharpening and shifting of the bands at 
early times seen in the n-heptane spectra is more likely to be due to vibrational relaxation, as seen 
in all other solvents, than redistribution of different C-H bond coordination isomers.  
When the relative energies of coordination complexes via different C-H bonds in n-heptane were 
considered, the results depended on the DFT methodology employed. At the PBE0/def2-
TZVPP//BP86/SVP(P) level with COSMO solvent correction in heptane, coordination through a 
C-H bond on one of the terminal carbon atoms was more stable than through an internal C-H bond 
by 13 kJ mol-1. However, when a dispersion correction was applied to account for non-covalent 
interactions, the opposite trend was observed, with the ‘internal’ form predicted to be 5 kJ mol-1 
lower in energy than the ‘terminal’ complex. Given the small energy differences involved, 
conclusive determination of the thermodynamically preferred binding mode in n-heptane σ-
complex was not possible computationally. Previous NMR spectroscopic studies of transition 
metal alkane complexes have revealed that a mixture of isomeric C-H bound complexes are 
observable, suggesting that the energy difference between different C-H coordination modes is 
likely to be small.234–236 
Toluene can act as a two-electron donor to the metal centre as a σ-complex via a C-H bond 113tol(σ) 
or through an 2(C=C) π-complex via a double bond 113tol(π). The DFT-calculated infrared 
spectrum for 113tol(σ) is a close match to the other σ-complexes, such as n-heptane, whereas the 
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bands in 113tol(π) were predicted to be ca. 10 cm-1 lower in wavenumber. The experimental data 
resemble the latter case – the bands for the toluene complex are lower than those of σ-complexes 
formed in other solvents. On this basis the product in toluene was assigned as 113tol(π).  
In CH2Cl2, the initial solvent complex could conceivably occur through a σ-complex or 
coordination of a Cl lone pair. Comparison of the experimental band positions with other σ-
complexes shows that the broad absorbance containing the two low-wavenumber bands is lower 
than other σ-complexes, but the higher band is approximately in the same place. The geometry 
optimisations performed resulted only in the Cl-bound solvent complex, leading to the tentative 
assignment of 113CH2Cl2 as a Cl-bound solvent complex.  
The calculated energies of the solvent complexes in n-heptane, CH2Cl2 and toluene help to explain 
why complex 113OH2 forms in these solvents, but not in ether solvents or in DMSO. The calculated 
free energy changes of ligand substitution show that 113OH2 is predicted to be more 
thermodynamically stable than 113hep, 113tol(π), and 113CH2Cl2 but less stable than 113MeCN, 
113THF(σ), 113DMSO(S) and 113DMSO(O), consistent with the experimentally-observed formation of 
113OH2 only in n-heptane, CH2Cl2 and toluene. 
2.5 Discussion 
2.5.1 Triplet Excited State 
Bands assigned to a short-lived triplet excited state were observed in all solvents, although the 
relative amounts formed in each case were not quantified. In each case, this feature decayed 
rapidly in the first few picoseconds as a single exponential, suggesting that only one excited state 
is present. As discussed in Section 2.3.1, the ground state bleach bands recover partially on the 
picosecond timescale, which indicates that the molecules forming this excited state do not 
dissociate but return to the ground state, as happens for the two 3MLCT states in [Cr(bpy)(CO)4]. 
The triplet excited state lifetimes in a range of solvents are compiled in Table 8. Note that 
photolysis at 400 nm in MeCN and at 355 nm in n-Bu2O did produce small changes in the region 
expected for the excited state bands but these were too weak to quantify precisely with a single 
exponential fit. The excited state lifetime in all the solvents are statistically identical.  
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Table 8: Summary of the lifetimes of the non-dissociative excited state.  
Complex Solvent Atmosphere  (excited state) (ps) 
88 [Mn(ppy)(CO)4] MeCN Air 4.1 ± 0.2 
88 n-Heptane Air 3.7 ± 0.8 
88 CH2Cl2 Air 3.6 ± 0.9 
88 Toluene Air 4.6 ± 0.5 
88 1,4-Dioxane Air 5.2 ± 0.5 
88 DMSO Air 3.8 ± 0.3 
88 THF Air 5.6 ± 0.8 
88 THF N2 5.1 ± 0.7 
94 (ester derivative) THF Air 6.3 ± 0.7 
95 (COOH derivative) THF Air 6.1 ± 0.7 
 
This can be compared with the isoelectronic complex [Cr(bpy)(CO)4], in which the photoproduct 
distribution is reversed: the dominant photoproducts are two non-dissociative triplet excited states 
and CO dissociation is a minor pathway.200 In the previous work on [Cr(bpy)(CO)4], pump 
wavelengths of 500 nm [to study 1MLCT(bpy) excitations only] and 400 nm [both 1MLCT(bpy) 
and 1MLCT(CO) excitations] were employed. The low-energy 1MLCT(bpy) transitions dominant 
in [Cr(bpy)(CO)4] are less CO-dissociative than 1MLCT(CO) excited states, resulting instead in 
more intersystem crossing and excited state formation.200 Lowering the pump wavelength 
increased the population of 1MLCT(CO) excitations and led to more CO dissociation, although 
the majority of the bleached intensity still recovered at 400 nm.202 Vlček and co-workers 
suggested that the 1MLCT(CO) states are more CO-dissociative than the 1MLCT(bpy) states but 
that they still lead to some intersystem crossing causing non-dissociative triplet excited state 
formation.200 
The calculations in Section 2.2.2 on page 109 for [Mn(ppy)(CO)4] showed two transitions at 345 
and 342 nm. Due to the proximity of these two bands to one another it was not possible to 
distinguish their different characters from the experimental data obtained at 355 and 400 nm pump 
wavelengths. The 342 nm band was dominated by an orbital transition involving removal of 
electron density from Mn-CO bonding orbitals in the plane of the ppy ligand and population of 
Mn-CO antibonding orbitals of the mutually trans carbonyl ligands. This is similar to the CO-
dissociative 1MLCT(CO) excited states calculated for [W(en)(CO)4] and is likely to contribute to 
the strong observed preference for CO dissociation.  
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It is interesting to consider the role of the other major orbital component implicated in the DFT 
calculated absorption spectrum of [Mn(ppy)(CO)4], which dominates the character of the 345 nm 
excitation in the DFT-predicted spectrum. It is mainly a π→π* transition on the ppy ligand but 
features some transfer of electron density from the Mn to the ppy ligand. Since the DFT 
calculations suggest that this is a prominent contributor to the low-energy excitations of 
[Mn(ppy)(CO)4], it appears that this component also plays a role in the strongly CO dissociative 
photochemistry observed. If this were the case, it would imply that CO dissociation also 
outcompetes intersystem crossing for the excitation dominated by the ppy π→π* orbital 
transition. Calculations of the potential energy surface for this excitation could be used to help 
determine whether this predominately ligand-based excitation is bound along the Mn-COax 
coordinate and thereby influences CO dissociation. It is known that the 1MLCT(bpy) transitions 
have a small barrier to CO loss as indicated by the temperature dependence of the quantum yield 
for CO dissociation. Similar experiments on [Mn(ppy)(CO)4] could be used to determine whether 
CO dissociation has an energy barrier.  
Similarly, an understanding of the relative energies and orbital characters of the triplet excited 
states may help to explain why only a single non-dissociative triplet excited state is accessed in 
[Mn(ppy)(CO)4] when two are sequentially populated in [Cr(bpy)(CO)4].175 The short-lived triplet 
excited state decays to produce a longer-lived triplet and it is this second triplet state that decays 
back to the ground state.175 Calculations of the triplet excited states of [Cr(bpy)(CO)4] did indeed 
predict two low-lying triplet excited states close together in energy, originating from excitation 
of electrons from the Cr(dxy) and Cr(dz2-y2) orbitals into the bpy π* manifold.198  In 
[Mn(ppy)(CO)4] (circa 5 ps), the lifetime of the triplet excited state is close to the shorter of the 
two lifetimes for [Cr(bpy)(CO)4], but appears to decay to the ground state, suggesting that this is 
already lowest-energy triplet excited state.  
Although the behaviours of these two major orbital transitions cannot be deconvoluted in the 
spectra due to the very similar predicted transition energies (342 nm for the predominately 
1MLCT(CO) transition and 345 nm for the mostly ppy π→π* transition), it appears that in 
[Mn(ppy)(CO)4] both these transitions result in CO dissociation outcompeting intersystem 
crossing. It is important to investigate the sub-ps dynamics of [Mn(ppy)(CO)4] photochemistry in 
future work, in order to understand the balance between ultrafast intersystem crossing to produce 
the triplet excited state and CO dissociation.  
Quantum yield measurements would be required to quantify the balance between the excited 
states and its wavelength dependence. These results could then be compared with the 
[Cr(bpy)(CO)4] case. Pryce and co-workers estimated the quantum yield for CO loss in 
[Cr(CO)5C(NC4H4)(Me)] based on the extent of recovery of the bleached bands.194 In this work 
the bleached bands recovered by around 25 % in MeCN giving a very crude estimate of 0.75 for 
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the overall quantum yield for CO loss.194 A problem with estimating quantum yield in this way is 
that the vibrational excitation of the bleached bands, due to relaxation of the excited states and 
geminate recombination, distorts the bleaches. A global fitting approach was considered, but the 
variation in the bleach band shapes during the early times makes it difficult to separate the excited 
state contribution from the other processes – it would be necessary to model how the vibrational 
relaxation and geminate recombination evolve over time to estimate the extent of excited state 
recovery, and such a detailed analysis due to lack of data on these processes. 
2.5.2 Binding Mode and Reactivity of Solvent Complexes 
Using TRMPS in conjunction with DFT calculations, the binding modes of different solvents to 
the facial tricarbonyl moiety and subsequent reactivity have been probed. The assignment of the 
ether solvent and DMSO isomerisations, as well as the toluene binding modes, show how 
vibrational spectroscopy can distinguish different binding modes of many ligands. However, a 
limitation of TRIR spectroscopy apparent in this work is that it is not possible to distinguish the 
different possible C-H σ-complexes formed by the same solvent molecule due to the very similar 
positions of the carbonyl stretching bands in these complexes.  
Low-temperature NMR spectroscopy has proved to be an insightful technique for studying metal 
carbonyl alkane complexes.124 When TRIR studies by George and co-workers showed that 
[CpRe(CO)2(n-heptane)], formed from photolysis of [CpRe(CO)3] in n-heptane, had a lifetime on 
the millisecond timescale at 298 K, the use of NMR spectroscopy to study alkane complexes 
became a possibility, as at lower temperatures the complexes had long enough lifetimes for NMR 
measurements.230 Ball and co-workers incorporated a continuous irradiation system within an 
NMR spectrometer at 180 K, characterising [(Cp)Re(CO)2(cyclopentane)] by its highly shielded 
environment (1H chemical shift of -2.32 ppm) and the reduction in the magnitude of the 1JC-H 
coupling constant compared to the free ligand.237 This was followed up by a similar study in n-
pentane, which showed that all three C-H environments can bind to the dicarbonyl, with a slight 
preference for the internal CH2 C-H bonds compared to the terminal CH3 C-H bonds.234 Very 
rapid exchanging of the geminal C-H bonds was observed, and intramolecular isomerisation of 
the different C-H environments (sometimes called ‘chain-walking’) also took place but was much 
slower, on the timescale 1-10 s-1 at 173 K.234 An energy barrier for chain-walking consistent with 
this timescale (~30 kJ mol-1) was measured for Rh and Ir complexes with ethane prepared by low-
temperature protonation.238 The NMR spectroscopic studies have also been extended to the less 
stable [CpMn(CO)2(alkane)] complexes, with a mixture of three of the four possible C-H bound 
isomers forming in isopentane: the C-H bond on the tertiary carbon was too sterically hindered to 
coordinate.235 Any chain-walking was again slow on the NMR timescale at low temperature 
(130 K).235,236  
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It is therefore likely that similar studies on [Mn(ppy)(CO)3(n-heptane)] would show that a mixture 
of C-H σ-complexes is formed, eventually equilibrating with one another through chain-walking. 
If the barriers to interconversion of the [Mn(ppy)(CO)3(n-heptane)] σ-complexes by chain-
walking are comparable to those measured at low temperature for the 4d and 5d metals Rh, Re 
and Ir discussed above, the half-life for the chain-walking reaction would be on the order of 10 ns 
at 300 K. However, as 3d metals typically form weaker alkane complexes,217 the barrier to chain-
walking may be expected to decrease. If the barrier to chain-walking decreased to ~10 kJ mol-1 
for [Mn(ppy)(CO)4] derivatives, chain-walking would occur on the picosecond timescale at 300 
K. Since the metal-carbon bond strengths are greater at the bottom of a triad it is expected that 
the [Mn(ppy)(CO)3(n-heptane)] σ-complexes may be more labile than the examples in the 
literature where chain-walking barriers have been measured. As a result, and in the absence of 
NMR data for the barrier in [Mn(ppy)(CO)3(n-heptane)], chain-walking on the picosecond 
timescale in [Mn(ppy)(CO)3(alkane)] complexes remains a possibility.  
In ether solvents and DMSO, most or all initial solvent coordination took place via C-H σ-
complexes, followed by isomerisation to the thermodynamically more stable O-bound isomer 
(and S-bound isomer in the case of DMSO) on a timescale strongly dependent on the solvent. 
Initial solvation occurred within the first few ps. Coordination of the solvent on this timescale 
could be considered a stochastic process or dependent on the structure of the first solvation sphere 
of the [Mn(ppy)(CO)4] prior to photolysis – more specifically on the orientation of the solvent 
molecules with respect to the newly-formed Lewis acidic site on the metal. In many of the 
solvents, it is difficult to tell whether the initial solvation is stochastic or not because there are 
many more C-H bonds in the solvents tested than O or S atoms, and the broadness of the 
vibrationally excited early bands makes small amounts of the O- or S-bound photoproducts 
difficult to detect. In 1,4-dioxane the ratio of C-H bonds to O atoms is just 2:1, and the lack of 
significant absorption at lower wavenumbers than the band positions of 113THF(σ) suggests that 
very little 113THF(O) is directly formed.  
Several possible mechanisms for the isomerisation of the C-H bound complexes to their O or S-
bound forms were considered and these are shown in Scheme 34. An intramolecular isomerisation 
could be envisaged, in which the same solvent molecule that coordinated to the metal as a σ-
complex undergoes a migration to coordinate through the O atom. For C-H bonds that are remote 
from an O atom, a chain-walking mechanism of the sort discussed above is invoked, with 
intramolecular isomerisation to a series of σ-complexes until the O atom coordinates to the metal. 
Intermolecular substitution pathways were also considered: these rely on stochastic complexation 
of the photolysed tricarbonyl fragments with different solvent molecules to form labile σ-
complexes in different C-H environments. Again, this sampling of the different coordination 




Scheme 34: Intermolecular and intramolecular mechanisms for isomerisation of 113THF(σ) to 
113THF(O). 
In the case of purely random binding of solvent molecules, it would be expected that the lifetime 
of each σ-complex would simply be proportional to the number of C-H bonds in the solvent 
molecule. However, the ratio of the lifetime of the σ-complex and number of C-H bonds for THF 
is only around half that of n-Bu2O (Table 9), so purely random solvent binding does not account 
for the differences in observed lifetimes. It is possible that energetic or conformational 
preferences in the different solvents prevent solvent complex formation from being completely 
random. 
Table 9: Lifetimes of the C-H to O isomerisation of the three ether solvents reported in Section 2.3.5 




H bonds per O 
Atom 








4 10.8 ± 1.2 12.8 ± 0.8 2.7 3.2 
THF 8 15.1 ± 2.2 18.9 ± 1.6 1.9 2.4 
n-Bu2O 18 103 ± 26 88 ± 29 5.7 4.8 
 
Attempts to calculate a transition state for the ‘chain-walking’ isomerisation of C2-bound to 
113THF(σ) could not 113THF(O) locate a transition state for this pathway. However, both the 
intermolecular and chain-walking isomerisation mechanisms have been investigated 
computationally by Harris and co-workers for the analogous isomerisation of alcohol solvent 
complexes after photolysis of [Cr(CO)6].227 Simulations of the kinetics of the intermolecular and 
intramolecular pathways showed that the two mechanistic pictures are very difficult to 
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distinguish, even when binding energies of the different σ-complexes are taken into account to 
‘bias’ the chain-walk mechanism. The difficulty in distinguishing the mechanisms arises because 
the distribution of the different σ-complexes becomes random in both the chain-walk and 
intermolecular mechanisms.227 
It is interesting to note that Harris and co-workers did not observe a C-H σ-complex in MeOH or 
EtOH.227 Instead, the vibrationally excited bands cooled over the first 30 ps to give the O-bound 
solvent complex, compared to lifetimes of the longer-chain alcohol σ-complexes of  greater than 
100 ps.227 These results were interpreted in terms of fast isomerisation compared to the timescale 
of vibrational relaxation, so that the isomerisation is obscured by the broad bands at early times.227 
In the ether solvents measured in this Chapter,  the overall isomerisation reaction takes place up 
to an order of magnitude faster (lifetime of ca. 10 ps in 1,4-dioxane) than for the fastest 
isomerisations observed in alcohol solvents.227 Meanwhile, the methyl groups in DMSO did form 
C-H σ-complex at short times, which decays with a lifetime of around 10 ps, in agreement with 
the observations of Harris and co-workers that σ-complex coordination and isomerisation takes 
place for alcohols such as propan-2-ol, the most similar structural analogue to DMSO that was 
studied.227 It is therefore surprising that little or no σ-complex with the [Mn(ppy)(CO)3] fragment 
appeared to form to the methyl group in MeCN or to the two C-H bonds in CH2Cl2. For the 
isomerisation to be completely obscured by vibrational cooling in these experiments, 
isomerisation would have to be extremely fast, with a lifetime of only a few picoseconds. 
However, it could also be the case that initial solvation yields direct formation of 113S as the 
major pathway in MeCN and CH2Cl2, rather than an initial C-H σ-complex. Indeed, DFT 
calculations did not return a σ-complex for these complexes, only 113MeCN and 113CH2Cl2. 
Although a transition state was not located for σ-complex migration, calculations on the migration 
of DMSO from 113DMSO(O) to the more thermodynamically-favoured 113DMSO(S) found the 




Figure 58: Structure of 113DMSO(O), 113DMSO(S)] and [TSDMSO] showing Mn-O and Mn-S bond lengths. 
Atom colours: carbon grey, hydrogen white, manganese pink, nitrogen blue and oxygen red. Energies 
are Gibbs energies at 298 K at the D3-PBE0/def2-TZVPP//BP86/SVP(P) level with COSMO solvent 
correction in DMSO. 
The transition state for conversion of 113DMSO(O) to 113DMSO(S) lies 48 kJ mol-1 higher in energy 
than 113DMSO(O). The Mn-O and Mn-S distances increase considerably in the transition state 
compared to the bound complex, such that DMSO is only weakly bound to the metal in the 
transition state. This suggests that an intramolecular shift from 113DMSO(O) into 113DMSO(S) has a 
somewhat dissociative character rather than being a ‘slip’ from the O to S atom. This could also 
be interpreted as an intermolecular mechanism where a second DMSO ligand comes in to 
coordinate after elongation of the Mn-O distance. The barrier of 48 kJ mol-1 suggests a half-life 
for the interconversion of 113DMSO(O) to 113DMSO(S) on the timescale of tens of microseconds. 
Experimentally, however, the interconversion of 113DMSO(O) to 113DMSO(S) was not observed: in 
the TRIR experiment the bands for 113DMSO(O) and 113DMSO(S) were still visible at 800 μs, whilst 
in the continuous irradiation experiments both 113DMSO(O) and 113DMSO(S) decayed too rapidly to 
build up in concentration and be observed. 
In the future, it would be interesting to ‘spike’ the THF or DMSO isomerisation experiments with 
water (or D2O to avoid overlap with the metal carbonyl region) as a competitor to solvent binding 
and to assess whether the water complex of 113 can form at short times. In such an experiment, 
it might be expected that the solvent σ-complex (and possibly the O/S-bound forms) would form 
in competition with the water complex at short times. As discussed in this Section, there is 
unlikely to be a water σ-complex as no such complex was seen for MeCN or CH2Cl2, but a 
‘spiked’ organic solvent experiment would be a useful method to test for this, circumventing the 
low solubility of [Mn(ppy)(CO)4] in water. This kind of experiment may also provide more 
information about whether the solvent binding at early times is truly statistical or whether the 
composition of the solvation sphere around the metal leads to a bias towards one or the other of 









2.5.3 PhotoCORM Design 
The comparison of the TRIR studies on [Mn(ppy)(CO)4] in this Chapter with previous work on 
[Cr(bpy)(CO)4] illustrates how changes to the metal, oxidation state, and nature of the co-ligands 
can result in large changes to the fundamental photochemical behaviour of photoCORMs, in a 
pair of isoelectronic complexes. The dominance of CO dissociation over non-dissociative excited 
state formation in [Mn(ppy)(CO)4] is a desirable behaviour for a photoCORM as it can reduce the 
intensity of irradiation required. Further study of the ultrafast intersystem crossing measurement 
of the quantum yield for CO loss from [Mn(ppy)(CO)4] and derivatives may be informative in 
controlling this balance. 
In all solvents tested, CO loss is followed by solvation to form fac-[Mn(ppy)(CO)3(S)]. For a 
CORM in aqueous solvent, direct formation of fac-[Mn(ppy)(CO)3(OH2)] is therefore expected, 
similar to the [Mn(tpm)(CO)2(OD2)]+ observed by Nuernberger and co-workers.191 Complex 
113OH2 was prepared by substitution of an alkane ligand by trace water in this work but the low 
solubility of [Mn(ppy)(CO)4] in aqueous solvent precluded study of its direct formation in water. 
This tricarbonyl water complex is stable at least into the microsecond timescale from the TRIR 
experiments, whilst the analogous acetonitrile complex is also stable. No other photoproducts 
from the prior mass spectrometry study in Section 1.4 were observed to form on the microsecond 
timescale or faster. Indeed, the bands for 113OH2 appeared to persist for minutes to hours in n-
heptane in continuous LED irradiation experiments monitored by in situ infrared spectroscopy, 
and the bands for 113MeCN were also observable on this timescale when the experiment was 
performed in MeCN. Subsequent degradation of the tricarbonyl species may therefore be slow 
after initial CO loss under these conditions. The in situ irradiation experiments also suggested that 
thermodynamically favourable multinuclear OH-bridged Mn tricarbonyl clusters may form when 
113OH2 degrades. The study of the photochemistry and chemical reactivity of these clusters may 
prove informative for understanding the degradation method of this family of photoCORMs. Such 
clusters were not within the mass range of the detector in the ESI mass spectrometry studies159 
and were not isolated in this work or a previous study where similar bands were observed in 
DMSO.231   
2.5.4 Implications of TRIR Results for Catalysis 
The photochemistry of [Mn(ppy)(CO)4] is of additional interest due to its relevance to catalysis. 
The Mn-catalysed alkenylation of sp2 centres is thought to involve [Mn(ppy)(CO)4] in catalyst 
activation, and is a desirable synthetic transformation due to its use of an Earth-abundant metal 




Scheme 35: General catalytic cycle for a manganese carbonyl-catalysed alkenylation reaction. R = 
aryl. 
The proposed mechanism, based on DFT calculations and NMR spectroscopic characterisation, 
involves cyclometallation of the substrate 2-phenylpyridine to produce [Mn(ppy)(CO)4].241 The 
catalyst activation is completed by loss of an axial CO ligand and coordination of an alkyne 
substrate molecule. Insertion of the alkyne into the Mn-C bond of the ppy ligand can then take 
place giving intermediate 120, an analogue which has been characterised by NMR 
spectroscopy.242 Coordination of a second 2-phenylpyridne ligand is then followed by protonation 
of the alkene by the alkyne starting material to product.  
 In the current catalytic methodologies, high temperatures are required to encourage CO 
dissociation to activate the catalyst.243 However, a photochemical method for catalyst activation 
could also be envisaged, and the characterisation of some [Mn(ppy)(CO)4] photochemistry in this 
Chapter has led to investigations in this area.244 Further, TRIR studies of [Mn(ppy)(CO)4] have 
since been performed with a focus on alkyne solvents: the wide range of timescales encompassed 
by a TRMPS experiment allows structural characterisation of the alkyne π-complex and its 
insertion into the Mn-C bond to the ppy ligand, providing experimental validation of the proposed 
mechanism in Scheme 35.244 
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The results of this work also suggest that wider implications for solvation of transition metal 
catalysts can be probed using complex [Mn(ppy)(CO)4]. In many catalytic processes, pre-catalysts 
are activated by ligand loss and the catalytic cycles involve steps in which ligand dissociation 
leads to coordinatively unsaturated complexes.245 In such cases, it is likely that weak interactions 
with solvent molecules occur, even though such unsaturation is formally described as a ‘vacant’ 
coordination site.  
One example where solvation is believed to play a critical role in is the isomerisation of allyl 
alcohol to propanal using the photochemically-activated precatalyst [Fe(CO)5]. The isomerisation 
reaction works well in alkane solvents but poorly in stronger donors such as alcohols or 
pyridine.246 Strongly-coordinating solvents such as alcohols or pyridine were proposed to compete 
with the alkene substrate to bind to the 1[Fe(CO)4], forming stable [Fe(CO)4(S)] solvent 
complexes that inhibit the formation of the on-cycle intermediate [Fe(CO)3(η2-alkene)] 
complex.246 
Understanding the structure and reactivity of catalyst solvent complexes may therefore assist in 
designing new catalysts and rationalising their reactivity. The complex featured in this work, 
[Mn(ppy)(CO)4], could be a useful tool in understanding how solvent molecules interact with 
Lewis acidic ‘vacant’ metal coordination sites. The structural information from, and sensitivity to 
electronic environment of, the carbonyl reporter ligands in TRIR spectroscopy provides a handle 
to characterise the nature of metal-solvent complexes. It is also advantageous for studying metal-
solvent interactions that photodissociation is the major photoproduct for [Mn(ppy)(CO)4] and the 
excited state bands only complicate the spectra for a few ps, allowing the chemistry of the solvent 
complexes to be assessed without convolution of the spectra from other photoproducts. 
2.6 Conclusions 
The study of the ultrafast photochemical behaviour of [Mn(ppy)(CO)4] in this Chapter has 
provided insight into the primary photochemistry of this family of photoCORMs. The qualitative 
balance of CO loss and non-dissociative excited state formation is reversed compared to the 
isoelectronic [Cr(bpy)(CO)4]. The orbital contribution involved in the relevant transitions were 
studied by DFT calculations to rationalise this: the band irradiated for [Mn(ppy)(CO)4] contains 
a transition resembling a strongly CO-dissociative 1MLCT(CO) whereas the lowest-energy 
excited states for [Cr(bpy)(CO)4] are less CO-dissociative 1MLCT(bpy) states. 
The chemistry of the photoproducts after CO loss was studied from ps to μs timescales using 
TRIR spectroscopy and using in situ infrared spectroscopy in continuous irradiation experiments. 
In weakly-coordinating solvents such as n-heptane, toluene and CH2Cl2, initial solvent 
coordination was followed by substitution with a water ligand to form fac-[Mn(ppy)(CO)3(OH2)]. 
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In ether solvents and DMSO isomerisation reactions form C-H σ-complexes to the more stable 
O- and S-bound forms were observed, with lifetimes of 10-100 ps. This work shows how TRIR 
studies of [Mn(ppy)(CO)4] can provide fundamental insight into metal carbonyl photochemistry 




3 Synthesis and Evaluation of CO-Release from a Series 
of Ferrocenyl CORMs 
Many of the CORMs synthesised and examined in the wider field can be broadly categorised as 
displaying one of three release mechanisms: thermally triggered (i.e. unstable in aqueous 
solution), protein-triggered and photochemically triggered (Chapter 1).107,247 However, it is 
desirable to develop CORMs that can release CO in response to other triggers, for example the 
redox state of target cells, to gain new methods for selectivity in CO release.  
This Chapter outlines the synthesis and characterisation of three novel Mn(I) tetracarbonyl 
CORMs containing the redox-active group ferrocene. The impact of using a redox-active co-
ligand in a CORM is evaluated by studying the electrochemistry and CO release properties of the 
Mn(I) complexes.  
The synthetic route to complex 134 was developed in collaboration with Samuel Andrew, an 
MChem student whom I mentored in the laboratory, and the DFT calculations on complex 134 
were performed by Professor Ian Fairlamb. 
3.1 Background 
The redox environment within a cell can be characterised by the concentrations of the redox-
active compounds, e.g. glutathione (GSH) and glutathione disulfide (GSSG) (Scheme 36).248 The 
2GSH/GSSG couple is connected to other key redox-active molecules within the cell through its 
reactivity. For example, the reduced form of the cofactor nicotinamide adenine dinucleotide 
phosphate (NADPH) reduces GSSG to 2GSH using the enzyme glutathione reductase, whilst 
GSH can be oxidised back to GSSG by reactive oxygen species such as peroxides.248 The redox 
chemistry of thiols is important in many proteins due to the thiol group present in the amino acid 
cysteine. Disulfide linkages between cysteine residues are critical for the structure and function 
of proteins.249 
However, it is the 2GSH/GSSG couple that is often considered the ‘redox buffer’ of mammalian 
cells, as its two components are present in millimolar concentrations, much higher than other 
individual redox-active molecules.250 The concentrations of the two components of the 
2GSH/GSSG couple can therefore be used to gauge the redox environment of the cell. Different 
potentials are associated with the status of the cell.248,251 Proliferation occurs in a reducing 
environment (ca. -240 mV vs NHE), whilst differentiation (ca. -200 mV) and apoptosis (ca. -170 
mV) take place at successively higher potentials.248 The concentrations also vary within different 
compartments of the cell, so that there is highly localised control of the redox environment.248 For 
example, in the endoplasmic reticulum, where protein synthesis takes place, the redox couple 
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2GSH/GSSG reflects a more oxidising environment than the cytosol, which has been attributed 
to the need for disulfide bond formation in the endoplasmic reticulum during protein synthesis.252  
 
Scheme 36: The glutathione (GSH) and glutathione disulfide (GSSG) redox couple is the main 
intracellular redox buffer. 
As well as being indicative of the status of healthy cells, changes in redox state are important in 
disease. A wide range of disease states are associated with the production of reactive oxygen 
species which are then involved in redox signalling,253 including in cardiovascular disease and 
cancer, for which CO may be a future treatment. Whether the production of reactive oxygen 
species is a cause, a symptom of, or a response to a disease, these changes in the redox 
environment may be exploitable in drug design, including CORMs. The immune system itself 
also uses redox potentials: for example, phagocytes can respond to pathogens by engulfing them 
and producing superoxide anions (which are converted into hydrogen peroxide) to destroy the 
pathogenic organism.254 This inherent oxidative response of the immune system could be 
exploited to achieve selective CO release, the CORM acting alongside the immune response.  
The importance of the redox environment in which CO release takes place is beginning to be 
investigated and exploited. Studies on non-metal photoCORM 129 (Scheme 37) exploited the 
redox buffer of the cell by demonstrating the thiol-sensing properties of this compound, resulting 
in CO release sensitive to the cellular environment.255 PhotoCORM precursor 125 reacts with 
thiols to generate photoCORM 129, which is fluorescent, enabling sensing of this common redox-
active functional group.255 The thiols are soft nucleophiles and attack the Michael acceptor, 
followed by attack of a second nucleophile at the carbonyl (e.g. an amine for amino acids such as 
cysteine)256 to hydrolyse the ester, forming 129 and cyclic by-product 130. Subsequent CO loss 
could then be monitored as CO release results in the formation of non-fluorescent products.255 
The concentrations of GSH and GSSG are several orders of magnitude higher inside the cell than 
in extracellular environments and therefore represent a target for obtaining CO release within 






Scheme 37: Reaction of compound 125 with thiols leads to the formation of photoCORM 129.255 An 
example reaction mechanism for the reaction of 125 with cysteine is shown. 
Additionally, it has been shown that CO loss from photoCORM 131 (Scheme 38) may be 
triggered not only photochemically, but also by chemical reaction with the strong oxidant H2O2, 
a constituent of cellular reactive oxygen species.257 However, more than two equivalents of the 
very reactive H2O2 were used to garner CO release - it was unclear whether such a ratio of CORM 
to oxidant would occur physiologically. To further extend this work, it would be desirable to gain 
greater control of the redox potential leading to CO release by altering the metal and co-ligands. 
Controlling the potential of redox-triggered CO release could then lead to specific targeting of 




Scheme 38: PhotoCORM 131 can be activated by reaction with H2O2 as well as by visible light.257 
It is well-known that weaker σ-donors and stronger π-acceptors result in higher redox potentials 
required to oxidise metal centres,258 a principle explained by the lower electron density present 
on the metal in the presence of such ligands. This point illustrates the compromise that must be 
struck between the number of equivalents of CO contained within a CORM and achieving a redox 
potential that is biologically relevant, which makes direct redox-triggered CO release at the metal 
carbonyl centre challenging. For example, the studies on the amino carbene complex 
[(CO)5CrC(NC4H8)CH3] showed a small amount of CO release upon oxidation, but again at a 
strongly oxidising potential of +360 mV vs Fc/Fc+.194  
The introduction of a redox active co-ligand to promote CO release may help to circumvent this 
problem by promoting reactivity at more relevant redox potentials. The incorporation of a well-
studied electrochemical tag into a CORM also provides a mechanistic reporter group that could 
be used to study CORM degradation. 
A good example of a redox-active moiety that can be introduced is ferrocene. Ferrocene is stable 
in air and water. It has low chronic toxicity in mammals,259 and many of its derivatives have low 
toxicity to healthy cells.260 The extensive synthetic chemistry of ferrocenyl compounds has 
allowed a range of ferrocenyl drug candidates to be synthesised and studied. Functionalisation of 
the ferrocene co-ligand could be exploited to modulate the redox potential and influence CO 
release. Ferrocenyl derivatives have already been shown to be effective against cancer cells,261 
malaria,262 and as broad-spectrum antimicrobials.263–266 
One of the biggest successes to date in the development of ferrocenyl drugs has been the 
development of the antimalarial drug ferroquine.267 This ferrocenyl derivative of the antimalarial 
chloroquine and is used as a racemate (Figure 59). Ferroquine has yielded promising results in 
phase II clinical trials.268 Combination therapy with another antimalarial agent, eliminated the 




Figure 59: Structures of Chloroquine and Ferroquine. 
Two modes of action are believed to contribute to the effects of ferroquine. The first is binding 
through the quinoline moiety to the protein haematin, preventing aggregation of this protein into 
haemazoin.270 This is a key step in how the Plasmodium parasites dispose of toxic free haem 
groups and inhibiting the disposal of haem kills the parasite. The second effect is attributed to the 
ferrocenyl moiety.270 The highly oxidising environment inside the parasite’s digestive vacuole, 
used by eukaryotic cells for digestion and excretion, causes oxidation of the ferrocenyl group to 
form ferricenium cations.270 The ferrocene/ferricenium couple enables ferrocenyl compounds to 
participate in Fenton-type chemistry271 where the FeII/FeIII centre catalyses the disproportionation 
of hydrogen peroxide into hydroxide and hydroperoxide radicals: 
             Fe2+ + H2O2 → Fe3+ + HO• + OH−                                                               (Equation 5) 
                             Fe3+ + H2O2 → Fe2+ + HOO• + H+                            (Equation 6) 
In this way, the ferrocenyl group affects the oxidative environment around it by producing 
damaging radical reactive oxygen species. It was recently observed that ferroquine also possesses 
anti-cancer activity, inhibiting the growth of prostate cancer tumours in an in vivo study.272 
Ferrocifen and its derivatives serve as another example of a well-studied family of ferrocenyl 
therapeutic compounds.273 This family of compounds is based on analogues of the breast cancer 
drug 4-hydroxytamoxifen (Figure 60). Incorporation of the ferrocenyl moiety still enables the 
compound to bind to its oestrogen receptor target, albeit less strongly than 4-hydroxytamoxifen.273 
The ferrocenyl moiety is associated with cytostatic activity preventing tumour growth.274,275 Many 
structural analogues have since been synthesised, including varying the length of both alkyl 
chains, replacing the phenol functional group with other hydrogen-bonding moieties, and using 
other metallocenes in place of ferrocene, giving a diverse family comprising hundreds of 




Figure 60: The replacement of a phenyl group in the active anti-cancer compound tamoxifen with a 
ferrocenyl group gives ferrocifen, the parent compound of a family of anti-cancer drug candidates. 
The aim of the work in this Chapter was to synthesise and characterise ferrocenyl CORM 
complexes 132-134. Complexes 132 and 133 are based on the air- and water-stable Mn(I) 2-
phenylpyridyl (ppy) tetracarbonyl framework. As introduced in Section 1.4, the Mn(I) ppy 
complexes are typically air- and water-stable and some of the Mn(I) ppy complexes and their 
degradation products have favourable toxicity profiles.159. Stability to air and water is 
advantageous when developing new CO release triggers as it means that the background 
degradation of the complex is slow, making any other CO release triggers more selective.   
 
Figure 61: Three ferrocenyl CORM targets for synthesis and characterization.  
The synthesis of Mn(I) ppy complexes 132-134 was to be followed by an evaluation of their 
thermal, photochemical, and electrochemical CO release properties. The effect of different linker 
lengths between the Fe and Mn centres in the Mn(I) ppy three complexes can be studied. 
Complexes with a large separation of the Mn tetracarbonyl and ferrocenyl units could be attractive 
if CO release could be accompanied by additional therapeutic benefits from the ferrocene. On the 
other hand, incorporating the ferrocenyl group closer to the site of the CO release would be 
expected to increase the likelihood of a direct redox-triggered CO release process. 
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3.2 Synthesis of Ferrocenyl CORMs 
3.2.1 Synthesis of Compound 132 
The synthetic route to compound 132 is similar to previous structurally-related CORMs that use 
the same modular design. Previous work on the synthesis of biotinylated CORM 48 (Section 
1.2.2.5), led to a synthetic pathway to alkyne 46.137 The triazole ring of 48 was then produced in 
the final step using a copper(I)-catalysed variant of the Huisgen [3+2] dipolar cycloaddition 
reaction (Scheme 40).137 
 
Scheme 39: Prevously-used conditions for click chemistry with alkyne 46. 
The same synthesis can be applied to Mn(I) ppy complex 132 to install a ferrocenyl group that is 
remote to the Mn carbonyl moiety (Scheme 40). 
 
Scheme 40: The triazole ring of compound 132 and synthetic equivalents needed for the 
retrosynthesis, 135 and 46. 
The manganese (I) centre in the product is derived from dimanganese decacarbonyl, 42 (Scheme 
41). Reduction in a sodium amalgam produces Na+[Mn(CO)5]- which readily undergoes 
nucleophilic substitution with benzyl chloride to produce NaCl and [BnMn(CO)5], 87, a well-
known precursor to manganese-based CORMs.184 The bromide-containing analogue of this 
species, [BrMn(CO)5], which can be synthesised by adding Br2 to oxidise [Mn2(CO)10],276 could 
also have been used to perform the cyclometalation, although the reaction is less clean and 
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additionally requires a base due to the ‘σ-complex-assisted metathesis’ mechanism of this 
reaction.241 
 
Scheme 41: Synthesis of the cyclometalating reagent [BnMn(CO)5]. 
Alkyne intermediate 46, a convenient building block for a modular approach to CORM design, 
was synthesised in good yield using a previously developed synthetic route.137 The steps involved 
in the preparation of alkyne 46 are summarised in Scheme 42.  
 
 
Scheme 42: Synthesis of ‘clickable’ alkyne complex 46. The yields are those achieved in this work. 
The first step in the synthesis was to construct the 2-phenylpyridine moiety, beginning with the 
Suzuki-Miyaura coupling of 2-bromopyridine, 136, with 4-hydroxybenzeneboronic acid, 137, 
catalysed by Pd and mediated by base. Subsequent deprotonation of the alcohol 138 with sodium 
hydride, followed by nucleophilic substitution with propargyl bromide produced alkyne 139.  
Typically, the cyclometalation step would be performed by simply heating the phenylpyridine 
ligand together with benzyl pentacarbonyl manganese(I) in a hydrocarbon solvent. However, in 
the case of alkyne-containing species 139, there is a complication: the alkyne must first be 
protected with a triisopropylsilyl (TIPS) group for the cyclometalation to produce the desired 
product. Cyclometalation of 139 did not proceed cleanly, giving multiple products. This may be 
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because unprotected alkyne can bind to the Mn centre in an undesired side reaction that leads to 
insertion of the alkyne into the Mn-C bond of the ppy.137 Such insertion reactions play a key role 
in the application of Mn carbonyl complexes in catalysis.241  
However, installation of the bulky TIPS group prevents the undesired addition of the alkyne to 
the manganese centre. Similar reactions are known in the literature; the yields of these reactions 
are minimised when the alkynes are TIPS-protected.277 Following the cyclometalation, 
deprotection was achieved in good yield with tetra n-butylammonium fluoride (TBAF) trihydrate. 
Despite this reaction inducing some dissociation of the phenylpyridine from the manganese, 
TBAF trihydrate in a CH2Cl2/acetonitrile mixture was previously found to be a superior 
deprotecting agent to KOH, KF, and dry TBAF in THF.137 In any case, the desired product and 
the traces of free ligand from deprotection reaction were separable by flash column 
chromatography on silica gel.  
The second component of the Huisgen cycloaddition, azidoferrocence, 135, was made from 
ferrocene in two steps (Scheme 43) using literature reactions.278,279   
 
Scheme 43: The two-step synthesis of azidoferrocene, compound 135, from ferrocene. 
In the first step, ferrocene was lithiated using t-butyl lithium and then brominated with 
1,2-dibromotetrachloroethane to produce bromoferrocene. When working with tBuLi it is critical 
that appropriate safety precautions are taken to protect against the highly pyrophoric nature of 
this reagent.   
 It is often difficult to separate ferrocene, mono- and dihalogenated ferrocenes by conventional 
techniques. A novel purification protocol developed by Long and co-workers allows the 
brominated product to be separated from unreacted ferrocene based on the redox potentials of the 
two compounds.280 The redox potential for the oxidation of bromoferrocene lies some 170 mV 
above that of the ferrocene/ferricenium couple, allowing removal of the ferrocene under 
moderately oxidising conditions.280 The crude mixture suspended in hexane was repeatedly 
washed with an aqueous solution of 200 mM FeCl3 to oxidise the ferrocene. The resulting 
ferricenium ions partitioned into the aqueous layer whilst the unoxidised bromoferrocene 
remained in the hexane layer. 
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The second step in the synthesis of 132 is a copper (I)-catalysed substitution reaction with sodium 
azide, which produced azidoferrocene in moderate yield.279 The low yield was attributed to 
decomposition of the azidoferrocene product in solution during the reaction, but sufficient 
material for the final step was obtained. 
Finally, target molecule 132 was synthesised from the two fragments using the copper(I)-
catalysed Huisgen cycloaddition (Scheme 44). The procedure for the synthesis of analogous 
compounds by Ward137 was adapted for this work; reactions were performed at twice the catalyst 
and reductant loadings, reducing the reaction time from 40 h to 18 h and resulting in a yield of 
61%.  
 
Scheme 44: The final step in the synthesis of compound 132. 
Monitoring of the reaction by TLC analysis showed azidoferrocene degrading faster than the 
alkyne 46. Some of the unreacted alkyne 46 was recovered during purification of the target by 
column chromatography. This suggests that using even larger amounts of CuSO4 and sodium 
ascorbate may improve the yield further as more of the azide will react before it degrades. An 
additional improvement in the yield would be worth the use of these comparatively inexpensive 
reagents. However, the good yield of 61% in this experiment provided an adequate amount of 
material for further study. 
Complex 132 was extensively characterised. The carbonyl region of the infrared spectrum closely 
resembles that of alkyne 46 and ppy parent compound 88, showing four strong carbonyl bands at 
2076, 1991, 1977 and 1931 cm-1 consistent with the Cs and pseudo-C2v symmetries discussed in 
Chapter 2. The carbonyl stretches are essentially unchanged from the starting material, which is 
expected given the distance from the carbonyls to the site of the reaction. This confirms that the 
Mn(I) tetracarbonyl centre was carried through the reaction and purification steps intact. No loss 
of axial CO ligands or coordination of the triazole to the Mn(I) centre took place during the 
reaction or purification. The terminal alkyne C-H stretch at 3302 cm-1 has also been lost during 
the reaction. The strong azide stretch at around 2100 cm-1 seen in the azidoferrocene starting 
material was also lost, whilst new bands at 1567 and 1519 cm-1 in the product may be attributed 
to stretches within the triazole ring in the product.  
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Figure 62: Infrared spectrum of complex 132 recorded in CH2Cl2 solution. 
Characterisation by NMR spectroscopy allowed full assignment of the proton NMR spectrum 





Figure 63: A 700 MHz 1H NMR spectrum of complex 132 in CDCl3 at 298 K. Expansions of the spectrum are shown in the insets. 
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Proton A was assigned on the basis of its high chemical shift of 8.72 ppm; a deshielded doublet 
from this position on the ring is a distinguishing feature of 2-phenylpyridines.281 By using the 1H-
1H COSY spectrum, B, C and D were then assigned by following the correlations around the 
pyridyl ring. Nuclear Overhauser effects were observed between the pairs of protons F and H, and 
G and H, suggesting that these protons are spatially close (within ca. 5 Å). Given that G is a 
singlet, protons F and G can be assigned, leaving E as the remaining aromatic resonance in the 
ppy moiety. 
In addition to H, three other two-proton resonances are seen between 4 and 5 ppm. One of these 
three is a singlet at 4.82 ppm and must be the isolated CH2 protons I as it is the only other expected 
two-proton singlet. The other two are triplets from protons K and L of the ferrocene ring. A key 
finding was the presence of a nuclear Overhauser effect between the triazole proton J (the 
remaining singlet in the aromatic region at 7.84 ppm, formerly the terminal alkyne proton) and 
the pair of protons K on the ferrocene ring (4.83 ppm), showing that these protons from the two 
reagents are now in the same region of the same molecule. The other remaining triplet at 4.26 
ppm is therefore L, and M is clearly the five-proton singlet at 4.22 ppm. 
The accurate mass ESI mass spectrum shows the pseudo molecular ion corresponding to 
protonated [132]+ with an m/z value of 617.0292. Interestingly, a small set of peaks for the 
protonated 132 with the loss of one molecule of CO is also seen, though this degradation may be 
occurring within the spectrometer and no evidence for a tricarbonyl species has been noted in the 
other characterisation methods.   
Crystals of 132 were obtained by layering n-pentane on top of a chloroform solution of 132 in an 
NMR tube. Yellow needle-like crystals were obtained from which a suitable single crystal for X-
ray diffraction was found. The structure is shown in Figure 64. Comparison with other Mn(I) 
phenylpyridine complexes indicates a slight distortion from the idealised octahedral structure, for 
example the C(1)-Mn(1)-N(1) bond angle is 80.04(18)ᵒ due to the rigidity of the 2-phenylpyridine 
system. There is also distortion of the trans-carbonyls at 168.8(2)ᵒ for the C(14)-Mn(1)-C(15) 
angle. These angles are very close (within one degree) of other known Mn(I) ppy complexes.184,282 
The bond lengths within the first coordination sphere of the Mn in complex 132 are also 
essentially identical to structures of [Mn(ppy)(CO)4] and related complexes with derivatised ppy 
ligands.184,282 As expected, the Mn-C bonds trans to the N and C donors of the ppy ligand are 
shorter than those trans to CO ligands, reflecting the stronger donor properties of the N and C 





Figure 64: An X-ray crystal structure of compound 132 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å):  C(1)-Mn(1) 
= 2.056(5), C(12)-Mn(1) = 1.836(6), C(13)-Mn(1) = 1.805(6), C(14)-Mn(1) = 1.853(5), C(15)-Mn(1) = 
1.867(5), N(1)-Mn(1) = 2.059(4). Selected bond angles (ᵒ):  C(1)-Mn(1)-N(1) = 80.04(18), C(12)-Mn(1)-
C(1) = 174.9(2), C(14)-Mn(1)-(C15) = 168.8(2), C(13)-Mn(1)-N(1) = 172.65(19), C(13)- Mn(1)-C(12) = 
92.3(2), C(15)-Mn(1)-(C1) = 84.1(2) 
3.2.2 Synthesis of 133 
Bromo-substituted CORM 133 has previously been demonstrated as a competent coupling partner 
in Suzuki-Miyaura cross-coupling reactions with arylboronic acids, as discussed in Section 1.4184 
Direct functionalisation of CORMs is synthetically appealing to facilitate access to a wide range 
of structures, so similar chemistry was attempted to synthesise compound 132.  
A Suzuki-Miyaura cross-coupling was performed on cyclometalated bromide 91 to test whether 
132 could be synthesised directly. The initial reaction conditions developed for functionalisation 




Scheme 45: Conditions for direct CORM functionalization with compound 133 unsuccessfully 
applied to ferroceneboronic acid. 
Using the conditions shown in Scheme 45, no trace of product was detected by proton NMR or 
IR spectroscopy, nor by ESI mass spectrometry. Ferroceneboronic acid is a more challenging 
substrate for a Suzuki-Miyaura coupling than many arylboronic acids due to its increased 
susceptibility to electrophilic aromatic substitution.283 This leads to rapid protodeboronation, 
which causes ferroceneboronic acid to degrade to ferrocene – the rate of deboronation is at least 
106 times faster for FcB(OH)2 compared to PhB(OH)2.283 Ferrocene was observed in the crude 1H 
NMR spectrum after the reaction in Scheme 45. Furthermore, the literature procedures for Suzuki-
Miyaura cross-couplings with ferroceneboronic acid generally require temperatures of 70 ᵒC or 
above.284–286 Such high temperatures are not feasible when using starting material 87, as the ‘Mn-
phenylpyridine’ moiety begins to degrade when heated above 70 ᵒC, yielding the protonated ppy 
ligand.184  
A low-temperature catalytic system to couple starting materials 91 and 144 was required. An 
excellent candidate for this is Buchwald’s dimeric palladium mesylate pre-catalyst 97 (Scheme 
46).185 This pre-catalyst is apparently activated more rapidly than traditional palladium 
precatalysts and its use has been demonstrated with substrates such as furanboronic acid that are 
prone to protodeboronation and traditionally considered difficult substrates. Crucially, the 
procedure requires only mild temperatures, typically proceeding in less than one hour at room 




Scheme 46: The attempted application of palladium mesylate dimer pre-catalyst 97 to the synthesis 
of 133. 
After 3 hours at 40ᵒC, a faint new spot was visible on the TLC plate, matching the Rf of the free 
phenylpyridine ligand. Again, no product 133 could be identified using TLC, NMR or mass 
spectrometry. Indeed, experiments at both 40 and 60 ᵒC with pre-catalyst 97 did not yield any 
conversion to product by 1H NMR spectroscopy or ESI mass spectrometry, suggesting along with 
the nature of the successful reactions in the literature that a higher temperature is required for 
ferroceneboronic acid, above that at which the Mn carbonyl moiety degrades.  
Inversion of the functional groups on the starting materials was considered for the Suzuki-
Miyaura reaction. In this case, the CORM would be functionalised with a boronic acid (144) for 
coupling with bromoferrocene (Scheme 47). However, the Mn carbonyl moiety may not tolerate 
the acidic conditions used to unmask the boronic acid (see Section 3.4.3), so instead the boronic 
acid functional group would have to be carried through the cyclometalation, a further challenge 
in functional group tolerance. The synthesis of bromide 91 in good yield, in fewer steps, makes it 
a generally more useful building block for CORM functionalisation, when less challenging 
boronic acids are used. Although further catalysts and conditions tolerant to the Mn(CO)4 moiety 




Scheme 47: Possible retrosynthesis for a boronic acid CORM suitable for Suzuki-Miyaura couplings. 
As a result, the more straightforward synthetic route of preparing protonated ligand 148 and then 
cyclometalating was attempted. This removes the temperature constraints in the Suzuki-Miyaura 
cross-coupling as the Mn centre is installed after the cross-coupling. Compound 148 has been 
previously synthesised using a Grignard reagent in a modest yield of 38%287 (Scheme 48) with 
starting material 147 accessible by Suzuki-Miyaura coupling of 4-bromophenylboronic acid with 
iodoferrocene.288  
 
Scheme 48: Previous synthesis of protonated ppy ligand 148 reported in the literature.287 
An improvement in the yield of compound 148 was achieved using a Suzuki-Miyaura coupling 
of ppy derivative 82 and ferroceneboronic acid 144 to afford the product in a reasonable 55% 
yield (Scheme 49). The conditions used were based on previous Suzuki couplings of 
ferroceneboronic acid with an aryl bromide.289 Further optimisation of this reaction could be 
carried out by a screening of catalyst, solvent and base combinations, and microwave heating 
could also be employed to decrease the reaction time. However, the reaction provided sufficient 




Scheme 49: Synthesis of CORM 133. 
The characteristic four strong metal carbonyl stretching bands at 2074, 1990, 1975, 1931 cm-1 in 
the infrared spectrum of 133 in CH2Cl2 solution indicated that the synthesis was successful (a 
spectrum is shown in Section 3.3.1). The metal carbonyl stretching band positions are the same 
as for complex 132 within the 2 cm-1 spectrometer resolution. Proton NMR spectra (Figure 65) 
also confirmed that the cyclometalation reaction had taken place. Comparison of the spectra of 
protonated ligand 148 with cyclometalated complex 133 confirms the deprotonation and the 
desymmetrisation that takes place upon cyclometalation. The two sets of two protons on the 
phenyl ring in compound 148 that formed a pair of doublets were lost upon cyclometalation, 
giving three separate resonances. There was also a small shift in the ferrocenyl protons upon 
installation of the Mn tetracarbonyl moiety,  
 
Figure 65: Stack of 700 MHz NMR of complex 133 (top) and protonated ligand 148 (bottom) recorded 
in CDCl3 at 298 K. 
Single crystals of protonated ligand 148 and complex 133 were grown enabling X-ray structures 




























Figure 66: X-ray crystal structure of protonated ligand 148 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): C(9)-C(12) 
= 1.485(5), C(5)-C(6) = 1.472(5), C(16)-N(1) = 1.366(5), C(7)-C(8) = 1.383(5), C(3)-C(4) = 1.421(5), 
C(1)-Fe(1) = 2.037(4) Selected bond angles (ᵒ): C(6)-C(5)-C(1) = 124.0(3), N(1)-C(12)-C(9) = 116.8(3) 
Selected torsion angles (ᵒ): C(8)-C(9)-C(12)-N(1) = 21.6(5), C(1)-C(5)-C(6)-C(7) = 8.9(6).  
 
Figure 67: An X-ray crystal structure of compound 133 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): C(11)-
Mn(1) = 2.0538(13), C(22)-Mn(1) = 1.8622(15), C(23)-Mn(1) = 1.8344(14), C(24)-Mn(1) = 1.8048(14), 
C(25)-Mn(1) = 1.8541(15) , N(1)-Mn(1) = 2.0694(12) Selected bond angles (ᵒ): C(11)-Mn(1)-N(1) = 
79.83(5), C(24)-Mn(1)-N(1) = 172.14(5), C(23)-Mn(1)-C(11) = 176.65(6), C(25)-Mn(1)-C(22) = 
167.63(6), C(23)-Mn(1)-N(1) = 97.07(6), C(24)-Mn(1)-C(23) = 90.79(6). Selected torsion angles (ᵒ): 
N(1)-C(5)-C(6)-C(11) = 0.49(17), C(10)-C(9)-C(12)-C(13) = 20.3(2). 
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As with complex 132, there is a slight distortion of the octahedral geometry at the Mn due to the 
rigid bidendate ppy ligand as is common for Mn(I) ppy complexes. The torsion angle between the 
phenyl and pyridyl rings changes upon cyclometalation, from 21.6(5)° in protonated ligand 148 
to 0.49(17)° in complex 133 reflecting the requirement for a more planar ring system in order for 
ppy to coordinate to the metal. This observation is inverted in the torsion angle between the phenyl 
and ferrocenyl Cp ring: in 148 the two rings are nearly planar with a torsion angle of 6.7(6)° but 
upon cyclometalation this increases to 20.3(2)°.  
3.2.3 Synthesis of 134 
Target complex 134 exhibits planar chirality and was synthesised as a racemate. The conditions 
in this Section were developed by Samuel Andrew, an MChem student, under my mentorship.290 
The synthetic route to complex 134 requires cyclometallation of protonated ligand 149. Initial 
attempts so synthesise 134 involved a Suzuki-Miyaura cross-coupling (Scheme 50). 
 
Scheme 50: Initial synthesis of protonated ligand 134 via a Suzuki-Miyaura reaction. 
The poor yield of this reaction was again attributed to protodeboronation taking place during the 
reaction; the crude NMR spectrum in CDCl3 revealed an intense singlet at 4.15 ppm 
corresponding to ferrocene, which was not present in the boronic acid starting material spectrum. 
As a result of this, an alternative synthetic route was employed involving a Negishi coupling. 
Rather than rely of the use of boronic acid 144, Negishi couplings utilise a zincated intermediate 




Scheme 51: Synthesis of protonated ligand 149 via a Negishi coupling followed by cyclometallation 
with [BnMn(CO)5].  
The Negishi coupling afforded 2-pyridylferrocene, 149, in good yield. The subsequent 
cyclometalation to produce target 134 also proceeded in good yield, despite the deprotonation of 
a cyclopentadienyl ring in this reaction compared to a phenyl ring in other cases (Figure 68).  
A crystal structure of complex 134 could not be obtained as the complex degraded over time to 
produce protonated ligand 149. The NMR spectra of precursor 149 and complex 134 are shown 
in Figure 68. The NMR spectra show only small changes in chemical shift to the protons on the 
pyridyl ring, but more diagnostic of a successful reaction is the desymmetrisation of the Cp ring 
upon cyclometalation. The two sets of two protons in starting material 149 were replaced by three 
different chemical environments in 134 confirming that the expected substitution pattern had been 
achieved. 
 
Figure 68: Stack of 700 MHz NMR spectra of complex 134 (top) and protonated ligand 149 (bottom) 
in CD2Cl2 at 298 K.  
The infrared spectrum of complex 134 (see Section 3.3.1) in the metal carbonyl region showed 
bands at 1932, 1976, 1988 and 2077 cm-1. The positions and relative intensities of the bands are 
similar to the ppy complexes, confirming that cyclometallation took place to afford complex 134. 
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3.3 Electrochemistry of Complexes 132-134 
An electrochemical study was carried out to understand the redox properties of compounds 132-
134 and compare them to their corresponding ppy or fcpy protonated ligands. This study also 
provides guidance for spectroelectrochemical experiments, where structural information will be 
elucidated under potential control.  
As all compounds were readily soluble in CH2Cl2; this solvent was selected for the first 
electrochemical experiments. The electrolyte was present in relatively high concentration (1 M) 
during the experiment because of the high solution resistance of CH2Cl2.291,292 This causes two 
undesirable effects. Firstly, it increases the size of the Ohmic potential drop – the change in 
potential caused by a current flowing through the cell. Although it is possible to correct for 
this,291,293 using additional electrolyte can avoid this. Secondly, it increases the peak separation in 
cyclic voltammograms away from the theoretical peak separation for a reversible couple of 59/n 
mV (where n is the number of electrons transferred).293 This can give the illusion of slow 
interfacial electron transfer when in fact this is not the case. Both the above effects were 
minimised by using a high concentration of electrolyte. Blank voltammograms were recorded 
with solvent and electrolyte to verify that the electrolyte concentration did not cause any artifacts 
in the baseline.  
Cyclic voltammetry was used to establish that all compounds displayed a reversible one-electron 
redox couple based on oxidation of the ferrocenyl moiety. The midpoint potential, E1/2, provides 





Figure 69: Cyclic voltammogram of complex 132. Scan rate: 100 mV s-1, solvent: CH2Cl2, electrolyte: 
1 M tetra n-butylammonium hexafluorophosphate, analyte concentration: 5 mM. 
The redox potential was measured against a silver pseudo-reference electrode, which was 
calibrated using ferrocene as an internal standard (Figure 70). When the redox potential of the 
complex to be measured was too similar to the Fc/Fc+ couple, the 
acetylferrocene/acetylferricenium couple was used (+270 mV vs Fc/Fc+).294 The potential scale 
has been set such that the midpoint potential of the Fc/Fc+ couple is at 0 V.  





















Figure 70: Cyclic voltammogram of a CH2Cl2 solution of 5 mM of both compound 132 and ferrocene. 
The electrolyte concentration was 1 M tetra n-butylammonium hexafluorophosphate and the scan 
rate was 100 mV s-1. 
The potential window from -1 V to +600 mV vs Fc/Fc+ was investigated and only a single redox 
couple was found within this range, corresponding to the ferrocenyl group in each compound. No 
reaction of the Mn(I) centre was observed within the potential window of the experiments. Recent 
work on Mn(I) tricarbonyl complexes has shown that an irreversible oxidation can occur above 
+1 V vs Fc/Fc+ in these complexes.295 Addition of a fourth tricarbonyl ligand is likely to increase 
this potential even further in complex 132 due to the additional π back-donation of the CO ligand 
stabilising the lower oxidation state of the metal.258 Such activity is unlikely to have a therapeutic 
relevance because of the extremely high redox potential required to effect the oxidation.  
Although the peak separation between the oxidative and reductive peaks, ΔE, of complex 132 
was 74 mV compared to the theoretical value of 59 mV, the peak separation for the Fc/Fc+ couple 
internal standard was 80 mV. Since the Fc/Fc+ couple is known to be a fully reversible one-
electron couple, the behaviour of 132 was deduced to also be a one-electron reversible couple. 
Repeated scans showed the identical redox behaviour to the first scan.  




where i is peak current and v is the scan rate. For a reversible redox couple in solution, the current 
function should remain constant as the scan rate is changed.293 The result for compound 132 is 
shown in Table 10. The current function remains roughly constant across this range of scan rates, 
again supporting the reversibility of this redox couple.  

























Table 10: How the current function varies with scan rate for complex 132. All solutions contained 
1 mM 132 and 1 M electrolyte in CH2Cl2. 
Scan rate (mV s-1) 50 100 150 200 
𝑖
√𝑣
 (μA s1/2 mV-1/2) 0.29 0.28 0.29 0.30 
 
Electrochemical measurements were extended to complexes 133 and 134 as well as protonated 
ligands 148 and 149. The peak positions and separations are shown in Table 11. 
Table 11: Summary of cyclic voltammetry data. 
Compound Eox (mV, vs 
Fc/Fc+) 
Ered (mV, vs 
Fc/Fc+) 
ΔE (mV) E1/2 (mV, vs 
Fc/Fc+) 
ia/ic 
132 +257 +183 74 +220 1.05 
133 +90 -27 117 +31 0.94 
148 (ligand) +105 -10 115 +48 1.03 
134 -82 -194 112 -138 1.04 
149 (ligand) +125 +27 98 +76 0.97 
 
The data show that the peak separations between the anodic and cathodic waves, ΔE, are 
consistently higher than the theoretical maximum value of 59 mV due to solution resistance; this 
was verified by the similar peak separation of the ferrocene internal standard. The ratio of the 
anodic and cathodic peak currents, 
𝑖𝑎
𝑖𝑐
, was close to one in all cases, confirming the reversibility 
of the oxidations in all of the compounds tested. 
Complex 132 is rather difficult to oxidise in comparison to ferrocene and the other ferrocene-
containing complexes in this work. Ferrocenyl triazoles appear to be electron-deficient according 
to the literature: the redox potentials of other triazole-conjugated ferrocenes are above 200 mV vs 
Fc/Fc+.279 Table 11 also shows the effect of cyclomanganation upon the redox potential of the 
ferrocene when comparing complexes 133 and 134 with their respective protonated ligands 148 
and 149. Cyclometalation causes the redox potential of the ferrocenyl moiety to decrease, making 
oxidation more favourable. This is consistent with the coordination to the Mn(I) tetracarbonyl 
moiety having an overall electron-donating effect upon the ligand. For complex 134, where a Cp 
ring of the ferrocene forms part of the first coordination sphere of the Mn, the effect is much more 
dramatic than for the distantly conjugated ferrocene in complex 132. This illustrates how changes 
in redox behaviour in these complexes could be used to sense changes in the environment of the 
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ligand during CO release, although this would be a much more powerful analytical technique if 
the CO release were itself redox-triggered. Future work could involve irradiating the CORM in 
solution during repeated cyclic voltammetry scans to observe CORM degradation.  
3.3.1 Infrared Spectroelectrochemistry 
The response of the infrared stretches of the carbonyl stretches to oxidation of the ferrocenyl 
moiety in complexes 132-134 were assessed by infrared spectroelectrochemistry. The results 
illustrate the importance of the linker length in determining the extent of communication between 
the iron and manganese centres.  
As with the electrochemistry, complexes 132-134 were studied in dichloromethane due to their 
high solubility in this solvent. For each complex, an infrared initial spectrum was recorded at the 
Open Circuit Potential (OCP). An oxidising potential step to +1 V versus the silver wire pseudo-
reference electrode was then applied and infrared spectra were recorded at 30 second intervals 
until no further change was observed (600 seconds). A reducing potential step to -500 mV versus 
the silver wire pseudo-reference electrode was then applied and infrared spectra were again 
recorded every 30 seconds until no further change was observed (600 seconds). Key spectra for 
each compound are shown in panels A-C of  Figure 71, and panel D provides an example of 
successive spectra after a potential step. The band positions of the species depicted in Figure 71 




Figure 71: Infrared spectroelectrochemistry of complexes 132-134 (panels A−C, respectively). Initial 
spectra before the potential steps are shown at the Open Circuit Potential (OCP). Experiments were 
performed in CH2Cl2 at a concentration of 5.0 mM in the presence of 1.0 M tetra n-butylammonium 
hexafluorophosphate as the electrolyte. All spectra are subject to a single point baseline correction 
at 2050 cm-1. (D) Selected spectra from the oxidation step of panel C showing the isosbestic points 
upon oxidation. 
Table 12: Summary of the infrared stretching band positions of the neutral and cationic ferrocenyl 
Mn complexes studied by infrared spectroelectrochemistry. 
Compound ν(CO) (1) (cm-1) 
B2 
ν(CO) (2) (cm-1) 
A1 
ν(CO) (3) (cm-1) 
B1 
ν(CO) (4) (cm-1) 
A1 
132 1931 1977 1991 2076 
[132]+ 1931 1977 1991 2076 
133 1931 1975 1990 2074 
[133]+ 1936 1980 1995 2078 
134 1932 1976 1988 2077 
[134]+ 1964 2000 2010 2089 
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Triazole 132 (Table 12, bottom) shows no response of the carbonyls to oxidation. Complex 133 
(Table 12, centre) shows a slight increase in wavenumber of the carbonyls (approximately 5 cm-1), 
Complex 134 (Table 12, top) showed a significant shift of approximately 30 cm-1 in the metal 
carbonyl stretches for all four peaks when an oxidizing potential is applied. The increase in 
stretching frequency is consistent with a removal of electron density from the manganese, 
resulting weaker pi-backbonding to the carbonyl groups. The increase in the infrared band 
positions upon the oxidation of complexes 132-134 is tabulated for each vibrational mode inTable 
13. 
Table 13: The increase in carbonyl stretching wavenumber upon formation of the cations of 132-134, 
relative to the neutral molecule, derived from the spectroelectrochemical experiment in Figure 71. 
Compound ν(CO) (1) (cm-1) 
B2 
ν(CO) (2) (cm-1) 
A1 
ν(CO) (3) (cm-1) 
B1 
ν(CO) (4) (cm-1) 
A1 
[132]+ 0 0 0 0 
[133]+ 5 5 5 4 
[134]+ 32 24 22 12 
The Table shows that for complex 134 and its cation, the shift in the stretching wavenumber is 
strongly dependent on the nature of the vibrational mode. It is noteworthy that the band that shows 
the greatest shift in wavenumber is the B2 band, the asymmetric stretch of the two carbonyls in 
the plane of the ppy ligand, whereas the smallest shift in wavenumber is exhibited by the high-
wavenumber A1 band involving the mutually trans carbonyl ligands, while the other two modes 
showed an intermediate shift. This suggests that oxidation may have a greater electron-
withdrawing effect upon the two carbonyl ligands in the plane of the ppy ligand. The DFT 
calculations shown for the parent ppy complex 88 in Figure 31: DFT-optimised structure and 
calculated molecular orbitals for [Mn(ppy)(CO)4] (carbon grey, hydrogen white, manganese pink, 
nitrogen blue, oxygen red). Isosurfaces shown at 0.5 e Å -3.Figure 31 (as discussed in Section 
2.2.2) show that the HOMO of 88 is based largely on the ppy ligand, in particular on the phenyl 
ring. Oxidation therefore removes electron density from the ppy ligand, which would weaken π-
backbonding to the CO ligands in the plane of the ppy ligand, particularly the CO ligand trans to 
the electron-rich phenyl ring, causing the infrared stretching wavenumber to increase more than 
for other modes. Althugh in the case of complex 134 a ferrocenyl(pyridyl) ligand is present rather 
than ppy, calculations on 134 confirmed an analogous structure of the HOMO to that of 88, with 
much of the electron density residing on the ferrocenyl moiety of the ligand (the calculations and 
discussion are presented in Section 3.4.3). 
The trend observed from complexes 132-134 is consistent with a through-bond communication 
between the two metal centres and suggests that redox-active ligands should be incorporated into 
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the first coordination sphere of the manganese carbonyl for the redox behaviour to have a 
significant effect upon the reactivity of the Mn centre. Consistent with the reversibility of this 
process in the electrochemical results, the spectroelectrochemistry shows that the oxidized 
ferricenium cation of each complex can be repeatedly oxidised and then reduced back to the 
neutral form. The presence of numerous isosbestic points in the conversion between the oxidised 
and reduced species also helps to support the conclusion that no other species are present during 
the experiment. This means that these compounds are unlikely to be useful for redox-triggered 
CO release, but their redox-active groups may provide a secondary application as a mechanistic 
reporter group or as a way of studying the effect of a redox event adjacent to a neighbouring 
carbonyl group. 
3.4 Photochemistry and CO Release 
3.4.1 Monitoring Photolysis By UV-Visible Spectroscopy  
The photochemical CO release properties of complexes 132-134 were also tested for comparison 
to the previously-studied Mn(I) tetracarbonyl complexes containing a ppy ligand.184 
Compound 132 was assessed for photochemical degradation using 400 nm light. This wavelength, 
on the boundary of the visible spectrum, is on the tail of the metal-to-ligand charge transfer band 
observed in [Mn(ppy)(CO)4]. Photochemical degradation and CO release at 400 nm has been 
demonstrated for other manganese(I) tetracarbonyl ppy complexes, as discussed in Chapter 2. The 
UV-visible absorption spectrum of complex 132 is shown in Figure 72 and closely resembles that 
of [Mn(ppy)(CO)4] (see Section 2.2.1). No band associated with the ferrocenyl group of 132 was 
observed in the visible region; the lowest energy band tails off at 400 nm. However, complex 133, 
where the ferrocene is conjugated to a phenyl ring rather than a triazole ring, does display the 
expected low-energy band for ferrocene (see Appendix 3). 
Irradiation was performed using a 400 nm LED embedded within a cuvette lid using a power 
supply developed by the workshops in the chemistry department at the University of York. Further 
details are given in the Experimental section of this thesis. Irradiation was performed in a cycle 
of 2 min on, 3 min off, and UV-visible spectra were recorded every 5 min, with the LED off, to 
monitor degradation. A typical experiment is shown below (Figure 72), where the power used 




Figure 72: UV-visible monitoring of the degradation of compound 132 in CH2Cl2 when irradiated 
with 400 nm light at a power of 2.4 W, beginning at 23 min. The final three spectra were the result of 
20 W irradiation. The concentration of 132 was 33 μM. Arrows show the changes in the bands over 
time. 
The first five spectra were recorded before any irradiation and are all coincident, proving the 
short-term stability of 132 in the dark. Upon irradiation, a clear change in the spectrum is seen as 
the absorbance of the peak around 270 nm decreases. The absorbance at 270 nm was monitored 
over time. Below (Figure 73) is a comparison of 2.4 and 6.0 W power 400 nm irradiation. A 
significantly faster degradation is seen when the power is increased. 








































Figure 73: Comparison of 2.4 and 6.0 W irradiation of a solution of 33 μM compound 132 at 400 nm. 
Error bars are shown on the 2.4 W run. Three repeats were performed – the median data set was 
plotted with error bars corresponding to one standard deviation.   
Three repeats were performed at 2.4 W, which showed comparable results. A control experiment 
with a solution stored in the dark showed the same absorbance as the first five spectra after the 
end of the experiment. The degradation appears to tail off well before the absorbance reaches 
zero; the degradation product likely has a similar spectrum to the starting material. Confirmation 
of this was obtained by irradiating at a high power of 20 W for the final three cycles – further 
degradation was minimal in the following UV-vis spectra suggesting the photochemical 
degradation was complete. A band at around 270 nm appears to be retained in the photoproducts, 
although this is to be expected as the transition is assigned as a ppy (π→π*) transition. It was not 
possible to conclude whether the ppy ligand has been lost from the metal on this information 
alone.  
The similarity of the spectra is unsurprising as the band at 270 nm is due to the phenylpyridine 
moiety.130 The higher-wavelength metal-to-ligand charge transfer band might be used to monitor 
this process instead, but the absorbance is low at the concentration used. The ferrocene moiety 
absorbs in this region too, which may further complicate the use of this band. Regardless, a clear 
change in the absorbance spectrum is indicated upon irradiation, showing that a photochemical 
reaction takes place, and matching the degradation profile of structurally similar compounds.137, 
130,159  
3.4.2 In situ Infrared Spectroscopic Studies of CORM Degradation 
Photochemical degradation was also studied using in situ ATR-IR spectroscopy, to compare the 
results to studies on the continuous irradiation experiments in Chapter 2. It was also anticipated 
that the structural information from the infrared spectra could help to determine whether the 
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triazole moiety in complex 132 can coordinate to the manganese centre after axial CO 
dissociation. Initially, the behaviour of complexes 132 and 133 will be discussed. Experiments 
with complex 134 be then be reported in Section 3.4.3. 
The results for complex 132 will be discussed first. A 365 nm LED was used continuously at a 
power of 6.0 W – a shorter wavelength was used compared to the 400 nm LED in the UV-visible 
study in Section 3.4.1. This wavelength was chosen as it is nearer to the centre of the CO-
dissociative band of the Mn(I) tetracarbonyl ppy complexes, so this wavelength is expected to 
speed up the photolysis so that large quantities of photoproduct could be observed. The results 
for complex 132 irradiated in DMSO solution are shown in Figure 74 and Figure 75. The spectra 
shown are difference spectra against a spectrum recorded just before the start of the LED 




Figure 74: Selected in situ infrared spectra of a 12 mM DMSO solution of complex 132 showing the 
changes upon LED irradiation (6.0 W, 365 nm). The results are presented as difference spectra with 
reference to a spectrum recorded immediately before irradiation began. The resolution used was 
2 cm-1. The times given are the time since the irradiation began. 
 
Figure 75: Peak heights of selected wavenumbers over the course of the irradiation experiment with 
12 mM complex 132 in DMSO. 
The spectra show that complex 132 displays very similar photochemical decomposition to 
[Mn(ppy)(CO)4] (complex 88, Section 2.3.6). The complex was stable in the absence of 
irradiation for over 30 minutes. The only photoproduct visible after 15 minutes of irradiation was 
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a species with bands at 1901, 1931 (overlapping with a bleach), and 2010 cm-1. This is essentially 
identical to the behaviour observed for 88 in Chapter 2, where the tricarbonyl photoproduct bands 
were observed at 1902, 1928 and 2013 cm-1 and were assigned to facial tricarbonyl dimer or 
cluster species. In later spectra, these three bands began to decay away and a small band at 1861 
cm-1 slowly grew in, compared to a band that grew in at 1870 cm-1 for [Mn(ppy)(CO)4]. The 
degradation pathway of substituted ppy complex 132 therefore appears to be the same as its parent 
complex, which could implicate the formation of tricarbonyl dimers or clusters in the degradation 
of these complexes. 
Another photochemical in situ infrared degradation study was performed on complex 133, also in 
DMSO. Selected spectra and a trace of peak heights over time are shown in Figure 76 and Figure 
77 respectively. The results indicate that compound 133 has the same CO release mechanism as 
compounds 88 and 132 - the photoproduct bands appear to be the same in the three DMSO 
experiments. Therefore, the effect of any triazole coordination to the Mn centre was not 
observable on this timescale. 
 
Figure 76: Selected in situ infrared spectra of a 20 mM DMSO solution of complex 133 showing the 
changes upon LED irradiation (6.0 W, 365 nm). The results are presented as difference spectra with 
reference to a spectrum recorded immediately before irradiation began. The resolution used was 2 
cm-1. The times given are the time since the irradiation began. 
 
































Figure 77: Peak heights of selected wavenumbers over the course of the irradiation experiment of 20 
mM 133 in DMSO. 
3.4.3 CO Release to Myoglobin 
To directly verify that the photochemical degradation of the ferrocenyl complexes results in CO 
release, a UV-visible spectroscopic assay was performed with myoglobin (Mb). An example is 
shown with complex 133. The CO release profile of the complexes was tested in the dark and 
upon irradiation with 400 nm light. When CO is released by a CORM, it binds to the haem group 
of deoxymyoglobin (deoxy-Mb), yielding carboxymyoglobin (Mb-CO). The distinct UV-visible 
spectra of deoxy-Mb and Mb-CO enable quantification of the CO lost (Figure 78).  
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Figure 78: UV-visible spectra of standard samples of deoxy-Mb and Mb-CO. 
When the compound was administered to the buffered deoxy-Mb solution in DMSO (to a final 
DMSO concentration of 0.5%), some precipitation of the complex occurred: the upwards 
translation of the deoxy-Mb spectrum in the presence of complex 133 is indicative of turbidity of 
the solution (Figure 79). 
 
Figure 79: UV-visible standard spectrum of deoxy-Mb (black) compared to the spectrum at the start 
of Mb assay when complex 133 has been added to give a 40 μM solution containing 0.5% DMSO 
(red). 
Relatively poor water solubility has also been observed for other substituted ppy tetracarbonyl 
CORMs - derivatisation to install ester or carboxylic acid groups has been used to address this. 
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Additionally, the 40 μM concentration of 133 used in this assay was selected to match the ~60 
μM deoxy-Mb concentration, which is needed to give a sufficiently intense absorbance spectrum, 
rather than because 40 μM is proposed as a therapeutic concentration. For instance, concentrations 
of CORM-3 as low as 1 μM have been shown to completely inhibit growth of Pseudomonas 
aeruginosa cultures.102 A commonly-employed correction method, based on the isosbestic points 
of deoxy-Mb and Mb-CO, was applied to correct the spectra for CORM absorbance and 
scattering. A translation to match the spectra at the 510 nm isosbestic point was applied to correct 
for the turbidity (Figure 80). 
 
Figure 80: Standards and experimental spectra corrected based on the isosbestic point at 510 nm. 
The corrected spectrum at 510 nm now appears similar to the deoxy-Mb standard, but the 
absorbance or scattering caused by complex 133 is not uniform across the wavelength range of 
500-600 nm. As a result, a ‘spectrum’ for the dissolved complex and any scattering caused by 
precipitation can be extracted from the data by fitting the absorbances at the four isosbestic points 
(Figure 81).  






























Figure 81: A spectrum due to CORM absorbance and scattering from precipitation, generated from 
the four isosbestic points of deoxy-Mb and Mb-CO. 
Over time, the composition of the solution changes as a complex releases CO, and degradation 
products form. To account for the changes over time, the fitting process described must be 
performed on each spectrum individually so that a spectrum similar to that in Figure 81 is obtained 
from the raw data for each timepoint. Subtraction of this spectrum from the 510 nm corrected 
spectrum then results in the fully-corrected data (Figure 82). 

























Figure 82: Experimental spectra after the isosbestic point correction for a Mb assay featuring 
irradiation of 40 μM complex 133. Spectra recorded every 10 minutes. 
The errors in the fitting can be estimated by generating spectra from the deoxy-Mb and Mb-CO 
standards for given deoxy-Mb and Mb-CO concentrations, then comparing them to the corrected 
spectra. An example is shown in Figure 83, showing that the generated spectra match the corrected 
ones well and that there is no systematic error across the wavelength range. 






















Figure 83: The error from the four-point correction of each experimental spectrum assessed by the 
difference between the corrected experimental spectrum and spectra of the appropriate 
concentration generated from the deoxy-Mb and Mb-CO standards. 
Based on the change in absorbance at 540 nm throughout the experiment, the concentration of 
Mb-CO can be quantified (see Experimental Section for further details). For complex 133, this 
leads to the CO release profile shown in Figure 84. Upon 400 nm LED irradiation of a 40 μM 
solution of complex 133, CO release was observed to take place. Irradiation took place inside the 
UV-visible spectrometer, with cycles of 2 minutes on, 3 minutes off to prevent the LED from 
heating the solution. 





























Figure 84: The release of CO to deoxy-Mb by a 40 μM solution of complex 133. The experiment was 
run in the dark until irradiation with a 400 nm LED at a power of 5.0 W began where indicated. 
Irradiation was performed in cycles of 2 minutes on, 3 minutes off. 
 
The spectrum shows that complex 133 behaves similarly to other Mn(I) tetracarbonyl ppy 
complexes by displaying stability towards buffered deoxy-Mb in the dark (<1 μM Mb-CO after 
25 min in the dark) and releasing CO to deoxy-Mb when irradiated with 400 nm light. The CO 
release was relatively slow compared to related ppy derivatives: the irradiation may have been 
hindered by the turbidity of the solution concentration of complex 133. The assay was stopped 
after 4 hours before it went to completion, as degradation of the myoglobin and CO escape from 
the solution can cause problems beyond this point. Despite its poor solubility, complex 133 has 
been demonstrated as a photoCORM similar to other derivatives with substituted ppy ligands. 
Complex 134 was also tested with a myoglobin assay, the results are shown in Figure 85. 



















Figure 85. The release of CO to deoxy-Mb by a 10 μM solution of complex 134. The experiment was 
run in the dark until irradaition with a 400 nm LED at a power of 5.0 W began where indicated. 
Irradiation was performed in cycles of 2 minutes on, 3 minutes off. Experiment performed in 
collaboration with Samuel Andrew. 
In this case, complex 134 appeared to release CO to myoglobin in the dark (thermal CO release). 
Although it is not known which CO ligand would be lost, the strong trans effect of the CO ligands 
would suggest that the mutually trans CO ligands are labile to ligand substitution. When 
irradiation was started, as indicated on the graph, the rate of CO release was accelerated further. 
The CO release tails off at a [CO-Mb] concentration of 25 μM, suggesting that 2.5 equivalents of 
CO were released per molecule of 134. Although complex 134 displayed photochemical CO 
release at the same wavelength as its ppy analogues, this was far less selective than the ppy-based 
CORMs.  
The reason for the lower thermal stability of complex 134 was considered. Unlike for the ppy-
based derivatives, old NMR samples of 134, especially in CDCl3 solvent, were observed to 
contain protonated ligand 149. This was hypothesised to be the result of trace acid formed by 
decomposition of the chloroform (Scheme 52), which could promote the protonation of the Mn-
C bond to release protonated ligand 149.  
 
Scheme 52: Decomposition of chloroform under ambient light and air. 
To test the sensitivity of complex 134 to protonation, a solution of the complex was exposed to 
non-coordinating acid [HNMe2Ph]BF4. Successive injections of the proton source were made 





















(Figure 86) and the changes in intensity of the starting material and any degradant infrared 
stretching bands were monitored (Figure 87). 
 
Figure 86: Effect of successive additions of the proton source [HNMe2Ph]BF4 to a 20 mM solution of 
134 in CH2Cl2 as monitored by in situ infrared spectroscopy of the carbonyl bands. Experiment 
performed in collaboration with Samuel Andrew. 
 
































Figure 87: Effect of successive additions of the proton source [HNMe2Ph]BF4 to a 20 mM solution of 
134 in CH2Cl2 as monitored by in situ infrared spectroscopy of the carbonyl bands. The changes to 
selected bands are shown. Experiment performed in collaboration with Samuel Andrew. 
The data show that complex 134 does not degrade in ambient conditions in CH2Cl2 over ca. ten 
minutes under ambient conditions, having showed no change in the infrared spectrum over this 
period before any acid was added. This is consistent with the spectroelectrochemical data in 
Section 3.3, where no degradation was observed by infrared spectroscopy or cyclic voltammetry 
during the ca. ten minutes taken to prepare and run the experiments.  
Upon successive injections of the non-coordinating proton source [HNMe2Ph]BF4, a clear 
changein the infrared spectrum was observed immediately. Decay of starting material bands at 
1979 cm-1 and 1991 cm-1 as each addition is made show that the acid is degrading compound 134. 
Of the other two carbonyl stretching bands of 134, the 2085 cm-1 band was too weak to reliably 
track, while the 1932 cm-1 band grew in intensity when [HNMe2Ph]BF4 was added. A broad band 
at 2035 cm-1 also grew in upon additions of the acid, suggesting that a metal carbonyl-containing 
degradation product may form from this reaction.  
The results for photochemical degradation of 132 and 133 in Section 3.4.2 presented the 
possibility of a facial tricarbonyl complex or cluster species, based on two low-wavenumber 
bands between 1900-1950 cm-1 followed by a higher-wavenumber band at around 2010 cm-1 
(though these wavenumbers are in DMSO). A similar complex could be present in Figure 86, 
although the data is not conclusive. The broadness and intensity of the 1932 cm-1 feature suggest 
that multiple bands may be present, but due to overlap with the starting material it is difficult to 
discern whether two bands are present. Since the 1932 cm-1 feature gets broader as more acid is 
added, difference spectra after acid addition against the solution before acid addition would show 
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a peak either side of the starting material band at 1932 cm-1. However, this would be a misleading 
way to present the data as it is far from clear that there are two degradant bands in that region of 
the spectrum. Therefore, this experiment does not rule out that similar fac tricarbonyl species to 
those proposed for 88, 132 and 133 are present, but it is not conclusive evidence on its own.  
The only degradation product that is confirmed for complex 134 is protonated ligand 149 as 
observed by NMR spectroscopy. A future experiment could involve and NMR study. similar to 
this in situ infrared study, to observe 149 forming as a proton source is added. However, if any 
paramagnetic degradation products or precipitation occurs, thiese could present problems for such 
an experiment. 
To aid interpretation of why 134 appears more sensitive to protonation than 132 and 133, the 
molecular orbitals for complex 134 were calculated by DFT (Figure 88) in order to make a 




Figure 88: Frontier molecular orbitals of complex 134 as calculated by DFT 
(PBE0/DGTZVP/DEF2TV level of theory). 
The calculations show that the electron density within each of the four highest occupied molecular 
orbitals is mainly located on the ferrocenyl group, with the lowest unoccupied molecular orbitals 
located on the pyridyl ring. This finding can be compared to the calculations on [Mn(ppy)(CO)4] 
in Chapter 2, in which the electron density in the highest occupied molecular orbitals had most 
electron density on the phenyl ring and Mn centre, and the lowest unoccupied molecular orbitals 
were located on the pyridyl ring. Therefore, the Fcpy and ppy ligands have a similar distribution 
of the electron density within the cyclometalated ligand. The experimental evidence shows that 
the ppy complexes are stable to buffer solution in the dark but that complex 134 degrades. This 
suggests that the Mn-C bond to the Cp ring in complex 134 is even more susceptible to protonation 
than the complexes featuring the ppy ligand. 
In the case of triazole 132, substantial precipitation from the 0.5% DMSO water solution 
prevented the measurement of any CO release. The myoglobin assay experiment was performed 
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in the dark for the first 30 minutes and with cycles of 2 minutes 365 nm LED irradiation per 5 
minutes after that.  As shown in Figure 89, the only change in the spectra over time was a steady 
increase in the absorbance across all wavelengths, without any change in shape from deoxy-Mb 
to Mb-CO. This shows that the dominant process occurring was a large increase in the turbidity 
of the solution – it was concluded that this was caused by scattering from precipitate of complex 
132. So little of the complex is present in solution that the CO release was negligible. However, 
given the similar photochemical behaviour observed for 133-134, it would be expected that 
solubilisation of 132 would lead to measurable CO release in buffer solution. 
 
Figure 89; Precipitation of complex 132 when a 40 uM solution in phosphate buffer 0.5% DMSO was 
made. Irradiaition at 400 nm and a power of 5 W in cycles of 2 minutes on, 3 minutes off from 30 min 
did not lead to CO release. 
3.4.4 TRIR Studies 
Since complex 133 displayed thermal stability and photochemical CO release at 400 nm, its 
ultrafast photochemical behaviour was also studied to compare it to the results with 
[Mn(ppy)(CO)4] and derivatives in Chapter 2. Difference spectra at selected picosecond delays 
after a 355 nm pump pulse are shown in Figure 90. 
































Figure 90: A TRMPS experiment with ferrocenyl CORM 133 in THF. A pump wavelength of 355 nm 
was used. 
The results show essentially identical behaviour the other complexes in the family of 
[Mn(ppy)(CO)4]. Small bands corresponding to a short-lived triplet excited state decayed within 
the first few ps and were too weak to be quantified. Loss of CO is the dominant photochemical 
process and the isomerisation from complex 150THF(σ) to 150THF(O) was again observed Scheme 
53). The kinetics of the isomerisation are shown in Figure 91. 






































Scheme 53: The coordination of THF following CO loss from complex 133, and subsequent 
isomerisation, shows the same behavior as [Mn(ppy)(CO)4] 
 
Figure 91: Kinetic plots from 5 to 100 ps to monitor the isomerisation of 150THF(σ) to 150THF(O) using 
the 150THF(σ) band at 1913 cm-1 and the 150THF(O) band at 1998 cm-1. The dotted lines represent single 
exponential fits with lifetimes of (21.0 ± 1.1) ps and (25.1 ± 2.6) ps for the growth of the 1998 cm-1 
band and loss of the 1913 cm-1 band respectively. 
The single exponential lifetimes for the growth of 150THF(O) and decay of 150THF(σ) were measured 
to be (21.0 ± 1.1) ps and (25.1 ± 2.6) ps respectively. This is a marginally slower lifetime than the 
other ppy ligands tested which were around 16-18 ps and could suggest that the additional steric 
bulk of the ferrocenyl moiety impedes movement or access of THF solvent molecules to the first 
coordination sphere. 
The behaviour of 132 was also studied to examine whether triazole coordination to the Mn centre 
competes with solvent coordination after CO dissociation, a feature embedded in the original 
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design of this CORM. In order to allow the maximum amount of time for the triazole to 
coordinate, a weakly-coordinating solvent was used: n-heptane. This means that even if n-heptane 
coordinates before the triazole, it may be possible for ligand substitution to occur before the 
expected formation of the tricarbonyl aqua complex on the microsecond timescale. The results 
are shown in Figure 92. 
 
Figure 92: A TRMPS experiment with ferrocenyl CORM 132 in n-heptane showing short pump-probe 
delays. The asterisks denote the excited state bands. A pump wavelength of 355 nm was used. 
 


































Figure 93: A TRMPS experiment with ferrocenyl CORM 132 in n-heptane showing long pump-probe 
delays. A pump wavelength of 355 nm was used. 
The spectra show formation of a tricarbonyl species that persists for tens of microseconds. The 
two low-wavenumber bands coalesce to give a feature with a maximum at 1908 cm-1 with the 
other bands at 2009 cm-1. After 10 μs, this species begins to be replaced by a tricarbonyl species 
with lower-wavenumber bands at 1902 and 1997 cm-1, analogous to the events observed with 
[Mn(ppy)(CO)4]. The timescale of the reaction and shift of the bands is characteristic of the 
formation of 151hep followed by intermolecular reaction with water to form 150OH2. Therefore, 
the presence of the triazole moiety in complex 132 has no effect on its photochemical behaviour, 
even on the ultrafast timescale (Scheme 54). 
 
Scheme 54: The CO loss from complex 132 results in a C-H σ-complex with the n-heptane solvent 
followed by displacement of n-heptane by water. 
 

































3.5 Solubilisation of 132 by Oxidation 
In the case of 132, the CORM was not soluble enough to study in water, precipitating out of 
solution (Section 3.4.3). To address the poor water solubility of 132, oxidation to the 
corresponding ferricenium salt was attempted. The resulting cationic compound in combination 
with a water-soluble counterion could be used to solubilise 132. Compounds containing the 
ferricenium moiety, coupled with water-soluble counterions such as trichloroacetate, 
tetrachloroferrate and picrate (Figure 94), have previously been shown to possess anti-cancer 
activity, due to the production of reactive oxygen species.296 The ferrocene analogue was able 
infiltrate tumour cells but did not exhibit the toxicity of the ferricenium cation.296 As a result, it 
could be advantageous to use complex 132 as a ferricenium salt rather than as a neutral complex.  
 
Figure 94: Water-compatible anions used with the ferricenium cation in anti-cancer studies. 
Oxidation of the ferrocenyl group is frequently performed under harsh conditions, combining 
oxidants such as DDQ or benzoquinone with strong acid.294 When the milder of these two 
oxidants, benzoquinone, was tried with compound 132, in conjunction with HPF6, some 
degradation of the metal carbonyl moiety was observed by infrared spectroscopy in the crude 
mixture. Given the stability of 132 over a wide potential window and the proven sensitivity of 
complex 134 towards protonation, it would appear that the Mn phenylpyridine group is not stable 
to the acid added. It is also unfeasible to perform the oxidation step earlier in the synthesis as the 
CuAAC reaction demands the use of reducing conditions.  Alternative, acid-free conditions, 
incorporating a water-compatible anion, were sought.  
Silver (I) was considered as a milder method to oxidise 132. Because silver(I) possesses a 
reduction potential of +650 mV vs. the ferrocene/ferricenium couple in dichloromethane, there is 
a strong thermodynamic driving force to oxidise 132 (+220 mV in dichloromethane vs. the 
ferrocene/ferricenium couple, vide supra, Figure 70, page 187). Silver (I) triflate was chosen as 




Scheme 55: Oxidation of compound 132 to increase water solubility. 
Upon combination of 132 with silver(I) triflate, a deep green solution immediately formed, 
indicative of oxidation of the yellow starting material to the ferricenium salt. The ferricenium 
cation [132]+ was detected by ESI mass spectrometry (see Appendix 7), instead of the protonated 
ion seen in the mass spectra of the neutral compound, showing that oxidation took place. An 
infrared spectrum of [132]+ was recorded and showed that the carbonyl groups were intact after 
this reaction, mirroring the spectroelectrochemical results and showing that the Mn carbonyl 
moiety remained intact during exposure to the oxidant. Further characterisation proved difficult 
due to the small scale of the reaction and the paramagnetism of the product. A 1H NMR spectrum 
was recorded but due to the paramagnetism of the product the peaks were extremely broad, and 
nothing was seen in the typical chemical shift region for a ferricenium cation (around 30-40 ppm 
due to paramagnetic FeIII).  
The oxidation of 132 to improve the solubility could facilitate studies in aqueous solution, 
including biological activity and toxicity studies. However, the standard myoglobin CO release 
assay remains inaccessible for this compound due to the presence of the reductant sodium 
dithionite during the assay, which would be expected to reduce the oxidised complex. Other 
methods would be required to study CO release, and options such as headspace analysis by gas 
chromatography, in situ infrared spectroscopic studies and mass spectrometric detection of 
degradation products can be explored. The cationic ferricenium group could serve as a good mass 
spectrometry tag to monitor CO degradation products. 
Future experiments to work towards solubilising complex 132 by oxidation should focus on 
trialling the oxidations with complex 133, as this complex is more stable than 134 and displays a 
small shift of ca. 5 cm-1 upon oxidation. Although this complex has better water solubility than 
217 
 
complex 132, testing the oxidation on this complex would allow more conclusive confirmation 
that all of the material had been chemically oxidised.  
3.6 Conclusions 
A series of ferrocenyl CORMs, complexes 132-134, has been synthesised, characterised and 
evaluated for CO release properties through thermal, photochemical and redox triggers. Infrared 
spectroelectrochemistry has shown how the redox-active ferrocenyl moiety communicates with 
the Mn tetracarbonyl centre when the length of linker between them is varied.  
Although direct redox-triggered CO release was not observed in this work, the 
spectroelectrochemical measurements show that significant changes to the metal carbonyl 
electronic environment can only be achieved with a ligand in the first coordination sphere of the 
metal carbonyl. However, in complex 134 where the ferrocenyl moiety is closest to the Mn centre, 
sensitivity towards protonation induces slow thermal CO release. This method of decomposition 
was supported by DFT calculations showing that the HOMO of complex 134 is located on the 
ferrocenyl moiety. 
All three of the complexes in this work displayed photochemical CO release with 400 nm 
irradiation. This was detected directly using myoglobin for the more water-soluble complexes 
133 and 134. The photochemical behaviour of dark-stable complexes 132 and 133 was monitored 
with both in situ infrared spectroscopy and ultrafast TRIR spectroscopy. Similar photochemical 
behaviour was observed to [Mn(ppy)(CO)4] on timescales from picoseconds to minutes. The 
dominant ultrafast behaviour is CO loss to form a solvated tricarbonyl species, with a small 
proportion of a short-lived triplet excited state. Upon continuous irradiation over longer 
timescales, in situ infrared spectroscopy suggested that the solvated tricarbonyls react further to 
form species tentatively assigned as multinuclear Mn cluster species as was assigned for 
[Mn(ppy)(CO)4]. The triazole moiety of complex 132 did not coordinate to the Mn centre upon 
CO loss. 
Since all three ferrocenyl complexes synthesised in this work could still display CO release, they 
could be considered as possible dual mechanism drug compounds due to the combination of 
photochemical CO release and the therapeutic properties of the ferrocenyl moiety. Solubilisation 
of 132 in water may be achievable in the future by oxidation to the ferricenium salt with a suitable 
counterion. 






4 Characterisation of Cyclometalated Azo Mn(I) 
CORMs 
The Mn(I) tetracarbonyl ppy complexes investigated so far in this Thesis display photochemical 
CO release when UV light or 400 nm visible light is used.159,184,297 As discussed in Chapter 1, it 
is important to develop photoCORMs that release CO using low-power visible or near-infrared 
wavelengths of light. In the literature, replacement of pyridyl N-donor ligands with π-accepting 
azo ligands has been shown to increase the CO release wavelength in a different series of Mn(I) 
photoCORMs.127 The work in this Chapter investigates the effect on the CO release properties 
when the nitrogen donor of the ppy ligand is replaced with an azo functional group in Mn(I) 
tetracarbonyl complexes. The photochemical CO release to myoglobin and the ultrafast 
photochemistry of azo complexes are compared to the ppy analogues. The redox behaviour of the 
cyclometalated azo complexes is also briefly explored with a view to designing reductively-
activated CORMs. 
4.1 Background 
4.1.1 Using Azo Ligands to Make Visible Light-Activated 
PhotoCORMs 
The superior tissue penetration and reduced toxicity of visible and near infrared light relative to 
UV irradiation has led to a demand for photoCORMs that release CO at these wavelengths.125 
Recent research by Mascharak and co-workers has focussed on increasing the CO release 
wavelength of Mn(I), Re(I) and Ru(II) photoCORMs from the UV into the visible by varying the 
nature of the co-ligands. The outcomes from this work led Mascharak and co-workers to propose 
the use of π-acceptor co-ligands to increase the wavelength of CO release.127 This previous work 
was considered in the design of the novel complexes described in this Chapter. 
The initial work by Mascharak’s group on Mn(I) tricarbonyl complexes 155-157 (Figure 95) 
revealed that the use of pyridyl and amine N donor groups led to CO-dissociative MLCT bands 
with maxima in the UV region, with λmax values of  330 nm for complex 155 (Figure 95, left) and 
350 nm for complex 156 (Figure 95, centre).298 Additional conjugation in the co-ligand was 
achieved by replacing the pyridyl ring with a quinoline (Figure 95, right). This change had a small 
effect, increasing the λmax value of the CO-dissociative band to 360 nm.298 The extinction 
coefficient of the CO-dissociative MLCT band in complex 157 was also higher than in complexes 
155 and 156. In conjunction with quantum yield for CO loss, a large extinction coefficient could 




Figure 95: Pyridyl and amine Mn(I) tricarbonyl complexes studied by Mascharak and co-workers.298  
Subsequent work on the conjugated imine complexes shown in Figure 96 led to large red-shifts 
of the CO-dissociative MLCT bands.299 The UV wavelengths required to excite the CO-
dissociative MLCT bands in complexes 155-157 was shifted in complexes 158a and 158b to give 
λmax values of 500 and 535 nm respectively.299 This significant increase in CO release wavelength 
was attributed to the low-lying π* orbital of the imine ligand donor compared to pyridyl and amine 
ligands yielding a lower-energy LUMO in the imine complexes.299 Calculations using TD-DFT 
were used to study the orbitals involved in the CO-dissociative transition (not necessarily the 
HOMO and LUMO). The calculations showed that the LUMO is involved in the CO-dissociative 
MLCT transition, so lowering the LUMO by incorporating a π-acceptor co-ligand increases the 
transition wavelength.299 The occupied orbital involved in the CO-dissociative transition in these 
complexes was predominately the HOMO-2; like the HOMO these orbitals are based primarily 




Figure 96: Energy differences between the metal-based occupied orbitals and the LUMO involved in 
the MLCT transition of Mn(I) tricarbonyls with different N-donor and bromide/MeCN co-ligands. 
Image adapted with permission from Acc. Chem. Res., 2014, 47, 2603–2611.127 Copyright 2014 
American Chemical Society. 
The calculations, shown in Figure 96, confirmed that the increased conjugation on the imine co-
ligand upon going from complex 158a to 158b lowers the energy of the ligand-based LUMO and 
lowers the overall transition energy. This illustrates how conjugated systems can be utilised and 
tuned to alter the CO release wavelength. The occupied metal-based HOMO-2 also experiences 
a slight lowering in energy in 158b relative to 158a but this is counteracted by the even greater 
stabilisation of the LUMO, which is the dominant effect.127 
The effect of CORM co-ligands on tuning occupied metal-based orbital energy levels was also 
considered by Mascharak’s group. In this case it is desirable to raise the energy of the occupied 
orbitals, thus lowering the transition energy. Comparing complexes 158b and 158c, replacement 
of the bromide ligand with the moderate π-acceptor ligand MeCN resulted in the MLCT band 
blue-shifting to below 450 nm (Figure 96), in large part because the occupied HOMO-2 orbital 
was raised in energy (though a slight lowering of the LUMO was also predicted).299 The σ-donor 
bromide ligand raised the HOMO-2 energy substantially compared to use of MeCN, so that the 
bromide complexes had the more desirable (longer) CO release wavelengths. This led to the 
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conclusion that stronger σ-donor co-ligands with poor π-acceptor properties are ideal co-ligands 
for visible light CO release as these types of ligands raise the energy of metal-based orbitals 
depopulated by MLCT transitions.127,299 This point, however, must be weighed against the 
advantages of including multiple CO ligands on a metal centre. Release of multiple equivalents 
of CO per photoCORM is a desirable property, but additional CO ligands may lower the 
wavelength of activation.  
The imine complexes had a higher quantum yield for CO loss than the pyridyl and amine 
complexes. Cations 158c and 158d displayed quantum yields for CO loss of (0.130 ± 0.005) and 
(0.208 ± 0.005) respectively, whereas complexes 155-157 all had quantum yield values of < 0.1 
near the maxima of their MLCT bands.299 A reason for the significantly higher quantum yield of 
complex 158c compared to complex 158d was not proffered. The difference between these 
complexes is the presence of a sulfide substituent on the imine ligand. Although coordination of 
the sulfide group to the metal centre was not observed, this shows that even distant substituents 
can have a notable influence on the photochemistry observed. 
Another strong π-acceptor ligand that was assessed was 2-phenylazopyridine (azpy).300 One of 
the complexes synthesised that featured the azpy ligand was complex 159 in Figure 97. TD-DFT 
calculations showed that CO release was initiated by MLCT excitation of the HOMO-1, an orbital 
with substantial M-CO bonding character, into the ligand-based LUMO.300 Replacement of the 
imine functional group with an azo group led to an even greater red-shift of the MLCT band to 
give a λmax value of 586 nm. Furthermore, the quantum yield for CO dissociation within the MLCT 
band further increased to (0.48 ± 0.01).300 The key conclusion of the studies by Mascharak and 
co-workers was that the wavelength at which photoCORMs can release CO can be dramatically 
increased by careful choice of co-ligands; π-acceptor ligands lead to a low-lying LUMO in the 




Figure 97: Mn(I) tricarbonyl complex featuring an azo group as one of the N-donors, developed by 
Mascharak and co-workers. Image adapted with permission from Acc. Chem. Res., 2014, 47, 2603–
2611.127 Copyright 2014 American Chemical Society. 
Further improvements to the CO-release wavelength in a related system were reported in a study 
by Zobi and co-workers, who introduced electron-withdrawing substituents to 2,2'-azopyridines 
to tune the λmax wavelength for the visible light CO-dissociative band. (Figure 98).301 These 
complexes released CO to myoglobin upon visible light irradiation, but complexes 160c-e also 
released CO in the dark with a half-life for CO release of less than an hour.301  
 
Figure 98: General structure of complexes synthesised by Zobi and co-workers.301 
The large extinction coefficients and red-shifted MLCT bands observed in metal carbonyl 
compounds through use of N-donor ligands with low-lying π* orbitals raises the question of 
whether a similar methodology could be employed to increase the CO-release wavelength of 
[Mn(ppy)(CO)4] derivatives. Cyclomanganated complexes of substituted azobenzenes with Mn(I) 
carbonyls have been known since the 1960s, having been synthesised by Heck302. Bruce and co-
workers have cyclomanganated a variety of substituted azobenzenes.303 However, the 
photochemical properties of this class of complexes has not been studied in detail and only one 
compound has been evaluated as a photoCORM: complex 161 (Figure 99).137 
Complex X Y λmax (nm)
160a Me H 625
160b H H 630
160c Br H 661
160d CF3 H 678





Figure 99: Visible light azo dye photoCORM 161 synthesised and tested by Fairlamb and co-workers. 
The graph is from the PhD thesis of Jonathan Ward and shows the decomposition of 161 upon 
irradiation with 2.4 W power LED light, as assessed by UV-visible spectroscopy.137 
Complex 161 displayed promising initial results as a photoCORM due to its photochemical 
decomposition at 465 nm, with slower degradation at 525 nm also observed.137 Direct evidence 
that decomposition of 161 resulted in CO release was also obtained through a myoglobin assay.137 
As previously shown in Section 2.2.2, [Mn(ppy)(CO)4] itself shows no absorption bands above 
~400 nm and therefore cannot release CO photochemically further into the visible spectrum. The 
CO release from complex 161 at 465 nm suggests that, as with Mascharak’s complexes, 
replacement of a pyridine donor with an azo group increases the CO-release wavelength.  
Unfortunately, complex 161 also degrades slowly in buffered myoglobin in the dark, which 
reduces the selectivity of the CO release, and it must be stored under an inert atmosphere to 
prevent decomposition.137 The synthesis of complex 161 (Scheme 56) is also problematic: the 
cyclometalation is low-yielding and results in the production of a large number of impurities that 
are challenging to separate from the desired product.  It is known that azo dyes can degrade 
photochemically through radical chemistry to form compounds such as anilines, phenols and 
hyroxyhydrazines.304,305 Azobezenes are also known to isomerise between the cis and trans 
isomers, both photochemically with visible light and thermally above 70 °C.306 It is therefore 
possible that isomerisation of the free azobenzene product is also a problem in the purification. 
Any isomerisation at the high cyclometalation reaction temperature is less likely to be an issue in 
the Mn geometry locks the geometry of the azobenzene such that only the trans azobenzene-
derived ligand can complex to the metal. The array of coloured impurities suggests that 
decomposition involves substantial structural changes to the strongly-absorbing azo ligand. The 
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resulting chromatographic separation resulted in further decomposition leading to a 5% yield.137 
As a result, an improved synthetic route to complex 161 is required. It would also be useful to 
develop stable alternatives to complex 161 that are easier to handle and store. Therefore, the 
synthesis of some photoCORMs related to complex 161, bearing azo co-ligands, will be carried 
out in this Chapter and their CO-release properties will be evaluated in light of the ligand systems 
already developed in the literature.127 
 
Scheme 56: Synthesis of complex 161. 
4.1.2 Redox Properties of Azo Compounds 
In addition to its photochemical properties, the azo ligand also represents a redox-active co-ligand 
that could be used to promote redox-activated CO release. The Mn(I) tetracarbonyl system 
remains a desirable system from which to initiate redox-triggered CO release due to its stability, 
the facile installation of organic co-ligands and the typically low toxicity of analogous complexes. 
In the earlier work on ferrocenyl CORMs (Chapter 3), some requirements for redox activation 
CORMs via co-ligands were considered. Spectroelectrochemistry of the ferrocenyl compounds 
showed that such a co-ligand should be placed directly in the first coordination sphere of the metal 
for a redox event to have a significant effect upon the electron density at the manganese centre. 
Azo dye co-ligands fulfil the requirements of a biologically-relevant redox couple that could be 
installed directly into the metal centre. The N=N double bond can be reduced to form the 
corresponding hydrazine, which can be reduced further to the anilines in which the azo bond has 
been cleaved. The electrochemistry of the azo complexes synthesised will therefore be studied to 
evaluate reduction as an additional method of triggering CO-release. 
There are examples of azo-containing redox-active pro-drugs. Sulfasalazine (163 Scheme 57) is 
one such example. This drug is used to treat arthritis, ulcerative colitis and inflammatory bowel 
disease and is featured in the World Health Organisation “List of Essential Medicines”.307 The 
active ingredient is the metabolite mesalazine, 164, which is formed by reductive cleavage of the 
azo bond within the anaerobic environment of the small intestine and colon.308 It is conceivable 
that the redox properties of the azo group could be adapted for the delivery of carbon monoxide. 
225 
 
Reduction of the azo moiety would be expected to weaken the π-backbonding to the azo co-ligand 
and therefore weaken its coordinating ability. Loss of the co-ligands has been shown to play a 
role in activation of CORMs for CO release, as shown in the literature mass spectrometry study 
described in Section 1.4 and the experimental data revealing possible formation of Mn tricarbonyl 
clusters in Chapter 2. 
 
Scheme 57: Structures of the prodrug Sulfasalazine and its degradation products. 
4.2 Synthesis of Azo Dye Complexes 
The cyclomanganation of a variety of electron-rich and electron-poor substituted azobenzenes is 
known.309 Electron-rich azobenzene 167 and electron-poor azobenzene 169 were synthesised to 
exploit the robustness of the cyclomanganation reaction. If the preliminary studies on the visible 
light-triggered or redox-activated CO-release of these compounds were successful, it would then 
be possible to synthesise a series of substituted complexes to study the effect of substituents on 
CO release wavelength, extinction coefficient, CO release rate and redox potential.  
 The electron-rich and electron-poor azobenzenes 167 and 169 were synthesised by literature 
methods by oxidation of the corresponding anilines: 167 by copper-catalysed aerobic oxidation310 




Scheme 58: Synthesis of azo ligands 167 and 169. 
Earlier work by Bruce and co-workers showed that cyclometalation of azobenzene with one 
equivalent of [MeMn(CO)5] yielded the mononuclear Mn tetracarbonyl complex.312 Subsequent 
reaction of the mononuclear complex with a second equivalent of [MeMn(CO)5] enabled the 
formation in 7% yield of a dinuclear complex in which two cyclometalations occurred on the 
same azobenzene ligand.313 In contrast, the use of [BnMn(CO)5] to cyclometalate azobenzene 
produced the dinuclear complex in much greater yield initially, even when only one equivalent of 
[BnMn(CO)5] was used.314 The dinuclear complex was isolated in >80% yield when two 
equivalents of [BnMnCO)5] were used and it was shown that the dinuclear complex reacted with 
free azobenzene to produce the mononuclear complex.303  
Cyclometalation of the protonated azo ligands 167 and 169 was performed using either 
[MeMn(CO)5] (174) or [BnMn(CO)5] (87) (Scheme 59). The use of one equivalent of 
[MeMn(CO)5] was anticipated to deliver a relatively clean conversion of ligand into the 
mononuclear complexes whereas two equivalents of [BnMn(CO)5] were used to promote 
formation of dinuclear complexes. This means that some of the CORMs synthesised in this work 
could deliver up to eight equivalents of CO per molecule - the number of equivalents of CO 




Scheme 59: Synthesis of complexes 170-173. 
The results of the syntheses are summarised in Table 14. A solution of the azobenzene and 
[MeMn(CO)5] in degassed toluene at reflux gave the expected mononuclear Mn tetracarbonyl 
complexes 170 and 172. In agreement with previous observations on other azobenzenes by Bruce 
and co-workers, only one Mn(CO)4 fragment was transferred to the product when one equivalent 
of [MeMn(CO)5] was used.312 This provided a clean method of generating dinuclear complexes 
171 and 173. 
The synthesis of dinuclear complexes 171 and 173 was achieved with two equivalents of 
[BnMn(CO)5. The reaction was run until all of the [BnMn(CO)5] was consumed (3 hours, 
monitored by infrared spectroscopy) and this provided a mixture of both the mono- and dinuclear 
complexes. The major products after 3 hours were the mononuclear complexes. The mono- and 
dinuclear complexes were isolable by column chromatography on silica gel. The synthesis with 
[BnMn(CO)5] is therefore convenient for generating both the mononuclear and dinuclear 
complexes in a single reaction and purification, provided the two complexes are readily separable. 
Based on Bruce’s earlier observations, a shorter reaction time could be used in the future to 
optimise for a greater yield of the dinuclear complex, although in this case the yields of both 
complexes were sufficient to provide the material needed for further study. 
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Table 14: Yield of isolated products for cyclometalation reactions with [MeMn(CO)5] and 
[BnMn(CO)5]. Yields are based on the amount of azobenzene ligand used. 
Ligand Product 
Yield With [MeMn(CO)5] 
(1 eq.) (%) 
Yield With [BnMn(CO)5] 
(2 eq.) (%) 
 
167 
170 58 66 
171 0 22 
 
169 
172 52 62 
173 0 21 
 
The infrared spectra of complexes 172 and 173 are shown in Figure 100.  


























Figure 100: Normalised infrared spectra of complexes 172 (black) and 173 (red) in CH2Cl2 solution 
recorded at 2 cm-1 resolution. 
Unlike the related ppy complexes in Chapters 2 and 3, which exhibit four infrared stretching 
bands, mononuclear complex 172 displayed only three bands. Though many of the cyclometalated 
azo complexes in the literature possess four infrared stretching bands in the metal carbonyl region, 
the central two bands at ca. 2000 cm-1 are typically only spaced by approximately 5 cm-1, 
compared with > 10 cm-1 for the ppy complexes. It is therefore likely that the central two bands 
are coalescent for complex 172. The infrared spectrum of cyclometalated azo dye CORM 161 
was previously found to have only three infrared bands in the metal carbonyl region with an 
intense, asymmetrical central band. In dinuclear complex 173, the four different stretching modes 
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of the tetracarbonyl moiety can each be observed, and the spectrum resembles that of the ppy 
complexes derived from 88. A comparison of the band positions is provided in Table 15. The 
Table reveals that the force constants for the vibrations in the azo complexes are larger for the 
azo complexes than for ppy complex 88, consistent with the increased π-acceptor ability of the 
azo ligand compared to ppy. There is some variation in how much the bands shift by depending 
on the nature of the vibrational mode. Upon with moving from complex 88 to complexes 172 and 
173, the respective bands responded in an analogous fashion to oxidation of ferrocenyl CORM 
134 (Section 3.3.1). As was the case in the infrared spectroelectrochemistry of 134, the smallest 
shift on moving from ppy to azo ligands is in the high-wavenumber A1 band, as this vibration 
involves the two mutually trans carbonyl ligands, whereas the low-wavenumber B2 normal modes 
involving ligands trans to the ppy/azo ligands showd the largest increase in wavenumber. Also 
mirroring the spectroelectrochemistry of 134, the two central bands ν(CO) (2) and ν(CO) (3) 
shifted by similar values to one another, despite involving the mutually cis and mutually trans 
carbonyls respectively. It is interesting that the impact on the infrared bands of moving from a 
ppy-based ligand to an azo ligand is similar to that of oxidation of complex 134. The infrared 
spectra of 88, 172 and 173 in THF are essentially identical to the CH2Cl2 spectra. 
Table 15: Comparison of metal carbonyl infrared stretching band wavenumbers in CH2Cl2 and THF 
between ppy complex 88 and azo complexes 172 and 173. 








88 CH2Cl2 1932 1975 1990 2075 
88 THF 1932 1974 1989 2073 
172 CH2Cl2 1960 2003 (bands coalescent) 2084 
172 THF 1959 2001 (bands coalescent) 2082 
173 CH2Cl2 1963 1999 2019 2079 
173 THF 1964 1998 2017 2078 
 
The aromatic region of the 1H NMR spectra for azobenzene 169 and its corresponding 




Figure 101: 400 MHz NMR spectra of compounds 169, 172 and 173 in CDCl3 at 298 K. 
The aromatic protons in the free azobenzene 169 appear as two multiplets displaying second-
order effects resulting from the AA'XX' spin system. Upon cyclometalation to form the 
mononuclear complex 172, the molecule is desymmetrised; only one of the two rings displays the 
AA'XX' multiplets. The protons on the cyclometalated ring comprise very deshielded proton A, 
with a small ‘W’ coupling to proton B, which in turn displays a larger coupling to proton C on 
the adjacent carbon atom. After a second cyclometalation to form dinuclear complex 173, 
desymmetrisation of the second ring takes place, leading to a similar pattern of resonances for the 
desymmetrised ring in mononuclear complex 172. 
Crystal structures of complexes 170 and 173 were obtained to confirm the structure of these 
compounds (Figure 102 and Figure 103 respectively). In the mononuclear complex 170, the 
planarity of the aromatic system is disturbed to accommodate the five-membered manganacycle. 
The structure of dinuclear complex 173 is almost planar due to the additional geometric 
constraints of the second manganese centre. As expected, consistent with the ppy complexes 
reported in the literature137,184,282 and Chapter 2, in both azo complexes the Mn-C bonds trans to 












Figure 102 An X-ray crystal structure of compound 170 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): N(1)-N(2) 
= 1.278(2), C(9)-Mn(1) = 2.0346(19), C(15)-Mn(1) = 1.869(2), C(16)-Mn(1) = 1.815(2), C(17)-Mn(1) = 
1.858(2), C(18)-Mn(1) = 1.846(2), N(1)-Mn(1) = 2.0505(16)  Selected bond angles (ᵒ): C(9)-Mn(1)-N(1) 
= 77.92(7), C(16)-Mn(1)-N(1) = 168.53(8), C(18)-Mn(1)-C(9) = 176.45(8), C(17)-Mn(1)-C(15) = 
173.45(8), C(18)-Mn(1)-N(1) = 98.56(7), C(16)-Mn(1)-C(18) = 92.82(8).  
 
Figure 103: An X-ray crystal structure of compound 173 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): N(1)-N(2) 
= 1.299(3), C(1)-Mn(1) = 2.018(2), C(10)-Mn(1) = 1.877(3), C(11)-Mn(1) = 1.861(3), C(12)-Mn(1) = 
1.801(3), C(13)-Mn(1) = 1.849(3), N(1)-Mn(1) = 2.083 (2) Selected bond angles (ᵒ): C(1)-Mn(1)-N(1) = 
77.74(9), C(12)-Mn(1)-N(1) = 167.63(10), C(13)-Mn(1)-C(1) = 177.44(11), C(10)-Mn(1)-C(11) = 
173.17(11), C(13)-Mn(1)-N(1) = 104.11(10), C(13)-Mn(1)-C(12) = 88.19(12).  
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The N=N bond of dinuclear complex 173 shows a significant lengthening from that of the 
corresponding free azobenzene309 169, from 1.250(2) Å to 1.299(3) Å. The lengthening of the azo 
bond upon cyclometalation reflects the π back-donation from the metal into the azo π* and is 
therefore indicative of the nature of the bonding. A similar lengthening of the N=N bond was 
reported for the double cyclometalation of unsubstituted azobenzene itself.315 Although complex 
173 possesses different substituents on the azobenzene, the N=N bond length of this mononuclear 
complex lies in between these two values at 1.278(2) Å.  
Ligand 176 (Scheme 60) was also synthesised in an effort to develop a ‘push-pull’ chromophore 
ligand. Incorporation of electron-rich donors and electron-poor acceptors in chromophore 
molecules is a well-known strategy to lower the energy gaps between frontier molecular orbitals, 
leading to intense visible light absorption, as summarised in a recent comprehensive review.316 
‘Push-pull’ azobenzene 176 was synthesised by oxidation of aniline to nitroso compound 175, 
which was then converted to azo dye 175 using aniline 166.317  
 
Scheme 60: Synthesis and cyclometallation of azobenzene 176. 
A preliminary attempt to cyclometalate ligand 176 with [MeMn(CO)5] resulted in the formation 
of the two regioisomers 177 and 178. However, the regioisomers were not separable by silica gel 
or alumina column chromatography. The regioisomers were observed in the crude material by 1H 





Figure 104: A 400 MHz spectrum of the crude material after cyclometalation of azobenzene 176 with 
[MeMn(CO)5] recorded at 298 K in CDCl3.  
The NMR spectrum contained some unreacted azobenzene starting material 176 (green triangles) 
despite complete consumption of the [MeMn(CO)5] having been indicated by infrared 
spectroscopy during reaction monitoring. This may be due to a difference in sensitivity of the two 
techniques or decomposition of the [MeMn(CO)5]. Since metal carbonyls are strong absorbers of 
infrared light, infrared spectroscopy is expected to be a more sensitive technique than NMR 
spectroscopy in this case, suggesting that the MeMn(CO)5 degraded through a side-reaction 
during the cyclometalation. The non-integrated peaks near the CHCl3 peak (from 7.1-7.3 ppm) 
correspond to the residual toluene reaction solvent. The two regioisomers appeared in 
approximately a 5:1 ratio and were assigned based on the spectra of complexes 170 and 172. The 
highly deshielded single-proton resonance at 8.72 ppm, from the desymmetrised -CO2Et 
substituted ring, is diagnostic of desymmetrisation of the benzene ring in complex 172, closely 
resembling the 8.76 ppm resonance from the similar proton in complex 172.  
Although the two possible sites for cyclometalation of 176 are meta to either the -CO2Et or -OMe 
substituents, the electronic properties of these substituents clearly still have an influence on the 
regioselectivity of the reaction. Earlier work by Bruce and co-workers on the regioselectivity of 
the cyclomanganation of substituted azobezenes showed that cyclometalation is typically 
selective towards electron-poor sites of aromatic rings.303  
An indication of the electron-donating or electron-withdrawing influence of a substituent can be 
obtained by considering the Hammett parameters for meta-substituted aromatics, σm. The σm 
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values are +0.12 for -OMe and +0.37 for -CO2Et.318 Less positive values indicate superior 
electron-donating groups, meaning that the position meta to the -OMe group is more electron rich 
than the carbon atom meta to the -CO2Et group. However, cyclometalation meta to the -OMe 
group is preferred on cyclometalation of azobenzene 176. This cyclometalation reaction therefore 
appears to display an unusual regioselectivity for a more electron-rich site. 
Preparative HPLC may be employed in future work in order to separate the two regioisomers. It 
may be possible to purify a single ‘push-pull’ complex by using an excess of [BnMn(CO)5]. This 
would ensure that all the monocyclometalated complexes were converted into the 
dicyclometalated complex, which may then be chromatographically separable.  
Given the successful synthesis and purification of the initial mono- and dinuclear complexes 170-
173, these complexes were evaluated as photoCORMs before further synthetic work. The idea of 
a ‘push-pull’ azo photoCORM could then be re-evaluated in light of these tests on the 
photoCORM and redox properties of cyclometalated azo Mn tetracarbonyl complexes. 
4.3 Photochemical CO release 
4.3.1 Calculated and Experimental UV-Visible Absorption Spectra 
Before assessing the CO release of the complexes, UV-visible spectra were recorded to assess 
where the compounds absorb. This was intended to inform the choice of LED used for irradiation 
if specific transitions were identifiable. The ethoxy derivatives 172 and 173 were taken forward 
for study as a test system to assess the photochemical properties of the azo-derived complexes. 
The ester-substituted compounds were initially chosen due to the likelihood of the ester or 
corresponding carboxylic acid affording high water solubility for biological studies and easy 
functionalisation. Success with this group of compounds could then lead to a new modular CORM 
design based on functionalising the ester. Figure 105 shows an overlay of the UV-visible spectra 
of ester-substituted azobenzene 169 with cyclometalated complexes 172 and 173. The spectrum 




Figure 105: UV-visible spectra in CH2Cl2 of azo compound 169, and cyclometalated complexes 172 
and 173. The dashed lines represent the LED wavelengths used for irradiation of the complexes to 
probe CO dissociation. 
The spectra show that ligand 169 has only a relatively weak visible absorption band centred at 
around 500 nm, with the stronger azo π-π* occurring mainly in the UV region of the spectrum. 
Upon cyclometalation to form complex 172, another band with a λmax value of 434 nm appears in 
the spectrum with  (434 nm) = (3.0 ± 0.2) × 103 dm3 mol-1 cm-1. The position, appearance, and 
extinction coefficient of this band resemble the MLCT band for [Mn(ppy)(CO)4] in Section 2.2.2, 
except the wavelength has undergone a bathochromic shift of around 80 nm into the visible 
region. This is an encouraging result as this irradiation of the MLCT band for [Mn(ppy)(CO)4] 
provides efficient CO release. This transition therefore warrants further investigation of its CO-
release properties. 
Complex 173 exhibits bands throughout the visible region and appears to show a further 
bathochromic shift of all bands compared to 172. However, the relative intensities of the bands 
has also changed and so this result should be treated with caution; it may be that the transitions 
being observed in 173 are very different to those in 172. To probe this, TD-DFT calculations 
could be employed to predict the orbital transitions involved within each band. However, a 
practical method to determine which transitions are CO-dissociative is to irradiate the complexes 
with several different wavelengths of UV or visible LED lights in the presence of myoglobin. The 
wavelengths of LED used are overlaid on the spectrum in Figure 105. 
























 169 20 M
 172 21 M
 173 20 M
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4.3.2 Photochemical CO Release to Myoglobin 
To test the thermal stability and confirm the wavelength range of the photochemical CO-
dissociative transitions, CO release to myoglobin was quantified. Incubation in the dark was 
followed by LED irradiation with various wavelengths of UV or visible light. As discussed in 
Section 1.3.2.1, the CO release assay relies on the change in absorbance of myoglobin at 540 nm 
upon binding CO. However, the azo dye CORMs synthesised in this Chapter also absorb at this 
wavelength. It is also likely that any degradation products containing the azo ligand would also 
absorb in this region of the spectrum. As a result, only low concentrations (10 μM) of the 
complexes were used compared to myoglobin (50-60 μM) and a full isosbestic point correction 
to the spectra (as described in Section 3.4.3) was performed. The results for complex 172 are 
summarised in Figure 106 and Table 16. 
 
Figure 106: The CO release profiles of 172 in the dark and upon LED irradiation. A concentration 
of 10 μM 172 was used for all assays, with 50-60 μM myoglobin. Irradiation was performed at a 
power of 6.0 W in cycles of 3 minutes off, 2 minutes on from 30 minutes onwards.  
The results show that slow CO release from complex 172 takes place in the dark during the first 
30 minutes of the experiment, with 1-4 μM [CO-Mb] forming within this time. This could be due 
to reactivity such as protonation of the cyclometalated azo ligand, reaction with the phosphate 
buffer, water, Mb or the reducing agent sodium dithionite. After establishing this slow 
background level of CO release, the data show that LED irradiation at either 365, 400 or 465 nm 
accelerates the rate of CO release. This indicates photochemical irradiation enhances CO release 
within this wavelength range (365-465 nm). Irradiation with 525 nm and 590 nm LEDs did not 
result in an enhancement in the rate of CO release compared to the initial 30 minutes in the dark 
– the slow, linear profile of the early dark CO release continues throughout the experiment. 
























Although a full-length control with no irradiation was not performed to confirm this, the 
experiments with 525 and 590 nm were concluded to effectively measure the slow ‘background’ 
of CO release observed in the dark, since no enhancement is seen of the initial dark CO release 
and because the traces are very similar for both wavelengths. In any case, any such enhancement 
would be extremely small and unlikely to be useful for CORM applications. 
The observation of some photochemical CO release at 465 nm represents a success of the CORM 
design. The 465 nm release shows that incorporation of an azo dye co-ligand has shifted the CO 
release wavelength further into the visible region compared to the family of ppy complexes 
[Mn(ppy)(CO)4], which display no electronic absorption bands at 465 nm (Section 4.1.1). This is 
the desired effect predicted from the work on analogous complexes by Mascharak and co-
workers.127 However, the rates of CO release at both 400 and 465 nm for complex 172 were still 
relatively slow given the high power of irradiation used when compared to complex 161 (Table 
16). At the end of the experiment, after 30 minutes in the dark and 12 × 5-minute on/off cycles of 
irradiation (24 minutes of irradiation in total), the 365 nm experiment resulted in the release of 
2.2 equivalents of CO to myoglobin per Mn, whereas 1.3 equivalents per Mn were released at 400 
and 465 nm. Thus, although the experiments at 400 and 465 nm gave an increase from the 
background ‘thermal’ CO release seen in the ineffective 525 and 590 nm experiments, the data 
show that UV irradiation at 365 nm was still the most efficient method of triggering CO release 
from complex 172.  
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Table 16: Comparison of the CO release experiments for a range of Mn(I) carbonyl complexes to 
compare the release profile of 172 with complexes 90, 91, 95, 133, 134 and 161. The starting 
concentration of CORM was 10 μM in all cases except for complex 133, where it was 40 μM. 
Complex Wavelength / nm Power / W Eq. CO Released After 
12 Irradiation Cycles 
per Mn 
172 365 6.0 2.2 
172 400 6.0 1.3 
172 465 6.0 1.3 
172 525  6.0 0.5 
172 590 6.0 0.5 
161 465 2.4 2.3137 
90 400 2.4 2.6184 
91 400 2.4 2.6184 
95 400 2.4 2.9159 
133 400 5.0 1.0 (Chapter 3) 
134 400 5.0 2.5 (Chapter 3) 
 
When considering the data in Table 16, it should be remembered that complex 172 displayed slow 
background CO release without irradiation and that the 0.5 eq. CO was released at 525 and 590 
nm was thermal release. It is likely that a similar number of CO equivalents was released 
thermally in conjunction with the successful photochemical release at 365-465 nm, and so only a 
proportion of the total equivalents released were photochemically-triggered. Complex 161 also 
displayed thermal release to some extent, but caution should be taken in quantitatively comparing 
the background ‘thermal’ release rates of the two complexes as neither Ward’s study or this work 
included a full control over the entire length of an assay; the only test for thermal CO release was 
the initial 30-minute incubation in the dark.  
Table 16 also shows a comparison with 172 and some CORMs derived from complex 88, 
[Mn(ppy)(CO)4]. The ppy-based derivatives were all stable to the experimental conditions in the 
dark and it is known that all CO release is photochemically triggered.159 Although there is no 
comparable data for the equivalents of CO released by complex 88 itself at 10 μM, several of its 
derivatives (Cl and Br labelled complexes 90 and 91 and carboxylic acid derivative 95) have been 
tested and yielded 2.6-2.9 equivalents of CO per Mn at 400 nm, far more than 172 and at a lower 
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irradiation power.159,184 Therefore, despite an apparent shift of the CO release wavelength into the 
visible, the ppy-derived complexes appear to release CO much more rapidly than 172 at 400 nm. 
Similarly, complex 161 releases more CO at 465 nm than does 172. 
Finally, Table 16 shows the ferrocenyl complexes 133 and 134 that were discussed in Chapter 3. 
The CO release from complex 172 is comparable to the very slow CO release from ferrocenyl 
complex 133 at high power and 400 nm wavelength. However, as discussed in Chapter 3, complex 
133 appeared to have poor water solubility compared to the other complexes, so the value of 1.0 
equivalents per Mn is likely to be an underestimate and accounts for the difference with the other 
ppy derivatives. No such solubility issues were identified for complex 172 – there was no sign of 
any wavelength-indepentdent increase in absorbance throughout the assay as had been observed 
in all experiments with complexes 132 (insoluble) and 133 (partially soluble). Complex 134, 
which was water soluble, released 2.5 equivalents of CO per molecule, through both thermal and 
photochemical release. It is notable that despite there being two CO release mechanisms at work, 
complex 134 (and 161) still release around 2.3-2.5 equivalents of CO, only slightly less than the 
ppy derivatives. This supports the hypothesis that the poor CO release rate observed for 172 is 
inherently a feature of this complex rather than as result of the mixed thermal/photochemical 
release mechanism.  
The number of equivalents of CO released by exhaustive photolysis of 172 was evaluated by 
allowing the 365 nm irradiation experiment to run until no further change in the myoglobin spectra 




Figure 107: Exhaustive CO release from 10 μM 172 using 365 nm LED irradiation. Irradiation was 
performed at a power of 6.0 W in cycles of 3 minutes off, 2 minutes off from 30 minutes onwards.  
The data shows exhaustive CO release after 30 minutes of incubation with myoglobin in the dark 
followed by two hours of irradiation. The graph levels off at a [CO-Mb] concentration of 24 μM, 
so that 2.4 equivalents of CO were released per molecule of 172. This is similar to the 
tetracarbonyl ppy complexes, which appear to release 2.5-3 equivalents of CO per molecule of 
photoCORM as reported in Section 3.4.3 and in the literature.184 Non-integer values for CO can 
be understood based on side-reactions such as CO insertion into the Mn-C bond of the ppy159 and 
the possible formation of cluster species detected in this Thesis. It is also possible that not all of 
the CO released by CORMs gets captured by the myoglobin assay. 
The CO release profile of doubly-cyclometalated complex 173 was also studied. Thermal CO 
release and irradiation with 590, 525, and 400 nm LEDs was performed. The results, shown in 
Figure 108, showed little photochemical CO release at these wavelengths.        



















      
Figure 108: The CO release behavior of 10 μM 173 in the dark and upon LED irradiation. Irradiation 
at 525 and 400 nm was performed at a power of 6.0 W in cycles of 3 minutes off, 2 minutes off from 
30 minutes onwards. 
The data in Figure 108 highlights the instability of complex 173 in the dark leading to a small 
amount of slow CO release and shows that irradiation with 525 nm LED did not accelerate the 
CO release. When the 525 nm LED was replaced by a 400 nm LED, a slight acceleration in the 
CO release was observed indicating that at shorter wavelengths complex 173 does exhibit some 
photochemical CO release. However, the rate of the CO release at 400 nm for complex 173 
appeared to be slower than for 172 at the same wavelength. This observation and the lack of 
sensitivity to visible light suggests that the CO-dissociative transitions for the doubly-
cyclometalated complex 173 lie at shorter wavelengths than 173.   
4.3.3 Ultrafast Time-Resolved Infrared Spectroscopy of 172 and 173 
The ultrafast photochemistry of complexes 172 and 173 was studied using TRMPS, the same type 
of pump-probe experiment employed in Chapter 2. The aim of the study was to gain an 
understanding of the primary photochemistry of these complexes to understand why they display 
such inefficient photochemical CO release compared to the analogous ppy complexes. As with 
the ppy complex 88 in Chapter 2, it was not possible to perform TRIR spectroscopy on the azo 
complexes in aqueous solution due to the tens of millimolar concentrations required for the 
experiment, several orders of magnitude higher than would be anticipated for a therapeutically 
relevant effect.74 




















4.3.3.1 Complex 172 
Based on the irradiation experiments in the myoglobin assays, which indicated that the most 
efficient CO loss occurs with 365 nm LED irradiation, a pump wavelength of 355 nm was used. 
Spectra at short pump-probe delays for complex 172 in THF solution are shown in Figure 109. A 
scaled ground state spectrum of 172 is provided as a reference, and the band positions for all 
ground states and solvents used are tabulated in Section 7.1.1. For clarity, the spectra at 2 and 100 
ps are also compared individually in Figure 110. 
 
Figure 109: TRIR spectra of complex 172 in THF under air at picosecond pump-probe delays. A 
pump wavelength of 355 nm was used. The arrows indicate the direction of change in absorbance of 
the bands over time. A scaled spectrum of the ground state of complex 172 in THF is shown for 
reference. 
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Figure 110: TRIR spectra of complex 172 in THF under air at picosecond pump-probe delays 
comparing the delays at 2 and 100 ps – the data are from the same experiment as that in Figure 109. 
A scaled spectrum of the ground state of complex 172 in THF is shown for reference. 
The TRIR difference spectra at short pump-probe delays appeared very different to those of 
[Mn(ppy)(CO)4]. The dominant photoproduct in the difference spectra at short pump-probe delays 
exhibited broad bands with apparent maxima at around 1976 cm-1 and 2040 cm-1 that appeared 
within the first 1-2 ps. The bands of this species did not resemble the solvated facial tricarbonyl 
species observed in the related experiments with [Mn(ppy)(CO)4]. Instead, this photoproduct 
closely resembled the minor photoproduct 3[Mn(ppy)(CO)4]: the short-lived non-dissociative 
triplet excited state. The predominant photoproduct observed in Figure 109 was therefore assigned 
as a triplet excited state, 3[172]-(1).   
The reasons for the assignment of this excited state as a triplet are its lifetime (between ca. 5-10 
ps, Table 17), and the resemblance of the spectra to the 3MLCT states of [Mn(ppy)(CO)4] and the 
isoelectronic [Cr(bpy)(CO)4]. In all cases the initial excitation is assumed to be to a singlet excited 
state (or states), since direct transitions to triplets are spin-forbidden and therefore much weaker. 
However, the lifetime of the excited state of complex 172 in Figure 109 is much longer than would 
be expected for the 1MLCT state. For comparison, the singlet excited state in [Cr(bpy)(CO)4] 
decays within 100 fs due to the competing processes of CO loss and triplet excited state 
formation.175 Given the behaviour of [Cr(bpy)(CO)4] and [Mn(ppy)(CO)4] it is likely that ultrafast 
CO dissociation, and intersystem crossing to form the 3MLCT excited state, occur in <1 ps from 
the 1MLCT state in complex 172. Dissociation of CO in <1 ps was observed in [Mn(ppy)(CO)4] 
but the same cannot be confirmed for complex 172 with the data in Figure 109 due to the overlap 
of the weak solvated tricarbonyl bands with other bands. For [Mn(ppy)(CO)4] and 
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[Cr(bpy)(CO)4], the MLCT nature of the excitation was apparent from TD-DFT calculations 
(Section 2.2.2); similar calculations could in future be performed to compare the charge transfer 
in azo complex 172. 
The band for 3[172]-(1) at around 2040 cm-1 decayed on the ps timescale and was replaced with 
a new set of bands corresponding to a second photoproduct with bands at 2023 and 2068 cm-1 
(Figure 112). The small positive absorbance at 1976 cm-1 remained essentially unchanged on the 
picosecond timescale but there were changes to the nearby bleach bands in this region as the first 
photoproduct was consumed and the second grew in, suggesting that both photoproducts also had 
bands in this region. The second photoproduct was also assigned as an excited state, 3[172]-(2), 
because the bands were broad and did not resemble the solvated facial tricarbonyl species 
observed with [Mn(ppy)(CO)4]. For example, the high-wavenumber band at 2068 cm-1 in this 
excited state was far higher than the carbonyl stretches of any of the CO dissociation products 
observed so far.  The lifetime of the initial photoproduct 3[172]-(1) was measured based on the 
absorbance at 2040 cm-1, and this was compared to the growth of 3[172]-(2) (Table 17).  
 
Figure 111: Kinetic profiles of selected TRIR bands for 172 on the picosecond timescale. The dashed 
lines are single exponential fits. 
The single exponential lifetimes for the loss of 3[172]-(1) and growth of 3[172]-(2) are the same 
within the 95% confidence intervals of the fits. This evidence supports the hypothesis that 
consecutive population of the two excited states takes place, as opposed to re-population of the 
ground electronic state upon decay of the short-lived excited state. 
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Table 17: Single exponential lifetime of the decay of 3[172]-(1) and growth of 3[172]-(2) with 95% 
confidence intervals. 
Wavenumber / cm-1 τ  / ps 
2040 (growth) 6.9 ± 2.0 
2023 (decay) 8.1 ± 1.5 
2068 (decay) 6.3 ± 1.0 
 
Spectra at ns pump-probe delays from the same experiment as the data in Figure 109 are shown 
in Figure 112. The data show that the 3[172]-(2) persisted for the first few tens of nanoseconds 
before decaying. The kinetics of the decay compared to the recovery of the bleach bands is shown 
in the first order exponential fits in Figure 113, and the lifetimes are subsequently tabulated in 
Table 18.  
 
Figure 112: TRIR spectra of complex 172 in THF under air at nanosecond pump-probe delays. A 
pump wavelength of 355 nm was used. The arrows indicate the direction of change in absorbance of 
the bands over time. A scaled spectrum of the ground state of complex 172 in THF is shown for 
reference. 
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Figure 113: Kinetic profiles of selected TRIR bands for 172 on the nanosecond timescale. The dashed 
lines are single exponential fits. 
Table 18: Single exponential lifetime of 3[172]-(2) and concurrent bleach recovery with 95% 
confidence intervals. 
Wavenumber / cm-1 τ  / ns 
1975 10.3 ± 1.1  
2024 8.3 ± 0.6 
2067 8.4 ± 0.6  
1958 (bleach recovery) 8.9 ± 1.1 
1997 (bleach recovery) 8.8 ± 1.7 
2002 (bleach recovery) 8.8 ± 1.7 
2083 (bleach recovery) 8.8 ± 1.6 
 
The loss of 3[172]-(2) was accompanied by near-complete recovery of the ground state bleach 
bands, all with the same single exponential lifetime. Compared to [Mn(ppy)(CO)4], there was a 
much better match of the bleach bands to the decaying excited state bands – this could be because 
vibrational relaxation was complete by the nanosecond timescale, whereas the excited state in 
[Mn(ppy)(CO)4] decayed on the picosecond timescale and may have been convoluted by the 
effects of vibrational relaxation and geminate recombination. 
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The final band to discuss in the difference spectra in Figure 109 and Figure 112 is the small, low-
wavenumber band at 1917 cm-1. The 1917 cm-1 band was assigned to facial tricarbonyl complex 
179THF(O) (Scheme 61). The assignment was confirmed by looking at the difference spectrum after 
a pump-probe delay of 1 μs, when the excited state bands had decayed away (Figure 114). An 
additional band at 2010 cm-1, overlapping a bleach, is visible in the spectrum, consistent with the 
pattern of two closely spaced (in this case coalescent) low-wavenumber bands separated from a 
single band at high-wavenumber as observed for the facial tricarbonyl complexes in Chapter 1 
and in the literature.200 This photoproduct persists into the microsecond timescale before being 
removed by the flow system. Studying its reactivity at longer times would require an in situ 
infrared experiment with LED irradiation such as those in Section 3.4.2, although the continuous 
irradiation in such an experiment may prevent the distinction of thermal and photochemical 
reactivity. If it could be made in adequate yield, would be desirable in future work to isolate this 
species for further characterisation and to assess its thermal and photochemical reactivity. 
 
Figure 114: TRIR spectrum of 172 in THF under air at a pump-probe delay of 1 μs. A pump 
wavelength of 355 nm was used. A scaled spectrum of the ground state of complex 172 in THF is 
shown for reference. 
The 1917 cm-1 band grew in with a single exponential lifetime of (24.2 ± 3.9) ps, showing that it 
was not part of the excited states, discussed above, that dominate the photochemistry of 172. The 
time taken for the 179THF(O) band to initially grow in may be dictated by vibrational relaxation 
causing the band to sharpen, or by isomerisation from C-H σ-complex 179THF(σ) to produce 
179THF(O) (Scheme 61). Vibrational relaxation is typically accompanied by a small shift of the 
band to higher wavenumber,319 but this was not observed in the spectra in Figure 109. However, 
if isomerisation from 179THF(σ) to 179THF(O) were taking place, a broad band at higher wavenumber 
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corresponding to 179THF(σ) should be present at short pump-probe delays, and no such band was 
observed in Figure 109. It would seem unlikely that THF coordinates selectively through the O 
atom in this case given the isomerisations observed in Chapter 2. It is possible that the band for 
179THF(σ) was masked by overlaps with the 1958 cm-1 bleach band and the excited state 
photoproducts that also absorb in this region, particularly because the bands for the excited states 
dominate the spectra with photodissociation seemingly only a minor pathway.  
 
Scheme 61: Formation of complex 179THF(σ). Dashed arrows have been used to reflect the lack of 
direct evidence for the mechanistic pathway. 
4.3.3.2 Complex 173 
The behaviour of the dinuclear complex 173 was also studied using TRMPS. Similar behaviour 
was observed to that of complex 172. At short pump-probe delays (Figure 115 and Figure 115), 
a short-lived excited state like the one observed for 172 was observed, denoted 3[173]-(1) 
decaying with a lifetime of circa 10 ps (Table 19). By 100 ps, a second excited state 3[173]-(2) 
dominated the spectrum. Excited state 3[173]-(2) grew in with a lifetime of (9.0 ± 1.0) ps measured 
at 2053 cm-1, matching the decay of 3[173]-(1). Again, one only one bleach band  (at 2017 cm-1) 
showed any recovery as 3[173]-(1) decayed, and this most likely due to absorption 3[173]-(1)  that 
forms on this timescale. A feature at low wavenumber with a maximum at around 1945 cm-1 was 
observed in these spectra, which was not observed in the spectra for 172. This is likely to be the 
tail of the larger band at 1975 cm-1 rather than a separate band: excited states with MLCT character 




Figure 115: TRIR spectra of 173 in THF under air at picosecond pump-probe delays. A pump 
wavelength of 355 nm was used. The arrows indicate the changes of the photoproduct bands over 
time. A scaled spectrum of the ground state of complex 173 in THF is shown for reference. 
 
Figure 116: TRIR spectra of 173 in THF under air comparing 2 and 100 ps pump-probe delays for 
clarity. The arrows indicate the changes of the photoproduct bands over time. The graph shows the 
same data as Figure 115.  
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Table 19: Single exponential lifetimes for the decay of the 3[173]-(1) bands and growth of the 3[173]-
(2) band at 2054 cm-1, with 95% confidence intervals. 
Wavenumber / cm-1 τ  / ps 
1945 10.6 ± 0.9 
1975 9.9 ± 0.9 
2035 9.5 ± 0.6 
2054 (growth of second 
excited state) 
9.9 ± 0.6 
 
As was the case for 172, the long-lived excited state decayed on the nanosecond timescale with 
concomitant recovery of the bleaches, as shown in Figure 117 and Table 20. The lifetime was 
longer than for 172 at ~30 ns compared to ~10 ns. 
 
Figure 117: TRIR spectra of 173 in THF under air at nanosecond pump-probe delays. A pump 
wavelength of 355 nm was used. The arrows indicate the changes of the photoproduct and bleach 
bands over time. A scaled spectrum of the ground state of complex 173 in THF is shown for reference. 
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Table 20: Single exponential lifetimes for the decay of the 3[173]-(2)  bands. The single exponential 
lifetimes for concomitant bleach recovery are also given. The fits are reported with 95% confidence 
intervals.  
Wavenumber / cm-1 τ  / ns 
1990 28.4 ± 3.6  
2024 28.1 ± 3.4  
2054 27.6 ± 3.5  
1961 (bleach recovery) 26.8 ± 5.4 
2017 (bleach recovery) 29.3 ± 9.1 
2079 (bleach recovery) 29.9 ± 5.2 
 
Following the decay of 3[173]-(2), a small set of bands resembling a solvated facial tricarbonyl 
species was observed, confirming that CO dissociation takes place in the UV for complex 173 to 
give 180THF(O), Scheme 62. No additional bands carbonyl stretching bands were observed 
compared to 180THF(O) This suggests that the infrared stretching bands of the remaining 
“Mn(CO)4” moiety in the molecule did not shift in wavenumber by a sufficient amount to be 
detected. 
 
Figure 118: TRIR spectrum of 173 in THF under air at a pump-probe delay of 1 μs. A pump 
wavelength of 355 nm was used. A scaled spectrum of the ground state of complex 173 in THF is 
shown for reference. 
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Scheme 62: Formation of complex 180THF(O). Dashed arrows have been used to reflect the lack of 
direct evidence for the mechanistic pathway. 
4.3.3.3 Discussion of Ultrafast Results 
The ultrafast photochemical behaviour observed for the two complexes 172 and 173 is strikingly 
different to the behaviour of [Mn(ppy)(CO)4] (Chapter 2) and more closely resembles 
[Cr(bpy)(CO)4]. Photochemical CO loss is the dominant process for [Mn(ppy)(CO)4] but in 172 
and 173 the major photoproducts are two consecutively populated excited states, representing a 
significant change in the balance of the fundamental primary photochemical steps. The balance 
between 3MLCT formation and CO loss in the azo complexes 172 and 173 is skewed much more 
in favour of excited state formation compared to [Mn(ppy)(CO)4] and its derivatives. This 
qualitative comparison explains why photochemical CO release from the azo complexes to 
myoglobin was slower than for the ppy analogues, since CO release from the azo complexes 
appears to be very inefficient. Quantum yield measurements for CO dissociation would enable 
quantification of this comparison.  
Like [Mn(ppy)(CO)4], which displayed one excited state with a lifetime that decayed on the ps 
timescale, the azo complexes 172 and 173 exhibited short-lived excited states - 3[172]-(1) and 
3[173]-(1) respectively - on the ps timescale. Rather than the short-lived excited state decaying 
back to the ground state as observed for [Mn(ppy)(CO)4], in both azo complexes the short-lived 
excited state was replaced by a second excited state, 3[172]-(2) 3[173]-(2) respectively. It was this 
second state that decayed back to the ground state on the ns timescale, as confirmed by the kinetic 
profiles of the product bands. This is consistent with a hypothesis in which, after excitation to the 
unobserved singlet state, intersystem crossing occurs to a triplet that is above the lowest-energy 
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triplet state. Subsequent internal conversion would then enable relaxation to the lowest-energy 
triplet state, which would be the longer-lived state that decays on the ns timescale.   
The hypothesis proposed above is analogous to the [Cr(bpy)(CO)4] system where two sequentially 
populated ‘trapping’ triplet excited states compete with CO dissociation, and [Mn(ppy)(CO)4] 
where one triplet excited state was seen. Studies using femtosecond TA spectroscopy were used 
to show consecutive population of the two excited states in [Cr(bpy)(CO)4]. In this Chapter, the 
excellent spectral resolution of the TRIR experiments (compared to the UV-visible TA 
experiments) provides compelling evidence supporting similar behaviour to [Cr(bpy)(CO)4] in an 
isoelectronic system. The transfer between the two triplet states in 172 and 173 takes place with 
a lifetime of ~10 ps, comparable to the analogous process in [Cr(bpy)(CO)4]. However, the 
second, lowest energy, triplet excited state in [Cr(bpy)(CO)4] decays with a lifetime of <100 ps,319 
whereas with the azo complexes the analogous lifetime is on the ns timescale. The assignments 
proposed for the states in this study, essentially analogous to [Cr(bpy)(CO)4], are summarised in 
a Jablonski diagram, Figure 119. 
 
Figure 119: Jablonski diagram summarising the behavior of azo complexes 172 and 173.  
 The reason for the longer lifetime of the low-energy triplet excited state in the azo complexes 
compared to [Cr(bpy)(CO)4] is unclear. Calculations from TD-DFT or quantum mechanical 
methods would enable the orbital character of the triplet states of the azo complexes - and the 
relative intensities of the transitions between them - to be investigated. However, the much shorter 
lifetime of 3[172]-(1) and 3[173]-(1) compared to 3[172]-(2) and 3[173]-(2) can be readily 
explained by considering the spin state of each species: when the second triplet state decays back 
to the ground state, this process is spin-forbidden, whereas when first triplet state is converted 










τ ≈ 7 ps
τ ≈ 9 ns
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4.4 Investigation of the Redox Properties of Complex 172 
The slow CO release in the dark displayed by complexes 172 and 173 (Section 4.3.2) could be 
caused by the presence of the reductant sodium dithionite, which is used to generate deoxy-Mb. 
The electrochemistry of complex 172 was therefore studied to probe the redox properties of a 
cyclometalated azo dye CORM. A cyclic voltammogram in the presence of ferrocene as an 
internal standard (to calibrate the pseudo-reference electrode) was recorded to obtain an overview 
of the redox chemistry of complex 172 (Figure 120). The experiment was performed in a glovebox 
to avoid the baseline signal from O2 reduction at the working electrode.  
 
Figure 120: Cyclic voltammogram of a 1.0 mM solution of complex 172 in CH2Cl2 under Ar. The 
electrolyte was 100 mM tetrabutylammonium hexafluorophosphate. A scan rate of 100 mV s-1 was 
used. 
The results of the electrochemistry are summarised in Table 21. Complex 172 displayed two 
reversible reductions at low potentials with E1/2 values of -1.311 and -1.792 V vs Fc/Fc+. As was 
observed for the compounds studied in Chapter 3, the peak separations, ∆E, were higher than the 
theoretical value of 59 mV, but this is likely due to solution resistance. The peak current ratios 


















Table 21: Summary of the cyclic voltammetry data of complex 172. 
E1/2 (V, vs 
Fc/Fc+) 
Eox (V, vs Fc/Fc+) Ered (V, vs 
Fc/Fc+) 
∆E (V) ia/ic 
-1.311 -1.241 -1.381 0.140 0.93 
-1.792 -1.692 -1.891 0.199 1.00 
 
The reversible electrochemical behaviour of azobenzene and its substituted derivatives has been 
well-studied (Scheme 63). Azobenzene reduction in dimethylformamide (DMF) or MeCN solvent 
results in two one-electron reductionss followed by rapid protonation of the dianion from the 
acetonitrile solvent.321 Subsequent re-oxidation of the protonated dianion afforded azobenzene in 
a two-electron oxidation.321  Study of 4-nitroazobenzene revealed two reversible one-electron 
reductions without formation of a protonated dianion, presumably due to additional stabilisation 
of the dianion by the electron-withdrawing nitro groups.322 
 
Scheme 63: Literature redox behaviour of azobenzenes as determined by cyclic voltammetry in 
acetonitrile. Left: azobenzene. Right: 4,4'-nitroazobenzene. 
The behaviour in Figure 120 is similar to the behaviour observed for 4-nitroazobenzene in MeCN, 
where two reversible reductions form a non-protonated dianion.322  In the literature, the two 
reductions for 4-nitroazobenzene occurred in MeCN at -0.870 and -1.195 V vs the saturated 
calomel electrode (SCE).323 The Fc/Fc+ couple lies at +400 mV vs SCE in MeCN,324 giving 
reductions of -1.270 and -1.595 V vs Fc/Fc+, similar to the potentials observed for complex 172 
in CH2Cl2. 
Structural information about the two reductions was sought using infrared and UV-visible 
spectroelectrochemistry. 
4.4.1 Infrared Spectroelectrochemistry 
Infrared spectroelectrochemistry was performed in CH2Cl2 solvent. The infrared 
spectroelectrochemistry experiment for complex 172 is shown in Figure 121. All data in Figure 
121 were recorded in the same experiment which comprised measurement of the spectrum of 172 
at the open circuit potential (OCP) followed by a potential step to – 1 V for 600 s, then followed 
by a potential step to +1 V which was applied for 240 s. The potentials were measured with respect 
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to a Ag wire pseudo-reference electrode. The infrared spectroelectrochemistry was performed in 
a sealed cell in an air-purged spectrometer. 
 
Figure 121: Infrared spectroelectrochemistry experiment with complex 172 in CH2Cl2 at a 
concentration of 5.0 mM in the presence of 1.0 M tetra n-butylammonium hexafluorophosphate. 
Panel A: Complex 172 at the open circuit potential of +446 mV vs the Pt pseudo-reference electrode, 
followed by a potential step to -1 V. Panel B: Further spectra after longer times at -1 V. Panel C: 
Initial spectra after the potential step to +1 V. Panel D: Further spectra after longer times at +1 V. 
In panel A of Figure 121, the spectrum at the OCP (before the application of a potential step) 
shows the three metal carbonyl bands (2084, 2004 and 1960 cm-1) and ester carbonyl band (1715 
cm-1) of complex 172, with the central metal carbonyl band containing the coalescence of one of 
the A1 modes with the B1 mode. Within 120 s of stepping from an open circuit potential of +446 
mV down to -1 V vs Fc/Fc+, the bands for starting species 172 were completely replaced by those 
of a second species 172a. Species 172a had four stretching bands in the metal carbonyl region 
(2059, 1975, 1955 and 1911 cm-1) and a single ester carbonyl band (1682 cm-1). The pattern of 
positions and intensities in the metal carbonyl resembled the spectrum of other tetracarbonyl 
cyclomanganated spectra where the central two bands are no longer coalescent. The carbonyl 
bands for 172a were shifted downwards relative to starting material 172, consistent with 172a 
being a more reduced species than 172. Further changes in the infrared spectrum occurred within 
10 minutes of the reductive -1 V potential step (Figure 121, panel B). The bands for species 172a 
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were replaced by a second reduced tetracarbonyl species 172b with the bands shifted to even 
lower wavenumber (2045, 1954, 1938 and 1890 cm-1). This suggests that this new species retains 
the same structure of the first coordination sphere around the Mn, albeit with much more electron 
density available for backbonding. 
When no further changes were observed in the spectrum at -1 V (10 minutes), a potential step to 
+1 V vs Fc/Fc+ was performed to assess the reversibility of the reduction (Figure 121, panel C). 
The spectra show loss of 172b and formation of a previously unseen species 172c. Three metal 
carbonyl stretching bands (at 2071, 1988 and 1946 cm-1) were observed but it is possible that the 
A1 and B1 modes overlap as was the case in neutral complex 172. The metal carbonyl bands are 
shifted upwards by 25-45 cm-1 compared to the second reduced species, consistent with an 
oxidation reaction having taken place. The ester band shifted back up to 1715 cm-1 in the oxidation 
product, the same wavenumber as in starting complex 172.  
As the potential was held at +1 V vs Fc/Fc+ for even longer (Figure 121, panel D) the bands of 
the 172c decayed to be replaced by the neutral starting complex 172. This suggest that species 
172c is most probably a tetracarbonyl species as well, given the ease of re-formation of 172. The 
use of such a high potential to re-oxidise the reduced species back to complex 172 also confirms 
that the reduced species and the neutral complex 172 cannot be oxidised further using strongly 
oxidising potentials. As with the ferrocenyl CORMs discussed in Section 3.3, it is anticipated that 
a very high potential would be needed to affect oxidation of the Mn(I) tetracarbonyl centre.  
Both the cyclic voltammogram and the infrared spectroelectrochemistry show reversible 
behaviour overall, as 172 is re-formed upon oxidation. Importantly, CO release is not achievable 
by reduction of the azo moiety. Repeats of the spectroelectrochemistry experiment with 200 mV 
potential steps in an attempt to access the first reduced species without forming the second 
reduced species were not successful despite the 500 mV gap between their redox potentials in the 
cyclic voltammogram. This may be due to drifting of the potential applied over time due to the 
use of a silver wire pseudo-reference electrode in this experiment. 
The infrared spectroelectrochemistry shows different intermediates upon oxidative and reductive 
potential steps, whereas the cyclic voltammogram appears to show two reversible one-electron 
steps. The same observations were made in a repeat experiment in EtOH. Including starting 
material 172, four species were observed in the infrared spectroelectrochemistry. The simplest 
scheme to relate the species observed is summarised in Scheme 64. The infrared stretches of the 




Scheme 64: Summary of the formation of the species listed in Table 22 during infrared 
spectroelectrochemistry. 
Table 22: Summary of the infrared stretching bands observed in spectroelectrochemistry of 172. 
Species Mn(CO)4 1 / 
cm-1 
Mn(CO)4 2 / 
cm-1 
Mn(CO)4 3 / 
cm-1 




172 1960 2004 (bands coalescent) 2084 1715 
172a 1911 1955 1975 2059 1682 
172b 1890 1938 1954 2045 1686 
172c 1946 1988 (bands coalescent) 2071 1715 
 
Possible assignments for species 172a-c were considered. An explanation of the observed 
behaviour is aided by considering possible chemical steps using a square scheme (Scheme 65). 
The first reduction of 172 led to a large negative shift in the wavenumber of the metal carbonyl 
bands, suggestive of formation of an anionic species, so that 172a would be assigned as [172]-. 
The second reduction step resulted in a further, but considerably smaller, decrease in 
wavenumber. Also, the ester carbonyl band changed little during the second reduction. A possible 
explanation for these observations is that the dianion has undergone rapid protonation after its 
formation (kc >> k2 in Scheme 65). This would decrease the electron richness of the doubly-
reduced species consistent with the smaller shifts in the metal carbonyl and ester bands upon the 
second reduction. As such, the second reduced species 172b was tentatively assigned as [172H]- 
in Scheme 65. The second reduction would therefore be described as an ‘EC’ process: an electron 
transfer (E) preceding a chemical (C) step. This reduction product appeared to be unreactive under 
the reducing conditions, even with a protic impurity such as water present. This suggests that any 
formation of arylhydrazine species [172H2] is slow, as is the case in non-cyclometalated azo 
compounds.321,322  
When an oxidising potential was applied to 172b (or [172H]-), regeneration of 172 was observed 
via an intermediate different to the one observed in the reductive step. This species, 172c, could 
therefore be [172H], the product of the one-electron oxidation of [172H]-. As such, it is the 
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protonated form of intermediate observed during the reduction, [172]-. Comparison of the infrared 
bands of [172]- and [172H] (Table 22) shows that the carbonyl bands for [172]- are at lower 
wavenumber than for [172H]. This confirms that the metal centre is more electron-rich in [172]- 
compared to [172H], consistent with the assignments made. The final step would then involve 
deprotonation and oxidation of [172H] then occurred to yield 172. The lack of an observed 
deprotonated intermediate prior to re-oxidation suggests another ‘EC’ process where a rapid 
deprotonation follows the oxidation.  
It should be noted that the possible mechanism described by Scheme 65 still obeys the principle 
of microscopic reversibility, despite differenct mechanisms for the forward and reverse reactions. 
This is because the principle of microscopic reversibility operates under identical conditions for 
the forward and reverse reactions, whereas in the spectroelectrochemical data reported here the 
potential is changed between the reductive and oxidative steps, constituting a change in 
conditions. The square scheme shown in Scheme 65 is a common way of representing how the 
sweep direction can alter the reaction pathway. For example, Compton and co-workers recently 
used a nine-membered square scheme to illustrate the proton-coupled electron transfer reactions 
involved in catechol oxidation.325 
 
Scheme 65: Square scheme for complex 172 with proposed assignments of the species observed in the 
infrared spectroelectrochemistry. 
Though the explanation suggested in Scheme 65 represents a plausible explanation of the 
behaviour, different assignments to the species cannot be ruled out. Square schemes containing 
alternative pathways could be envisaged. Given the very large potential steps made in the 
spectroelectrochemical experiment and the different experimental conditions, it is possible that 
species 172a could be the doubly-reduced species [172]2- or [172H]-, i.e. the two reductions from 
the cyclic voltammogram take place before spectra of [172]- can be recorded. A subsequent 
chemical step, such as a rearrangement, could then account for formation of species 172b. Re-
oxidation would then form species 172c before the reverse of the chemical step upon the second 
oxidation. However, it is unclear how the reduced species [172]2- or [172H]- would reversibly 
react as analogous species for other azobenzene derivatives are reported to be stable.322,323 The 
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cis-trans isomerisation often associated with azobenzenes326 also seems unlikely due to the 
photoactivation required for this reaction (the infrared spectroelectrochemistry was performed in 
the dark) and because the five-membered cyclometalated ring would become badly strained.  
Ligand loss followed by radical dimerisation was also considered as an alternative pathway. Such 
dimers have been observed in spectroelectrochemical studies on the reduction of 
[Mn(bpy)(CO)3Br] (181), during investigations of the catalytic CO2 reduction properties of Mn(I) 
complexes (Scheme 66).327–330 However, reductive radical dimerisation to form 184 in these 
complexes is reliant on the loss of the labile Br- ligand to create a vacant coordination site on the 
metal and no such labile ligand is present in complex 172, making this chemistry unlikely in 
complex 172. As a result, the protonation behaviour described in Scheme 64 seems the most likely 
explanation for the behaviour seen. 
 
Scheme 66: Species observed in the spectroelectrochemistry of 181 during formation of CO2 
reduction catalyst 185. 
The difference in behaviour between the infrared spectroelectrochemistry and cyclic voltammetry 
could be attributed to the presence of water in the infrared spectroelectrochemical experiment. 
The cyclic voltammetry was performed in a dry Ar glovebox whereas the spectroelectrochemical 
cell could only be used outside of a glovebox. The dianion [172]2- would be expected to be basic 
enough to deprotonate water, but not basic enough to deprotonate CH2Cl2, possibly leading to the 
difference in behaviour under the different experimental conditions. This also explains why a 
repeat of the spectroelectrochemical experiment in EtOH yielded essentially identical behaviour. 
Further experiments could be performed to test this, such as performing the 
spectroelectrochemistry in dry solvent. Repeating the voltammogram while titrating in water or 
another proton source could confirm the mechanism as it would affect the peak current ratio of 
the second reduction if the protonation behaviour above were taking place. The scan rates of the 
cyclic voltammogram could also be changed to check whether any further reaction of the two 
reduced species occurs – this would help compensate for the differences in timescale between the 
cyclic voltammetry and spectroelectrochemistry experiments. However, given that the goal of this 
experiment was to look for CO-release, a more detailed mechanistic investigation to confirm this 
hypothesis was not carried out in this project. 
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4.4.2 UV-Visible Spectroelectrochemistry 
The behaviour of complex 172 was also studied with UV-visible spectroelectrochemistry. As with 
the infrared experiment, a spectrum at the open circuit potential (OCP, in this case measured as 
+0.01 V vs the Ag/AgCl reference electrode) and then a potential step to -1.00 V vs Ag/AgCl was 
used to prepare the reduced species. Following this, a potential of +1.00 V vs Ag/AgCl was 
applied to re-oxidise the reduced species. The experiment was performed under air and under an 
Ar atmosphere, with the same behaviour observed in both cases. The results, under air in CH2Cl2 
solution, are shown in Figure 122.  
 
Figure 122: UV-visible spectroelectrochemistry experiment with complex 172 in CH2Cl2 at a 
concentration of 100 μM in the presence of 500 mM tetra n-butylammonium hexafluorophosphate. 
Panel A: Complex 172 at the open circuit potential of +0.01 V vs Ag/AgCl, followed by a potential 
step to -1 V vs Ag/AgCl. Panel B: Further spectra after longer times at -1 V vs Ag/AgCl. Panel C: 
Time evolution of the bands observed in panels A and B. Panel D: Spectra after a potential of +1 V 
vs Ag/AgCl was applied. 
In the first five minutes after the reductive potential was applied (Figure 122, panel A), the starting 
band at 336 nm for complex 172 decayed and the growth of new bands with maxima at 298, 470 
and 518 nm grew in. At later times after the reduction began (Figure 122, panel B), the band at 
470 nm continued to grow in whilst the band at 518 nm began to decay, as indicated by the plot 
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in Figure 122, panel C. This observation is consistent with the formation of two species and these 
are assumed to be the same species observed in the infrared spectroelectrochemistry, [172]- and 
[172H]-  
When the potential was stepped from -1.0 V up to +1.0 V to re-oxidise [172H]-, the spectrum of 
172 was regenerated (Figure 122, panel D). No intermediate species could be observed in the re-
oxidation experiment, whereas an intermediate, assigned as [172H] was observed in the infrared 
spectroelectrochemistry. It may be that species [172H] was not observed because its electronic 
absorption spectrum is too similar to either 172 or [172H]-. Infrared spectroscopy was used to 
probe the metal carbonyl environment whereas the electronic transitions in UV-visible 
spectroscopy primarily reflect the π-system of the azo ligand, which could explain the 
discrepancy. A summary of the observations of the UV-visible spectroelectrochemistry is 
provided in Scheme 67. 
 
Scheme 67: Relationship between the species observed in the UV-visible spectroelectrochemical 
experiment on 172. 
The key conclusion of this experiment is that regeneration of 172 was again observed upon 
oxidation, indicating that reduction does not lead to appreciable electrochemical CO release. 
4.5 Conclusions 
The success of a previous Mn(I) photoCORM design strategy of achieving visible light CO 
release by replacing pyridyl donor groups with azo donors prompted an analogous study for 
cyclometalated tetracarbonyls in this Chapter. Mononuclear and dinuclear cyclometalated azo dye 
complexes 172 and 173 were investigated as visible photoCORMs both by assessing CO release 
to deoxy-Mb and by studying their primary photochemistry with ultrafast TRIR spectroscopy. 
The electrochemical properties of complex 172 were also studied to test for reductively-activated 
decomposition of 172 which may lead to CO release.  
The small family of novel cyclometalated complexes reported were synthesised using the same 
methods as their known analogues. Unusual regioselectivity was observed when unsymmetrical 
azo ligand 176 was cyclometalated, with the more electron-rich position being the site of 
cyclomanganation. This reaction may be of further interest for synthetic applications and 
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mechanistic investigations into cyclometalation reactions due to the role of cyclometalated 
complexes as pre-catalysts in alkenylation reactions. 
Visible light CO release was observed up to 465 nm for complex 172, which is higher than can 
be used for [Mn(ppy)(CO)4]. Despite this observation, the approach of using azo ligands was not 
successful in improving the photoCORM properties overall. Unlike their ‘ppy’ analogues, the azo 
complexes 172 and 173 displayed slow degradation in the dark. The fastest wavelength for CO 
release was still in the UV part of the spectrum for both complexes 172 and 173. Furthermore, 
the photochemical CO release was far slower than for many [Mn(ppy)(CO)4] derivatives even 
with higher-power irradiation, suggesting that the CO release from the azo complexes is relatively 
inefficient. This relatively inefficient CO release was probed by measuring their ultrafast 
photochemical behaviour. Unlike [Mn(ppy)(CO)4], where CO loss is the dominant process, 
complexes 172 and 173 mainly form non-dissociative triplet excited states, which internally 
convert to a lower-energy state on the ps timescale and decay back to the ground state on the ns 
timescale. This explains the inefficient photochemical release from the azo complexes in the 
myoglobin assay in this Chapter.  
When applied in this Chapter, the design strategy of Mascharak and co-workers proved effective 
at moving the CO-dissociative band further into the visible region, since CO-release was observed 
at 465 nm for complex 161, well above where [Mn(ppy)(CO)4] absorbs. However, the rate of CO 
loss at all wavelengths tested (365, 400, 465, 525 and 590 nm) was slower than the pyridyl donor 
analogues. This highlights the importance of considering the changes in the primary 
photophysical and photochemical steps, not just CO release wavelength, when changing the 
nature of the N-donor ligand. Changing the ppy ligand for an azobenzene-dervied alternative did 
enable CO-release above 400 nm but it dramatically altered the branching ratio between loss of 
CO and excited state formation. The design principles from Mascharak and co-workers cannot 
therefore be applied universally to photoCORMs because even if the wavelength of the MLCT 
band increases, there is no guarantee of efficient CO release at the higher wavelength. The effect 
on the efficiency of CO release must therefore be considered along with the increase in photolysis 
wavelength. 
The key result from the electrochemical investigations on complex 172 is that the reductions of 
complex 172 do not activate it towards irreversible reactivity or activate CO release. The 
voltammetric redox behaviour of 172 in dry CH2Cl2 comprises two reversible reductions, similar 
to the behaviour of azobenzene and its derivatives in MeCN. The resulting dianion may be 
protonated depending on the availability of a proton source. When very strongly reducing 
potentials were applied to complex 172 any decomposition was slow. The infrared 
spectroelectrochemistry in wet CH2Cl2 and in EtOH, shows that even reduction in the presence 
of protic species does not result in significant decomposition of the azo moiety or the Mn 
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5 Synthesis, Imaging, and Antimicrobial Testing of a 
Coumarin-Tagged CORM 
Previous studies have indicated that photochemical CO-release from [Mn(ppy)(CO)4] derivatives 
can reduced the growth rates of cultures of E. coli  and S. aureus.137 Greater understanding of the 
antimicrobial action of this class of photoCORMs could be gained by imaging them in 
mammalian and bacterial cells. This Chapter describes the installation of a fluorophore into a 
[Mn(ppy)(CO)4]-derived photoCORM for applications in imaging and cytometry. Studies on the 
toxicity of the CO released by this fluorophore-tagged CORM towards E. coli are also reported 
and compared to other related photoCORMs. 
The confocal microscopy work in this Chapter was performed in collaboration with Dr Karen 
Hogg and Dr Peter O’Toole of the Imaging and Cytometry Technology Facility, Department of 
Biology, University of York. The reader is referred to the digital file in any cases where the 
microscopy image contrast has been lost in the printing process. An initial supply of coumarin 
alkyne 196 for preliminary synthetic work was provided by Dr Paul Scattergood and Professor 
Paul Elliott of the University of Huddersfield before further quantities were synthesised by myself 
at the University of York.  
5.1 Background 
The impact of photochemical CO-release from carboxylic acid-substituted [Mn(ppy)(CO)4] 
derivative  95 on the growth of wild-type E. coli W3110 and S. aureus 8325-4 cells was assessed 
by Dr Jonathan Ward in his PhD work.137 Culturing E. coli or S. aureus with 95 in the presence 
of 400 nm irradiation reduced the growth rate of bacteria in liquid cultures compared with dark 
and CORM-free controls. The results for E. coli are shown in Figure 123. The OD600 (optical 
density, i.e. absorbance / scattering, at 600 nm) increases proportionally with the number of 
bacterial cells and is therefore a measure of the extent of bacteria growth in each culture. It should 
be noted that the CORM-free controls were still performed in the presence of CORM solubilising 
agent DMSO because it is known that E. coli can use DMSO as an energy source through the 




Figure 123: Growth curves for E. coli showing the effect of complex 95 both in the dark (orange 
circles) and in the presence of irradiation (green triangles). Control experiments with no CORM in 
the dark (blue diamonds) and with irradiation (red squares) are also overlaid. Where irradiation 
took place, a 400 nm LED drawing 2.4 W power was used for 3 minutes off, 2 minutes on between 1-
3 hours. This data is taken from the PhD thesis of Jonathan Ward.137 
When media containing CORM 95 was irradiated before the addition of E coli, to exhaustively 
release CO prior to bacterial growth, the antimicrobial effect was alleviated (Figure 124). This 
important control experiment shows that it is the release of CO that is having the antimicrobial 
effect. The concentration of complex 95 used in these assays was 100 μM. The effective 
concentration of CO throughout the experiment was not measured but the release profile from 
myoglobin assays can be used as a guide.184 In cells, it is possible that localisation of the CORM 
leads to spatial variations in CO concentration as well as temporal variations. In separate 
experiments it was shown that such a concentration has only low cytotoxicity towards a 




Figure 124: Growth curves for E. coli showing the effect of pre-irradiated complex 95. The blue 
triangles represent no addition of CORM or irradiation, the red squares show the effect of adding 
CORM 95 after pre-irradiation. Error bars represent the standard deviation from three 
measurements. This data is taken from the PhD thesis of Jonathan Ward.137  
The way in which CORMs act as antimicrobials is not well-understood. Some Re(I)-based 
CORMs can enter cells before releasing CO, which may lend weight to the ‘Trojan horse’ theory 
of antimicrobial action by CO.181,182 However, it is unknown whether the Mn(I) CORMs studied 
in this Thesis can pass intact through the cell membrane to release CO inside cells, or if CO release 
instead takes place outside cells and CO diffuses in. The question of localisation is also important 
in enabling us to exploit interactions of CORMs with intracellular targets.56 
To study the entry of CORMs into cells, photoCORMs with luminescent properties have been 
developed to allow imaging by confocal fluorescence microscopy and flow cytometry, as 
discussed in Section 1.3.3.6. This enables the localisation of CORMs, and sometimes, their 
degradation products, to be studied so that the location of CO-release can be established.180 . Flow 
cytometry is also a useful tool as it can be used to sort cells based on multiple factors, such as 
fluorophore uptake and live-dead stains.182 These techniques provide a powerful method for 
correlating the localised CO-release from a CORM with antibacterial effects.   
5.2 Synthesis of a Functionalisable Azide-Containing CORM 
Building Block 
The use of modularity in CORM design through click chemistry, described in Section 1.2.2.5, 
provides a convenient strategy for introducing a fluorophore into the ligand of a photoCORM. To 
increase the range of CORMs that can be made using the stable [Mn(ppy(CO)4] moiety, it is 
desirable to make an azide-functionalised analogue of alkyne 46. This would make the click 
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chemistry-derived modular design of [Mn(ppy(CO)4] derivatives more flexible, because the 
CORM could then be conjugated with either azide- or alkyne-containing reagents depending on 
the most convenient synthesis of the other component. Indeed, the CORM azide may well prove 
to be easier to access as the addition of the alkyne into the manganese is no longer a problem. 
This would eliminate the need for protection and deprotection, which should be advantageous in 
shortening the synthesis and working to increase the overall yield. A synthetically straightforward 
choice is benzyl azide 188 (Scheme 68).  
 
Scheme 68: Summary of the synthesis of an azide CORM building block, compound 188. 
Azide 188 can be made by building on the Suzuki reaction previously employed to make alcohol 
138. This alcohol is readily converted into the corresponding bromide, 187, using PBr3. The 
cyclometalation and azidation reactions could conceivably be performed in either order. The 
decision to cyclometalate before the addition of the azide was initially taken to open up the 
possibility of making the azidation and CuAAC reactions a one-step transformation, avoiding the 
need to routinely isolate azide 188.  
 
Scheme 69: Possible radical cross-coupling side-reaction in the synthesis of 187.332 
However, [Mn(CO)5]˙ radical precursors such as Mn2(CO)10 and BrMn(CO)5 can behave as pre-
catalysts for radical cross-coupling reactions with benzyl bromides such as 186.332 A similar side-
reaction could take place in the synthesis of compound 186. However, it appears than 
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[BnMn(CO)5] is a poor catalyst for the radical cross-coupling reactions as only cyclometalated 
complex 187 was obtained, and this was synthesised in good yield. The aromatic region of the 1H 
NMR spectrum of cyclometalated complex 187 matched up well with the other 2-phenylpyridine 
complexes discussed in this Thesis, showing the loss of one proton and desymmetrisation of the 
AA'XX' phenyl ring upon cyclometalation. The NMR spectral evidence was combined with the 
strong metal carbonyl IR stretching bands at 2074, 1990, 1975 and 1931 cm-1 in CH2Cl2, in 
agreement with analogous compounds. A low-resolution LIFDI mass spectrum showed two peaks 
of close to 1:1 intensity at 412.94 and 414.94 mass units, consistent with the formation of the 
molecular cation. These two intense peaks are due to the similar isotopic abundance of 79Br and 
81Br, and confirms that the benzyl bromide group has been carried through the reaction intact. 
Elemental analysis also corroborated this empirical formula and confirmed that complex 187 
could be made with satisfactory purity. The cyclometalation therefore proceeded successfully 
without the formation of radical coupling products. This shows that relatively sensitive substrates 
can be used in this chemistry as long as the manganese reagent is chosen carefully with radical 
side-reactions in mind. Following cyclometalation, a simple SN2 reaction of benzyl bromide 187 
with NaN3 affords azide 188 in excellent yield. Based on the initial amount of 2-bromopyridine 
starting material, the overall yield across this four-step synthesis is 67%, highlighting the excellent 
yields obtained throughout the route. A suitable single crystal was obtained by slow evaporation 
from a saturated solution in n-pentane and the structure was solved, Figure 125. The bond lengths 
and angles reflect a very similar geometry around the Mn centre to the other complexes discussed 




Figure 125: An X-ray crystal structure of compound 188 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.054(3), C(13)-Mn(1) = 1.841(3), C(14)-Mn(1) = 1.796(3), C(15)-Mn(1) = 1.857(3), C(16)-
Mn(1) = 1.842(3), N(1)-Mn(1) = 2.073(2). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 79.53(11), 
C(16)-Mn(1)-C(11) = 172.33(12), C(13)-Mn(1)-(C15) = 166.55(12), C(14)-Mn(1)-N(1) = 172.93(12), 
C(14)- Mn(1)-C(16) = 93.50(13), C(15)-Mn(1)-(C11) = 81.79(12). 
A test CuAAC reaction was then performed using phenylacetylene to show that the metal 
carbonyl framework can survive the reaction conditions. An organic solvent system333 was 
utilised in order to solubilise both components; this necessitated the use of a CuI catalyst as 
opposed to the copper(II) and ascorbate system previously used in the aqueous conditions (Section 
3.2.1). The 80% yield of the isolated triazole 189 suggests that 188 could be a useful building 
block for conjugating CORMs with click chemistry. The high yields through this relatively 
straightforward synthesis, and the lack of a requirement for protecting group chemistry, represents 
an improved modular system for making [Mn(ppy)(CO)4] derivatives and introduces extra 




Scheme 70: Demonstration of CuAAC conditions with novel azide 188. 
A suitable single crystal of 189 was grown and the structure solved. Unsurprisingly, the geometry 
around the Mn centre experiences little change compared to azide 188. The organic backbone of 
the compound conforms to a “V” shape due to the two planar pi-systems separated by the benzyl 
carbon. Intermolecular pi-stacking interactions were also observed between the aromatic planes.  
 
Figure 126: An X-ray crystal structure of compound 189 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.0574(14), C(21)-Mn(1) = 1.8595(14), C(22)-Mn(1) = 1.8025(15), C(23)-Mn(1) = 1.8303(15), 
C(24)-Mn(1) = 1.8476(14), N(1)-Mn(1) = 2.0661(11). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 
79.64(5), C(23)-Mn(1)-C(11) = 173.00(6), C(24)-Mn(1)-(C21) = 168.48(6), C(22)-Mn(1)-N(1) = 




5.3 Synthesis of a Coumarin-Tagged CORM 
Having demonstrated the stability and reactivity of azide 188 in suitable click chemistry 
conditions, a conjugate incorporating a fluorescent alkyne was synthesised. Alkynyl coumarin 
196 was selected as the fluorescent tag (Scheme 71). The fluorophore in the resulting conjugate 
complex would be too remote to undergo a change in fluorescence emission wavelength that 
would be diagnostic of CO release, but the fluorescent tag was anticipated to allow monitoring of 
[Mn(ppy)(CO)4] derivatives inside cells.  
There were several reasons for the choice of alkyne 196. Firstly, the 7-diethylammcoumarin 
fluorophore is a relatively small fluorescent tag, which helps to avoid the properties of the 
fluorophore completely dominating those of the product and influencing the observed localisation 
of the CORM. Ideally, the fluorophore itself should have a minimal effect compared to the rest 
of the [Mn(ppy)(CO)4]-derived click product, so that the result can be related to other click 
product derivatives.  
Secondly, the coumarin fluorophore has a λmax value at a longer wavelength than the dissociative 
MLCT band that causes CO release in [Mn(ppy)(CO)4]. The maximum of the fluorophore 
absorption band (408 nm) lies on the outer edge of the [Mn(ppy)(CO)4] CO-dissociative band 
(which tails off beyond 400 nm). This is important because it means that imaging of the 
fluorophore can take place without photolysing the CO ligands. Localisation of the CORM and 
its effect upon the cells could therefore be monitored through fluorescence microscopy both 
before and after photochemical CO release.  
Thirdly, alkyne 197 is readily accessible through a robust synthetic method from the literature,334 
as summarised in Scheme 71. Briefly, 7-(diethylamino)coumarin, (192) was synthesised by the 
condensation of commercially-available salicylaldehyde (190) with diethyl malonate (191) 
followed by ester hydrolysis and decarbonylation to give 192. Bromination in the 3-position with 
Br2 afforded 193, which was used to install an alkyne through a Sonogashira coupling with 
trimethyl(silyl) (TMS) acetylene to give TMS-protected alkyne 195. Deprotection with TBAF 




Scheme 71: Synthesis of coumarin alkyne 196. 
With alkyne 196 in hand, the copper-catalysed azide-alkyne cycloaddition with azide-
functionalised CORM derivative 197 was performed, Scheme 72. The same conditions for this 
reaction were used as for the test reaction with phenylacetylene described above in Scheme 70. 
 
Scheme 72: CuAAC conditions for the synthesis of 197. 
The reaction proceeded to completion (consumption of starting materials by TLC) in 6 hours, and 
purification by silica gel flash column chromatography gave target complex 197 in a good yield 
of 78%. The infrared spectrum of the product has the same four metal carbonyl bands as observed 
for azide 188 and click product 189, confirming that the [Mn(ppy)(CO)4] moiety was carried 
through the synthesis intact. The crystal structure of 197 was also obtained using CH2Cl2/n-
pentane layering. The structure shows a similar “V” shaped organic backbone to triazole 189 due 




Figure 127: An X-ray crystal structure of compound 197 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.048(2), C(28)-Mn(1) = 1.853(3), C(29)-Mn(1) = 1.864(3), C(30)-Mn(1) = 1.8310(3), C(31)-
Mn(1) = 1.8451(3), N(1)-Mn(1) = 2.065(2). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 79.45(9), 
C(31)-Mn(1)-C(11) = 174.82(10), C(28)-Mn(1)-(C29) = 168.69(12), C(30)-Mn(1)-N(1) = 171.61(10), 
C(30)- Mn(1)-C(31) = 90.66(12), C(28)-Mn(1)-(C11) = 81.32(10). 
The UV-visible spectrum of 197 was recorded in CH2Cl2 to assess where the excitation band of 
the coumarin fluorophore lay. Two strong absorption bands were observed in the spectrum, with 
λmax values of 408 and 264 nm (Figure 128).  
 
Figure 128: UV-Visible spectrum of 197 in CH2Cl2 at a concentration of 26.2 μM.  
The higher-energy band was assigned to the 2-phenylpyridine aromatic system (π-π*) – a similar 
band is observed in ppy parent complex 88 (as was shown in Figure 29). The band at 408 nm was 
assigned to the coumarin-derived fluorophore. The 7-diethylaminocoumarin moiety has been 
used extensively as a fluorescent tag in other studies and so absorption and emission spectra of 























several different derivatives are already known, including triazole ‘click’ products derived from 
complex 196.335–338 In this group of previously-known compounds, the coumarin peak has been 
observed between 400-430 nm depending on the derivative,335–338 consistent with that observed 
in Figure 128. It is notable that changing the solvent from CH2Cl2 to phosphate-buffered saline 
did not significantly shift the wavelength of the coumarin triazole moiety,338 suggesting that the 
coumarin moiety of complex 197 will have an excitation maximum at approximately 408 nm in 
the phosphate-buffered saline solution used for imaging in this work. Another way to confirm this 
assignment might have been to compare the UV-visible spectrum of complex 189 with that of 
197 to observe the effect of incorporation of the coumarin fluorophore.  
The emission spectra of coumarin triazole analogues to 197 have also been well-studied. 
Excitation of the coumarin absorption maximum in 7-diehtylaminocoumarin-conjugated triazoles 
complexes related to 197 has been shown to result in fluorescence with a maximum intensity in 
the region of ca. 480-500 nm.335–338 The parent compound, 192, exhibits slightly higher-energy 
coumarin excitation/fluorescence, absorbing at 350-380 nm and fluorescing at 390-445 nm.339 
The exact wavelengths were solvent-dependent, but there was little change in wavelengths upon 
moving from halogenated solvents such as chlroform to polar protic solvents such as ethanol.339 
The lengthening of the excitation and emission wavelengths of the coumarin fluorophore in click 
products are expected due to conjugation with the triazole moiety. For further comparison, 
coumarin alkyne 196 has an excitation maximum at 425 nm and the fluorescence maximum is at 
488 nm in phosphate-buffered saline, and therefore its properties resemble the conjugated triazole 
products more than parent fluorophore 192.340 The click chemistry in synthesising 197 was 
therefore expected to alter the properties of the fluorophore in a predictable manner.  
If this study is taken forward in future work, it will be necessary to perform a detailed study of 
the emission spectrum of 197, rather than simply relating its properties to those of previously-
known analogues. Optimal imaging will be obtainable if the exact excitation wavelength in the 
media to be used is used and the emission spectrum is recorded. The emission spectrum may be 
wavelength-dependent, and this would be valuable information for the imaging study. Measuring 
the emission spectrum will allow more optimised collection of the emission wavelength range of 
the fluorophore. A control with complex 189, which contains the same metal carbonyl moiety and 
triazole linker, could also be performed. For the initial preliminary studies described here, the 
similarity of the UV-visible absorption spectrum to known compounds with well-studied 
emission properties was enough to provide guidance on the excitation and emission wavelengths. 
However, the emission spectrum of complex 197 itself should be recorded to guide any future, 
more comprehensive, imaging studies with complex 197 than the work described here. As an 
example, it may be desirable to irradiate the cells and observe whether the CORM degradants 
enter/leave the cells after CO release – this could help inform toxicity studies of the degradants. 
In order to do this, the emission spectrum over time would need to be studied. 
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The CO-dissociative MLCT band, typically observed between 350-400 nm (based on Figure 30 
and literature data)159 is obscured by the coumarin band in Figure 128, but by analogy to 
[Mn(ppy)(CO)4] this band is expected to exist in the region 350-400 nm. The spectrum confirms 
that excitation of the coumarin fluorophore could be performed at wavelengths longer than those 
that would cause CO release from the MLCT band.  
A myoglobin CO release assay of 197 is shown in Figure 129. The assay confirms that this 
compound behaves as a CORM. An assay using 10 μM 197 with ca. 47 μM deoxy-Mb revealed 
similar properties to the other 2-phenylpyridine based manganese tetracarbonyl CORMs: stable 
in the dark with the release of approximately 2.7 equivalents of CO per molecule of CORM upon 
irradiation with a 400 nm LED. This number of CO equivalents is comparable to the literature 
studies of halogen-substituted ppy complexes discussed in Chapter 1,184 and summarised in Table 
16. As with other [Mn(ppy)(CO)4] derivatives, the CO-release is relatively slow at 400 nm, most 
likely because the very edge of the MLCT band is being irradiated, although the release is still 
considerably faster than the 400 nm release from azo compounds 172 and 173 described in 
Chapter 4. The rate of release of 197 at 400 nm is comparable to the fastest CO release achieved 
by azo complex 172, although for the azo complex a lower wavelength of 365 nm and a higher 
power had to be used to achieve this. As the LEDs used also contain a range of wavelengths up 
to a range of around 10 nm, it may be that the broadness of the LED irradiation introduces some 
CO release from wavelengths slightly below 400 nm. This will be similar for all the complexes 
where LEDs were used, but when comparing LED irradiation to laser excitation in TRIR 
spectroscopy or confocal microscopy, this could be an important distinction. Although the 
coumarin fluorophore does not absorb in the region of the Mb studied, a 4-point correction was 





Figure 129: Myoglobin CO release assay with 10 μM compound 197 and ca. 47 μM myoglobin. 
Irradiation with a 400 nm LED at a power of 4.8 W began at 18.3 min and was provided in cycles of 
3 minutes off, 2 minutes on.  
5.3.1 Confocal Microscopy with Human 293T Embryonic Kidney Cells 
Having assessed the CO release properties of 197, preliminary confocal fluorescence microscopy 
experiments were performed, in order assess whether CORM 197 could be imaged in live cells. 
Solutions of 197 (in a >>99:1 v/v PBS:DMSO solvent mixture to aid solubility of the CORM) 
were added to cultures of 293T embryonic kidney cells. The cells were incubated at 37 ᵒC for 30 
min before being placed onto a slide and imaged. Figure 130 shows the CORM at a final 
concentration of 50 nM using a 405 nm laser to excite the fluorophore. 
 
Figure 130: T293 cells after incubation with 50 nM 197 for 30 min. Left: Fluorescence response of 
197 - emission collected between 410 nm to 597 nm. Centre: Image recorded of the cells in the same 
region, using white light. Right: Overlay of the emission and white light images. Each image is 425 x 
425 μm. 
Figure 130 shows that the coumarin fluorophore has entered the cells. This may be due to the 
whole of CORM 197 entering the cells or just a fluorescent fragment of the molecule following 
degradation. Although CORM 197 was stable in the dark in a myoglobin assay, there is no direct 
evidence that the tetracarbonyl centre fluorophore has remained intact in these experiments. In 




















antimicrobial studies where [Mn(ppy)(CO)4] derivatives were incubated with bacterial cells in 
media, the CO-derived antimicrobial effect required light for the E. coli to experience a 
detrimental effect. This suggests that the tetracarbonyl moiety is stable in biological systems, 
including when growth media is present.  
The fluorescence appears to originate mainly in the cytoplasm of the cells, with the nucleus visible 
as a darker spot. In this image, only some nuclei can be seen – this is because the “Z” slice taken 
by the microscope does not contain the nuclei of all cells (vide infra).  
 
Figure 131: CORM-free control experiment using T293 cells. Each image is 425 x 425 μm. Left: 
Fluorescence response from the cells and solution - emission collected between 410 nm to 597 nm. 
Centre: Image recorded of the cells in the same region, using white light. Right: Overlay of the 
emission and white light images. Each image is 425 x 425 μm. 
A control experiment, in which an equal amount of CORM-free DMSO/PBS solution was 
administered, confirmed that the administration of CORM 197 (Figure 131) results in greater 
fluorescence in the cytoplasm. Note that the same image recording and processing setting were 
used for both images. This experiment provides a measurement of the background level of 
autofluorescence by the cells for comparison to images in which the fluorophore is present. 
Although the cytoplasmic and nuclear membranes appear intact in most of the cells, the number 
of living and dead cells cannot be determined from these images alone. It is crucial to know 
whether or not the cells in the culture are still alive; if the cells are dead it is likely that their 
membranes are no longer intact, so that all compounds in the surrounding medium appear to have 
been taken up.  
A propidium iodide stain was used to discriminate live and dead cells. Propidium iodide (PI) is 
able to unselectively intercalate nucleic acids, upon which the fluorescence of the stain is 
enhanced. Ordinarily, PI is excluded from viable cells and is unable to bind to the nucleic acids 
that they contain. However, in necrotic and apoptotic cells, the stain can enter the cells and the 
enhanced fluorescence can be ‘switched on’. Figure 132 shows the effect of adding propidium 
iodide to the cells incubated with 50 nM 197. Note that the slide was removed from the 
microscope to add PI, so the field of view is different to Figure 130. However, both images are 




Figure 132: Addition of PI (2 μL of 400 μg / mL stain added to a 350 μL well) as a live/dead stain. 
Top left: CORM 197 fluorescence (50 nM, excitation 405 nm, emission 410-597 nm). Top right: white 
light image of the cells. Bottom left: PI fluorescence (excitation 561 nm, emission 569-740 nm). Bottom 
right: Overlay of all three images. Each image is 425 x 425 μm. 
The images show that most of the cells appear to be alive after taking up the fluorophore. Some 
red nuclear staining is seen on some of the cells, suggesting that a small proportion are dead. 
There are also some other unusually-shaped ‘PI stains’ that do not appear to show nuclear 
staining, the origin of which is not certain. However, crucially the experiment shows that most of 
the cells are viable as they exclude PI. More detailed viability studies could be performed on 
human cell lines to understand the toxicity of this compound to human cells but overall these 
results correlate well will other mammalian cell toxicity screens of [Mn(ppy)(CO)4]-derived 
complexes, which show the compounds to be non-toxic.159 
A series of “Z-stack” images was also recorded, whereby the thin “Z slice” (in the plane of t 
sampled by the microscope is changed slightly between each image to move up through the cells. 
In Figure 133, 24 images are shown, each separated in Z by 0.76 μm. During the series, the 
cytoplasm and nuclei of all cells are seen, so that coumarin fluorophore and PI uptake can be 
examined in every cell. The images show that all cells have taken up the coumarin fluorophore, 
but far fewer are stained with PI, suggesting that the fluorescent material from 197 is taken up by 
viable cells. The detection of fluorescence inside the cells through the course of the Z stack 





Figure 133: Z-stack images using the same conditions as Figure 132.  
5.3.2 Confocal Microscopy with E. coli 
Having established the feasibility of conducting fluorescence microscopy of mammalian cells 
using CORM 197, preliminary imaging was then carried out with W3110 E. coli cultures to asses 
uptake of complex 197 in bacteria. Figure 134 shows an initial CORM-free control experiment 
where a DMSO/PBS solution was incubated with the cells. This shows the low background 




Figure 134: Autofluorescene control images after a CORM-free PBS/DMSO solution was added to 
the culture and incubated for 30 min. Left: 405 nm excitation with 410-627 nm emission. Right: Image 
recorded with white light. Image sizes are 135 x 135 μm. 
Figure 135 shows the effect of incubating the E. coli in the presence of 10 μM 197 for 30 min. A 
high concentration was chosen to ensure that any fluorescence inside the cells was discernible 
above the autofluorescence background – it is more difficult to obtain high-quality images due to 
the much smaller size of bacterial cells than mammalian cells. The motion of the bacterial cells 





Figure 135: Addition of 10 μM CORM 197 to an E. coli culture. Top left: Coumarin fluorescence 
(excitation 405 nm, emission 410-556 nm). Top right: PI fluorescence (excitation 561 nm, emission 
566-719 nm). Bottom left: White light. Bottom right: Overlay of all three images. Image sizes are 135 
x 135 μm. 
Live-dead PI staining was again carried out and the images in Figure 135 show some uptake of 
the fluorophore with apparent exclusion of PI. Larger, brighter spots visible in the images could 
be due to a small amount of CORM precipitation. More DMSO could be added to reduce this 
problem, since the culture only contains 0.01% DMSO due to the serial dilutions of the CORM 
stock. Cultures should not exceed 1% DMSO as DMSO-induced inhibition and stimulation of 
growth have been reported in mammalian cells have been reported and E. coli possess DMSO 
reductases.331,341 These effects will be examined in more detail in the toxicity studies in Section 
197.  
These preliminary results suggest that the coumarin-tagged CORM 197 may enter viable bacterial 
cells. The next step would be the use of flow cytometry to correlate fluorophore uptake into the 
cells with death after irradiation. However, before the commencement of such studies, it was first 
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necessary to check the toxicity of CORM 197 to E. coli using growth curves similar to those 
described in the Introduction.  
5.4 Toxicity Studies With Mn(I) PhotoCORMs 
With the preliminary imaging results in hand, it was necessary to assess whether CO-release from 
CORM 197 was toxic to bacteria. Antimicrobial assays were performed with BL21 E. coli cells 
as a model organism. Although large numbers of E. coli are present in gut flora, this well-studied 
bacterium can also act as a pathogen. It has already been shown (Section 1.3.1) that CO-release 
from several CORMs leads to greater toxicity than CO gas in E. coli.74,130 The intention of these 
experiments was to use growth curve experiments similar to those performed by Ward for 
complexes 37 and 95 (TryptoCORM). Control experiments were used to show that both fresh 
CORM addition and irradiation were necessary for an antimicrobial effect.137   
Before discussing the results of the studies on compound 197, an important point about the 
method should be highlighted. In earlier E. coli growth curve experiments by Ward, bacteria used 
for the growth curves were removed from agar plates that had been stored at 4°C for between 
several days and several weeks.137 An increased antimicrobial effect was noted when older plates 
were used in these studies with TryptoCORM.137 A plating study confirmed that the number of E. 
coli colonies able to form from each culture decreased as the age of the plate increased.137 This 
led to the hypothesis that the antimicrobial effect of TryptoCORM towards E. coli appeared more 
potent when older plates were used because fewer cells were alive on the older plates. Changes 
in the biochemistry of the E. coli over the storage period were also considered and may also 
contribute to the age effect observed. For example, the level of expression of haem-containing 
proteins that constitute targets for CO may change depending on the age and stress of the bacteria. 
Even when the cells from older plates were allowed to grow to a comparable OD600 to cultures 
from the newer plates, the effect of TryptoCORM on bacteria derived from the older plates were 
still much more pronounced, which suggests that the number of living cells alone may not account 
fully for the age effect.137 Regardless of the origins of the age effect, previous work suggests that 
older plates made E. coli  more susceptible to the antimicrobial effects of CO release. 
For the experiments reported in this Chapter, a different method was used to prepare the bacteria. 
The bacteria used in the antimicrobial assays reported in this Thesis were freshly cultured in media 
in an incubator at 37°C for ~16 hours and were then diluted into fresh media immediately before 
the antimicrobial assay. Using fresh starter cultures every day provides a way of standardising the 
preparation of the bacteria used in the assay. However, the bacteria used in the starter culture 
experiments had less time to be weakened towards the effects of CO-release compared to cultures 
prepared by the first method. It is unclear to what extent either of the above methods relate to a 
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real bacterial infection; these studies were envisaged as a proof-of-concept and a mechanistic tool, 
rather than as an infection model. 
The first growth curve experiments performed were used to examine the effect of DMSO and 400 
nm irradiation on the cultures and assess the reproducibility of the new starter culture method; the 
results are shown in Figure 136. 
 
Figure 136: Growth curves with E. coli BL21 under the conditions shown. Each point is the mean of 
three separate repeats from different cultures, and the error bars show standard deviation. 
Irradiation with a 2.4 W power 400 nm LED took place between 1 and 3 hours and comprised cycles 
of 3 minutes off, 2 minutes on.  
To test the conditions of the assay, L-TryptoCORM was added to the cultures and irradiated, since 
this compound is known to have an antimicrobial effect. Initially, a starting OD600 of 0.05 was 
used to match the starting OD600 in Ward’s experiment.137 A low concentration of 25 μM 
TryptoCORM was initially used to test the limits of the assay and in case of poor solubility for 
197. The results are shown in Figure 137.  
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Figure 137: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The TryptoCORM concentration used was 25 μM. Irradiation 
with a 2.4 W power 400 nm LED took place between 1 and 3 hours and comprised cycles of 3 minutes 
off, 2 minutes on. 
The growth curves show that L-TryptoCORM did not have an antibacterial effect under these 
conditions. Ward showed that 100 μM TryptoCORM led to no growth whatsoever of E. coli over 
an 8-hour culture.137 Numerous other variables were tested with these conditions. Modifications 
included increasing the CORM concentration to 100 μM, irradiating from 0-2 hours in the assay 
rather than 1-3 hours in order to prevent the bacteria from growing too quickly and blocking out 
the irradiation. Other variables altered included changing the shaking rate from 180 to 90 rpm to 
reduce oxygenation of the culture and slow the growth of the cultures, and diluting the LB media 
to 50%, which still did not lead to any antimicrobial effect when starter cultures were used. The 
use of 10% LB resulted in growth that was too slow to discern any effect of the CORM. These 
results are provided in Appendix 5. 
It was hypothesised that the lack of any antimicrobial effect in this experiment could be due to 
the use of a starter culture, resulting in more bacteria being alive and growing at the start of the 
experiment compared to Ward’s experiments. To account for this, a growth curve was performed 
using a lower starting OD600 value (lowered from 0.05 to 0.001). These results are provided in 
Appendix 5. Although the bacteria grew significantly in the dark over the 8-hour experiment, all 
the experiments where irradiation was used failed to grow, suggesting that the 400 nm irradiation 
is damaging to the bacteria at low OD600 values. Finally, when a starting OD600 of 0.005 was 
used, the results from Ward’s study of TryptoCORM were replicated, Figure 138. 
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Figure 138: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The TryptoCORM concentration used was 100 μM. Irradiation 
with a 2.4 W power 400 nm LED took place between 0 and 2 hours and comprised cycles of 3 minutes 
off, 2 minutes on. 
The results show a very clear antimicrobial effect of TryptoCORM when the lower starting 
OD600 was used. A combination of both irradiation and the addition of TryptoCORM was 
required to have the antimicrobial effect. A repeat of the same experiment with a starter culture 
derived from a fresh plate produced similar results, confirming that the observed effect can be 
reproduced (see Appendix 5). In the previous experiments with higher OD600 values, either not 
enough light could penetrate through the culture, or enough bacteria survived the CO-release to 
continue growing. It seems that using a lower starting OD600 with a starter culture compensates 
for the increased number of live, growing cells compared to Ward’s method.137 
The toxicity of compound 197 was then studied. The use of L-TryptoCORM now serves as a 
useful positive control. As mass spectrometry studies on complex 95 have shown that the 
protonated ppy ligand is a possible by-product of CO-release, the Mn-free coumarin protonated 
ppy compound 199 was also synthesised for use as a negative control (Scheme 73). If an 
antimicrobial effect were to be observed, the appropriate iCORM control (using pre-irradiated 
CORM 197 to release all of the CO before adding to the cultures) could also be performed, both 
in the dark and with irradiation. 




















Scheme 73: Synthesis of compound 199. 
The results of the growth curves with CORM 197 and Mn-free control compound 199 are shown 
in Figure 139. A control experiment with both DMSO and irradiation would usually be performed 
but this control did not grow at all in this experiment. This was excluded as an anomalous result 
since there is little difference between the irradiated cultures with or without DMSO in the other 
experiments performed throughout this Chapter.  
 
Figure 139: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The concentrations of 197 and 199 used were 100 μM. Irradiation 
with a 2.4 W power 400 nm LED took place between 0 and 2 hours and comprised cycles of 3 minutes 
off, 2 minutes on. 
The high concentrations (100 μM) of compounds 197 and 199 led to some precipitation even 
when 1% DMSO was used to solubilise the complexes. The results in Figure 139 show that 
irradiation has a slightly detrimental effect upon the growth of the bacteria, and the presence of 
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CORM 197 or control compound 199 in DMSO has no additional killing effect compared to 
irradiation of the culture with no additives. 
When the same experimental conditions were used to test another [Mn(ppy)(CO)4] derivative 95, 
a small antimicrobial effect was observed, Figure 140. Complex 95 is highly soluble in water and 
does not form any precipitate at 100 μM concentration.  
 
Figure 140: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The concentration of 95 used was 100 μM. Irradiation with a 2.4 
W power 400 nm LED took place between 0 and 2 hours and comprised cycles of 3 minutes off, 2 
minutes on. 
There was a slight lag in the growth of the bacteria compared to the irradiated DMSO control 
culture when CORM 95 and irradiation were both added. A repeat of the experiments in Figure 
140 with a starter culture from a different plate also showed only a small effect of irradiation of 
CORM 95 compared to the DMSO controls (Appendix 5). This shows that there was a small 
antimicrobial effect for complex 95, but it was far less pronounced than for L-TryptoCORM under 
the same conditions (Figure 138). Therefore, a reproducible, but only very small, antimicrobial 
effect was observed for complexes 197 and 95. Not only is complex 197 is a poor CORM, but 
other [Mn(ppy)(CO)4] derivatives appear to have low antimicrobial activity. 
The control experiments in this Thesis, and those performed by Ward with iCORMs of L-
TryptoCORM, provide strong evidence that the antimicrobial effects that were observed were 
related to CO-release.130 Yet the data show that the [Mn(ppy)(CO)4] derivatives appear to have a 
smaller antimicrobial compared to TryptoCORM at the same concentration. This is an intriguing 
result given that the [Mn(ppy)(CO)4] derivatives release 2.7-3.2 equivalents of CO per molecule 
to myoglobin under 400 nm irradiation whilst TryptoCORM releases only 2.1 equivalents of CO 
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per molecule. Myoglobin assays have shown that TryptoCORM releases CO much more rapidly 
at 400 nm than [Mn(ppy)(CO)4] derivatives.130,137,159 It is possible that CO-release rate is more 
influential than the overall quantity of CO released by a CORM. A faster rate of CO-release would 
give a higher concentration of CO for a shorter time, which could be to be more effective at killing 
bacteria than exposure to lower concentrations of CO over longer times.  
If the CO release does indeed occur intracellularly, different uptake levels of the tetracarbonyl 
ppy CORMs and TryptoCORM could also account for the different extents of the antimicrobial 
effect through differences in the localised CO concentrations. It may be that the biologically-
derived co-ligand in TryptoCORM improves uptake either through mimicking tryptophan in 
entering cells through membrane transporter proteins,342 or by conveying a suitable balance of 
water solubility and lipophilicity to increase entry into the cell. 
5.5 Conclusions 
The use of Click chemistry has been extended in this Chapter with the synthesis of complex 188. 
A flexible, modular system for CORM synthesis based on [Mn(ppy)(CO)4] derivatives is now 
available which, unlike the synthesis of alkyne 46, does not require protecting group chemistry. 
Coumarin-tagged photoCORM 197 was imaged in the presence of live mammalian and bacterial 
cells using confocal microscopy. The remote nature of the fluorophore makes it difficult to 
confirm from these experiments alone whether the Mn(I) tetracarbonyl moiety remained intact 
upon entry to the cells. However, irradiation is required in other [Mn(ppy)(CO)4] derivatives in 
order to cause the CO-induced antimicrobial effect, 137 suggesting that, at least in the case of E. 
coli 197 enters the cells without releasing CO.  
The preliminary imaging results reported here suggest that 197 behaves similarly to the 
luminescent Re(I) photoCORMs studied in the literature.169,181,182 The growing number of imaging 
studies showing that CORMs can enter cells before releasing CO lends weight to the ‘Trojan 
horse’ picture of CORM antimicrobial activity in which CO-release takes place within the cell. It 
is unclear how much of a role is played by transfer of extracellular CO into cells, but the increased 
toxicity of CORMs compared to CO gas74 suggests that entry of CORMs into cells before CO 
release could be important in creating high intracellular concentrations of CO. 
However, the antimicrobial activity of 197 and related derivative 95 was poor compared to the 
known antimicrobial TryptoCORM. The antimicrobial effects of all compounds were smaller than 
those observed in previous work due to the use of starter cultures.137 Given the lack of 
antimicrobial activity towards E. coli of CO released by 197, a follow-up to the preliminary 




6 Conclusions and Future Work 
6.1 Photochemical CO-release from [Mn(ppy)(CO)4] and 
related complexes 
6.1.1 TRIR Studies for PhotoCORM Design 
As described in the Introduction, metal carbonyl complexes capable of light-induced CO-release 
(photoCORMs) have been previously shown to hold promise in therapeutic applications ranging 
from vasorelaxation to antibiotic drug design. However, it has been difficult to develop 
compounds in which the CO-release is activated by NIR or visible light irradiation rather than 
UV which has unwanted toxic side-effects and a limited tissue penetration depth. The challenge 
in the production of such photoCORMs can be at least partially attributed to the fact that there 
was limited experimental insight into the mechanism of light-activated CO release, a problem 
which this Thesis has sought to rectify. The ultrafast TRIR studies in Chapters 2 and 4 show how 
this powerful technique can be used to understand the behaviour of photoCORMs. In conjunction 
with TD-DFT calculations the structural information provided by such infrared spectroscopy 
measurements has allowed the nature of the initial photoproducts to be determined.  
In Chapter 2, the formation and stability into the μs timescale of tricarbonyl solvent complexes 
formed by loss of one CO from [Mn(ppy)(CO)4] compound 88 proves the mechanism of the start 
of the photo-activated CO release degradation pathway. These measurements were complemented 
by solution in situ IR experiments that probed the products generated after several minutes, 
enabling the tentative assignment of facial tricarbonyl Mn hydroxy clusters. In the future it would 
be desirable to investigate the timescale in between those spanned by these two IR techniques. 
Modern FTIR spectrophotometers could be used to record scans every few seconds across a small 
wavenumber range to probe the mechanism that converts fac-[Mn(ppy)(S)(CO)3] to the final 
degradation products. It would also be helpful if follow-on work from this Thesis modified the 
flow system used in the TRIR experiments. At the moment the experimental setup is designed to 
remove the photoproducts following the first ‘pump’ pulse.210 However, it is desirable to 
understand what happens when the products of initial CO loss absorb a second photon because in 
assays like the myoglobin experiment CO release is usually induced by continuous irradiation. 
Nuernberger and co-workers191 employed two consecutive pump pulses to address this question 
but found that the initial photoproduct [Mn(tpm)(CO)2(OD2)]+ was unreactive. If 113MeCN and 
113OH2 can be isolated in the future, their stability could be exploited to afford a mg-scale 




Figure 141: Key photoCORMs studied and compared in this Thesis. 
This Thesis also reports how the TRIR studies have been extended to study the photochemical 
reactivity of less efficient CO-releasing molecules complexes 172 and 173 (Figure 141). The 
spectral resolution provided by infrared spectroscopy of the carbonyl bands again provides a 
useful way of distinguishing the photoproducts. Compared to [Mn(ppy)(CO)4] the azo complexes 
more closely resembled the behaviour of [Cr(bpy)(CO)4] by forming two consecutively-populated 
unreactive excited states as the major photoproducts, with little CO photodissociation. In the 
future, these results could prompt more extensive theoretical calculations on [Mn(ppy)(CO)4] and 
complexes 172 and 173 to try and explain the differences in behaviour. Comparing the rates of 
CO dissociation versus intersystem crossing of the different complexes would be particularly 
informative. Quantum yield measurements for CO loss and quantification of the branching ratios 
between excited state formation and CO dissociation would also provide a useful method of 
comparing the complexes discussed in this Thesis with one another and with other studies.127 
Quantum yield measurements would require use of a monochromatic light source and an 
actinometer for calibration purposes.  
The incorporation of azo ligands into Mn tetracarbonyl complexes was inspired by Mascharak 
and colleagues’ work on visible light-activated tri-carbonyl CORMs.127 Unfortunately, the use of 
azo ligands in place of a pyridyl N-donor in complex 88 increased the CO-release wavelength at 
the expense of efficient CO release. This result emphasises that to develop practically useful light-
triggered CO-releasing molecules there must be a consideration of more factors than just the CO-
release wavelength, whilst this principle provides a starting point for rational photoCORM design 
they are not comprehensive enough to guarantee success. Based on the work in Chapter 4 it is 
now suggested that a different method of attaining CO-release at longer wavelengths would be to 
use a photosensitiser in a similar manner to Schiller and co-workers.134 Rather than use two 
separate molecules, the synthetically flexible click chemistry described in this Thesis with 
previously-known alkyne 46, or novel azide 188, could be used to append a photosensitiser to a 
photoCORM (Figure 142). The effect of combining the photosensitiser and CORM could be 
292 
 
compared to co-administration of distinct photoCORM and photosensitiser molecules to explore 
how photosensitisation may best be applied to photoCORMs in the solution phase.  
 
Figure 142: Alkyne 46 developed by Jonathan Ward and used in this Thesis, and complementary 
novel azide 188, developed in this Thesis. 
6.1.2 Isomerisation of ether and DMSO solvent C-H σ-complexes  
The ether solvent and DMSO results show that ‘vacant’ or ‘solvated’ coordination sites on metals 
can play host to ultrafast isomerisations, providing an interesting example of fleeting C-H 
activation despite stronger donor ligands being present. This has implications for our 
understanding of metal-solvent complexes, which are ubiquitous in catalysis. Other than alcohol 
solvent (S) isomerisations observed by Harris and co-workers with [Cr(CO)5(S)] , which are at 
least an order of magnitude slower than the THF and 1,4-dioxane isomerisations observed in this 
Thesis, there appears to be relatively little published data on such reactions. It would be interesting 
to test the behaviour of [Mn(ppy)(CO)4] in alcohol solvents to compare the rates of isomerisation 
with those observed by Harris and co-workers. The rate of isomerisation is clearly highly solvent-
dependent but the effect of different metal complexes has not been explored.  A vast range of 
metal carbonyl complexes displaying photochemical CO-release is available to study, including 
many of the photoCORMs discussed in this Thesis. 
The mechanism by which the isomerisation occurs could not be identified. Future experiments 
could focus on performing photolysis at low temperatures for NMR studies that could distinguish 
a ‘chain-walk’ mechanism from an intermolecular mechanism. The dependence of the lifetimes 
associated with the isomerisations upon temperature could also be examined to obtain activation 
parameters which may reveal more about the mechanism. 
6.2 Redox-Tagged CORMs 
The synthesis and characterisation of three novel ferrocenyl CORMs was performed, 
incorporating two organometallic therapeutic groups within the same molecule. Electrochemical 
and infrared spectroelectrochemical measurements showed that the redox-active ferrocenyl group 
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must be located in the first coordination sphere of the Mn if ferrocene oxidation is to have a 
significant effect upon the Mn-CO bonds. However, no redox-triggered CO-release was observed 
for any of the complexes. Photochemical release from complex 133, and both thermal and 
photochemical release from complex 134, were quantified using the myoglobin CO-release assay. 
Taking these results into account, azo complex 172 was also investigated as a possible 
reductively-triggered CORM since the complex comprises a redox-active group in the first 
coordination sphere of a metal carbonyl. Despite very large changes in the metal carbonyl bands 
upon reduction, no redox-triggered CO-release occurred. This work may be able to guide future 
studies in the area of redox-activated CO-release. 
 
Figure 143: Novel redox-active CORMs tested for redox-triggered CO-release in this Thesis. 
Although electrochemical reduction was unsuccessful, the metabolism of complex 172 and other 
azo CORMs by azoreductase enzymes could also be assessed. Azoreductases present in bacteria 
in the gut and on skin have been shown to reduce a variety of azo dyes including 
sulfasalazine,308,343,344 and if these enzymes could be used to cleave the azo bond in 172 then this 
could lead to CO release in the gut.   
Future work on reductive activation of azo dye CORMs could take inspiration from the 
mechanism of reduction of the prodrug sulfasalazine. Tautomerization of the azo group to form a 
hydrazone, promoted by the para phenoxy substituent, can be used to assist the reductive cleavage 
of the azo bond, as has been shown by electrochemical studies on the reduction of sulfasalazine 




Scheme 74: Cleavage of azo dyes with p-phenoxy substituents. 
This is because the hydrazone tautomer is more easily reduced than the azo tautomer, yielding the 
corresponding hydrazine after protonation. Subsequent reduction of the hydrazine to yield two 
aniline products can then take place resulting in complete cleavage of the azo bond. The effect of 
complete cleavage of the azo bond upon the stability of the Mn(I) tetracarbonyl moiety could then 
be investigated. 
A possible redox-tagged co-ligand system for future investigation would be catecholates. 
Catechol is converted into 1,2-benzoquinone upon 2-electron oxidation (Scheme 75). 
Quinone/hydroquinone redox couples are commonly encountered in biology and represent 
biocompatible ligands.346 There is some precedent in the literature for metal carbonyl catecholate 
complexes. For example, the tungsten complex [Et4N]2[W(CO)4-(O2C6H4)] 204 was shown to 
release one equivalent of CO upon dissolution in MeCN.347 A di-tert-butyl-substituted catecholate 
205 was then used in order to stabilise the tricarbonyl degradation product so that it could be 
crystallised.347 A thermally stable complex would be advantageous for gaining more selective 
CO-release. Changes in the bonding to the metal centre upon oxidation to the benzoquinone could 
be investigated as a way to labialise the catecholate and initiate decomposition of the complexes. 
Some examples of known complexes are shown below in Scheme 75.347–349 Many of the known 
complexes were produced via photolysis, as these ligands have been used to trap the products of 
photolysis or metal carbonyls and other organometallic species. However, there are examples of 
thermal reactions too. However, complexes shown would likely require further functionalisation 




Scheme 75: Interconversion of catechol and 1,2-benzoquinone. Known metal carbonyls with 
catecholate co-ligands. 
6.3 Antimicrobial and Imaging Studies 
Coumarin-tagged photoCORM 197 was imaged in the presence of live mammalian and bacterial 
cells using confocal microscopy. The results suggested that 197 behaves similarly to the 
luminescent Re(I) photoCORMs studied in the literature.169,181,182 Confirmation of whether the 
manganese centre survived entry into the cells could have been tested by synthesising other 
coumarin CORMs. Complex 209 (Figure 144) was synthesised in York, where the Mn is in the 
first coordination sphere of the fluorophore, with scope for performing imaging.350 In complex 
209 it is more likely that CO-release would result in changes in the fluorescence properties of the 
coumarin, though the coumarin may also affect the CO-release properties. Given the poor toxicity 
results against E. coli for [Mn(ppy)(CO)4] derivatives this study was not continued. However, the 
question of whether [Mn(ppy)(CO)4] could enter mammalian cells remains of significant interest 
as CO has many other applications apart from being an antimicrobial. 
 




A suggestion for future work would be modulating the CO-release rates from [Mn(ppy)(CO)4] 
derivatives, or from TryptoCORM, to study the effect on the antimicrobial properties. The 
simplest way to do this would be to use different irradiation powers in growth curve experiments 
and assess how the antimicrobial activity is affected. Control experiments for the effect of the 
irradiation would be critical. Such experiments could then be used to test whether the rate of CO 
loss is more influential than the number of CO ligands lost per molecule of CORM. If this 
hypothesis were upheld this would allow a focus to be placed on faster CO release rates for 
CORMs intended as antimicrobials.  
The solubility of some of the [Mn(ppy)(CO)4] CORMs could also be improved so that higher 
concentrations could be used without precipitation. One strategy would be to use click chemistry 
to PEGylate the drug sphere of the CORM, which could be achieved using 187 and commercially-
available reagent 210 (Scheme 76). 
 
Scheme 76: PEGylation to produce more water-soluble [Mn(ppy)(CO)4] derivatives that retain 
synthetic flexibility. 
Future work could also focus instead on TryptoCORM, which appears to have several desirable 
properties: visible light CO release, a pronounced antibacterial effect against E. coli, and scope 
for further functionalisation for imaging. In the future it may be possible to use room-temperature 
tryptophan arylation reactions351 to functionalise TryptoCORM and produce fluorescent 











The TRIR measurements were performed at the ULTRA352 facility using the Time-Resolved 
Multiple Probe Spectroscopy mode of operation,210 (TRMPS) at the Central Laser Facility (STFC 
Rutherford Appleton Laboratories, Oxfordshire, UK). The experiments were driven by a 10 kHz 
repetition rate Ti:Sapphire amplifier (Thales) as a probe source, producing 40 fs pulses at 800 nm. 
The Ti:Sapphire laser output was used to pump an Optical Parametric Amplifier (TOPAS, Light 
Conversion Ltd.) followed by a AgGaS Difference Frequency Mixing stage which produced 
tuneable mid-IR probe beam of ~500 cm-1 useable bandwidth. The IR probe beam was split to 
form reference and probe beams, which were passed through spectrographs onto MCT array 
detectors (IR Associates). The probe beam spot size at sample was ca. 80 × 80 μm2. High speed 
data acquisition systems (Quantum Detectors) allowed 10 kHz acquisition and processing of the 
probe and reference pulses to generate a pump-on pump-off infrared absorption difference signal. 
The excitation source for the TRIR experiments was the output of the 1 kHz titanium sapphire 
amplifier (Spectra Physics Spitfire XP, 100 fs pulse length) equipped with another TOPAS OPA, 
pulse energy at sample attenuated down to 1 μJ and focused down to ca. 150 × 150 μm2 spot). 
Both ULTRA amplifier and Spitfire amplifier were optically synchronised by sharing the same 
seed from 68 MHz Ti:Sapphire oscillator. The seed beam was delayed with an optical delay line 
before the 1 kHz amplifier to accommodate for the 100 fs -14.7 ns time delays between pump and 
probe. To go beyond 14.7 ns and up to 100 μs, subsequent seed pulses are selected from the 68 
MHz seed pulse train accompanied by the appropriate setting of the optical delay line. The 
polarisation of the excitation beam at sample was set to be at 54.7° with respect to the probe. 
Solutions of the manganese complexes were prepared at a concentration of ca. 15-20 mM in the 
appropriate solvent and flowed through a Harrick cell for the duration of the experiment. 
Experiments were performed under air at room temperature unless otherwise stated. Atmospheres 
of CO or N2 were achieved by evacuating and backfilling the vessel using a Schlenk line.  
The order in which the different pump-probe delays were collected was randomised, and three 
cycles of the experiment were run to generate an averaged dataset at each delay. The spectra were 
also normalised using the reference detector to account for shot-to-shot noise. Spectra were then 
viewed as averaged, normalised difference spectra against background spectra recorded at pump-
probe delays of 900-1000 μs. The resulting data were then manipulated by firstly subtract the 
reference data to obtain a difference spectrum and then a first- or second-order polynomial fitting 
to the baseline was performed. The data were then exported as comma-separated variable files 
and imported into Origin 2018. Spectral calibration was then performed, either using a 190 μm 
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polystyrene standard or by using the known positions of the bleach bands. This allowed for 
detector pixels to be allocated to specific frequencies. The overlap in detection frequency between 
the two detectors was then removed manually. Data were then analysed in Origin 2018 and kinetic 
fits performed with the ExpGro and ExpDec functions with the errors reported as 95% confidence 
intervals. 
7.1.1 Calibration of Spectra 
The spectrograph provides a linear relationship between the pixel number and wavelength which 
can be used to fit the data, and the wavelengths were then converted into wavenumbers. Specific 
detector pixels were assigned to vibrational wavenumbers by fitting the data to the bleach bands 
of the starting material. The wavenumber of the bleach bands used, determined at a 2 cm-1 
resolution with a Unicam Research Series FTIR spectrometer, are given in Table 23. 
Table 23: Stretching frequencies used to calibrate the TRIR spectra. 
Compound Solvent IR stretching frequency (cm-1) 
88 MeCN 1933 1976 1989 2076 
88 Toluene 1933 1976 1990 2074 
88 CH2Cl2 1932 1975 1990 2075 
88 n-Heptane 1940 1981 1994 2077 
88 1,4-Dioxane 1933 1975 1990 2074 
88 nBu2O 1937 1977 1992 2075 
88 DMSO 1927 1970 1987 2073 
88 THF 1932 1974 1989 2073 
94 THF 1933 1975 1990 2074 
95 THF 1933 1975 1990 2074 
133 THF 1931 1973 1988 2072 
172 THF 1959 2001 2082 
173 THF 1964 1998 2017 2078 
 
7.2 Myoglobin CO-Release Assay 
Myoglobin (from equine heart, ~10 mg) was dissolved in 10 mL phosphate-buffered saline 
solution (10 mM, pH 7.4). Sonication in an Ultrawave SFE590 sonic bath (full power, 25 kHz 
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frequency, circa 5 seconds) was used to aid dissolution. The resulting solution was filtered 
through cotton wool.  
To a 1 mL PMMA disposable cuvette, was added 1 mL of the myoglobin solution. Sodium 
dithionite (1 mg) was added and the solution was mixed with a pipette. A UV-visible spectrum 
was recorded and this was taken to be the standard spectrum for deoxymyoglobin. 
Immediately after the recording of the deoxymyoglobin spectrum, the same sample was bubbled 
with CO gas for ca. 30 seconds. The UV-visible spectrum recorded after bubbling with CO was 
taken as the standard spectrum for carboxymyoglobin. This solution was then discarded. 
A stock solution of the CORM to be tested was prepared. The solvent was typically DMSO in 
order to solubilise the complex. The stock solution was 200 times the final concentration of 
CORM desired for the experiment. The stock solution (5 μL) was added to 995 μL myoglobin 
solution, so that only 0.5% DMSO was used in the experiment.    
A cuvette containing 1 mL myoglobin solution was incubated within the spectrometer for 15 
minutes to ensure the temperature inside the cuvette reached 37.5°C. Once this was achieved, 
sodium dithionite (1 mg) was added, followed by 5 μL of the CORM stock solution. The solution 
was mixed with a pipette after each addition. A layer of paraffin oil (0.5 mL) was then added 
above the myoglobin solution to prevent CO escape. It is best to complete these additions quickly 
and begin recording spectra as soon as possible as thermal CO release may start immediately. 
For photochemical CO release, an irradiation control unit, developed by workshops staff in the 
chemistry department at the University of York, was used. The control unit enables the power 
drawn by the LED irradiation source to be set, and has a timer that allows cycles of irradiation to 
repeatedly take place. The LEDs used were installed into plastic lids that fit over the top of the 
disposable PMMA cuvettes. This ensures that samples can be irradiated with well-defined 




Figure 145: Irradiation control unit developed at the University of York. On the left side is a dimmer 
switch and power readout to control the power drawn by the LED. On the right side is a 
programmable timer function that allows repeated on/off cycles. 
 
Figure 146 Left: LED embedded in a cuvette lid to irradiate samples inside a UV-visible spectrometer 
during myoglobin CO release assays. Right – The LED lid attaches to a PMMA cuvette and plus into 
the back of the irradiation control unit, which is in turn powered by the mains.  
The data were processed according to the procedures outlined by Fairlamb and co-workers.160 The 
four isosbestic points shared by deoxymyoglobin and carboxymyoglobin were used to correct the 
data for absorbance or precipitation of the CORM or its degradation products. Firstly, the raw 
spectra were corrected at the isosbestic point at 510 nm by translating the spectra at all 
wavelengths. Any differences in the absorption at the other three isosbestic points compared to 
the standard spectra was assumed to be caused by the CORM or its degradation products. The 
absorbances at the isosbestic points were fitted using nonlinear regression to produce a spectrum 
of the CORM absorbance, which can then be subtracted from the experimental data.  
The concentration of carboxymyoglobin was extracted from the spectra based on the absorbance 
at 540 nm. From the standard spectrum of carboxymyoglobin, it is possible to calculate the 
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saturated carboxymyoglobin concentration, Mb-COmax, using Equation 7, where OD540 is the 
absorbance at 540 nm of the Mb-CO standard spectrum and ε1 is the extinction coefficient of Mb-
CO at 540 nm [ε1 = 15.4 mM-1 cm-1].  
 




    [Equation 7] 
 
In order to measure the Mb-CO concentration from the OD540 in the experimental spectra, a 
second extinction coefficient is needed, as both deoxymyoglobin and carboxymyoglobin are 
present in the solution in the intermediate spectra. The second extinction coefficient, ε2, accounts 
for the change in absorbance at 540 nm (ΔOD540) as Mb-CO grows in. A reference point, the 
change in absorbance at the 510 nm isosbestic point ΔOD510, is used to ensure that the change in 
absorbance at 540 nm is caused only by conversion of deoxymyoglobin to carboxymyoglobin 
(Equation 8).   
 
ε2  =  
(∆OD540 − ∆OD510) × 1000
Mb-COmax
 
    [Equation 8] 
   
Using the modified extinction coefficient ε2, it is now possible to calculate the Mb-CO 
concentration in any of the sample spectra run in the assay using Equation 9. 
 
Mb-CO =  
(∆OD540 − ∆OD510) × 1000
ε2
 




The electrode potential, E, of a redox couple at equilibrium is given by the Nernst equation 
(Equation 10),353 where n is the number of electrons, ared and aox are the activities of the reduced 
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and oxidised species respectively, and x and y are the stoichiometric coefficients of the reduced 
and oxidised species in the cell half-reaction respectively. 







𝑦   [Equation 10] 
However, the potential of one redox couple alone cannot be measured without reference to 
another. When two redox processes are coupled in an electrochemical cell, the Nernst equations 
for each redox process may be combined to give the more common Nernst equation: Equation 11, 
where Eo is the standard reduction potential. In the equation, the oxidised form of species ‘a’ 
oxidises the reduced form of species ‘b’.353  









𝑦   [Equation 11] 
In an equilibrium electrochemical cell, a net current flows between the two electrodes and a 
reaction occurs until equilibrium is reached and the potential difference between the electrodes 
reaches zero. In dynamic electrochemistry, however, a potentiostat sets a potential difference 
chosen by the user, forcing the composition of the solution near the electrode to change.353  
The experiments carried out in this project employ the dynamic electrochemical technique of 
cyclic voltammetry. 293 In one scan, the potential of the working electrode is swept in a linear 
fashion between two potentials E1 and E2, and then back to E1. The current, proportional to the 
number of electrons transferred, is measured as a function of potential. Peak shapes arise from 
redox reactions; this is because the electron transfer rate is a function of potential. Initially the 
electron transfer rate increases as the potential does, but once the concentration of a species at the 
electrode surface is depleted, diffusion begins to limit the rate, causing a peak after which the 
current decreases. 
 A ‘blank’ scan is recorded without the species of interest present to identify the capacitive 
current. This current contribution arises from the migration of charged species in solution in 
response to the changing potential of the electrode rather than the net transfer of any electrons 
across the electrode-solution interface.  
The cell used for these experiments comprises three electrodes. These are termed the ‘working’ 
(where the reaction of interest happens),‘counter’ (which passes an opposite and equal current to 
the working electrode) and ‘reference’ (which contains another redox couple and provides a stable 
reference potential) electrodes. The potentiostat sets a potential difference between the working 
electrode and the counter electrode such that the potential difference between the working and 
reference electrodes is equal to the desired value. This setup is preferable over a two electrode 
system as it enables most of the current to pass between the working and counter electrodes, so 
that no reactions take place at (or within) the reference electrode. The three electrode system also 
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minimises the Ohmic potential drop between the working and reference electrodes (in accordance 
with Ohm’s law this is linearly proportional to the current).293   
The non-aqueous solvents used in this project necessitate the use of a ‘pseudo-reference’ 
electrode; most reference electrodes are usually compatible only with aqueous solutions. A 
pseudo-reference electrode differs from a standard reference electrode in that it does not contain 
another redox couple (a platinum wire was used in this work). The system is calibrated against 
the reversible ferrocene/ferrocenium couple (Fc/Fc+) under the conditions of the experiment with 
either an internal or external standard. 
7.3.1 Spectroelectrochemistry 
Infrared spectroelectrochemistry was performed using an Optically Transparent Thin Layer 
Electrochemical (OTTLE) cell comprising a liquid IR cell with a Pt grid working electrode, Pt 
wire counter electrode and an Ag wire pseudo-reference electrode. 
 UV-visible spectroelectrochemistry was performed using an OTTLE cell composed of a quartz 
cuvette (path length 1 mm), a Pt grid working electrode, a Pt wire counter electrode and an 
Ag/AgCl reference electrode. 
Experiments could be performed under an Argon atmosphere by flowing Ar over the solution to 
be studied. 
7.4 E. coli Growth Curves 
7.4.1 Media and Agar Plates 
Luria broth (LB) growth media was made up containing a solution of 10 g/L tryptone, 5 g/L yeast 
extract and 10 g/L NaCl in deionised water from a Milli-Q purification system. The media was 
diluted accordingly if a less nutrient-rich media was required. The media was sterilised in an 
autoclave.  
To make LB agar, the same concentrations a solution of 10 g/L tryptone, 5 g/L yeast extract, 10 
g/L NaCl and 15 g/L agar was made in deionised water from a Milli-Q purification system. Once 
the LB agar was sterilised in an autoclave and had cooled, but not set, the agar was poured out 
into a petri dish and allowed to set. The plate was left to set in a sterile laminar flow hood to avoid 
contamination. Once the plate had set, the E. coli were streaked out onto the plate with a loop and 
allowed to grow at 37°C for between 16-24 h. Subsequent to this, the plates were stored at 4°C. 




7.4.2 E. coli Growth Curve Experiments 
Safety: This work was performed in a microbiology laboratory. Although the E. coli used in this 
work present a minimal risk to healthy humans, microbiological safety precautions were taken. 
Work surfaces were sanitised with 70% ethanol before and after work took place. Personal 
protective equipment (goggles, lab coat, and non-sterile gloves sanitised with 70% ethanol) was 
worn and as is standard good practice in any laboratory handwashing was always undertaken 
after leaving the laboratory. 
A starter culture was prepared the night before the growth curve experiment. In a sterile laminar 
flow hood using aseptic technique, cells from a single colony on an agar plate were transferred 
into an 8 mL plastic bijou tube containing 3 mL LB and grown overnight (16 hours) in a 
shaker/incubator (180 rpm, 37°C).  
Immediately before the start of the growth curve experiment, the OD600 of the starter culture was 
measured. An aliquot of the starter culture was removed, diluted into LB in a 1 mL PMMA 
cuvette, and the OD600 was measured using a nanodrop spectrophotometer (Thermo Scientific). 
The measured OD600 of the starter culture was then used to calculate the volume of starter culture 
to add to each experiment for the desired starting OD600. 
The cultures for the growth curves were also performed as 3 mL cultures in 8 mL plastic bijou 
tubes. In a sterile laminar flow hood using aseptic technique, LB media (3 mL minus the required 
volume of E. coli stock) was initially added into each tube by pipette. For the DMSO controls, 15 
μL DMSO was then added to the cultures, and for experiments where a CORM was added, 15 μL 
of a DMSO stock solution was added. The concentration of the CORM stock was calculated to 
give the desired final concentration in a 3 mL culture. The required amount of E. coli stock from 
the starter culture was then added to the bijou tubes, the cultures were mixed, and aliquots were 
removed to measure the starting OD600. Finally, the tubes were covered in aluminium foil and 
sterile plastic caps. For the cultures where irradiation was carried out, LEDs were embedded in 
the caps, and these were wiped with ethanol and left to dry in a laminar flow cabinet prior to use 
to ensure sterility. The cultures were grown in a shaker/incubator (usually 180 rpm unless 
otherwise stated) at 37°C. 
Bacterial growth was monitored by taking aliquots every hour in a sterile laminar flow hood and 
measuring the OD600. Prior to measurement the aliquots were diluted as appropriate in LB in 1 
mL PMMA cuvettes to avoid measured OD600 values above 1. The measured OD600 was then 
multiplied by the dilution factor to give the final value. The suspensions in the cuvettes were 
gently mixed immediately prior to measuring the OD600 to ensure that the suspended cells were 
dispersed in a homogenous manner. 
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7.5 Confocal Microscopy 
Confocal microscopy was performed using a Zeiss LSM 780 multiphoton confocal microscope 
on an Axio Observer.Z1 invert. Excitation was provided by 458, 488 or 514 nm laser lines 
depending on the fluorophore. Images were viewed and processed using the Zen Lite or Zen 2010 
software packages (Zeiss). 
7.6 Single Crystal X-Ray Diffraction 
Diffraction data was collected at 110 K on an Agilent SuperNova diffractometer with Mo-Ka 
radiation (l = 0.71073 Å). Data collection, unit cell determination and frame integration were 
carried out with CrysalisPro. Absorption coefficients were applied using face indexing and the 
ABSPACK absorption correction software within CrysalisPro. Structures were solvedand refined 
using Olex2354 implementing SHELX algorithms and the Superflip355–357 structure solution 
program. Structures were solved by Patterson, charge flipping, or direct methods and were refined 
with the ShelXL358 package using full-matrix least squares minimisation. All non-hydrogen atoms 
were refined anisotropically. Hydrogen atoms were placed using a “riding model” and included 
in the refinement at calculated positions. 
7.7 Reagents, Conditions and Solvents 
Reactions in O2 free or anhydrous conditions were performed with dry, degassed solvents under 
an inert atmosphere, effected using either standard Schlenk techniques (under N2) or a balloon (of 
argon), as specified in the relevant procedures. For reactions performed at ‘room temperature’, 
the temperature was between 13-25°C, but usually 21°C. 
Commercial chemicals were purchased from either Acros Organics, Alfa Aesar, Fluorochem or 
Sigma-Aldrich and were used without further purification unless otherwise stated. Dry Et2O, 
tetrahydrofuran, toluene, CH2Cl2 and n-hexane were dispensed from a Pure Solv MD-7 solvent 
machine and stored in oven-dried ampoules under N2. Dry tetrahydrofuran and Et2O were then 
degassed by bubbling with N2 and sonication. Water, EtOH and 
tBuOH were degassed by 
vigorous bubbling of N2 through the solution for at least 1 h.  
“Petrol” in the procedures below is used to mean the constituents of petroleum ether with boiling 
points between 40-60 ᵒC. 
7.8 Nuclear Magnetic Resonance Spectroscopy 
Solution 1H and 13C NMR analysis was carried out at 298 K (295 K for CH2Cl2) on Jeol 
ESC400/ESX400 and Bruker AV500/AV700 spectrometers. The spectra were processed in 
MNova software (version 11.0.3-18688, 2017). All coupling constants are quoted to the nearest 
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0.5 Hz. All chemical shifts in are reported in ppm and are referenced to the residual NMR 
solvent:359 
1H:  CDCl3: 7.26 ppm, DMSO-d6: 2.50 ppm, MeOH-d4: 3.31 ppm, CD2Cl2: 5.32 ppm 
13C: CDCl3: 77.36 ppm, DMSO-d6: 39.52 ppm, MeOH-d4: 49.00 ppm, CD2Cl2: 53.49 ppm).  
For the 13C NMR spectra of some of the tetracarbonyl manganese(I) complexes, the metal 
carbonyl peaks were not observed due to the long relaxation times of metal carbonyls. Infrared 
spectroscopy confirms the presence of these metal carbonyls. 
7.9 Infrared Spectroscopy 
Spectra were recorded on a Bruker Alpha IR spectrometer, usually at a resolution of 4 cm-1. 
Details of the method (ATR, transmission cell, solvent etc.) are given next to the data. Peak 
intensities are grouped qualitatively as very strong (vs), strong (s), medium (m) and weak (w), 
according to common convention.360 
7.10 Mass Spectrometry 
Electrospray Ionisation (ESI) mass spectrometry was carried out using a Bruker Daltronics 
microTOF spectrometer in positive ion mode with an Agilent Series 1200 liquid chromatography 
system. Liquid Injection Field Desorption Ionisation (LIFDI) was performed with a Waters GCT 
Premier mass spectrometer with an Agilent 7890A gas chromatograph. High resolution ESI data 
is within 5 ppm error of the theoretical value unless otherwise stated. All LIFDI data is within 
120 ppm error. 
Unless otherwise stated, the isotopes stated for the observed and calculated peaks are based on 
the mass of the isotope of highest abundance for each element: 1H, 12C, 14N, 16O, 23Na, 28Si, 55Mn, 
56Fe and 79Br.  
7.11 Elemental Analysis 
Elemental analyses were performed on an Exeter Analytical CE-440 Elemental Analyser. The 
quoted percentages composition of C, H and N were the average of two experiments. 
7.12 UV-Visible Spectroscopy 
All UV-visible spectra were recorded with a Jasco V-560 spectrometer using Quartz or PMMA 
cuvettes. Extinction coefficients (ε) were calculated by fitting measured absorbances to the Beer-




7.13 Melting Point Determination 
Melting points were measured on a Stuart SMP30 apparatus. Ramp rates of 2 or 3 ᵒC min-1 were 
used.  
7.14 Chromatography 
Thin layer chromatography (TLC) was carried out using aluminium-backed TLC plates (5554, 
Merck). Visualisation was by quenching of fluorescence using a lamp with λmax = 254 nm.  
Unless otherwise stated, flash column chromatography was performed using silica gel 60 
(Fluorochem or Merck, particle size 40-63 µm). 
7.15 Synthesis 
The synthetic procedures are reported in the order they are referred to in the main body of the 
Thesis. 
7.15.1 General Synthetic Procedures 
General Procedure 1: Cyclometalation of 2-phenylpyridines with BnMn(CO)5 
An oven-dried Schlenk tube containing a stirrer bar, BnMn(CO)5 (1 eq.) and the ligand to be 
cyclometalated (1 eq.) was evacuated and backfilled with N2 three times. Dry, degassed hexane 
(16 mL per mmol of BnMn(CO)5) was added via syringe and the solution was heated to reflux 
for 6-24 h. The Schlenk tube was covered in aluminium foil to exclude light. Reaction progress 
was monitored by IR spectroscopy by taking aliquots from the reaction mixture. 
When the reaction was complete, the reaction mixture was allowed to cool to room temperature 
and filtered through a pipette packed with cotton wool. Any solid product that precipitated out of 
solution was dissolved in a small amount of CH2Cl2. The solvent was removed under reduced 
pressure to yield the product. If required, further purification was performed using flash column 
chromatography. 
 
General Procedure 2: Cyclometalation of Azo Compounds with BnMn(CO)5 
To an oven-dried Schlenk tube, with stirrer bar, under a nitrogen atmosphere, were added the 
desired azo compound BnMn(CO)5 (2.0 eq., 1.0 mmol, 184 mg) and the desired azo compound 
(1.0 eq, 0.5 mmol). Dry toluene (5 mL) was added via syringe. Aluminium foil was placed around 
the Schlenk tube, which was then heated to reflux.  
To monitor the progress of the reaction, aliquots were removed from the reaction mixture and 
analysed by infrared spectroscopy. Complete consumption of BnMn(CO)5 was usually observed 
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after around 3 hours. At this point, the reaction mixture was allowed to cool to room temperature, 
diluted with CH2Cl2 and filtered through CeliteTM. The solvent was removed under reduced 
pressure. Flash column chromatography was performed using silica gel and either n-hexane/ 
CH2Cl2 or CH2Cl2/MeOH solvent systems as stated below. 
 
General Procedure 3: Cyclometalation with MeMn(CO)5 
To an oven-dried Schlenk tube, with stirrer bar, under a nitrogen atmosphere, were added the 
desired azo compound MeMn(CO)5 (1.0 eq., 0.2 mmol, 42 mg) and the desired azo compound 
(1.0 eq, 0.2 mmol). Dry toluene (2 mL) was added via syringe. Aluminium foil was placed around 
the Schlenk tube, which was then heated to reflux.  
To monitor the progress of the reaction, aliquots were removed from the reaction mixture and 
analysed by infrared spectroscopy. Complete consumption of MeMn(CO)5 was usually observed 
after 3-5 hours. At this point, the reaction mixture was allowed to cool to room temperature, 
diluted with CH2Cl2 and filtered through CeliteTM. The solvent was removed under reduced 
pressure. Flash column chromatography was performed using silica gel and either n-
hexane/CH2Cl2 or CH2Cl2/MeOH solvent systems as stated below. 
7.15.2 Compound Synthesis and Characterisation 
For known compounds, where literature procedures were followed, the appropriate references are 
given next to the name of the title compound. Additional references are given next to the 
characterisation data if:  
(i) Appropriate characterisation data are not provided in the same reference(s) as the 
procedure, or 
(ii) The title compound is known but was made via an alternative route. 
 
Benzyl pentacarbonyl manganese(I) (87)159       
 
In the first step of the reaction, a sodium amalgam was made. To an oven-dried Schlenk tube 
containing a magnetic stirrer was added mercury (3 mL). Sodium metal (4.4 eq., 11.7 mmol, 270 
mg) was added to the stirring mercury under a positive pressure of nitrogen. The sodium must be 
added slowly in small pieces to prevent the amalgam from getting excessively hot. In a separate 
oven-dried Schlenk tube, dimanganese decacarbonyl (1.0 eq., 2.68 mmol, 1.04 g) was dissolved 
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in dry, degassed tetrahydrofuran (40 mL). This solution was then added to the amalgam by 
cannula transfer, and the reaction mixture was stirred for 3 h. In another Schlenk tube, benzyl 
chloride (2.0 eq., 5.43 mmol, 625 μL) was dried under vacuum with stirring for 1 minute at 0 ᵒC. 
The tetrahydrofuran solution was transferred into the benzyl chloride at ambient temperature 
using a cannula filtration.  
The mixture was stirred at ambient temperature for 20 h, then filtered through Celite™ and 
washed with diethyl ether (5 × 20 mL). The filtrate was loaded onto silica and placed onto a 3 cm 
diameter pad of silica of approximately 3 cm depth. The pad was washed with petrol (3 × 40 mL) 
and the solvent was removed on the rotary evaporator. The remaining benzyl chloride was 
removed by placing the product under vacuum at room temperature for several hours. The title 
compound was obtained as pale brown crystals (1.14 g, 74% yield). 
 
MP: 38 ᵒC (lit 37-39°C);332 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.21-7.14 (m, 4H, Ar-H), 
6.97 (m, 1H, Ar-H), 2.40 (s, 2H, CH2); 13C NMR (101 MHz, CDCl3): δ (ppm) = 212.7, 210.2 
(Mn-C≡O); 152.1, 129.0, 128.7, 126.2, 123.8 (Ar); 11.45 (CH2); IR (tetrahydrofuran, cm-1): 2107 
(s), 2044 (m), 2005 (vs), 1988 (vs), 1716 (m), 1646 (w), 1596 (w), 1489 (w), 1362 (w), 1261 (w), 
1219 (w). 
Lab book reference: BJA-1-005 
 
Tetracarbonyl (2-(phenyl κ,C2-pyridine- κ,N) manganese(I) (88)137 
 
The reaction was performed using General Procedure 1 with BnMn(CO)5, (1.0 eq., 0.70 mmol, 
202 mg), 2-phenylpyridine (1.0 eq., 0.70 mmol 100 μL) and hexane (10 mL). Traces of grease 
were removed with an MeCN/n-hexane partition and the MeCN was removed under vacuum. The 
title compound was isolated as a yellow solid, 204 mg (87% yield). 
M.P.: 120°C (decomp.); 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.73 (d, J = 5.5 Hz, 1H, Ar-H), 
8.00 (dd, J = 7.5, 1.0 Hz, 1H, Ar-H), 7.79 (d, J = 8.0 Hz, 1H, Ar-H), 7.82-7.77 (m, 2H, Ar-H), 
7.29 (apr, td, J = 7.5, 1.0 Hz, 1H, Ar-H), 7.19 (apr, td, J = 7.5, 1.0 Hz, 1H, Ar-H), 7.11 (ddd, J = 
7.0, 5.5, 1.5 Hz, 1H, Ar-H); 13C NMR (126 MHz, CDCl3) δ = 220.4, 214.3, 175.1, 166.7, 154.2, 146.5, 
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141.95, 138.1, 130.6, 124.4, 124.3, 122.7, 119.6 (Ar-H); IR (CH2Cl2, cm-1): 2076 (s), 1989 (vs), 1977 
(vs), 1934 (vs), 1605 (m), 1578 (w), 1480 (m). 




To a round-bottomed flask was added a magnetic stirrer bar, 2-bromopyridine (1.0 eq., 
9.96 mmol, 1.57 g, 950 µL), 4-hydroxybenzeneboronic acid (1.5 eq., 15.0 mmol, 2.28 g), 
Pd(OAc)2 (0.005 mol%, 0.05 mmol, 11.8 mg), K3PO4 (2 eq, 20 mmol, 4.29 g),and ethylene glycol 
(60 mL). The reaction was heated in an oil bath to 80 ᵒC for 130 min, when the reaction was 
adjudged to be complete by TLC.  
The reaction mixture was then allowed to cool to room temperature before water (75 mL) and 
saturated brine (75 mL) were added and the product was extracted using CH2Cl2 (4 × 100 mL). 
The CH2Cl2 layers were dried with MgSO4, filtered, and the solvent removed on a rotary 
evaporator. The crude product was purified using flash column chromatography, beginning with 
petrol/EtOAc 2:3 v/v and moving to 1:1 v/v to elute the product. The solvent was removed to 
afford the title compound as a yellow oil (1.71 g, 93% yield). 
 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.65 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, Ar-H), 7.90 (d, J = 
8.5 Hz, 2H, Ar-H), 7.73 (apr. td, J = 7.5, 2.0 Hz, 1H, Ar-H), 7.68 (apr. dt, J = 8.0, 1.0 Hz, 1H, 
Ar-H) 7.40 (d, J = 8.0 Hz, 2H, Ar-H), 7.21 (ddd, J = 7.5, 5.0, 1.5 Hz, 1H, Ar-H), 4.69 (s, 2H, 
CH2), 3.13 (s, 1H, OH); 13C NMR (101 MHz, CDCl3): δ (ppm) = 157.8, 150.0, 142.5, 138.8, 
137.3, 127.6, 127.4, 122.4, 121.0 (Ar); 64.7 (CH2); IR (CH2Cl2, cm-1): 3608 (m), 3330 (broad), 
3050 (w), 2925 (w), 2880 (w), 1702 (w), 1591 (w), 1562 (w), 1472 (s), 1441 (s), 1415 (m), 1386 
(m), 1044 (m), 1021 (m); HRMS (ESI+): m/z = 186.0913 [MH]+ (C12H12NO requires 186.0919). 








A suspension of 60% (wt.) NaH (1.0 eq., 10 mmol, 398 mg) in mineral oil was added to an oven-
dried Schlenk tube with magnetic stirrer bar. The suspension was washed with dry n-hexane, 
which was removed by cannula filtration to yield pure NaH. The NaH was dissolved in dry, 
deoxygenated tetrahydrofuran (40 mL) and a solution of 2-(4'-hydroxyphenyl)pyridine (1.0 eq., 
10 mmol, 1.95 g) in tetrahydrofuran (40 mL) was added slowly by cannula transfer. The solution 
was refluxed in the Schlenk tube for 90 mins. Propargyl bromide (1.0 eq., 10 mmol, 1.49 g, 1.12 
mL) was added as an 80% (wt.) solution in toluene and the solution was refluxed for a further 40 
h, at which time TLC indicated completion of the reaction.  
After the orange-brown reaction mixture was allowed to cool to room temperature, water (40 mL) 
was added and the product was extracted using CH2Cl2 (4 × 50 mL). The organic layers were 
washed with saturated sodium carbonate (2 × 50 mL) and water (2 × 50 mL), before being dried 
with MgSO4 and filtered. The solvent was removed under reduced pressure to give the crude 
product. This was subsequently loaded onto silica using CH2Cl2 and purified using flash column 
chromatography with petrol/Et2O 7:3 v/v moving to 2:3 v/v to elute the product. Caution should 
be taken during dry loading so that the silica does not bump. The solvent was removed to give the 
title compound, a very viscous yellow oil (1.28 g, 57% yield).   
 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.69 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, Ar-H), 7.98 (apr. dt, 
J = 8.5, 2.0 Hz, 2H, Ar-H), 7.76-7.69 (m, 2H, Ar-H), 7.47 (d, J = 8.0 Hz, 2H, Ar-H), 7.22 (ddd, 
J = 5.5, 5.0, 2.0 Hz, 1H, Ar-H), 4.66 (s, 2H, CH2), 4.19 (d, J = 2.5 Hz, 2H, CH2), 2.48 (t, J = 2.5 
Hz, 1H, C≡C-H); 13C NMR (101 MHz, CDCl3): δ (ppm) = 157.6, 150.1, 139.4, 138.5, 137.1, 
128.8, 127.4, 122.5, 120.8 (Ar); 79.6 (C≡C-H); 74.8 (C≡C-H); 71.2 (benzylic CH2), 57.1 
(propargylic CH2); IR (CH2Cl2, cm-1): 3305 (s), 3052 (m), 2941 (m), 2864 (s), 1986 (m), 1940 
(m), 1594 (s), 1558 (m), 1469 (s), 1434 (m), 1357 (m), 1086 (s); HRMS (ESI+): m/z = 224.1801 
[MH]+ (C15H14NO requires 224.1075). 






To an oven-dried Schlenk tube containing a solution of 2-(4-[(prop-2-
ynyloxy)methyl]phenyl)pyridine (1.0 eq., 3.87 mmol, 0.865 g ) in dry, degassed tetrahydrofuran 
(40 mL) at -78°C was added a solution of LDA (1.0 eq., 3.87 mmol, 9.6 mL) in tetrahydrofuran 
via syringe over five minutes. The LDA was freshly prepared by lithiation of freshly distilled 
diisopropylamine using n-BuLi. After the addition of LDA was complete, the Schlenk tube was 
placed in an ice/water bath at 0°C for 10 minutes before being cooled back to -78 ᵒC for the 
addition of TIPS-Cl (1.0 eq., 3.87 mmol, 0.84 mL). The reaction mixture was then allowed to 
warm to room temperature and left for 19 h, at which point TLC indicated completion of the 
reaction.  
The reaction was quenched using saturated NH4Cl (30 mL) and extracted with Et2O (3 × 50 mL). 
The combined organic layers were washed with water (30 mL) and brine (30 mL), before being 
dried with MgSO4 and filtered. The solvent was removed to give the crude product, which was 
purified by flash column chromatography on silica, starting with petrol and moving to petrol/Et2O 
4:1 v/v. The solvent was removed to give the title compound as a yellow oil (1.25 g, 85% yield).  
 
1H NMR (400 MHz, CDCl3): δ (ppm) = 8.69 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, Ar-H), 7.99 (d, J = 
8.5 Hz, 2H, Ar-H), 7.77-7.71 (m, 2H, Ar-H), 7.47 (d, J = 8.0 Hz, 2H, Ar-H), 7.22 (ddd, J = 5.5, 
5.0, 2.5, 1H, Ar-H), 4.70 (s, 2H. CH2), 4.23 (s, 2H, CH2), 1.09 (m, 21 H, CH and CH3 from TIPS); 
13C NMR (101 MHz, CDCl3) δ (ppm) = 157.7, 150.2, 139.4, 138.8, 137.2, 129.0, 127.4, 122.5, 
120.9 (Ar); 103.4 (C≡C-Si); 88.4 (C≡C-Si); 70.7 (benzylic CH2); 57.8 (propargylic CH2), 18.4 
(TIPS CH3); 11.0 (TIPS CH); IR (CH2Cl2, cm-1): 2950 (s), 2870 (s), 2171 (w), 1977 (w), 1925 
(w), 1702 (w), 1590 (m), 1561 (w), 1469 (s), 1441 (w), 1354 (m), 1083 (s), 1031 (m), 1010 (m), 
997 (s); HRMS (ESI+): m/z = 380.2391 [MH]+ (C24H34NOSi requires 380.2410).  





Tetracarbonyl 2-(4'-[(3''-triisopropylsilyl-prop-2-ynyloxy)methyl]phenyl) κ,C2-pyridine- 
κ,N) manganese (I) (141)137 
 
The reaction was performed using General Procedure 1 with BnMn(CO)5, (1 eq., 2.93 mmol, 840 
mg), 2-(4-[(3-triisopropylsilyl-prop-2-ynyl-oxy)methyl]phenyl)pyridine (0.96 eq., 2.82 mmol, 
1.07 g) and hexane (40 mL). The title compound was isolated as a yellow solid (1.35 g, 88% yield) 
with no additional purification required. 
MP: 78°C (lit.: 82°C);137 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.72 (d, J = 5.5 Hz, 1H, Ar-H), 
7.92 (s, 1H, Ar-H), 7.87 (d, J = 8.0 Hz, 1H, Ar-H), 7.82-7.75 (m, 2H, Ar-H), 7.20 (dd, J = 8.0, 
1.5 Hz, 1H, Ar-H), 7.11 (ddd, J = 7.5, 5.0, 1.5 Hz, 1H, Ar-H), 4.70 (s, 2H, CH2), 4.30 (s, 2H, 
CH2), 1.11 (m, 21H, CH and CH3 from TIPS); 13C NMR (126 MHz, CDCl3): δ (ppm) = 220.2, 
215.5, 214.2 (Mn-C≡O);  175.4, 166.4, 154.2, 146.1, 141.5, 139.9, 138.14, 124.5, 124.4, 122.6, 
119.6 (Ar); 103.7, (C≡C-Si); 88.3 (C≡C-Si); 71.7 (benzylic CH2); 58.4 (propargylic CH2); 19.0 
(TIPS CH3); 11.5 (TIPS CH); HRMS (ESI+): m/z = 568.1327 [MNa]+ (C28H32MnNNaO5Si 
requires 568.1328); IR (CH2Cl2, cm-1): 3685 (vw), 3157 (vw), 2961 (m), 2946 (m), 2927 (m), 
2893 (m), 2866 (m), 2076 (s), 1991 (vs), 1976 (vs), 1933 (vs), 1605 (m), 1587 (m), 1567 (m), 
1479 (m), 1467 (m), 1351 (s). 
Lab book reference: BJA-1-006 
 
Tetracarbonyl 2-(4'-[(prop-2-ynyloxy)benzyl) κ,C2-pyridine- κ,N) manganese (I) (46)137  
 
To a solution of tetracarbonyl 2-(4'-[(3'-triisopropylsilyl-prop-2'-ynyloxy)methyl]phenyl) κ,C2-
pyridine-κ,N) manganese(I) (1 eq., 1.10 mmol, 599 mg) in CH2Cl2 (2 mL) was added a solution 
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of TBAF∙3H2O (1.2 eq., 1.32 mmol, 417 mg) in acetonitrile (10 mL). The brown solution was 
stirred under air for 25 min, at which time the reaction was judged to be complete by TLC analysis.  
Water (10 mL) was added and the product was extracted with CH2Cl2 (3 × 15 mL). The organic 
layers were combined, dried with MgSO4 and filtered. The solvent was removed in vacuo to yield 
the crude product, which was purified by flash column chromatography on silica gel, starting with 
petrol/EtOAc 10:1 v/v, moving to 20:3 v/v, to elute the product. The solvent was removed under 
reduced pressure to give the title compound as a light brown solid (0.253 g, 59% yield). 
MP: 115°C (decomp., lit.: 107°C);137 1H NMR (500 MHz, DMSO-d6): δ (ppm) = 8.76 (d, J = 5.5 
Hz, 1H, Ar-H), 8.24 (d, J = 8.0 Hz, 1H, Ar-H), 8.07-8.00 (m, 2H, Ar-H), 7.78 (s, 1H, Ar-H), 7.37 
(m, 1H, Ar-H), 7.12 (dd, J = 1.0, 8.0 Hz, 1H, Ar-H), 4.57 (s, 2H, CH2), 4.25 (t, J = 2.5 Hz, 2H, 
CH2), 3.52 (d, J = 2.5 Hz, 1H, C≡C-H); 13C NMR (126 MHz, CDCl3): δ 220.3, 214.4, 214.1 2 
(Mn-C≡O); 175.3, 166.3, 154.1, 146.1, 141.3, 139.3, 138.2, 124.3, 124.3, 122.7, 119.7 (Ar); 80.1 
(C≡C-H) 75.0 (C≡C-H); 72.3 (benzylic CH2); 57.7 (propargylic CH2); IR (CH2Cl2, cm-1): 3664 
(w), 3302 (w), 2964 (m), 2945 (m), 2929 (w), 2893 (m), 2866 (m), 2075 (s), 1991 (vs), 1976 (vs), 
1932 (vs), 1605 (m), 1588 (m), 1566 (w), 1478 (m), 1468 (m); HRMS (ESI+): m/z = 411.9992 
[MNa]+ (C19H12MnNNaO5 requires 411.9994). 
Lab book reference: BJA-1-007 
 
Bromoferrocene (143)280,278  
 
To an oven-dried Schlenk tube containing a magnetic stirrer bar, ferrocene (1.0 eq., 5.4 mmol, 
1.01 g) and KOtBu (0.12 eq., 0.67 mmol, 76 mg) was added dry, degassed tetrahydrofuran 
(50 mL). The solution was cooled to -78 ᵒC using a dry ice/acetone bath and tBuLi (2.0 eq., 10.8 
mmol, 7.83 mL of 1.38 M solution in hexanes) was added dropwise over 20 min, producing a 
light brown solution. After stirring for 1 h 30 min, 1,2-dibromotetrachloroethane (1.5 eq., 
8.1 mmol, 2.64 mg) was added. The resulting orange solution was stirred for a further 30 min, 
remaining at -78 o C. The cooling bath was removed and the solution was allowed to warm to room 
temperature. Water (30 mL) was added to quench the reaction. The product was then extracted 
using CH2Cl2 (3 × 50 mL) and washed with water (2 × 50 mL). The organic layers were combined, 
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dried with MgSO4 and filtered. The solvent was removed in vacuo to yield the crude product, 
contaminated with ferrocene (circa 10%, by NMR).  
Due to the poor separation of ferrocene and bromoferrocene using chromatography, the procedure 
of Long and co-workers280 was used to purify this material. The crude mixture was dissolved in 
hexane (25 mL) and was repeatedly washed with an aqueous solution of 200 mM FeCl3 (10  ×  25 
mL). The composition of the crude mixture was monitored by NMR spectroscopy, which showed 
that he purity of bromoferrocene improved after washing. The product was then washed with 
water until the aqueous layer was colourless and then dried with MgSO4, then filtered through a 
pad of silica (~10 g), washed through with hexane. Note: the purification process is sensitive to 
both the concentration and volume of FeCl3 solution used in each wash and this could be further 
optimised in future reactions by varying both parameters. The solvent was removed under reduced 
pressure to give the title compound as an orange solid (1.15 g, 80% yield). 
 
MP: 28°C; 1H NMR (400 MHz, CDCl3): δ (ppm) = 4.41 (t, J = 2.0 Hz, 2H, Cp-H), 4.23 (s, 5H, 
Cp-H), 4.10 (t, J = 2.0Hz, 2H, Cp-H); 13C NMR (101 MHz, CDCl3) δ (ppm) = 77.8, 70.7, 70.3, 
67.2 (Cp); IR (ATR, cm-1): 3096 (m), 2954 (w), 2922 (w), 2853 (w), 1774 (w), 1725 (w), 1408 
(m), 1381 (m), 1358 (m), 1344 (m), 1179 (w), 1151 (m), 1105 (s), 1054 (m), 1020 (m), 1001 (m), 
871 (s), 819 (s), 809 (s), 775 (m), 759 (m), 725 (s), 639 (m), 618 (m), 476 (vs) ; HRMS (EI): m/z 
= 263.9238 [M]+ (C10H9FeBr requires 263.9237). 
Lab book reference: BJA-1-008 
 
Azidoferrocene (135)279  
 
Bromoferrocene (1.0 eq., 1.0 mmol, 269 mg) and CuCl (1.1 eq., 1.1 mmol, 109 mg) were 
dissolved in degassed EtOH (4 mL). A solution of NaN3 (2 eq., 2.0 mmol, 132 mg) in degassed 
water (400 μL) was added and the solution was stirred in the dark under an argon balloon for 72 h. 
The product was extracted using petrol (4 × 25 mL). The organic layers were washed with water 
(2 × 25 mL) and brine (25 mL) and dried over Na2SO4. After filtration, the solvent was removed 
under reduced pressure to give the title compound as a red solid (109 mg, 49% yield). 
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MP: 53°C; 1H NMR (400 MHz, benzene-d6): δ (ppm) = 4.11 (s, 5H, Cp-H), 4.10-4.07 (m, 2H, 
Cp-H), 3.77-3.72 (s, 2H, Cp-H); 13C NMR* (101 MHz, CDCl3) δ (ppm) = 69.1, 65.2, 60.6 (Cp); 
IR (ATR, cm-1): 3260 (w), 3110 (w), 3090 (w), 2960 (w), 2923 (w), 2852 (w), 2437 (w), 2323 (w), 
2196 (w), 2107 (s), 1453 (s), 1407 (m), 1373 (m), 1283 (s), 1223 (w), 1163 (m), 1105 (m), 1057 
(m), 1023 (s), 999 (s), 915 (m), 818 (s), 738 (m). 
*The NMR signal for the carbon bonded to the azide group was not observed in the spectrum, the 
same situation was reported in the literature.279 
Lab book reference: BJA-1-009 
 
Tetracarbonyl(2-[4'-(([1-(ferrocenyl)-1H-1,2,3-triazol-4-yl]methoxy)methyl)phenyl-
κ,C2]pyridine-κ,N) manganese(I) (132) 
 
To a solution of tetracarbonyl 2-(4'-[(prop-2-ynyloxy)methyl]phenyl) κ,C2-pyridine- κ,N) 
manganese (I) (1.0 eq., 0.2 mmol, 78 mg) in N2-purged 
tBuOH (3 mL) was added azidoferrocene 
(1.0 eq., 0.2 mmol, 46 mg) and water (2.7 mL). Copper(II) sulfate (0.3 eq., 0.06 mmol, 200 μL of 
300 mM aqueous solution) and sodium ascorbate (0.6 eq., 0.12 mmol, 120 μL of 500 mM aqueous 
solution) were added and the reaction mixture was stirred at room temperature in the dark under 
an argon balloon. After 24 h, the reaction mixture was diluted with water (20 mL). The product 
was extracted with EtOAc (4 × 20 mL). The combined organic layers were dried with MgSO4 and 
filtered, before removal of the solvent yielded the crude product. The crude product was purified 
by flash column chromatography on silica, using petrol/EtOAc, starting with 3:2 v/v and moving 
to 1:1 v/v to elute the product. The solvent was removed to give the title compound (74 mg, 60% 
yield) as a yellow solid. 
 
MP: 143°C (decomp.); Rf: 0.40 (petrol/EtOAc 3:2 v/v); 1H NMR (500 MHz, CDCl3): δ (ppm) = 
8.72 (d, J = 5.5 Hz, 1H, Ar-H), 7.97 (d, J = 1.5 Hz, 1H, Ar-H), δ (ppm) 7.89-7.86 (m, 1H, Ar-H), 
7.84 (s, 1H, Ar-H), 7.81-7.76 (m, 2H, Ar-H), 7.21 (dd, J = 8.0, 1.5 Hz, 1H, Ar-H), 7.12 (ddd, J 
= 7.5, 5.5, 1.5 Hz, 1H, Ar-H), 4.83 (t, J = 2.0 Hz, 2H, Cp-H), 4.82 (s, 2H, CH2), 4.71 (s, 2H, 
CH2), 4.26 (t, J = 2.0 Hz, 2H, Cp-H), 4.22 (s, 5H, Cp-H); 13C NMR (126 MHz, CDCl3) δ (ppm) 
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= 220.3, 214.1, 214.0 (Mn-C≡O); 175.1, 166.1, 154.0, 145.9, 145.5, 140.7, 139.6, 138.0, 124.2, 
123.9, 122.5, 122.3, 119.5 (Ar); 94.0 (Cp); 73.0 (CH2); 70.3 (Cp); 66.8 (Cp); 64.2 (CH2); 62.3 
(Cp)  ; HRMS (ESI+): m/z = 617.0292 [MH]+ (C29H22N4O5MnFe requires 617.0315); IR (CH2Cl2, 
cm-1): 3048 (w), 2864 (w), 2076 (s), 1991 (vs), 1977 (vs), 1931 (s), 1606 (m), 1587 (m), 1567 
(w), 1519 (w), 1472 (m), 1432 (w), 1312 (w), 1108 (m); Elemental analysis (CHN): C: 56.28%, 
H: 3.48%, N: 8.69% (calc. for C29H21N4O5MnFe C: 56.52%, H: 3.44%, N: 9.09%); UV-visible 
spectrum (CH2Cl2): λmax (nm) = 270,  (270 nm) = (2.84 ± 0.5) × 104 dm3 mol-1 cm-1.  




To an oven-dried Schlenk tube containing a stirrer bar were added 4-bromobenzene boronic acid 
(1.5 eq., 4.60 mmol, 923 mg) and Pd(PPh3)4 (2 mol%, 0.061 mmol, 70.2 mg). tetrahydrofuran 
(20 mL) and saturated aqueous sodium carbonate solution (9.5 mL), both N2 saturated, were 
added, followed by 2-bromopyridine (1.0 eq., 3.15 mmol, 300 µL). The reaction was heated to 
60°C for 70 h.  
After the solution had cooled to room temperature, water (60 mL) was added and the product 
extracted with CH2Cl2 (3 × 60 mL). The yellow extract was dried with MgSO4, filtered and the 
solvent removed under reduced pressure. The crude product, an orange oil, was purified by flash 
column chromatography with petrol/EtOAc, starting with 9:1 v/v and moving to 20:3 v/v. 
Removal of the solvent in vacuo afforded the product contaminated with trace unreacted 
2-bromopyridine. This was removed by placing the compound under vacuum and heating in an 
oil bath to 45°C for several hours. The title compound was isolated as a white solid (551 mg, 77% 
yield). 
MP: 64°C (lit.: 64°C)137; 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.69 (d, J = 4.5 Hz, 1H, Ar-H), 
7.88 (d, J = 7.0 Hz, 2H, Ar-H), 7.76 (apr. td, J = 7.5, 1.5 Hz, 1H, Ar-H), 7.70 (d, J = 8.0 Hz, 2H, 
Ar-H), 7.60 (d, J = 8.5 Hz, 2H, Ar-H), 7.27-7.24 (m, 1H, under ref peak Ar-H); 13C NMR (101 
MHz, CDCl3) δ (ppm) 156.4, 150.0, 138.5, 137.0, 132.1, 128.6, 123.6, 122.6, 120.5 (Ar-H); 
HRMS (ESI+): m/z = 233.9916 [M-H]+ (C11H9NBr requires 233.9913). 






To an oven-dried Schlenk tube with stirrer bar were added 2-(4-bromophenyl)pyridine (1.0 eq., 
0.20 mmol, 46.8 mg), ferroceneboronic acid (2.0 eq., 0.40 mmol, 92.9 mg), Pd(OAc)2 (0.05 eq., 
0.001 mmol, 2.2 mg), PPh3 (0.21 eq., 0.43 mmol, 11.2 mg) and K2CO3 (4.0 eq., 0.80 mmol, 111 
mg). The Schlenk tube was evacuated and backfilled with N2 three times on a Schlenk line. 
Anhydrous, degassed toluene (10 mL) was added in one portion via syringe. The red reaction 
mixture was refluxed for 20 h, at which point TLC analysis showed complete consumption of the 
starting material and the appearance of a product spot. The reaction mixture was allowed to cool 
and the toluene was removed in vacuo. The mixture was re-suspended in chloroform (100 mL), 
washed with water (2 × 100 mL), dried with MgSO4 and filtered. The solvent was removed in 
vacuo and the crude product was purified by flash column chromatography on silica gel using 
petrol/EtOAc, starting with 9:1 v/v and moving to 8:2 v/v. Removal of the solvent in vacuo and 
additional drying on a high vacuum line gave the title compound as an orange powder (37.5 mg, 
55% yield). 
MP: 122°C; 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.69 (d, J = 4.5 Hz 1H, Ar-H), 7.93 (d, J = 
8.0 Hz, 2H, Ar-H), 7.73 (d, J = 4.0 Hz, 2H, Ar-H), 7.58 (d, J = 8.0 Hz 2H, Ar-H), 7.21 (dd, J = 
9.0, 4.0 Hz 1H, Ar-H), 4.71 (t, J = 2.0 Hz, 2H, Cp-H), 4.36 (t, J = 2.0 Hz, 2H, Cp-H), 4.05 (s, 
5H, Cp-H); 13C NMR (101 MHz, CDCl3) δ (ppm) = 157.4, 149.8, 140.5, 136.9, 136.8, 127.0, 
126.4, 121.0, 120.3 (Ar); 84.6, 69.8, 69.3, 66.7 (Cp); HRMS (ESI+): m/z = 340.0770 [M-H]+ 
(C21H18FeN requires 340.0789); IR (CH2Cl2, cm−1): 2967 (w), 2074 (s), 1990 (s), 1975 (s), 1931 
(s), 1733 (w), 1606 (m), 1583 (m),1563 (m), 1474 (m), 1425 (w). 








Tetracarbonyl (2-[4-Ferrocenyl]phenyl-κ,C2-pyridine-κ,N) Manganese(I) (133) 
 
This reaction was performed using General Procedure 1 with BnMn(CO)5 (1 eq., 0.25 mmol, 72.5 
mg), [4-(2'-pyridinyl)phenyl]ferrocene (1 eq., 0.25 mmol, 84.5 mg) and hexane (4 mL). Infrared 
spectroscopic analysis showed that the reaction was complete after 6 h. The title compound was 
purified by flash column chromatography, using petrol and then petrol/EtOAc 9:1 v/v. The solvent 
was removed in vacuo to afford a red microcrystalline solid (79 mg, 59% yield). 
 
MP: 138°C (decomp.); 1H NMR (700 MHz, CDCl3): δ (ppm) = 8.70 (d, J = 5.0 Hz, 1H, Ar-H), 
8.12 (s, 1H, Ar-H), 7.84 (d, J = 8.0 Hz, 1H, Ar-H), 7.77 (dd, J = 7.5, 7.5 Hz, 1H, Ar-H), 7.68 (d, 
J = 8.0 Hz, 1H, Ar-H), 7.28 (s, 1H, Ar-H), 7.08 (dd, J = 6.5 Hz, 6.0 Hz, 1H, Ar-H), 4.77 (t, J = 
2.0 Hz, 2H, Cp-H), 4.37 (t, J = 2.0 Hz, 2H, Cp-H), 4.09 (s, 1H, Cp-H); 13C NMR (176 MHz, 
CDCl3) δ (ppm) = 220.4, 214.2, 214.1 (Mn-C≡O), 174.2, 166.2, 153.8, 144.0, 141.4, 139.0, 137.7, 
123.9, 122.2, 121.8, 119.0 (Ar), 85.4, 69.8, 69.2, 67.1 (Cp); MS (LIFDI+): m/z = 505.04 [M+] 
(C25H16NO4FeMn requires 504.9809); IR (CH2Cl2, cm-1): 2967 (w), 2074 (s), 1990 (s), 1975 (s), 
1931 (s), 1733 (w), 1606 (m), 1583 (m), 1563 (m), 1474 (m), 1425 (w); Elemental analysis 
(CHN): C: 59.69%, H: 3.27%, N: 2.73% (C25H16NO4FeMn requires C: 59.44%, H: 3.19%, N: 
2.77%); UV-visible spectrum (CH2Cl2): λmax (nm) = 314, 378, 460;  (314 nm) = 
(2.29 ± .02) × 104 dm3 mol-1 cm-1;  (378 nm) = (8.00 ± .06) × 103 dm3 mol-1 cm-1;  (460 nm) = 
(2.04 ± 0.05) × 103 dm3 mol-1 cm-1. 










 2-(Ferrocenyl)pyridine (149) 
 
This reaction was performed by Sam Andrew under my supervision.290 
Bromoferrocene (1.0 eq., 1.9 mmol, 513 mg) was stirred in dry EtOAc  (10 mL) under nitrogen 
in an oven dried Schlenk tube at -78oC. After n-BuLi (1.1 eq., 2.0 mmol, 0.80 mL) was added 
dropwise, the solution was stirred for 15 minutes and then allowed to warm to room temperature 
and stirred for a further 10 minutes forming a bright orange precipitate. The reaction mixture was 
then cooled to -78oC and transferred under nitrogen to a Schlenk tube containing dry ZnCl2 (2.0 
eq., 3.8 mmol, 518 mg) at -78oC, allowed to warm to room temperature and stirred for 1 h. The 
reaction mixture was then transferred under nitrogen into a third Schlenk tube containing dry 
Pd(PPh3)4 (10 mol%, 0.19mmol, 220 mg). 2-Bromopyridine (2.5 eq., 4.75 mmol, 0.45 mL) was 
added dropwise and the reaction mixture stirred for 19 hours. The reaction was quenched with 
saturated aqueous NH4Cl solution (15 mL) and transferred into a separating funnel. The aqueous 
layer was extracted with chloroform (3 × 10 mL) and the organic phases combined and dried over 
MgSO4, then filtered. The solvent was then removed in vacuo to afford an orange powder. The 
crude mixture was purified by silica gel flash column chromatography (petrol/EtOAc 9:1 v/v) to 
afford the title compound as an orange powder, 371 mg (74% yield).  
 
Melting point: 90 – 92oC; Rf = 0.16 (petrol/Et2O 9:1 v/v); 1H NMR (400 MHz, CDCl3): δ (ppm) 
= 8.51 (ddd, J = 5.0, 2.0, 1.0 Hz, 1H, Ar-H), 7.57 (ddd, J = 8.0, 7.5 1.0 Hz, 1H), Ar-H, 7.41 (ddd, 
J = 8.0, 1.0, 1.0 Hz, 1H, Ar-H), 7.06 (ddd, J = 7.5, 5.0, 1.0 Hz, 1H, Ar-H), 4.92 (dd, J = 2.0, 2.0 
Hz, 2H, Cp-H), 4.40 (dd, J = 2.0, 2.0 Hz, 2H, Cp-H), 4.05 (s, 5H, Cp-H); 13C NMR (101 MHz, 
CDCl3): δ (ppm) = 159.3, 149.4, 136.0, 120.6, 120.2 (Ar); 83.7, 70.0, 69.7, 67.3 (Cp); HRMS 
(ESI+): m/z = 264.0473 [MH]+ (C15H14FeN requires 264.0470); IR (CH2Cl2, cm-1): 1609 (m), 1588 
(w), 1574 (w), 1469 (m), 1434 (m), 1277 (w). 
Lab book reference: N/A, see reference.290 
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(±)-Tetracarbonyl (2-ferrocenyl-κ,C2-pyridine-κ,N) manganese(I) (134) 
 
This reaction was performed using General Procedure 1 with BnMn(CO)5 (1 eq., 4.56 mmol, 131 
mg), 2-(ferrocenyl)pyridine (1 eq., 0.25 mmol, 84.5 mg) and n-hexane (10 mL). Infrared 
spectroscopic analysis showed that the reaction was complete after 20 h. The title compound was 
purified by flash column chromatography silica using petrol/Et2O/NEt3 (94:5:1 v/v) to afford the 
title compound as a dark red solid (162 mg, 83% yield). 
 
M.P.: 109−111°C; Rf = 0.28 (petrol/Et2O 9:1 v/v); 1H NMR (700 MHz, CD2Cl2): δ (ppm) = 8.50 
(d, J = 5.0 Hz, 1H, Ar−H), 7.65 (ddd, J = 8.0, 7.5, 1.0 Hz, 1H, Ar−H), 7.41 (d, J = 8.0 Hz, 1H, 
Ar−H), 7.02 (ddd, J = 7.5, 5.0, 1.0 Hz 1H, Ar−H), 4.93 (d, J = 2.0 Hz, 1H, Cp-H), 4.66 (dd, J = 
2.0, 2.0 Hz, 1H, Cp-H), 4.56 (d, J = 2.0 Hz, 1H, Cp-H), 4.07 (s, 5H, Cp-H). 13C NMR (176 MHz, 
CD2Cl2): δ (ppm) = 221.1, 213.2, 212.3, 211.7 (Mn−C≡O); 169.0, 154.4, 137.5, 120.2, 119.5 (Ar); 
103.1, 90.5, 77.4, 72.4, 69.6, 65.2 (Cp). MS (LIFDI+): m/z = 426.9565 [M+] (C19H12NO4MnFe 
requires 426.9543). Elemental analysis (CHN): C 53.00%, H 2.91%, N 3.20% (C19H12NO4MnFe 
requires C 53.18%, H 2.82%, N 3.26%). IR (CH2Cl2, cm-1): 2077 (s), 1988 (vs), 1976 (vs), 1932 
(vs), 1607 (m), 1498 (s); UV-visible spectrum (CH2Cl2): λmax (nm)  = 292, 486;  (292 nm) = 
(1.827 ± .013) × 104 dm3 mol-1 cm-1,  (486 nm) = (1.23 ± 0.05) × 103 dm3 mol-1 cm-1.  












To a 100 mL round-bottomed flask with stirrer bar were added p-anisidine (1.0 eq., 5.0 mmol, 
618 mg), cuprous chloride (0.2 eq., 1.0 mmol, 101 mg) and acetonitrile (25 mL). The reaction 
mixture was stirred under air at room temperature for 5 h, at which point thin layer 
chromatography showed complete consumption of p-anisidine. The reaction mixture was 
quenched using 2 M K2CO3 (25 mL) and the product extracted with Et2O (3 × 25 mL). The 
combined organic layers were washed with brine (25 mL), dried with anhydrous MgSO4, and 
filtered before the solvent was removed under reduced pressure. The crude product was purified 
by flash column chromatography on silica gel using EtOAc/petrol, starting with 1:9 v/v and 
moving to 1:2 v/v. Removal of the solvent afforded the title compound as a brown solid (378 mg, 
62% yield). 
 
MP: 156°C (lit.: 155-159°C);361Rf = 0.35 (EtOAc/petrol, 1:4, v/v); 1H NMR (400 MHz, CDCl3): 
δ (ppm) = 7.90-7.86 (m, 4H, Ar-H), 7.02-6.98 (m, 4H, Ar-H), 3.89 (s, 6 H, OCH3); 13C NMR (101 
MHz, CDCl3): δ (ppm) = 161.7, 147.2, 124.4, 114.3 (Ar); 55.6 (OCH3); HRMS (ESI+): m/z = 
243.1134 [M-H]+ (C14H15N2O2 requires 243.1134)l; IR (CH2Cl2, cm-1): 2842 (w), 1600 (s), 1583 
(m), 1504 (s), 1463 (m), 1441 (m) 1181 (s), 1148 (s), 1104 (m), 1031 (s). 




To a 250 mL round-bottomed flask with stirrer bar were added ethyl 4-aminobenzoate (1.0 eq., 
7.5 mmol, 1.24 g), iodobenzene diacetate (1.0 eq., 7.5 mmol, 2.43 g) and CH2Cl2 (60 mL). The 
reaction mixture was stirred under air at room temperature for 1 h, at which point thin layer 
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chromatography showed complete consumption of ethyl 4-aminobenzoate. The solvent was 
removed under reduced pressure and the crude product was purified by flash column 
chromatography on silica gel using EtOAc/petrol, starting with 1:19 v/v and moving to 1:4 v/v. 
Removal of the solvent afforded the title compound as an orange solid (940 mg, 77% yield). 
 
MP:  140°C (lit.: 135-136°C)361; Rf = 0.26 (CH2Cl2); 1H NMR (400 MHz, CDCl3): δ (ppm) = 
8.22-8.18 (m, 4H, Ar-H), 7.99-7.95 (m, 4H, Ar-H), 4.41 (q, 7.0 Hz, 4H, CO2CH2CH3), 1.42 (t, 
7.0 Hz, 6H, CO2CH2CH3); 13C NMR (101 MHz, CDCl3): δ (ppm) = 166.0 (CO2Et); 155.0, 132.8, 
130.7, 123.0 (Ar); 61.5 (CO2CH2CH3); 14.4 (CO2CH2CH3); HRMS (ESI+): m/z = 349.1150 [M-
Na]+ (C18H18N2NaO4 requires 349.1164); IR: 2983 (w), 1714 (s), 1603 (w), 1466 (w), 1409 (w), 
1366 (m), 1219 (w), 1174 (w), 1110 (m), 1015 (m); UV-visible spectrum (CH2Cl2): λmax (nm)  = 
330,  (330 nm) = (3.49 ± 0.04) × 104 dm3 mol-1 cm-1. 
Lab book reference: BJA-2-114 
 
Methyl pentacarbonyl manganese(I) (174) 
 
In the first step, a sodium amalgam was made. Mercury (6 mL) was added to an oven-dried 
Schlenk tube containing a magnetic stirrer. Sodium metal (4.0 eq., 21.4 mmol, 500 mg) was added 
to the stirring mercury under a positive pressure of nitrogen. The sodium must be added slowly 
in small pieces to prevent the amalgam from getting excessively hot.  
In a separate oven-dried Schlenk tube, dimanganese decacarbonyl (1.0 eq., 5.36 mmol, 2.07 g) 
was dissolved in dry, degassed tetrahydrofuran (40 mL). This solution was then added to the 
amalgam by cannula transfer, and the reaction mixture was stirred for 3 h. In another Schlenk 
tube, methyl iodide (2.0 eq., 10.7 mmol, 675 μL) was dried under vacuum with stirring for 1 
minute at 0ᵒC. The tetrahydrofuran solution was transferred into the methyl iodide at ambient 
temperature using a cannula filtration.  
The mixture was stirred at ambient temperature for 3 h, then filtered through Celite™ and washed 
with diethyl ether (5 × 20 mL). The filtrate was loaded onto silica and placed onto a 3 cm diameter 
pad of silica of approximately 3 cm depth. The pad was washed with petrol (3 × 40 mL) and the 
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solvent was removed on a rotary evaporator. The title compound was obtained as colourless 
crystals (785 mg, 35% yield). 
 
Rf = 0.84 (petrol); 1H NMR (400 MHz, CDCl3): δ (ppm) = -0.10 (s, 3H, Me); 13C NMR (101 
MHz, CDCl3): δ (ppm) = 213.7, 210.5 (Mn-C≡O); -19.2 (Me); IR (CH2Cl2, cm-1): 2906 (w), 2111, 
(w), 2009 (vs), 1986 (m). 
Lab book reference: BJA-1-079 
 
Tetracarbonyl(4,4’-methoxyazobenzene)manganese (170) 
Two methods were used to make complex 170.  
Method A: 
 
The title compound was prepared using general procedure 3 with [MeMn(CO)5] (1.0 eq., 0.20 
mmol, 48.8 mg), 4,4’-dimethoxyazobenzene (1.0 eq., 0.20 mmol, 42.5 mg) and toluene (2 mL). 
A reaction time of 3 hours was used. Flash column chromatography was performed starting with 
CH2Cl2 and moving to CH2Cl2/MeOH 99:1 v/v to afford an orange solid (47.6 mg, 58% yield). 
Lab book reference: BJA-2-091 
 







The title compound was prepared using general procedure 2 with 4,4’-dimethoxyazobenzene, (1.0 
eq., 0.5 mmol, 121 mg), [BnMn(CO)5] (2.0 eq., 1.0 mmol, 185 mg) and toluene (5 mL). Flash 
column chromatography was performed starting with n-hexane/CH2Cl2 7:3 v/v and moving to n-
hexane/ CH2Cl2 1:1 v/v to afford an orange solid (134 mg, 66% yield). 
Lab book reference: BJA-2-092 
 
M.P.: 74°C; Rf = 0.33 (n-hexane/ CH2Cl2, 1:1, v/v); 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.19 
(d, J = 7.5 Hz, 1H, Ar-H), 7.54-7.48 (m, 3H, Ar-H), 6.98 (d, 9.0 Hz, 1H, Ar-H), 6.83 (m, 1H, Ar-
H), 3.95 (s, 3H, OMe), 3.87 (s, 3H, OCH3); 13C NMR (126 MHz, CDCl3) δ (ppm) = 220.6, 213.3, 
211.3 (Mn-C≡O); 184.3, 162.1, 161.9, 160.9, 151.5, 133.8, 124.9, 123.9, 114.2, 112.3 (Ar); 56.0, 
55.9 (OCH3); HRMS (ESI+): m/z = 409.0243 [M-H]+ (C18H14MnN2O6 requires 409.0232); IR 
(CH2Cl2, cm-1): 2842 (w), 2081 (s), 1997 (vs), 1948 (vs), 1603 (w), 1580 (s), 1555 (m), 1503 (m), 
1465 (w), 1434 (w), 1368 (w), 1322 (w), 1201 (w), 1175 (w), 1126 (w), 1112 (w), 1029 (m); UV-
visible spectrum (CH2Cl2): λmax (nm)  = 378, 456,  (378 nm) = (2.166 ± .008) × 104 dm3 mol-




The title compound was prepared using general procedure 2 with 4,4’-dimethoxyazobenzene, (1.0 
eq., 0.5 mmol, 121 mg), [BnMn(CO)5] (2.0 eq., 1.0 mmol, 185 mg) and toluene (5 mL). The 
reaction time was 3 hours. Flash column chromatography was performed starting with n-
hexane/CH2Cl2 7:3 v/v and moving to n-hexane/ CH2Cl2 1:1 v/v to afford a purple solid (62.2 mg, 
22% yield). 
 
M.P.: 129°C (decomp.); Rf = 0.53 (n-hexane/ CH2Cl2, 1:1, v/v); 1H NMR (500 MHz, CDCl3): δ 
(ppm) = 8.47 (d, J = 9.0 Hz, 2H, Ar-H), 7.61 (d, J = 2.5 Hz, 2H, Ar-H), 6.84 (dd, J = 9.0 Hz, 2.5 
Hz, 2H, Ar-H), 3.98 (s, 6H, OCH3); 13C NMR (126 MHz, CDCl3) δ 220.7, 213.1, 210.3 (Mn-C≡O); 
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178.1, 161.1, 160.6, 129.9, 124.9, 111.9 (Ar); 56.0 (OCH3); MS (LIFDI+): m/z = 573.87 [M+] 
(C22H12Mn2N2O10 requires 573.93); IR (CH2Cl2, cm-1): 2842 (w), 2077 (s), 2012 (vs), 1989 (vs), 
1953 (vs), 1573 (s), 1554 (m), 1464 (w), 1434 (w), 1314 (w), 1176 (w), 1130 (w), 1121 (w), 
1030 (m); Elemental analysis (CHN): C: 45.96%, H: 2.06%, N: 4.77% (C22H12Mn2N2O10 
requires C: 46.01%, H: 2.11%, N: 4.88%); UV-visible spectrum (CH2Cl2): λmax (nm)  = 456, 
578,  (456 nm) = (2.79 ± .02) × 104 dm3 mol-1 cm-1,  (578 nm) = 
(1.254 ± 0.005) × 104 dm3 mol-1 cm-1.  
Lab book reference: BJA-2-092 
 
Tetracarbonyl(4,4’-dicarboethoxyazobenzene)manganese (172) 
Two methods were used to make complex 172.  
Method A: 
 
The title compound was prepared using general procedure 3 with MeMn(CO)5, (1.0 eq., 
0.20 mmol, 64.5 mg), 4,4’-dicarboethoxyazobenzene (1.0 eq., 0.20 mmol, 42.6 mg) and toluene 
(2 mL). The reaction time was 3 hours. Flash column chromatography was performed starting 
with CH2Cl2 and moving to CH2Cl2/MeOH 98:2 v/v to afford a red solid (50.9 mg, 52% yield). 






The title compound was prepared using general procedure 2 with 4,4’-dicarboethoxyazobenzene, 
(1.0 eq., 0.5 mmol, 161 mg), [BnMn(CO)5] (2.0 eq., 1.0 mmol, 184 mg) and toluene (5 mL). The 
reaction time was 3 hours. Flash column chromatography was performed starting with CH2Cl2 
and moving to CH2Cl2/MeOH 99:1 v/v to afford a red solid (152 mg, 62% yield). 
Lab book reference: BJA-2-087 
 
M.P.: 98°C (decomp.); Rf = 0.32 (CH2Cl2); 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.77 (s, 1H, 
Ar-H), 8.41 (d, J = 8.0 Hz, 1H, Ar-H); 8.22 (d, J = 7.5 Hz, 1H, Ar-H), 8.02 (d, J = 7.5 Hz, 1H, 
Ar-H), 7.63 (d, J = 8.0 Hz, 1H, Ar-H), 4.47-4.38 (m, 4H, CO2CH2CH3)), 1.48-1.39 (m, 6H, CO-
2CH2CH3); 13C NMR (126 MHz, CDCl3) δ (ppm) = 219.8, 212.4, 209.7 (Mn-C≡O); 181.4 (Ar); 
169.4  167.0, 165.7 (Ar/CO2Et); 160.3 142.3, 132.7, 132.5, 132.4, 131.0, 127.2, 122.4 (Ar); 61.9, 
61.9 (CO2CH2CH3); 14.7, 14.7 (CO2CH2CH3); HRMS (ESI+): m/z = 515.0286 [M-Na]+ 
(C22H17MnN2NaO8 requires 515.0263); IR (CH2Cl2, cm-1): 2983 (w), 2084 (s), 2004 (vs), 1960 
(vs), 1716 (s), 1604 (w), 1410 (w), 1389 (w), 1370 (w), 1234 (m), 1107 (s), 1035 (m), 1019 (m); 
Elemental analysis (CHN): C: 53.58%, H: 3.57%, N: 5.65% (C22H17MnN2O8 requires C: 53.67%, 
H: 3.48%, N: 5.69%); UV-visible spectrum (CH2Cl2): λmax (nm)  = 336, 434,  (336 nm) = 




The title compound was prepared using general procedure 2 with 4,4’-dicarboethoxyazobenzene, 
(1.0 eq., 0.5 mmol, 161 mg), [BnMn(CO)5] (2.0 eq., 1.0 mmol, 184 mg) and toluene (5 mL). The 
reaction time was 3 hours. Flash column chromatography was performed starting with CH2Cl2 
and moving to CH2Cl2/MeOH 99:1 v/v to afford a black solid (68.1 mg, 21% yield). 
 
M.P.: 108°C (decomp.); Rf = 0.45 (CH2Cl2); 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.83 (d, J = 
1.5 Hz, 2H, Ar-H); 8.67 (d, J = 8.5 Hz, 2H Ar-H); 8.02 (dd, J = 8.5, 1.5 Hz, 2H, Ar-H); 4.47 (q, 
J = 7.5 Hz, 4H, CH2), 1.46 (t, J = 7.5 Hz, 6H, CH3);13C NMR (126 MHz, CDCl3) δ (ppm) = 220.0, 
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212.3, 208.7 (Mn-C≡O); 178.3 (Ar); 169.0, 166.5 ((Ar/CO2Et); 142.1, 131.7, 129.1, 127.2 (Ar); 
62.0 (CO2CH2CH3); 14.7 (CO2CH2CH3); HRMS (ESI+): m/z = 680.9384 [M-Na]+ 
(C26H16Mn2N2NaO12 requires 680.9362); IR (CH2Cl2, cm-1): 2079 (s), 2019 (vs), 2000 (vs), 1963 
(s), 1714 (s), 1218 (m), 1110 (s), 1031 (w); Elemental analysis (CHN): C: 47.87%, H: 2.44%, N: 
4.20% (C26H16Mn2N2O12 requires C: 47.43%, H: 2.45%, N: 4.25%); UV-visible spectrum 
(CH2Cl2): λmax (nm)  = 404, 522, 622,  (404 nm) = (2.648 ± .010) × 104 dm3 mol-1 cm-1, 
 (522 nm) = (8.47 ± .06) × 103 dm3 mol-1 cm-1,  (622 nm) = (3.98 ± .03) × 103 dm3 mol-1 cm-1.  
Lab book reference: BJA-2-087 
 
Ethyl 4-[2-(4-methoxyphenyl)diazenyl]-benzoate (176)362 
 
To a round-bottomed flask with stirrer bar were added a solution of ethyl 4-aminobenzoate (1.0 
eq., 5.0 mmol, 825 mg) in CH2Cl2 (15 mL). Water (30 mL) was added, followed by oxone (2.0 eq., 
10.0 mmol, 3.08 g). The solution was stirred at room temperature for 3 hours, at which point thin 
layer chromatography showed consumption of ethyl 4-aminobenzoate. 
The product was extracted into CH2Cl2 (4 × 15 mL) and the combined organic layers were washed 
with 1 M HCl (2 × 15 mL), water (15 mL) and brine (15 mL). The extracts were then dried over 
anhydrous MgSO4 and filtered. The solvent was removed under reduced pressure to afford ethyl 
4-nitrosobenzoate, intermediate 175, in quantitative yield as a yellow solid. The product was 
immediately used in the synthesis of ethyl 4-[2-(4-methoxyphenyl)diazenyl]-benzoate without 
further purification. 
To a round-bottomed flask with stirrer bar were added ethyl 4-nitrosobenzoate (1.0 eq., 3.44 
mmol, 617 mg), p-anisidine (1.4 eq., 4.82 mmol, 594 mg) and acetic acid (14 mL). The reaction 
mixture was protected from light by aluminium foil and stirred at room temperature for 13 h.  
The reaction mixture was poured into water (40 mL) and the product extracted with EtOAc (4 × 
50 mL). The organic layers were combined and washed with water (100 mL), saturated aqueous 
sodium bicarbonate (3 × 100 mL) and brine (100 mL). After drying with anhydrous MgSO4 and 
filtration, the solvent was removed under reduced pressure. The crude product was purified using 
flash column chromatography on silica gel, starting with 1:1 v/v n-hexane/CH2Cl2 and moving to 
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CH2Cl2 to elute the product. Removal of the solvent gave the title compound as a bright orange 
powder (559 mg, 57% yield). 
 
MP: 102°C (lit.: 103-104°C)363; Rf = 0.15 (n-hexane/ CH2Cl2, 1:1, v/v); 1H NMR (400 MHz, 
CDCl3): δ (ppm) = 8.19-8.16 (m, 2H, Ar-H), 7.97-7.94 (m, 2H, Ar-H), 7.92-7.89 (m, 2H, Ar-H), 
7.05-7.01 (m, 2H, Ar-H), 4.41 (q, 7.0 Hz, 2H, CO2CH2CH3), 3.91 (s, 3H, OCH3), 1.43 (t, 7.0 Hz, 
3H, CO2CH2CH3); 13C NMR (101 MHz, CDCl3) δ (ppm) = 166.3 (Ar); 163.0 (CO2Et); 155.6, 
147.3, 131.9, 130.9, 125.5, 122.7, 114.6 (Ar);  61.5 (CO2CH2CH3); 56.0 (OCH3); 14.7 (CO2CH2-
CH3); HRMS (ESI+): m/z = 307.1047 [M-Na]+ (C16H16N2NaO3 requires 307.1059); IR (CH2Cl2, 
cm-1): 2841 (w), 1712 (s), 1603 (s), 1585 (m), 1502 (s), 1465 (m), 1407 (m), 1368 (m), 1140 (s), 
1109 (m), 1099 (m), 1030 (m), 1013 (m). 
Lab book reference: BJA-2-086, BJA-2-088 
 
Tetracarbonyl(ethyl 4-[2-(4-methoxyphenyl)diazenyl]-benzoate)manganese isomer 
mixture (177 ans 178) 
 
The two compounds were prepared as a mixture using general procedure 3 with [MeMn(CO)5] 
(1.0 eq., 0.50 mmol, 105 mg), ethyl 4-[2-(4-methoxyphenyl)diazenyl]-benzoate (1.0 eq., 0.50 
mmol, 142 mg) and toluene (5 mL). The reaction time was 3 hours. The two isomeric complexes 
could not be separated using silica gel chromatography and were characterised as a ~5:1 mixture 
of complex 177 to complex 178, which was a red solid (110 mg, 49 % yield). 







Tetracarbonyl 5-carboethoxy-2-([(4-methoxyphenyl)azo]phenyl κ,C1- κ,N) manganese (I)  
(177) 
 
Rf = 0.21 (n-hexane/CH2Cl2, 1:1, v/v); 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.72 (d, J = 1.5 
Hz, 1H, Ar-H), 8.31 (d, J = 8.0 Hz, 1H, Ar-H), 7.98 (dd, J = 8.0, 1.5 Hz, 1H, Ar-H), 7.66 (d, J = 
9.0 Hz, 2H, Ar-H), 7.01 (d, J = 9.0 Hz, 2H, Ar-H), 4.41 (q, 7.0 Hz, 2H, CO2CH2CH3)  3.91 (s, 
3H, OCH3), 1.43 (t, 7.0 Hz, 3H, CO2CH2CH3) 
 
Tetracarbonyl 5-methoxy-2-([(4-carboethoxyphenyl)azo]phenyl κ,C1- κ,N) manganese (I) 
(178) 
 
Rf = 0.21 (n-hexane/CH2Cl2, 1:1 v/v); 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.26 (d, J = 9.0 Hz, 
1H, Ar-H), 8.17 (d, J = 8.5 Hz, 2H, Ar-H), 7.62 (d, J = 2.5 Hz, 1H, Ar-H), 7.59 (d, J = 8.5 Hz, 
2H, Ar-H), 6.86 (dd, J = 9.0, 2.5 Hz, 2H, Ar-H), 4.42 (q, 7.0 Hz, 2H, CO2CH2CH3)  3.99 (s, 3H, 






In a round-bottomed flask, a solution of 2-(4'-hydroxybenzyl)pyridine (1.0 eq., 2.60 mmol, 483 
mg) in CH2Cl2 (30 mL) was cooled to 0°C in a water/ice bath and PBr3 (6 eq., 16 mmol, 1.5 mL) 
was added dropwise with stirring. The flask was covered in foil, allowed to warm to room 
temperature and left for 16 h. The reaction mixture was cooled back to 0°C and saturated sodium 
carbonate solution was added slowly to quench the reaction, ensuring that the temperature was 
kept below 5°C. When the solution reached pH 7, as checked by pH paper, the product was 
extracted with CH2Cl2 (3 × 50 mL), the organic layers dried with MgSO4 and filtered. The solvent 
was removed in vacuo to give the title compound as a white solid (559 mg, 87% yield). 
 
MP: 65 ᵒC (decomp., lit.: 45°C);364 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.70 (d, J = 5.0 Hz, 
1H, Ar-H), 7.98 (d, J = 7.5 Hz, 2H, Ar-H), 7.79-7.71 (m, 2H, Ar-H,), 7.50 (d, J = 8.0 Hz, 2H, 
Ar-H), 7.26-7.23 (m, 1H, Ar-H), 4.55 (s, 2H, CH2); 13C NMR (126 MHz, CDCl3) δ (ppm) = 156.8, 
149.9, 139.6, 138.6, 137.0, 129.6, 127.5, 122.5, 120.7 (Ar); 33.1 (CH2); HRMS (ESI+): m/z = 
248.0061 [M-H]+ (C12H11NBr requires 248.0075). 
Lab book reference: BJA-1-042 
 
Tetracarbonyl 2-(4-[bromomethyl]phenyl) κ,C2-pyridine- κ,N) manganese (I) (187) 
 
The reaction was performed using General Procedure 1 with BnMn(CO)5 (1.0 eq., 0.86 mmol, 
249 mg), 2-(4'-hydroxybenzyl)pyridine (1.0 eq., 0.86 mmol, 214 mg) and hexane (12 mL). 
Infrared spectroscopy showed that the reaction was complete after 24 h. The title compound was 
purified by flash column chromatography on silica gel, using petrol and then petrol/EtOAc 9:1 
v/v. The solvent was removed in vacuo to afford a yellow solid (318 mg, 89% yield). 
 
MP: 123°C (decomp.); 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.73 (d, 5.5 Hz, 1H, Ar-H), 7.95 
(d, 1.5 Hz, 1H, Ar-H), 7.87 (d, 8.0 Hz, 1H, Ar-H), 7.81 (apr. td, 7.5, 1.5 Hz, 1H, Ar-H), 7.75 (d, 
8.0 Hz, 1H, Ar-H), 7.23 (dd, 8.0, 2.0 Hz, 1H, Ar-H), 7.14 (ddd, 6.5, 5.5, 1.5 Hz, 1H, Ar-H), 4.56 
(s, 2H, CH2); 13C NMR (101 MHz, CDCl3) δ (ppm) = 220.0, 214.1, 213.8 (Mn-C≡O), 175.9, 
165.8, 154.0, 146.4, 141.7, 139.4, 138.1, 125.3, 124.2, 122.8, 119.6 (Ar), 34.2 (CH2); MS 
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(LIFDI+): m/z = 412.94 [M+] (C16H9NO4BrMn requires 412.9095); IR (CH2Cl2, cm-1): 2076 (s), 
1992 (vs), 1979 (vs), 1935 (vs), 1605 (m), 1583 (m), 1567 (m), 1477 (s), 1432 (w), 1272 (w); 
Elemental analysis (CHN): C: 46.49%, H: 2.22%, N: 3.31% (C16H9NO4BrMn requires C: 46.41%, 
H: 2.19%, N: 3.38%). 
Lab book reference: BJA-1-041 
 
Tetracarbonyl 2-(4'-[azidomethyl]phenyl) κ,C2-pyridine- κ,N) manganese (I) (188) 
 
To a solution of tetracarbonyl 2-(4'-bromobenzyl) κ,C2-pyridine- κ,N) manganese(I) (1.0 eq., 0.2 
mmol, 82.8 mg), in a mixture of water (0.2 mL) and acetone (0.9 mL) in a round-bottomed flask 
covered in aluminium foil was added sodium azide (1.7 eq., 0.34 mmol, 22 mg) in a single portion. 
The reaction mixture was stirred at room temperature for 24 h. The reaction was quenched by 
adding water (15 mL) and the product was extracted into EtOAc (3 × 10 mL). The combined 
organic layers were dried with MgSO4, filtered and the solvent removed in vacuo to afford the 
title compound as a yellow solid (71 mg, 94% yield). 
MP: 97°C (decomp.); 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.73 (d, J = 5.5 Hz, 1H, Ar-H), 
7.91-7.87 (m, 2H, Ar-H), 7.84-7.77 (m, 2H, Ar-H), 7.16-7.12 (m, 2H, Ar-H), 4.41 (s, 2H, CH2); 
13C NMR (126 MHz, CDCl3) δ (ppm) = 220.0, 214.1, 213.8, (Mn-C≡O) 176.0, 165.9, 154.0, 
146.2, 141.2, 138.0, 137.0, 124.2, 124.1, 122.7, 119.5, (Ar) 55.1 (CH2); MS (LIFDI+): m/z = 
375.98 [M+] (C16H9N4O4Mn requires 376.0004); IR (CH2Cl2, cm-1): 2100 (s), 2076 (s), 1991 (vs), 
1978 (vs), 1934 (vs), 1606 (m), 1586 (m), 1565 (m), 1479 (s), 1432 (w); Elemental analysis 
(CHN): C: 51.19%, H: 2.51%, N: 14.61% (C16H9N4O4Mn requires C: 51.08%, H: 2.41%, N: 
14.89%). 





manganese (I) (189) 
 
To a solution of tetracarbonyl 2-(4'-[azidomethyl]phenyl) κ,C2-pyridine- κ,N) manganese (I) (1.0 
eq., 0.129 mmol, 48.6 mg), phenylacetylene (1.1 eq., 0.137 mmol, 15 μL), and CuI (20 mol%, 
0.027 mmol, 5.2 mg) in dry DMF (400 μL) was added N,N-diisopropylamine (1.0 eq., 0.129 
mmol, 18 μL) dropwise. The reaction mixture was stirred under Ar in the dark at RT for 13 h, 
when the reaction was judged to be complete by TLC. The reaction mixture was diluted with 
CH2Cl2 (2 mL) and sat. aq. NH4Cl (5 mL). The product was extracted with CH2Cl2 (5 × 5 mL) 
and the organic layers were dried over MgSO4, filtered and the solvent removed under reduced 
pressure. The product was purified by flash column chromatography on silica gel using 
petrol/EtOAc (7:3 v/v) and the solvent was removed to afford the title compound as a cream-
coloured solid, 52.5 mg (80% yield).  
 
M.P.: 162°C (decomp.); Rf = 0.20 (petrol/EtOAc 7:3 v/v); 1H NMR (500 MHz, CDCl3): δ (ppm) 
= 8.74 (d, J = 5.5 Hz, 1H, Ar-H), 7.87 (d, J = 8.0 Hz, 1H, Ar-H), 7.84-7.80 (m, 3H, Ar-H), 7.77 
(s, 1H, trizaole), 7.74 (d, J = 8.0 Hz, 1H, Ar-H), 7.40 (t, J = 7.5 Hz, 2H, Ar-H), 7.31 (t, J = 7.5 
Hz, 2H, Ar-H), ), 7.16 (ddd, J = 7.0, 5.5, 1.5 Hz, 1H, Ar-H), 7.02 (dd, J = 8.0, 1.5 Hz, 1H, Ar-H), 5.63 
(s, 2H, CH2); 
13C NMR (126 MHz, CDCl3) δ (ppm) = 220.2, 214.2, 213.8 (Mn-C≡O); 176.9, 165.9, 
154.3, 148.5, 146.9, 141.1, 138.4, 136.5, 131.0, 129.1, 128.4, 126.1, 124.7, 124.0, 123.2, 120.0, 
119.9 (Ar); 54.8 (CH2); HRMS (ESI+): m/z = 479.0552 [M-H]+ (C24H16N4O4Mn requires 
479.0552); IR (CH2Cl2, cm-1): 2077 (s), 1992 (vs), 1979 (vs), 1936 (vs), 1606 (m), 1586 (m), 1568 
(w), 1477 (s), 1470 (m), 1075 (w), 1046 (w) 




7-(Diethylamino)coumarin (192)334  
 
4-Diethylaminosalicylaldehyde (1.0 eq., 1.93 g, 10 mmol), diethylmalonate (2.0 eq., 3.2 g, 20 
mmol) and piperidine (1 mL) were combined in absolute ethanol (30 mL) and stirred for 6 h under 
reflux conditions. Ethanol was evaporated under reduced pressure, then concentrated HCl (20 
mL) and glacial acetic acid (20 mL) were added and the reaction mixture refluxed for another 6 
h. The solution was cooled to room temperature and poured into ice water (100 mL). NaOH 
solution (40%) was added dropwise to adjust pH of the solution to 5.0, and a pale precipitate 
formed immediately. After stirring for 30 min, the mixture was filtered, washed with water and 
dried under vacuum to afford the product as a brown solid (1.94 g, 89% yield). 
M.P.: 84-86°C (lit.: 87-89°C)365; 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.53 (d, J = 9.5 Hz, 1H, 
Ar-H), 7.24 (d, J = 9.0 Hz, 1H, Ar-H), 6.56 (dd, J = 9.0, 2.5 Hz, 1H, Ar-H), 6.49 (d, J = 2.5 Hz 
1H, Ar-H), 6.03 (d, J = 9.5 Hz 1H, Ar-H), 4.41 (s, 2H, CH2), 3.41 (q, J = 7.0 Hz, 4H, NCH2), 
1.21 (t, J = 7.0 Hz, 6H, CH3); 13C NMR (101 MHz, CDCl3) δ (ppm) = 162.7; 157.1, 151.0, 144.1, 
129.1, 109.5, 109.0, 108.6, 97.9 (Ar); 45.13 (CH2), 12.77 (CH3); HRMS (ESI+): m/z = 218.1180 
[M-H]+ (C13H16NO2 requires 218.1181); IR (CH2Cl2, cm-1): 2979 (m), 1722 (s), 1711 (m), 1617 
(s), 1605 (s), 1521 (m), 1417 (w), 1358 (w), 1197 (w), 1166 (w), 1130 (w). 







Br2 (360 μL, 7.0 mmol) was added dropwise to a solution of 7- diethylaminocoumarin (1.52 g, 
7.0 mmol) in acetic acid (40 mL), and the mixture was stirred at RT for 2 h. The resulting yellow 
solid was filtered, washed with acetic acid and dried under vacuum. The product was purified by 
silica gel flash column chromatography beginning with CH2Cl2/petrol (1:1 v/v) and moving to 
CH2Cl2 to elute the product, a yellow solid (1.5 g, 72% yield).  
 
Rf: 0.42 (CH2Cl2);  1H NMR (400 MHz, CDCl3): δ (ppm) = 7.88 (s, 1H, Ar-H), 7.20 (d, J = 9.0 
Hz, 1H, Ar-H), 6.57 (dd, J = 9.0, 2.5 Hz, 1H, Ar-H), 6.48 (d, J = 2.5 Hz 1H, Ar-H), 3.41 (q, J = 
7.0 Hz, 4H, NCH2), 1.21 (t, J = 7.0 Hz, 6H, CH3); 13C NMR (101 MHz, CDCl3) δ (ppm) = 158.7, 
156.3, 151.2, 145.1, 128.5, 109.5, 109.3, 103.0, 97.4 (Ar); 45.2 (CH2CH3); 12.8 (CH2CH3); ; 
HRMS (ESI+): m/z = 296.0270 [M-H]+ (C13H15NO2Br requires 296.0286); IR (CH2Cl2, cm-1): 
2982 (m), 2931 (w), 2902 (w), 2874 (m), 1727 (s), 1995 (w), 1619 (s), 1600 (m), 1520 (m), 1412 
(w), 1360 (w), 1245 (m), 1189 (w), 1131 (m) 




To a solution of 3-bromo-7-(diethylamino)coumarin (1.0 eq., 3.0 mmol, 888 mg) in anhydrous 
DMF (30 mL) was added [PdCl2(PPh3)4] (5 mol%, 0.15 mmol, 105 mg), CuI (5 mol%, 0.15 mmol, 
28.4 mg), triethylamine (2.0 eq., 5.9 mmol, 825 mmol), and trimethylsilylacetylene (3.0 eq., 9.0 
mmol 1.25 mL). The reaction mixture was stirred at 60°C for 7 h under N2. When the solution 
cooled to RT, it was diluted with water (30 mL) and extracted with CH2Cl2 (3 × 30 mL). The 
organic layers were combined, dried over MgSO4, and the solvent was removed under reduced 
pressure. The crude product was purified by silica gel flash column chromatography using 
petrol/EtOAc (4:1 v/v)   to afford the title compound as a yellow solid, 697 mg (74% yield).  
 
Rf = 0.42 (CH2Cl2); 1H NMR (400 MHz, CDCl3): δ (ppm) = 7.75 (s, 1H, Ar-H), 7.21 (d, J = 9.0 
Hz, 1H, Ar-H), 6.56 (dd, J = 9.0, 2.5 Hz, 1H, Ar-H), 6.47 (d, J = 2.5 Hz 1H, Ar-H), 3.41 (q, J = 
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7.0 Hz, 4H, NCH2), 1.21 (t, J = 7.0 Hz, 6H, CH3), 0.25 (s, 9H, SiMe3); HRMS (ESI+): m/z = 
314.1563 [M-H]+ (C18H24NO2Si requires 314.1576).  




A 1.0 M solution of TBAF in tetrahydrofuran (1.5 eq., 2.8 mmol, 2.8 mL), was added to a solution 
of TMS-alkyne (1.0 eq., 1.9 mmol, 593 mg) in tetrahydrofuran and MeOH (final ratio 4:1 v/v). 
The solution was stirred at 30°C for 6 h, at which point the solvent was removed in vacuo. The 
product was isolated by silica gel flash chromatography using petrol/EtOAc (7:3 v/v) to afford the 
title compound as a yellow solid (201 mg, 44% yield). 
 
Rf = 0.28 (petrol/EtOAc 7:3 v/v);  1H NMR (400 MHz, CDCl3): δ (ppm) = 7.78 (s, 1H, Ar-H), 
7.23 (d, J = 9.0 Hz, 1H, Ar-H), 6.58 (dd, J = 9.0, 2.5 Hz, 1H, Ar-H), 6.47 (d, J = 2.5 Hz 1H, 
Ar-H), 3.41 (q, J = 7.0 Hz, 4H, NCH2), 3.26 (s, 1H, C≡C-H), 1.21 (t, J = 7.0 Hz, 6H, CH3); 13C 
NMR (101 MHz, CDCl3) δ (ppm) = 161.3, 156.6, 151.5, 147.1, 129.2, 109.4, 108.1, 103.4, 97.4 
(Ar); 81.3, 78.7 (C≡C); 45.13 (CH2), 12.77 (CH3); HRMS (ESI+): m/z = 242.1170 [M-H]+ 
(C15H16NO2 requires 242.1181); IR (CH2Cl2, cm-1): 3301 (m), 2972 (m), 2108 (w), 1722 (m), 1623 
(s), 1591 (s), 1524 (m), 1412 (w) 1354 (w), 1192 (w), 1137 (m). 





yl)methyl]phenyl)-κ,C2-pyridine-κ,N) manganese (I) (197) 
 
A round-bottomed flask containing 2-(4'-azidomethyl-phenyl)pyridine (1.0 eq., 0.357 mmol, 75.0 
mg) was placed under an argon atmosphere and dissolved in dry tetrahydrofuran (3.5 mL). The 
solution was added to a round-bottomed flask under argon with stirrer bar containing 3-ethynyl-
7-(diethylamino)coumarin (1.0 eq., 0.357 mmol, 86.1 mg) and CuI (0.2 eq., 0.073 mmol, 14.0 
mg). DIPA (1.0 eq., 0.357 mmol, 50 μL) was added dropwise. The reaction mixture was stirred 
at room temperature for 6 hours whereupon the reaction was adjudged to be complete by TLC. A 
colour change of the reaction mixture from yellow to orange was observed over this period. 
The reaction mixture was quenched with CH2Cl2 (20 mL) and saturated aqueous NH4Cl (40 mL) 
was added. The product was extracted into CH2Cl2 (3 × 20 mL) dried over MgSO4, filtered and 
the solvent removed on the rotary evaporator. The product was isolated by silica gel flash 
chromatography using EtOAc to afford the title compound as a yellow solid (124 mg, 77% yield). 
 
MP: 162°C (decomp.); Rf: 0.05 (petrol/EtOAc 7:3 v/v); 1H NMR (500 MHz, CDCl3): δ (ppm) = 
8.73 (d, J = 5.5 Hz, 1H, Ar-H), 8.63 (s, 1H, Ar-H), 7.94 (d, J = 1.5 Hz, 1H, Ar-H), 7.86 (d, J = 
8.0 Hz, 1H, Ar-H), 7.81 (apr. td, J = 7.5, 1.5 Hz, 1H, Ar-H), 7.73 (d, J = 8.0 Hz, 1H, Ar-H), 7.40 
(d, J = 9.0 Hz, 1H, Ar-H), 7.14 (ddd, J = 6.5, 5.5, 1.5 Hz, 1H, Ar-H), 7.01 (dd, J = 8.0, 2.0 Hz, 
1H, Ar-H), 6.63 (dd, J = 9.0, 2.5 Hz, 1H, Ar-H), 6.52 (d, J = 2.5 Hz, 1H, Ar-H), 5.62 (s, 1H, Ar-
CH2), 3.43 (q, J = 7.0 Hz, 4H, N-CH2-CH3), 1.22 (t, J = 7.0 Hz, 6H, CH3); 13C NMR (126 MHz, 
CDCl3) δ (ppm) = 220.1, 214.2, 213.7 (Mn-C≡O); 176.7, 165.9, 161.0, 156.3, 154.2, 151.0, 146.8, 
142.5, 141.0, 138.6, 138.3, 136.5, 129.8, 124.6, 123.9, 123.1, 123.0, 119.8, 111.3, 109.6, 109.0, 
97.4 (Ar); 54.7 (benzylic CH2); 45.2 (NCH2CH3); 12.8 (CH3); HRMS (ESI+): m/z = 618.1168 
[M-H]+ (C31H25N5O6Mn requires 618.1185); IR (CH2Cl2, cm-1): 2983 (w), 2079 (s), 1992 (vs), 
1980 (vs), 1932 (vs), 1712 (s), 1607 (vs), 1508 (m), 1475 (w), 1415 (w), 1361 (w), 1245 (m), 
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1189 (w), 1134 (m); Elemental analysis (CHN): C: 60.37%, H: 4.07%, N: 11.06% 
(C31H24N5O6Mn requires C: 60.30%, H: 3.92%, N: 11.34%); UV-visible spectrum (CH2Cl2): λmax 
(nm)  = 264, 408,  (264 nm) = (4.13 ± 0.09) × 104 dm3 mol-1 cm-1,  (408 nm) = 
(3.65 ± 0.04) × 104 dm3 mol-1 cm-1. 




To a solution of 2-(4'-bromomethyl-phenyl)pyridine (1.0 eq., 0.81 mmol, 170 mg), in a mixture 
of water (0.6 mL) and acetone (2.4 mL) in a round-bottomed flask covered in aluminium foil was 
added sodium azide (1.3 eq., 1.0 mmol, 66.2 mg) in a single portion. The reaction mixture was 
stirred at room temperature for 16 h. The reaction was quenched by adding water (20 mL) and the 
product was extracted into EtOAc (3 × 20 mL). The combined organic layers were dried with 
MgSO4, filtered and the solvent removed in vacuo to afford the title compound as a yellow oil 
(102 mg, 70% yield).  
 
Rf = 0.18 (petrol/EtOAc 1:1 v/v); 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.70 (d, J = 4.5 Hz, 1H, 
Ar-H), 8.02 (d, J = 8.5 Hz, 2H, Ar-H), 7.80-7.72 (m, 2H, Ar-H), 7.44 (d, 8.5 Hz, 2H, Ar-H), 7.27-
7.23 (m, 1H, Ar-H), 4.41 (s, 2H, CH2); 13C NMR (101 MHz, CDCl3) δ (ppm) = 157.1, 150.1, 
139.8, 137.2, 136.4, 128.9, 127.7, 122.7, 120.9 (Ar); 54.8 (CH2); HRMS (ESI+): m/z = 211.0984 
[M-H]+ (C12H11N4 requires 211.0984). 







A round-bottomed flask containing 2-(4'-azidomethyl-phenyl)pyridine (1.0 eq., 0.357 mmol, 75.0 
mg) was placed under an argon atmosphere and dissolved in dry tetrahydrofuran (3.5 mL). The 
solution was added to a round-bottomed flask under argon with stirrer bar containing 3-ethynyl-
7-(diethylamino)coumarin (1.0 eq., 0.357 mmol, 86.1 mg) and CuI (0.2 eq., 0.073 mmol, 14.0 
mg). DIPA (1.0 eq., 0.357 mmol, 50 μL) was added dropwise. The reaction mixture was stirred 
at room temperature for 6 hours whereupon the reaction was adjudged to be complete by TLC. A 
colour change of the reaction mixture from yellow to orange was observed over this period. 
The reaction mixture was quenched with CH2Cl2 (20 mL) and saturated aqueous NH4Cl (40 mL) 
was added. The product was extracted into CH2Cl2 (3 × 20 mL) dried over MgSO4, filtered and 
the solvent removed on the rotary evaporator. The product was isolated by silica gel flash 
chromatography using EtOAc to afford the title compound as a yellow solid (124 mg, 77% yield). 
 
M.P.: 196-201°C; Rf = 0.18 (petrol/EtOAc 1:1 v/v); 1H NMR (400 MHz, CD2Cl2) δ (ppm) = 8.63 
(apr. dt, J = 5.0, 1.5 Hz, 1H, Ar-H), 8.55 (s, 1H, Ar-H), 8.23 (s, 1H, Ar-H), 8.01 (dt, J = 8.5, 2.0 
Hz, 2H, Ar-H), 7.76-7.70 (m, 2H, Ar-H), 7.42-7.37 (m, 3H, Ar-H), 7.24-7.19 (m, 1H), 6.63 (dd, 
J = 9.0, 2.5 Hz, 1H, Ar-H), 6.49 (d, J = 2.5 Hz, 1H, Ar-H), 5.59 (s, 2H, CH79r), 3.40 (q, J = 7.0 Hz, 
4H, NCH2), 1.18 (t, J = 7.0 Hz, 6H, CH3); 13C NMR (126 MHz, CDCl3) δ (ppm) = 161.0, 156.9, 
156.3, 151.1, 150.1, 142.7, 140.1, 138.7, 137.2, 135.7, 129.8, 128.8, 127.9, 122.9, 122.7, 120.9, 
111.1, 109.6, 109.0, 97.4 (Ar); 54.2 (benzylic CH2); 45.2 (CH2CH3); 12.8 (CH2CH3); HRMS 
(ESI+): m/z = 452.2095 [M-H]+ (C27H26N5O2 requires 452.2087); IR (CH2Cl2, cm-1): 3008 (w), 
2979 (m), 1715 (vs), 1607 (s), 1507 (w), 1471 (w), 1414 (w), 1355 (w), 1189 (w), 1134 (w). 




Appendix 1: Published Paper 
This Appendix contains the paper published with the contribution of the author in connection with 
the work described in this Thesis: 
B. J. Aucott, J. S. Ward, S. G. Andrew, J. Milani, A. C. Whitwood, J. M. Lynam, A. Parkin and 
































Appendix 2: X-Ray Diffraction Data 
Compound 132 
 
Figure 147: An X-ray crystal structure of compound 132 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å):  C(1)-Mn(1) 
= 2.056(5), C(12)-Mn(1) = 1.836(6), C(13)-Mn(1) = 1.805(6), C(14)-Mn(1) = 1.853(5), C(15)-Mn(1) = 
1.867(5), N(1)-Mn(1) = 2.059(4). Selected bond angles (ᵒ):  C(1)-Mn(1)-N(1) = 80.04(18), C(12)-Mn(1)-
C(1) = 174.9(2), C(14)-Mn(1)-(C15) = 168.8(2), C(13)-Mn(1)-N(1) = 172.65(19), C(13)- Mn(1)-C(12) = 






Table 24: Crystal data and structure refinement for compound 132.  
Identification code  ijsf1519  
Empirical formula  C29H21FeMnN4O5  
Formula weight  616.29  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  23.7914(8)  
b/Å  10.0173(3)  
c/Å  10.9284(3)  
α/°  90.00  
β/°  91.969(3)  
γ/°  90.00  
Volume/Å3  2602.98(14)  
Z  4  
ρcalcg/cm3  1.573  
μ/mm-1  1.091  
F(000)  1256.0  
Crystal size/mm3  0.216 × 0.1439 × 0.0548  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  3.42 to 51.82  
Index ranges  -28 ≤ h ≤ 26, -6 ≤ k ≤ 12, -12 ≤ l ≤ 13  
Reflections collected  9705  
Independent reflections  4891 [Rint = 0.0344, Rsigma = 0.0554]  
Data/restraints/parameters  4891/0/361  
Goodness-of-fit on F2  1.068  
Final R indexes [I>=2σ (I)]  R1 = 0.0592, wR2 = 0.1345  
Final R indexes [all data]  R1 = 0.0907, wR2 = 0.1516  
Largest diff. peak/hole / e Å-3  0.62/-0.50  
 







Figure 148: An X-ray crystal structure of compound 133 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): C(11)-
Mn(1) = 2.0538(13), C(22)-Mn(1) = 1.8622(15), C(23)-Mn(1) = 1.8344(14), C(24)-Mn(1) = 1.8048(14), 
C(25)-Mn(1) = 1.8541(15) , N(1)-Mn(1) = 2.0694(12) Selected bond angles (ᵒ): C(11)-Mn(1)-N(1) = 
79.83(5), C(24)-Mn(1)-N(1) = 172.14(5), C(23)-Mn(1)-C(11) = 176.65(6), C(25)-Mn(1)-C(22) = 
167.63(6), C(23)-Mn(1)-N(1) = 97.07(6), C(24)-Mn(1)-C(23) = 90.79(6). Selected torsion angles (ᵒ): 





Table 25: Crystal data and structure refinement for compound 133. 
Identification code  jml1523  
Empirical formula  C25H16FeMnNO4  
Formula weight  505.18  
Temperature/K  111(1)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å : 7.18991(17)  
b/Å  20.2412(6)  
c/Å  14.1249(3)  
α/°  90.00  
β/°  93.049(2)  
γ/°  90.00  
Volume/Å3  2052.71(9)  
Z  4  
ρcalcg/cm3  1.635  
μ/mm-1  1.356  
F(000)  1024.0  
Crystal size/mm3  0.229 × 0.1218 × 0.088  
Radiation  MoKα (λ = 0.71070)  
2Θ range for data collection/°  6.7 to 64.1  
Index ranges  -10 ≤ h ≤ 10, -29 ≤ k ≤ 30, -20 ≤ l ≤ 20  
Reflections collected  25249  
Independent reflections  6625 [Rint = 0.0334, Rsigma = 0.0291]  
Data/restraints/parameters  6625/0/289  
Goodness-of-fit on F2  1.063  
Final R indexes [I>=2σ (I)]  R1 = 0.0287, wR2 = 0.0660  
Final R indexes [all data]  R1 = 0.0353, wR2 = 0.0694  
Largest diff. peak/hole / e Å-3  0.44/-0.47  
 









Figure 149: X-ray crystal structure of protonated ligand 148 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): C(9)-C(12) 
= 1.485(5), C(5)-C(6) = 1.472(5), C(16)-N(1) = 1.366(5), C(7)-C(8) = 1.383(5), C(3)-C(4) = 1.421(5), 
C(1)-Fe(1) = 2.037(4) Selected bond angles (ᵒ): C(6)-C(5)-C(1) = 124.0(3), N(1)-C(12)-C(9) = 116.8(3) 




Table 26: Crystal data and structure refinement for compound 148. 
Identification code  ijsf1601_twin1_hklf4  
Empirical formula  C21H17FeN  
Formula weight  339.21  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  16.0034(9)  
b/Å  9.3009(4)  
c/Å  10.3112(5)  
α/°  90  
β/°  98.974(5)  
γ/°  90  
Volume/Å3  1516.00(13)  
Z  4  
ρcalcg/cm3  1.486  
μ/mm-1  7.935  
F(000)  704.0  
Crystal size/mm3  0.164 × 0.118 × 0.031  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  11.038 to 143.156  
Index ranges  -19 ≤ h ≤ 19, -11 ≤ k ≤ 11, -12 ≤ l ≤ 8  
Reflections collected  4139  
Independent reflections  4139 [Rint = ?, Rsigma = 0.0315]  
Data/restraints/parameters  4139/0/209  
Goodness-of-fit on F2  1.044  
Final R indexes [I>=2σ (I)]  R1 = 0.0460, wR2 = 0.1174  
Final R indexes [all data]  R1 = 0.0560, wR2 = 0.1231  







Figure 150: An X-ray crystal structure of compound 170 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): N(1)-N(2) 
= 1.278(2), C(9)-Mn(1) = 2.0346(19), C(15)-Mn(1) = 1.869(2), C(16)-Mn(1) = 1.815(2), C(17)-Mn(1) = 
1.858(2), C(18)-Mn(1) = 1.846(2), N(1)-Mn(1) = 2.0505(16)  Selected bond angles (ᵒ): C(9)-Mn(1)-N(1) 
= 77.92(7), C(16)-Mn(1)-N(1) = 168.53(8), C(18)-Mn(1)-C(9) = 176.45(8), C(17)-Mn(1)-C(15) = 





Table 27: Crystal data and structure refinement for compound 170. 
Identification code  ijsf1616  
Empirical formula  C18H13MnN2O6  
Formula weight  408.24  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  10.1379(2)  
b/Å  13.6627(2)  
c/Å  13.2843(2)  
α/°  90  
β/°  106.937(2)  
γ/°  90  
Volume/Å3  1760.21(5)  
Z  4  
ρcalcg/cm3  1.541  
μ/mm-1  6.453  
F(000)  832.0  
Crystal size/mm3  0.389 × 0.281 × 0.156  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  9.504 to 134.156  
Index ranges  -8 ≤ h ≤ 12, -16 ≤ k ≤ 16, -15 ≤ l ≤ 15  
Reflections collected  6206  
Independent reflections  3146 [Rint = 0.0281, Rsigma = 0.0363]  
Data/restraints/parameters  3146/0/246  
Goodness-of-fit on F2  1.048  
Final R indexes [I>=2σ (I)]  R1 = 0.0326, wR2 = 0.0844  
Final R indexes [all data]  R1 = 0.0352, wR2 = 0.0874  
Largest diff. peak/hole / e Å-3  0.27/-0.36  
 
Data collected and structure solved by Rachel R. Parker.  
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Compound 173  
 
Figure 151: An X-ray crystal structure of compound 173 with hydrogen atoms omitted for clarity. 
Atoms are displayed as thermal ellipsoids at 50% probability. Selected bond lengths (Å): N(1)-N(2) 
= 1.299(3), C(1)-Mn(1) = 2.018(2), C(10)-Mn(1) = 1.877(3), C(11)-Mn(1) = 1.861(3), C(12)-Mn(1) = 
1.801(3), C(13)-Mn(1) = 1.849(3), N(1)-Mn(1) = 2.083 (2) Selected bond angles (ᵒ): C(1)-Mn(1)-N(1) = 
77.74(9), C(12)-Mn(1)-N(1) = 167.63(10), C(13)-Mn(1)-C(1) = 177.44(11), C(10)-Mn(1)-C(11) = 




Table 28: Crystal data and structure refinement for compound 173. 
Identification code  ijsf1615  
Empirical formula  C26H16Mn2N2O12  
Formula weight  658.29  
Temperature/K  110.05(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  9.9783(5)  
b/Å  11.3469(6)  
c/Å  12.2798(4)  
α/°  78.620(4)  
β/°  84.152(4)  
γ/°  89.076(4)  
Volume/Å3  1355.92(11)  
Z  2  
ρcalcg/cm3  1.612  
μ/mm-1  8.193  
F(000)  664.0  
Crystal size/mm3  0.151 × 0.117 × 0.082  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  7.38 to 134.16  
Index ranges  -11 ≤ h ≤ 11, -13 ≤ k ≤ 13, -14 ≤ l ≤ 9  
Reflections collected  8747  
Independent reflections  4834 [Rint = 0.0341, Rsigma = 0.0476]  
Data/restraints/parameters  4834/0/381  
Goodness-of-fit on F2  1.046  
Final R indexes [I>=2σ (I)]  R1 = 0.0368, wR2 = 0.0921  
Final R indexes [all data]  R1 = 0.0431, wR2 = 0.0978  
Largest diff. peak/hole / e Å-3  0.57/-0.41  
 





Figure 152: An X-ray crystal structure of compound 188 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.054(3), C(13)-Mn(1) = 1.841(3), C(14)-Mn(1) = 1.796(3), C(15)-Mn(1) = 1.857(3), C(16)-
Mn(1) = 1.842(3), N(1)-Mn(1) = 2.073(2). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 79.53(11), 
C(16)-Mn(1)-C(11) = 172.33(12), C(13)-Mn(1)-(C15) = 166.55(12), C(14)-Mn(1)-N(1) = 172.93(12), 




Table 29: Crystal data and structure refinement for compound 188. 
Identification code  ijsf1613  
Empirical formula  C16H9MnN4O4  
Formula weight  376.21  
Temperature/K  110.05(10)  
Crystal system  orthorhombic  
Space group  P212121  
a/Å  8.87104(16)  
b/Å  10.98540(18)  
c/Å  15.5918(3)  
α/°  90  
β/°  90  
γ/°  90  
Volume/Å3  1519.45(5)  
Z  4  
ρcalcg/cm3  1.645  
μ/mm-1  7.359  
F(000)  760.0  
Crystal size/mm3  0.352 × 0.233 × 0.209  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  9.85 to 134.13  
Index ranges  -7 ≤ h ≤ 10, -13 ≤ k ≤ 9, -14 ≤ l ≤ 18  
Reflections collected  3399  
Independent reflections  2261 [Rint = 0.0176, Rsigma = 0.0290]  
Data/restraints/parameters  2261/0/226  
Goodness-of-fit on F2  1.101  
Final R indexes [I>=2σ (I)]  R1 = 0.0264, wR2 = 0.0671  
Final R indexes [all data]  R1 = 0.0271, wR2 = 0.0676  
Largest diff. peak/hole / e Å-3  0.34/-0.42  
Flack parameter -0.010(5) 
 






Figure 153: An X-ray crystal structure of compound 189 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.0574(14), C(21)-Mn(1) = 1.8595(14), C(22)-Mn(1) = 1.8025(15), C(23)-Mn(1) = 1.8303(15), 
C(24)-Mn(1) = 1.8476(14), N(1)-Mn(1) = 2.0661(11). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 
79.64(5), C(23)-Mn(1)-C(11) = 173.00(6), C(24)-Mn(1)-(C21) = 168.48(6), C(22)-Mn(1)-N(1) = 




Table 30: Crystal data and structure refinement for compound 189.  
Identification code  ijsf1603  
Empirical formula  C24H15MnN4O4  
Formula weight  478.34  
Temperature/K  110.05(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  22.2501(4)  
b/Å  10.85157(17)  
c/Å  8.51201(14)  
α/°  90  
β/°  92.1533(15)  
γ/°  90  
Volume/Å3  2053.76(6)  
Z  4  
ρcalcg/cm3  1.547  
μ/mm-1  0.684  
F(000)  976.0  
Crystal size/mm3  0.266 × 0.168 × 0.054  
Radiation  MoKα (λ = 0.71073)  
2Θ range for data collection/°  7.012 to 64.41  
Index ranges  
-31 ≤ h ≤ 33, -16 ≤ k ≤ 15, -12 ≤ l ≤ 
12  
Reflections collected  25949  
Independent reflections  6729 [Rint = 0.0306, Rsigma = 0.0293]  
Data/restraints/parameters  6729/0/298  
Goodness-of-fit on F2  1.075  
Final R indexes [I>=2σ (I)]  R1 = 0.0360, wR2 = 0.0843  
Final R indexes [all data]  R1 = 0.0459, wR2 = 0.0898  
Largest diff. peak/hole / e Å-3  0.42/-0.39  
 






Figure 154: An X-ray crystal structure of compound 197 with hydrogen atoms omitted for clarity.  
Atoms are displayed as thermal ellipsoids at 50 % probability. Selected bond lengths (Å):  C(11)-
Mn(1) = 2.048(2), C(28)-Mn(1) = 1.853(3), C(29)-Mn(1) = 1.864(3), C(30)-Mn(1) = 1.8310(3), C(31)-
Mn(1) = 1.8451(3), N(1)-Mn(1) = 2.065(2). Selected bond angles (ᵒ):  C(11)-Mn(1)-N(1) = 79.45(9), 
C(31)-Mn(1)-C(11) = 174.82(10), C(28)-Mn(1)-(C29) = 168.69(12), C(30)-Mn(1)-N(1) = 171.61(10), 




Table 31: Crystal data and structure refinement for compound 197. 
Identification code  ijsf1617  
Empirical formula  C31H24MnN5O6  
Formula weight  617.49  
Temperature/K  110.05(10)  
Crystal system  triclinic  
Space group  P-1  
a/Å  8.6041(5)  
b/Å  10.1823(3)  
c/Å  15.9801(8)  
α/°  85.026(3)  
β/°  80.913(4)  
γ/°  87.771(4)  
Volume/Å3  1376.78(11)  
Z  2  
ρcalcg/cm3  1.490  
μ/mm-1  4.371  
F(000)  636.0  
Crystal size/mm3  0.198 × 0.128 × 0.096  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  8.72 to 134.154  
Index ranges  -10 ≤ h ≤ 10, -12 ≤ k ≤ 6, -19 ≤ l ≤ 19  
Reflections collected  8858  
Independent reflections  4912 [Rint = 0.0332, Rsigma = 0.0468]  
Data/restraints/parameters  4912/0/390  
Goodness-of-fit on F2  1.071  
Final R indexes [I>=2σ (I)]  R1 = 0.0432, wR2 = 0.1180  
Final R indexes [all data]  R1 = 0.0472, wR2 = 0.1222  
Largest diff. peak/hole / e Å-3  0.30/-0.44  
 









Appendix 3: UV-Visible Spectroscopic Data 























































Figure 155 Left: Spectra of 132 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
132 in CH2Cl2 at 270 nm. The dashed line is a linear fit giving  (270 nm) = (2.84 ± 0.5) × 104 dm3 mol-
1 cm-1. 
























































Figure 156 Left: Spectra of 133 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
133 in CH2Cl2 at 460 nm. The dashed line is a linear fit giving  (460 nm) = 
(2.04 ± 0.05) × 103 dm3 mol-1 cm-1. 

















































Figure 157 Left: Beer-Lambert plot for 133 in CH2Cl2 at 378 nm. The dashed line is a linear fit giving 
 (378 nm) = (8.00 ± .06) × 103 dm3 mol-1 cm-1. Right: Beer-Lambert plot for 133 in CH2Cl2 at 314 nm. 
The dashed line is a linear fit giving  (314 nm) = (2.29 ± .02) × 104 dm3 mol-1 cm-1. 

















































Figure 158 Left: Spectra of 134 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot 
for134 in CH2Cl2 at 486 nm. The dashed line is a linear fit giving  (486 nm) = 
(1.23 ± 0.05) × 103 dm3 mol-1 cm-1. 




























Figure 159: Beer-Lambert plot for 134 in CH2Cl2 at 292 nm. The dashed line is a linear fit giving 
 (292 nm) = (1.827 ± .013) × 104 dm3 mol-1 cm-1. 






















































Figure 160 Left: Spectra of 169 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
169 in CH2Cl2 at 330 nm. The dashed line is a linear fit giving  (330 nm) = 
(3.49 ± 0.04) × 104 dm3 mol-1 cm-1. 















































Concentration (M)  
Figure 161 Left: Spectra of 170 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
170 in CH2Cl2 at 456 nm. The dashed line is a linear fit giving  (456 nm) = (5.84 ± .05) × 103 dm3 mol-
1 cm-1. 




















Concentration (M)  
Figure 162: Beer-Lambert plot for 170 in CH2Cl2 at 378 nm. The dashed line is a linear fit giving 
 (378 nm) = (2.166 ± .008) × 104 dm3 mol-1 cm-1. 
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Concentration (M)  
Figure 163 Left: Spectra of 171 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
171 in CH2Cl2 at 578 nm. The dashed line is a linear fit giving  (578 nm) = 
(1.254 ± 0.005) × 104 dm3 mol-1 cm-1. 





















Concentration (M)  
Figure 164: Beer-Lambert plot for 171 in CH2Cl2 at 456 nm. The dashed line is a linear fit giving 
 (456 nm) = (2.79 ± .02) × 104 dm3 mol-1 cm-1. 

















































Figure 165 Left: Spectra of 172 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
172 in CH2Cl2 at 434 nm. The dashed line is a linear fit giving  (434 nm) = (3.0 ± 0.2) × 103 dm3 mol-
1 cm-1. Spectra recorded by Alice de Palo under my supervision. 
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Concentration (M)  
Figure 166: Beer-Lambert plot for 172 in CH2Cl2 at 336 nm. The dashed line is a linear fit giving 
 (336 nm) = (1.58 ± .05) × 104 dm3 mol-1 cm-1. Spectra recorded by Alice de Palo under my 
supervision. 



















































Concentration (M)  
Figure 167 Left: Spectra of 173 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
173 in CH2Cl2 at 622 nm. The dashed line is a linear fit giving  (622 nm) = (3.98 ± .03) × 103 dm3 mol-
1 cm-1. 













































Concentration (M)  
Figure 168 Left: Beer-Lambert plot for 173 in CH2Cl2 at 522 nm. The dashed line is a linear fit giving 
 (522 nm) = (8.47 ± .06) × 103 dm3 mol-1 cm-1. Right: Beer-Lambert plot for 173 in CH2Cl2 at 404 nm. 





















































Figure 169 Left: Spectra of 197 in CH2Cl2 at the concentrations shown. Right: Beer-Lambert plot for 
197 in CH2Cl2 at 408 nm. The dashed line is a linear fit giving  (408 nm) = 
(3.65 ± 0.04) × 104 dm3 mol-1 cm-1. 
 






















Figure 170: Beer-Lambert plot for 197 in CH2Cl2 at 264 nm. The dashed line is a linear fit giving 




Appendix 4: TRIR Spectroscopic Data 
 
Figure 171 Left: TRIR spectra of [Mn(ppy)(CO)4] (88) photolyzed in THF under an atmosphere of 
CO to form solvent complexes 113THF() and 113THF(O). The triplet excited state bands are marked with 
asterisks. Right: Evolution of the 113THF() 1912 cm-1 band and the 113THF(O)  1999 cm-1 band from 5 
to 99 ps. The dashed lines are single exponential fits.  
 
Figure 172 Left: TRIR spectra of 94 photolyzed in THF to form the corresponding C-H σ- and O-
bound complexes. The triplet excited state bands are marked with asterisks. Right: Evolution of the 
σ- 1913 cm-1 band and the O-bound  1999 cm-1 band from 5 to 92 ps. The dashed lines are single 





Figure 173 Left: TRIR spectra of 95 photolyzed in THF to form the corresponding C-H σ- and O-
bound complexes. The triplet excited state bands are marked with asterisks. Right: Evolution of the 
σ- 1913 cm-1 band and the O-bound 1999 cm-1 band from 5 to 92 ps. The dashed lines are single 
exponential fits.  
 
Figure 174: Kinetic profiles of selected TRIR bands for 173 on the picosecond timescale. The dashed 
lines are single exponential fits. 









 1945 cm-1 3[173]-(1)
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Figure 175: Kinetic profiles of selected TRIR bands for 173 on the nanosecond timescale. The dashed 
lines are single exponential fits. 
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Appendix 5: Growth Curves 








 Dark no DMSO
 Dark + DMSO
 Dark + DMSO + TryptoCORM
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Figure 176: Growth curves with E. coli BL21 in 50% LB media under the conditions shown. All 
cultures containing DMSO were 1% DMSO by volume. The TryptoCORM concentration used was 
100 μM. Irradiation with a 2.4 W power 400 nm LED took place between 0 and 2 hours and 
comprised cycles of 3 minutes off, 2 minutes on. 







 Dark no DMSO
 Dark + DMSO
 Dark + DMSO + TryptoCORM
 Irrad no DMSO
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Figure 177: Growth curves with E. coli BL21 in 10% LB media under the conditions shown. All 
cultures containing DMSO were 1% DMSO by volume. The TryptoCORM concentration used was 
100 μM. Irradiation with a 2.4 W power 400 nm LED took place between 0 and 2 hours and 
comprised cycles of 3 minutes off, 2 minutes on. 
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2.0  Dark no DMSO
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Figure 178: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The TryptoCORM concentration used was 100 μM. Irradiation 
with a 2.4 W power 400 nm LED took place between 0 and 2 hours and comprised cycles of 3 minutes 
off, 2 minutes on. This is a repeat of the experiment in Figure 138. 
 







 Dark no DMSO
 Dark + DMSO
 Dark + DMSO + 95
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Figure 179: Growth curves with E. coli BL21 under the conditions shown. All cultures containing 
DMSO were 1% DMSO by volume. The concentration of 95 used was 100 μM. Irradiation with a 2.4 
W power 400 nm LED took place between 0 and 2 hours and comprised cycles of 3 minutes off, 2 





Appendix 6: NMR Spectra 
 





Figure 181: A 126 MHz 13C NMR spectrum of 87 in CDCl3. 
 




Figure 183 A 126 MHz 13C NMR spectrum of 88 in CDCl3. 
 




Figure 185 A 101 MHz 13C NMR spectrum of 138 in CDCl3. 
 




Figure 187: A 101 MHz 13C NMR spectrum of 139 in CDCl3. 
 




Figure 189: A 101 MHz 13C NMR spectrum of 140 in CDCl3. 
 




Figure 191: A 126 MHz 13C NMR spectrum of 141 in CDCl3. 
 





Figure 193: A 126 MHz 13C NMR spectrum of 46 in CDCl3. 
 




Figure 195: A 101 MHz 13C NMR spectrum of 143 in CDCl3. 
 




Figure 197: A 101 MHz 13C NMR spectrum of 135 in CDCl3. 
 





Figure 199: A 176 MHz 13C NMR spectrum of 132 in CDCl3. 
 









Figure 202: A 400 MHz 1H NMR spectrum of 148 in CDCl3. 
 




Figure 204: A 700 MHz 1H NMR spectrum of 133 in CDCl3. 
 




Figure 206: A 700 MHz 1H NMR spectrum of 149 in CD2Cl2. 
 









Figure 209: A 176 MHz 13C NMR spectrum of 134 in CD2Cl2. 
 




Figure 211: A 126 MHz 13C NMR spectrum of 167 in CDCl3. 
 




Figure 213: A 126 MHz 13C NMR spectrum of 169 in CDCl3. 
 






Figure 215: A 126 MHz 13C NMR spectrum of 174 in CDCl3. 
 




Figure 217: A 126 MHz 13C NMR spectrum of 176 in CDCl3. 
 
 




Figure 219: A 126 MHz 13C NMR spectrum of 170 in CDCl3. 
 




Figure 221: A 126 MHz 13C NMR spectrum of 171 in CDCl3. 
 




Figure 223: A 126 MHz 13C NMR spectrum of 172 in CDCl3. 
 




Figure 225: A 126 MHz 13C NMR spectrum of 173 in CDCl3. 
 




Figure 227: A 126 MHz 13C NMR spectrum of 187 in CDCl3. 
 




Figure 229: A 126 MHz 13C NMR spectrum of 188 in CDCl3. 
 
 




Figure 231: A 126 MHz 13C NMR spectrum of 189 in CDCl3. 
 




Figure 233: A 101 MHz 13C NMR spectrum of 192 in CDCl3. 
 




Figure 235: A 101 MHz 13C NMR spectrum of 193 in CDCl3. 
 





Figure 237: A 400 MHz 1H NMR spectrum of 196 in CDCl3. 
 





Figure 239: A 500 MHz 1H NMR spectrum of 197 in CDCl3. 
 




Figure 241: A 400 MHz 1H NMR spectrum of 198 in CDCl3. 
 




Figure 243: A 400 MHz 1H NMR spectrum of 199 in CD2Cl2. 
 
























cGMP Cyclic Guanosine Monophosphate 
CLF Central Laser Facility 
CO-Hb Carboxyhaemoglobin 
CORM Carbon Monoxide Releasing Molecule 
CORMA Carbon Monoxide Releasing Material 




DFT Density Functional Theory 
DMApy 4-Dimethylaminopyridine 
DMF Dimethyl formamide 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic acid 
en 1,2-diaminoethane 
EPR Electron Paramagnetic Resonance 
eq Equatorial 
ESI Electrospray Ionisation 
Et Ethyl 





GSH Glutathione  
GSSG Glutathione Disulfide 
GTP Guanosine Triphosphate 
Hb Haemoglobin 
HO  Haem Oxygenase 
HO-1 Haem Oxygenase 1 
HO-2 Haem Oxygenase 2 
HO-3 Haem Oxygenase 3 
HOMO Highest Occupied Molecular Orbital 
ICP-MS Inductively Coupled Plasma Mass Spectrometry 
iNOS Inducible Nitric Oxide Synthase 
IR Infrared 
L Ligand 
LB Lysogeny Broth 
LDA Lithium diisopropylamide 
LDH Lactate dehydrogenase 
LED Light-Emitting Diode 
LIFDI Liquid Injection Field Desorption Ionisation 
LUMO Lowest Unoccupied Molecular Orbital 
M Metal  
m (IR) Medium 
m (NMR) Multiplet 







MLCT Metal-to-ligand Charge Transfer 
MO Molecular Orbital 
MP Melting Point 
n Normal 
NADP Nicotinamide Adenine Sinucleotide Phosphate 
NHE Normal Hydrogen Electrode 
NIR Near Infrared 
NMR Nuclear Magnetic Resonance 
NORM Nitrous Oxide Releasing Molecule 
NORMA Nitrous Oxide Releasing Material 
NOS Nitric Oxide Synthase 
OD600 Optical Density 600 nm 
OCP Open Circuit Potential 
PBS Phosphate Buffered Saline 
photoCORM Photochemical Carbon Monoxide Releasing Molecule 
PI Propidium Iodide 
PMMA Poly(methyl methacrylate) 
ppm Parts Per Million 
ppy 2-Phenylpyridyl 
py Pyridine 
Rf Retention Factor 
ROS Reactive Oxygen Species 
RT Room Temperature 
S Solvent 
s (IR) Strong 
s (NMR) Singlet 
sGC Soluble Guanylyl Cyclase 
417 
 
SOD Superoxide Dismutase 
t Triplet 
t Tertiary 
TA Transient Absorbance 
TBAF Tetrabutylammonium fluoride 
THF Tetrahydrofuran 
TIPS Triisopropyl Silyl 
TLC Thin Layer Chromatography 
tpm Tris(2-pyrazolyl)methane 
TRIR Time-Resolved Infrared 
TRMPS Time-Resolved Multiple Probe Spectroscopy 
UV Ultraviolet 
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